Translational Studies on Inflammation by unknown
Translational Studies on 
Inflammation
Edited by Ane C.F. Nunes
Edited by Ane C.F. Nunes
Inflammation is known worldwide, from the bench to the bedside, but it is a 
hard theme to approach with one single point of view.In this sense, a selection of 
translational studies would support the medical-scientific community to better 
understand the complex network of the inflammatory process, its maintenance, 
and potential treatment targets. The eleven chapters that compose this book 
present interesting insights into inflammation and its mechanisms, merging classic 
background with innovative approaches.From the molecular basis to experimental 
models, the chapters selected for this book bring to readers at different academic levels 
updated and practical data on inflammation. Find out what drives interdisciplinary 
medical research on inflammation and enjoy this informative collection.
Published in London, UK 
©  2020 IntechOpen 
©  SimCh / iStock
ISBN 978-1-78984-357-6




Translational Studies on 
Inflammation
Edited by Ane C.F. Nunes
Published in London, United Kingdom

Supporting open minds since 2005
Translational Studies on Inflammation
http://dx.doi.org/10.5772/intechopen.78112
Edited by Ane C.F. Nunes
Contributors
Samantha Giordano-Mooga, Sari Terrazas, Lauren Brashear, Anna-Katherine Escoto, Shannon Lynch, 
Dylan Slaughter, Neena Xavier, Norman Robert Estes II, Alireza Ziaei, Forough Kheiry, Mario 
Rosemblatt, Cristian Doñas, Alejandra Loyola, Mona A. Elsayed, Ayman Noreddin, Martijn Bastiaan 
Adriaan Van Doorn, Robert Rissmann, Salma Assil, Jaime Arias, Ana Arias, Maria Angeles Aller, Javier 
Blanco-Rivero, Sophia Ran, Nihit Bhattarai, Radhika Patel, Lisa Volk-Draper, I.N. Bolshakov, Anatoly 
V. Svetlakov, A.V. Eremeev, Yu.I. Sheina, Márcia Guimarães Da Silva, Natália Prearo Moço, Mariana 
De Castro Silva, Ramkumar Menon, Bruna Ribeiro de Andrade Ramos, Jossimara Polettini, Ane C.F. 
Nunes, Uma Ranjan Lal, Inder Pal Singh
© The Editor(s) and the Author(s) 2020
The rights of the editor(s) and the author(s) have been asserted in accordance with the Copyright, 
Designs and Patents Act 1988. All rights to the book as a whole are reserved by INTECHOPEN LIMITED. 
The book as a whole (compilation) cannot be reproduced, distributed or used for commercial or 
non-commercial purposes without INTECHOPEN LIMITED’s written permission. Enquiries concerning 
the use of the book should be directed to INTECHOPEN LIMITED rights and permissions department 
(permissions@intechopen.com).
Violations are liable to prosecution under the governing Copyright Law.
Individual chapters of this publication are distributed under the terms of the Creative Commons 
Attribution 3.0 Unported License which permits commercial use, distribution and reproduction of 
the individual chapters, provided the original author(s) and source publication are appropriately 
acknowledged. If so indicated, certain images may not be included under the Creative Commons 
license. In such cases users will need to obtain permission from the license holder to reproduce 
the material. More details and guidelines concerning content reuse and adaptation can be found at 
http://www.intechopen.com/copyright-policy.html.
Notice
Statements and opinions expressed in the chapters are these of the individual contributors and not 
necessarily those of the editors or publisher. No responsibility is accepted for the accuracy of 
information contained in the published chapters. The publisher assumes no responsibility for any 
damage or injury to persons or property arising out of the use of any materials, instructions, methods 
or ideas contained in the book.
First published in London, United Kingdom, 2020 by IntechOpen
IntechOpen is the global imprint of INTECHOPEN LIMITED, registered in England and Wales, 
registration number: 11086078, 7th floor, 10 Lower Thames Street, London,  
EC3R 6AF, United Kingdom
Printed in Croatia
British Library Cataloguing-in-Publication Data
A catalogue record for this book is available from the British Library
Additional hard and PDF copies can be obtained from orders@intechopen.com
Translational Studies on Inflammation




eBook (PDF) ISBN 978-1-83968-001-4
Selection of our books indexed in the Book Citation Index 
in Web of Science™ Core Collection (BKCI)
Interested in publishing with us? 
Contact book.department@intechopen.com
Numbers displayed above are based on latest data collected. 
For more information visit www.intechopen.com
4,500+ 




Contributors from top 500 universities








the world’s leading publisher of 
Open Access books




Dr. Ane C.F. Nunes is a geneticist, with her Masters and PhD. in 
Medical Sciences and Nephrology from the UFRGS/Brazil, and 
with postdoctoral experience in renal physiology from the UFRJ/
Brazil, clinical medicine and nephrology from the USP/Brazil, 
and nephrology and hypertension from the UCI/USA. She is a 
Professor of medical genetics, human genetics and molecular 
biology. Her research fields are human genetic diseases, cellular 
and molecular biology applied to nephrology, biochemistry, and microbiology with 
projects mainly in the following subjects: inflammatory markers, molecular diagno-
sis, DNA polymorphisms, chronic kidney disease (CKD), polycystic kidney disease, 
Fabry disease, rare diseases, cellular and murine models for CKD, RNA processing, 




General Aspects of Inflammatory Process and Immune System Network 1
Chapter 1 3
Introductory Chapter: Overview of the Cellular and Molecular Basis of 
Inflammatory Process
by Ane C.F. Nunes
Chapter 2 7
Spontaneous Prematurity, Innate Immune System, and Oxidative Stress  
at the Maternal-Fetal Interface: An Overview
by Natália Prearo Moço, Bruna Ribeiro de Andrade Ramos,  
Mariana de Castro Silva, Jossimara Polettini, Ramkumar Menon  
and Márcia Guimarães da Silva
Section 2
Clinical and Pharmacological Approaches 25
Chapter 3 27
Pharmacological Challenge Models in Clinical Drug Developmental Programs
by Salma Assil, Robert Rissmann and Martijn Bastiaan Adriaan van Doorn
Chapter 4 45
Sex Differences in Obesity-Induced Inflammation
by Sari Terrazas, Lauren Brashear, Anna-Katherine Escoto, Shannon Lynch,  
Dylan Slaughter, Neena Xavier, Norman Robert Estes II  
and Samantha Giordano-Mooga
Chapter 5 69
The Wound-Healing Portal Hypertensive Response
by Maria Angeles Aller, Javier Blanco-Rivero, Ana Arias and Jaime Arias
Chapter 6 101
Review and Implications of Traditional Indian Medicine for Inflammatory  
Bowel Disease




General Aspects of Inflammatory Process and Immune System Network 1
Chapter 1 3
Introductory Chapter: Overview of the Cellular and Molecular Basis of 
Inflammatory Process
by Ane C.F. Nunes
Chapter 2 7
Spontaneous Prematurity, Innate Immune System, and Oxidative Stress 
at the Maternal-Fetal Interface: An Overview
by Natália Prearo Moço, Bruna Ribeiro de Andrade Ramos,  
Mariana de Castro Silva, Jossimara Polettini, Ramkumar Menon  
and Márcia Guimarães da Silva
Section 2
Clinical and Pharmacological Approaches 25
Chapter 3 27
Pharmacological Challenge Models in Clinical Drug Developmental Programs
by Salma Assil, Robert Rissmann and Martijn Bastiaan Adriaan van Doorn
Chapter 4 45
Sex Differences in Obesity-Induced Inflammation
by Sari Terrazas, Lauren Brashear, Anna-Katherine Escoto, Shannon Lynch, 
Dylan Slaughter, Neena Xavier, Norman Robert Estes II  
and Samantha Giordano-Mooga
Chapter 5 69
The Wound-Healing Portal Hypertensive Response
by Maria Angeles Aller, Javier Blanco-Rivero, Ana Arias and Jaime Arias
Chapter 6 101
Review and Implications of Traditional Indian Medicine for Inflammatory 
Bowel Disease
by Uma Ranjan Lal and Inder Pal Singh
XII
Section 3
Role of Chronic Inflammation in Cancer 115
Chapter 7 117
Immuno-Oncology, Imaging Biomarkers and Response to Chemotherapy in  
Cancer Treatment
by Alireza Ziaei and Forough Kheiry
Chapter 8 133
TLR4-Induced Inflammation Is a Key Promoter of Tumor Growth,  
Vascularization, and Metastasis
by Sophia Ran, Nihit Bhattarai, Radhika Patel and Lisa Volk-Draper
Section 4
Therapeutic Perspectives for Inflammation 169
Chapter 9 171
The Potential Contribution of Nanoparticles in the Treatment 
of Inflammatory Diseases
by Mona A. Elsayed, Ayman Norredin
Chapter 10 187
Exploring Epigenetic Drugs in the Regulation of Inflammatory 
Autoimmune Diseases
by Cristian Doñas, Alejandra Loyola and Mario Rosemblatt
Chapter 11 213
The Experimental Bioengineering of Complete Spinal Cord Injury in 
Adult Rats
by I.N. Bolshakov, A.V. Svetlakov, A.V. Eremeev and Yu.I. Sheina
Preface
Inflammatory processes, their causes, and parameters are, by themselves, elements
of considerable debate in the medical-scientific community. Faced with a wide
range of questions and lines of action, it is pertinent to address studies on inflam-
mation using a translational approach. Based on this aspect, the idea of this book
grew.
Although this was an arduous task considering the many equally appropriate titles
that were submitted, the chapters that follow fulfill this interdisciplinary goal and 
we selected them based on quality and variety.
Readers will find in these four sections different translational studies about inflam-
mation from different points of view:
(1) General Aspects of Inflammatory Process and Immune System Network: This is
the introductory unit and the first chapter presented by me as the Academic Editor
summarizes the basis of inflammation and its interactions. An extension of this
approach is presented in the second chapter produced by Dr. Guimarães da Silva
group, which brings to this book an interest aspect of the ontogenetic effect of the
molecular panel related to innate immune system and oxidative stress.
(2) Clinical and Pharmacological Approaches: Four chapters that link experimental 
models and clinical information make up this unit. In the first one, Dr. Van Doorn
and collaborators report the pharmacological properties of some models used for
drug development. The second chapter, which was prepared by the Dr. Giordano-
Mooga group, is a comprehensive review on the impact of sex differences over
obesity, cardiovascular disease, diabetes, kidney disease, and its links with the
inflammatory process. The third chapter by the Dr. Arias group brings to this book
a well-detailed review on wound-healing response, with special emphasis on the
immunological and ontogenetic features of portal hypertensive inflammation. 
Closing this section, the fourth chapter is an in-depth presentation produced 
by Dr. Lal, which features the implications of the traditional Indian System of
Medicine for management of the inflammatory bowel disease.
(3) Role of Chronic Inflammation in Cancer: Because of its complex network of
interactions, cancer itself deserved an entire section to cover its specific inflamma-
tory characteristic. In this book, two comprehensive chapters compose this subject. 
In the first chapter, Dr. Ziaei describes the process by which chemotherapy com-
pounds act under an inflammatory condition. In the second chapter of this section, 
Dr. Ran and colleagues reviewed the role of the TLR4 pathway and its intricate
performance in inflammation and tumor spread.
(4) Therapeutic Perspectives for Inflammation: The final section of this book pres-
ents three chapters that cover some innovative proposals for inflammation manage-
ment. Opening this section is the chapter by Dr. Elsayed and Dr. Noreddin. They
present an overview of inflammation and nanomedicine. In the second chapter of
this section, Dr. Rosemblatt and colleagues review the role of epigenetic processes
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and the impact of these events in the development and management of the immune 
system and its inflammatory consequences. Closing this section and the book is an 
original study conducted by Dr. Bolshakov and group, which presents an innovative 
strategy based in cellular therapy to revert the damage in an experimental vertebral-
spine trauma, controlling potential clinical endpoints beyond inflammation.
As an Academic Editor, this project was a challenge that brought me tremendous 
pleasure to be in charge of reviewing such high-level proposals as those received.
We are grateful to all authors, contributors, and experts who took considerable 
effort to ensure that each chapter provided updated and innovative data for this 
special issue.
Thanks to the IntechOpen team for their support, especially to Ms. Sandra Maljavac 
for her constant assistance.
I wish all readers could reach same satisfaction as I have attained by editing this 
book.
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Tissue or cell injuries and assorted infections are targets to major studies on 
inflammation. These conditions play a central role for the understanding of the 
inflammatory mechanism as a pathophysiological process. In addition, tissue-
resident macrophages can create an adaptive response against stressed or unwell 
environments, which may lead to various pro-inflammatory pathways. Together, 
these conditions may be associated with a broad spectrum of acute and chronic 
inflammation in some of contemporary human disorders [1].
In general, inflammation is a natural response to avoid the progress from fester 
to deadly in any kind of injury. Its very well-balanced network of anti- and pro-fac-
tors should be constantly checked by the immune system to make sure the healing 
process does not miss your goal and becomes unreliable to the point of creating an 
incorrigible damage [1, 2].
Regardless of its etiology, patients suffering from inflammatory episodes or 
disorders have higher risk of facing other clinical complications. Acute and chronic 
inflammations have their particular dynamics and prognostics but, even if it is 
unclear in several aspects, it has been pertinent in addressing any analysis on 
inflammation under a translational approach.
In face of that, the following review is a summary report on essential aspects 
related to inflammation as a biological event, considering the potentially wide range 
of questions and action lines, from its molecular basis to some potential clinical 
outcomes.
2. Causes and early stages of inflammation
Different agents can promote inflammatory events, such as (a) necrosis, due 
to the decrease in blood flow and lack of nutrients and oxygen in the target tissue, 
which results in tissue death; (b) chemical or physical traumas, like radiation, 
burn, frostbite, corrosion by oxidizing, alkalis, or acid; (c) displaced or delayed 
immunological response due to genetic conditions or unstable metabolism; and 
(d) infections or coexistent microbiome unbalanced status, mainly from very 
common performers as bacteria, through endotoxins release, and virus, which 
encroach cells for its proliferation until the host wrecking [2–6].
Basic signs of inflammation are (1) edema or swelling caused by gradual 
deposit of fluid outside of blood vessels; (2) pain, caused by mechanical action 
of edema and/or direct response to prostaglandin, serotonin, and bradykinin 
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reactions; (3) redness, as a consequence of vasodilation at damage site; and (4) 
fever caused by pro-inflammatory mediators that contribute to the rise of local 
and/or systemic temperature [1, 2].
Vasoconstriction, the constriction of blood vessels, which increases blood pres-
sure, is one of the first and brief reactions to inflammatory process. In the begin-
ning of inflammatory process, it is followed by a counterreaction, the vasodilation. 
During vasodilation the blood flow increases into the target area, and it can take 
from few minutes to long-time periods to be released. These contractile events on 
the vessel affect the blood flow and, for consequence, the blood vessel wall perme-
ability. When the vessel wall becomes more permeable, the transit of fluids also is 
raised, beyond usual salt- and water-based liquids [7].
A protein-rich fluid, the exudate, increases its transposition through the wall, 
which affects the distribution of anti-inflammatory elements, as coagulation factors 
and antibodies, in the sense to refrain the spreading of infectious agents.
3. Cellular setup and molecular mediators
The inflammatory environment with fluid leaking out the blood vessels creates 
the conditions for white cell adhesion to the blood vessel wall since the blood flow 
starts to slowdown. This is the initial step of a serial process moving out the white 
cells from the vessel lumen to the interstitium of the damaged tissue.
Two major aspects related to the body’s reaction to inflammation are the speed and 
the amount of white cells taken to the target tissue. Phagocytes are the predominant 
form of leukocytes designated to clean up the site of injury, eating bacteria and strange 
elements, removing the cellular remains produced during the injury progress [2].
Neutrophils are a class of white cells involved in acute inflammation. This par-
ticular type of phagocyte holds granules of enzymes capable of destroying toxic 
substances, such as reactive oxygen species, proteins, and cells, making these cells the 
major components in the injury processing. For local and weak damages, the amount 
of circulating neutrophils is enough for inflammatory response. However, for wide 
damages, sources of neutrophils from the bone marrow are constantly requested for 
acting on the injured site as the early agents. Even if in its immature form, neutrophils 
can reach the local spot quickly after the inflammatory process starts [2].
Monocytes are the second group of blood cells requested for acting on the 
inflamed area, usually several hours after the beginning of this process. These 
white blood cells when matured are called macrophages, and they are responsible 
for the ultimate step of engulfing and disposing the invasive cells and foreign ele-
ments. Macrophages are also the predominant agents in the chronic inflammation 
healing [1–2].
The cells required to act at the site of inflammation actually move from blood 
vessels to injured tissue. Both neutrophils and macrophages use chemical recogni-
tion properties, called chemotaxis, to guide themselves through the pathway. 
While the lesion itself has an important role in the inflammation healing initiation, 
chemotaxis is responsible for determining how far fast and effective will be its 
processing. It is a complex network working from the chemical signals given out by 
the injured tissue. Structural compounds, such as endothelial cells, operate together 
with blood plasma elements, platelets, and mast cells, creating a chemical commu-
nications to address the differentiated white blood cells to the right site, according 
to each role and time frame [8, 9].
The blood plasma is an important source of inflammatory mediators. Some 
complex proteins are connected through its elaborate cascade pathways, such as the 
complement, coagulation factors, the fibrinolytic system, and the kinins.
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Activated complement proteins, for example, are able to increase vascular 
permeability, make mast cells release histamine, and work for neutrophils as 
chemotactic elements.
On the other hand, the vascular permeability is directly influenced by a serial 
process among the coagulation, fibrinolytic, and kinin systems. Coagulation, in 
a cascade of activations, contributes to fluid exudate formation, polymerizing 
fibrinogen to fibrin, which is part of the exudate. Fibrin, in its turn, is quickly 
broken by the plasmin produced from fibrinolytic system, resulting in chemical 
compounds that interfere with the permeability of blood vessels. Overlapping these 
events, the kinin system also generates mediators responsible to increase vascular 
permeability. Moreover, an essential kinin named bradykinin is in charge of two of 
the main uncomfortable effects of inflammation, itching and pain.
Prostaglandins are considered major inflammatory mediators. This type of fatty 
acids plays an essential role on the platelet cluster formation, also interfering on 
clotting process. Some prostaglandins can promote vascular permeability too. This 
group of molecules is targeted for many anti-inflammatory drugs, since they are 
related to fever and pain caused by inflammation [10, 11].
Another group of inflammatory mediators, including histamine, cytokines, and 
lysosomal compounds, has a significant role on the capacity to exchange the perme-
ability of vessels, even with its distinct characteristics. Histamines, for example, 
are the first line of agents released to increases vascular permeability, since they 
are easily accessed from mast cells and basophils. The activation of histamine H1 
receptors promptly changes some pro-inflammatory pathways. Moreover, the 
histamine regulates the synthesis of cytokine in some inflammation process, such 
as allergies. In turn, cytokines released by different cells exhibit features that affect 
vessel dilatation and the ability to chemically transport white blood cells through 
the blood vessel into the interstitium of injured parenchyma [7].
Closing this overview, it is important to highlight that the time of inflammation 
processing is the key to distinguish an acute response, which usually takes a couple 
of days, from a chronic inflammation, which trends to request long time for healing 
and its outcomes may persist. From autoimmune diseases to long-term inflamma-
tory sequels, many different targets may be addressed in classic inflammatory path-
way, alternative networks, and its upshots. From microbiome interactions, richly 
reported in recent studies [3–6], to chronic side effects of traditional or innovative 
treatments, many therapeutics targets have being studied to develop new inflam-
mation mediators that could be helpful, either in scientific or clinical decisions.
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Abstract
Despite the multifactorial etiology of prematurity, intra-amniotic infection is 
present in 25–40% of preterm pregnancies. Bacteria in amniotic cavity synthesize 
phospholipases associated with the production of prostaglandins that leads to 
rupture of fetal membranes and uterine contractions. Bacterial pathogen-associated 
molecular patterns (PAMPs) activate pattern recognition receptors (PRRs) such as 
Toll-like (TLRs) and NOD-like receptors (NLRs), triggering pathways that cul-
minate in the production of cytokines that further increase prostaglandin release. 
Importantly, endogenous molecules called damage-associated molecular patterns 
(DAMPs) released under stressful conditions can also activate PRRs. Risk fac-
tors for both preterm labor (PTL) and preterm premature rupture of membranes 
(PPROM), including infection-induced inflammation, may cause an increase of 
ROS release and depletion of antioxidant defenses. In spite of the similarity between 
the pathophysiology of PTL and PPROM, there are significant differences regard-
ing molecular mediators, degree of tissue damage, and oxidative stress present in 
these two conditions. PPROM seems to be a consequence of notable tissue damage 
resulting from chronic oxidative stress, while PTL is associated with minimal tissue 
degradation resulting from acute exposure and greater antioxidant status. A better 
understanding of prematurity pathophysiology and the differences between PTL 
and PPROM can benefit therapeutic approaches to prevent these important inflam-
matory syndromes.
Keywords: prematurity, innate immune system, oxidative stress
1. Introduction
Innate immune responses play a critical role at different stages of gestation, and 
a successful pregnancy depends on the balance between anti- and pro-inflamma-
tory molecules. In addition, normal pregnancy is marked by increased oxidative 
stress, due to increased fetal metabolism, decreased maternal antioxidant reserves, 
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or maternal supply of substrate. Disruption of these two major mechanisms, 
inflammation and oxidative stress, is closely linked to spontaneous prematurity.
2. Innate immunity and pattern recognition receptors (PRRs)
Innate immunity is a primordial defense system implicated in the identification 
and eradication of infectious agents that also recognizes products from damaged 
cells and works to eliminate them. The innate immune system acts through the 
recognition of molecular structures common to microorganisms, called pathogen-
associated molecular patterns (PAMPs) and endogenous molecules called damage-
associated molecular patterns (DAMPs) [1], which are passively released from 
damaged and dying cells, or actively secreted by immune cells or severely stressed 
cells [2].
PAMPs and DAMPs are recognized by pattern recognition receptors (PRRs) 
expressed by several cell types [1, 3]. Their ubiquitous localization in cells 
enables PRRs to recognize microorganisms present in distinct compartments. 
Membrane-bound PRRs are located in the plasma membrane, endosomal and 
lysosomal membranes, while cytosolic PRRs are located in the cytoplasm of 
cells [1, 3].
Toll-like receptors (TLR) are PRRs coupled to the cell membrane [4], composed 
of type I integral membrane glycoproteins, comprised of an ectodomain with a 
leucine-rich repeat domain (LRR), an endodomain with Toll/IL-1 receptor (TIR), 
that shares a 200-amino acid conserved region with interleukin-1 (IL-1) and IL-18 
receptors, and a short transmembrane domain [1, 5]. The ectodomain recognizes 
specific PAMPs, while the endodomain recruits adaptor molecules, enabling the 
intracellular cascade [5].
The first group of TLRs is responsible for the recognition of structural compo-
nents of microorganisms and comprises receptors expressed on the cell surface, 
including TLR-1, TLR-2, TLR-4, TLR-5, TLR-6, and TLR-11 [4]. The second group 
includes receptors exclusively expressed in intracellular vesicles, TLR-3, TLR-7, and 
TLR-9, which recognize nucleic acids from microorganisms [4, 6].
PAMPs’ recognition by TLRs activates intracellular pathways that lead to the 
activation of transcription factors responsible for the expression of genes involved 
in inflammatory and antiviral responses [1, 5, 6]. Among the transcription factors 
activated by TLR signaling, the most common factors are nuclear factor kappa-B 
(NF-κB), activating protein 1 (AP-1), interferon regulatory factor 3 (IRF3), and 
IRF7 [1]. Activation of NF-κB and AP-1 results in the transcription of several genes 
of pro-inflammatory effector molecules, such as cytokines and chemokines, while 
the activation of IRF3 and IRF7 leads to the production of type I interferons that are 
involved in antiviral immunity [1, 3].
Intracellular signaling through NF-κB and AP-1 is very well character-
ized [4, 7], and TLR-4 and TLR-9 are shown as examples of TLRs on the cell 
surface and in endosomes, respectively, in Figure 1. The activation of TLRs by 
PAMPs and DAMPs triggers the formation of a signaling complex, a myddo-
some, composed of protein MyD88 and interleukin-1 receptor-associated kinase 
1 (IRAK1) and IRAK4, leading to activation of pro-inflammatory transcription 
factors, NF-kB and AP-1.
Although infection is the main stimulus for inflammation, it can also be induced 
in sterile conditions [8]. Therefore, DAMPs are as important to sterile inflamma-
tion as PAMPs are to innate response to microorganisms. DAMPs are endogenous 
factors that in physiologic conditions are protected from cellular receptors. During 
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tissue damage, DAMPs are liberated from cells and are recognized by immune cells 
[9]. DAMPs can also be actively secreted by immune and severely stressed cells [2]. 
Evidence shows that PAMPs and DAMPs act in different ways to stimulate innate 
immunity. Antigen-presenting cells that are unresponsive to lipopolysaccharide 
(LPS) can be activated by necrotic cells, indicating that TLR-4 activation, regard-
less of LPS, occurs in response to endogenous ligands [10]. Similarly, TLR-3 recog-
nizes cells that undergo necrosis during acute inflammatory events, independently 
of the presence of viral PAMPs [11].
Among the cytosolic PRRs, nucleotide-binding oligomerization domain (NOD)-
like receptors (NLRs) are of great importance [1]. The NLR family is a class of 
intracellular receptors that lead to intracellular signaling associated to inflamma-
tion, after recognition of PAMPs and DAMPs [1]. Members of the NLR family are 
characterized by at least three domains: the first one is an LRR domain, responsible 
for the recognition of the ligand; the second is a NACHT domain that allows the 
formation of oligomers of NLRs; and the third is the effector domain, usually a 
Figure 1. 
Overview of TLR signaling pathways. Activation of TLRs on the cell surface or endosomal membranes and 
formation of myddosome complex, leading to activation of pro-inflammatory transcription factors NF-kB and 
AP-1. Communication between TLR and the myddosome occurs through interaction of the TIR domain of the 
Toll-like receptor with the TIR domain of MyD88 and depends on the adapter molecule called MAL, allowing 
the myddosome to form a helical structure. IRAK-4 activates IRAK-1, which undergoes autophosphorylation. 
Phosphorylated IRAK-1 then binds to TRAF-6, resulting in the activation of the TAK-1, which results in 
activation of the cascade of KKs that phosphorylate the inhibitory protein of NF-kB, leading to activation 
of NF-kB. Additionally, the activation of TAK-1 protein also results in activation of MAPKs, leading to 
activation of the transcription factor AP-1. AP-1, activator protein 1; IKK, IκB kinase; IRAK, interleukin-1 
receptor-associated kinase; MAL, MyD88-adapter-like protein; MAPK, mitogen-activated protein 
kinase; MYD88, myeloid differentiation primary response protein 88; TAB, TAK1-binding protein; TAK1, 
transforming growth factor β (TGF-β)-activated kinase 1; TRAF6, tumor necrosis factor receptor-associated 
factor 6. Adapted from Kawasaki and Kawai [4].
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caspase recruitment domain (CARD), responsible for the recruitment of accessory 
proteins [12].
The first NLRs described were NOD-1 and NOD-2 [13], which recognize pep-
tides from degradation of peptidoglycan (PG) that occurs during bacterial growth 
or destruction. Recognition of PGs by NOD-1 and NOD-2 leads to activation of 
intracellular pathways, which activate the transcription factor NF-κB, and results in 
the synthesis of several inflammatory cytokines [14, 15].
Members of the NLR family known as NLRP are capable of responding to 
cytoplasmic PAMPs and DAMPs through the formation of intracellular signaling 
complexes, termed inflammasomes [1]. Inflammasomes activate proteases from the 
caspase family during immune regulation in physiologic and pathologic conditions 
[16]. The typical structure of the inflammasome consists of NLRP, adaptor protein 
apoptosis-associated speck-like protein containing a CARD (ASC; also known 
as PYCARD), and pro-caspase [17]. This transient oligomer starts a cascade that 
culminates with activation of caspase-1 and production of the active form of IL-1β 
[18] and IL-18 [19].
The inflammasome NLRP3 is activated in response to several PAMPs, such as 
flagellin, muramyl dipeptide, LPS, and pore-formation toxins [1]. Moreover, it can 
be activated by DAMPs, reactive oxygen species (ROS), and environmental signals 
[16, 20]. Three models describing mechanisms of NRLP3 inflammasome activation 
have been suggested, which may not be mutually exclusive [21–23] (Figure 2). In 
the absence of activation mechanisms, NLRP3 inflammasome complex is autore-
pressed, owing to an interaction between NATCH domains and LRRs. When one or 
Figure 2. 
Mechanisms of NLRP3 inflammasome activation. PAMPs and DAMPs are able to induce the activation of the 
NLRP3 inflammasome by three principal mechanisms: (A) high concentrations of extracellular ATP lead to 
opening of PANX1 channels by binding to the P2X7 receptor, which results in K+ efflux and influx of PAMPs 
and DAMPs; (B) phagocytosis of PAMPs and DAMPs leads to disruption of the lysosomal membrane and 
consequent release of a putative NLRP3-activating molecule, such as cathepsin B; and (C) PAMPs and DAMPs 
can induce the production of ROS, which may active TXNIP to trigger NLRP3 activation. Activation of the 
NLRP3 inflammasome results in maturation of caspase-1 and release of mature forms of IL-1 and IL-18. ATP, 
adenosine triphosphate; DAMPS, damage-associated molecular patterns; LRR, leucine-rich repeat domain; 
PAMPs, pathogen-associated molecular patterns; PANX1, pannexin-1; ROS, reactive oxygen species; TXNIP, 
thioredoxin-interacting protein. Adapted from Tschopp and Schroder [23].
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more activation mechanism is present, this autorepression is removed, resulting in 
NATCH domain exposure. After this exposure, NLRP3 oligomerizes and recruits 
ASC and pro-caspase 1, leading to activation of caspase 1 and, consequently, matu-
ration and secretion of IL-1β and IL-18 [21, 22]. The immune response initiated 
by inflammasome activation shows a close relationship with both physiologic and 
pathologic processes, as immunological defense and development of inflammatory 
diseases [20].
3. Pregnancy, maternal immunity, and oxidative stress
During pregnancy, a tightly regulated immune system allows for fetal survival 
and its adequate development. Among the several modifications made by the 
maternal immune system to raise tolerance to the allograft fetus, changes in cyto-
kine profiles at the maternal-fetal interface are of great importance [24].
Recent data have shown that a successful pregnancy depends on a complex 
balance between anti- and pro-inflammatory molecules that changes through-
out pregnancy [25, 26]. First trimester is characterized by prevalence of the 
T helper cell type 1 (Th1) profile. During this stage, an inflammatory micro-
environment is necessary for repair and remodeling of the uterine epithelium 
damaged during implantation and for removal of cellular debris [27]. In the 
second trimester, there is a prevalence of a Th2 profile [28–30]. The increased 
anti-inflammatory activity is important for maintenance of gestation. During 
the third trimester and labor, the Th1 profile is again predominant systemi-
cally [31] in the placental tissue and amniotic fluid, supporting the theory 
that proinflammatory overload in the intrauterine environment is required for 
initiation and progression of labor [32, 33]. The final trimester is character-
ized by an influx of immune cells at the maternal-fetal interface and increased 
production of pro-inflammatory cytokines [34, 35]. This scenario is essential for 
the development of the physiologic processes of cervical remodeling, weakening 
and rupture of fetal membranes, and initiation of uterine contractility, which 
together culminate in labor [36, 37].
Recent studies have also demonstrated that normal pregnancy is marked by 
increased oxidative stress, due to increased fetal metabolism, decreased fetal 
antioxidant reserves, or maternal supply of substrate [38, 39]. Oxidative stress 
results from exacerbated production of ROS and/or decreased production of 
antioxidants. Increased oxidative stress has been described in the third trimester 
of normal pregnancies and labor [38]. During the process of labor, the intensity 
of uterine contractions increases uterus pressure and can cause interruption or 
reduction in the uteroplacental blood flow, causing cycles of cellular hypoxia and 
reoxygenation. These events of parturition are responsible for inducing increased 
oxidative stress in pregnant women, which must be controlled by their antioxidant 
system [40, 41].
3.1 Prematurity, inflammatory response, and oxidative stress
Prematurity is the leading cause of neonatal mortality and is also responsible 
for several short- and long-term morbidities. The risk for these complications is 
inversely proportional to gestational age at birth [42–44]. Preterm delivery (PTD) 
is defined as birth before 37 weeks of gestation, and the incidence of PTD among 
singleton pregnancies is 9.6% worldwide [45]. Spontaneous PTD can be divided 
into PTD, which is preceded by preterm labor (PTL) with intact membranes, or 
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thioredoxin-interacting protein. Adapted from Tschopp and Schroder [23].
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more activation mechanism is present, this autorepression is removed, resulting in 
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3.1 Prematurity, inflammatory response, and oxidative stress
Prematurity is the leading cause of neonatal mortality and is also responsible 
for several short- and long-term morbidities. The risk for these complications is 
inversely proportional to gestational age at birth [42–44]. Preterm delivery (PTD) 
is defined as birth before 37 weeks of gestation, and the incidence of PTD among 
singleton pregnancies is 9.6% worldwide [45]. Spontaneous PTD can be divided 
into PTD, which is preceded by preterm labor (PTL) with intact membranes, or 
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by preterm premature rupture of membranes (PPROM) [43, 46]. The incidence of 
PTL is approximately 60 and 30–40% for PPROM [27, 35, 47].
The etiology of prematurity is multifactorial and includes maternal, paternal, 
and genetic risks [48–52], as summarized in Table 1. Despite this multifacto-
rial etiology, studies show that intra-amniotic infections (IAI) are present in 
25–40% of preterm pregnancies; however, these frequencies are believed to be 
 underestimated [43, 53].
The main infection route into the amniotic cavity (AC) is the ascending of bacte-
ria present in the lower genital tract through the endocervical canal. Ascending 
bacteria can then cross the membranes and invade the AC, with subsequent prolif-
eration in the amniotic fluid. Once microorganisms reach this site, they may travel 
to the amnion, connective tissue, and even chorion and decidua [54]. The establish-
ment of inflammation in the chorioamniotic membranes in response to bacteria is 
called chorioamnionitis. Clinical chorioamnionitis (cCAM) occurs in 1–2% of term 
labors and in 5–10% of PTLs, and this prevalence increases in case of PPROM due to 
Maternal




Drugs and alcohol abuse
















Paternal High paternal age
Genetics Polymorphisms IL-1R,IL-1β, IL-6, IL-10, MMP-1, MMP-9, 
TLR-4, TNF-α, HPS47
IL-1R, interleukin 1 receptor; IL-1β, interleukin 1 beta; IL-6, interleukin 6; IL-10, interleukin 10; MMP-1, matrix 
metalloproteinase 1; MMP-9, matrix metalloproteinase 9; TLR-4, Toll-like receptor 4; TNF-α, tumor necrosis factor 
alpha; HPS47, heat shock protein 47.
Table 1. 
Risk factors for spontaneous prematurity.
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the compromised immune status of the fetal membranes [55]. Histological chorio-
amnionitis (hCAM) is defined by the presence of polymorphonuclear cells (PMN) 
in the chorioamniotic membranes. Most cases of hCAM are not followed by clinical 
signals and symptoms of infection; however, the diagnosis is made in approximately 
20% of term pregnancies and over 50% of PTLs [56–58].
The main microorganisms found in the AC of pregnant women with IAI are 
Ureaplasma urealitycum, Mycoplasma hominis, and Fusobacterium sp. Gram-negative 
bacilli such as Bacteroides sp. and Prevotella sp. are also occasionally found, along 
with Escherichia coli, Gardnerella vaginalis, and group B Streptococcus [59–61].
The main mechanism by which IAI leads to prematurity is through the produc-
tion of prostaglandins. Bacteria present in amniotic fluid synthesize phospholipases 
that, in turn, activate the liberation of arachidonic acid that is metabolized via 
cyclooxygenase, culminating in the production of prostaglandins. Concomitantly, 
activation of TLRs and NLRs by PAMPs present in these bacteria initiates produc-
tion and release of inflammatory cytokines, which increase the release of prosta-
glandins by macrophage, decidual, and amniotic cells [62, 63].
PTL and PPROM pathways are similar in etiology; however, according to 
Menon et al. [64], the major difference is the presence of molecular factors 
associated with infection, such as metalloproteinases and pro-apoptotic factors 
that are responsible for structural modifications and weakening of fetal mem-
branes in patients undergoing PPROM. These same factors are absent or mini-
mally expressed in PTL. Other differences between PTL and PPROM include the 
distinct response to microorganisms present in the AC [65–67] and the intensity 
of the inflammatory response [68].
Recently, new data have demonstrated the participation of oxidative stress in 
the physiopathology of PPROM [69, 70], suggesting that this pathology is similar 
to term pregnancies with regard to degradation, apoptotic signals, oxidative stress, 
and premature aging of fetal membranes [71, 72]. Increased levels of oxidative 
stress markers have been not only associated with the third trimester of normal 
pregnancy and labor [73] but also observed during second trimester pregnancy 
disorders, such as preeclampsia and low birth weight [74]. Hence, early senes-
cence, a mechanism leading to fetal membrane aging and immunological dysfunc-
tion, is a feature of PPROM [72, 75, 76]. Risk factors for both PTL and PPROM, 
including infection-induced inflammation, may cause an increase of ROS release 
and depletion of antioxidant defenses [76, 77]. In this way, Menon suggests that 
PPROM is characterized by pronounced tissue damage resulting from oxidative 
stress and proteolysis, while PTL has minimal tissue damage [76]. The greater 
tissue damage present in PPROM may be a consequence of chronic exposure to 
oxidative stress risk factors. PTL, in turn, may result from acute oxidative stress 
associated with a better antioxidant status, a scenario in which the capacity of cell 
resistance is maintained, while the inflammatory response required for initiation 
of labor pathway is preserved. PPROM also differs from PTL in its molecular 
signature linked to senescence of fetal membranes, where premature aging and 
tissue injury cause DAMPs’ release from fetal membranes, which can also contrib-
ute to rupture and secondary invasion of microbes due to an immunocompromised 
environment. Therefore, sterile inflammation by senescent fetal tissues is also a 
major contributor to PPROM pathology. We have reported differences in antioxi-
dants, telomere length (marker of aging), F2-isoprostanes (markers of oxidative 
lipid peroxidation), and senescence-associated β-galactosidase (senescence) in 
fetal membranes and amniotic fluid between PPROM and spontaneous preterm 
births without PPROM, illustrating the molecular differences between the two 
phenotypes [75, 78, 79].
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distinct response to microorganisms present in the AC [65–67] and the intensity 
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and premature aging of fetal membranes [71, 72]. Increased levels of oxidative 
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tissue injury cause DAMPs’ release from fetal membranes, which can also contrib-
ute to rupture and secondary invasion of microbes due to an immunocompromised 
environment. Therefore, sterile inflammation by senescent fetal tissues is also a 
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births without PPROM, illustrating the molecular differences between the two 
phenotypes [75, 78, 79].
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3.2  TLRs and NLRs at the maternal-fetal interface and pregnancy complicated 
by chorioamnionitis and prematurity
Regarding the maternal-fetal interface, expression of TLRs has mainly been 
investigated in chorioamniotic membranes and the placenta. TLR-2 and TLR-4 
are able to recognize most PAMPs present in pathogens involved in AC infections, 
which are associated with precocious activation of inflammatory response in 
amniochorionic membranes. Due to this, they are evaluated in most studies con-
cerning TLR expression at maternal-fetal interface.
TLR-2 recognizes microbial lipoproteins, peptidoglycans, and lipoteichoic acid 
from Gram-positive bacteria, lipoarabinomannan from mycobacteria, zymosan 
from fungi, and hemagglutinin from smallpox virus [80]. The large capacity of 
recognition shown by TLR-2 can be explained by its ability to form heterodimers 
with TLR-1 and TLR-6. The heterodimer TLR-1/TLR-2 recognizes tri-acetylated 
lipopeptides, while TLR-2/TLR-6 recognizes zymozan and diacetylated lipopep-
tides [80, 81]. TLR-4 recognizes LPS from Gram-negative bacteria, an important 
macrophage activator and initiator of septic shock [82].
Kim et al. [83] showed increased expression of TLR-2 in chorioamniotic mem-
branes with hCAM. Our group provided the first report of increase in TLR-1 and 
TLR-2 mRNAs in fetal membranes of preterm pregnancies with hCAM, when 
compared to preterm membranes without hCAM [84]. Kumazaki et al. [32] showed 
that placental macrophages from preterm pregnancies complicated by CAM had 
increased immunoreactivity to TLR-4, when compared to those without inflamma-
tory infiltrate or term placentas. Using immunohistochemistry techniques, Rindsjö 
et al. [85] demonstrated an important reduction in TLR-2 expression in placentas in 
the setting of hCAM and reasoned that the expression of this receptor is probably 
affected by inflammatory processes in the membranes. Moreover, Kacerovsky et al. 
[86, 87] showed that pregnant women with PPROM and microbial invasion of the 
AC had higher levels of soluble TLR-1, TLR-2, TLR-4, and TLR-6 in amniotic fluid.
The expression of TLR-2 and TLR-4 by amniotic epithelium suggests that the 
epithelium not only works as a mechanical barrier against microorganisms but 
also plays an important part in the activation of innate immunity [83]. According 
to Kim et al. [83], the increased expression of these receptors in term membranes 
reinforces the association between labor and inflammation, as described by Keelan 
et al. [88]. This upregulation of TLRs may enhance maternal and fetal protection 
against microbial invasion of the AC. However, Holmlund et al. [89] did not observe 
differences in TLR-2 and TLR-4 expression between trophoblastic cells, stimulated 
with zymozan and LPS, and nonstimulated trophoblasts. A possible explanation is 
that both receptors may be overexpressed in uterine tissue as a defense mechanism, 
which can protect the fetus against infection during pregnancy and labor. Gonzalez 
et al. [90] showed that pregnant and nonpregnant mice present different TLR 
expression in their uterine tissue and that the expression of TLR-2, -3, -4, and -9 
increases throughout pregnancy. This finding is in agreement with those of Beijar 
et al. [91], who reported lower expression of TLR-4 in first trimester villi, when 
compared to term villi. The apparent disagreement among studies may reflect 
differences in response to infection in distinct sites of the placenta and gestational 
tissues.
While several studies showed that gestational tissues express TLRs and are 
capable of responding to pathogens who present TLR-specific ligands, few stud-
ies have discussed the expression of NLRs at the maternal-fetal interface during 
normal and complicated pregnancies [92–97]. Gene expression of NOD1 was 
observed in the placenta of pregnant women at term [92, 93], while first trimester 
placenta villi expressed NOD1 and NOD2 mRNA, both by syncytiotrophoblast and 
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cytotrophoblast cells [94]. This differential expression is also observed function-
ally; the first trimester trophoblast cells trigger an inflammatory response following 
exposure to the NOD1 and NOD2 protein ligands, while trophoblast cells from 
term pregnancies only respond to the NOD1 ligand [94]. Interestingly, Wang et al. 
demonstrated that expression of NOD1 and NOD 2 in placental villi and decidua 
was higher in epithelium than in tissue stroma, reinforcing the idea that epithelial 
tissues are strongly involved in the host defense response at the maternal-fetal 
interface [96].
Regarding chorioamnionitis, Romero et al. [95] observed that the expression 
of NOD2 and NLRP3 in chorioamniotic membranes was higher during labor at 
term in the presence of histologic chorioamnionitis (hCAM), than in membranes 
without hCAM; however, only the NLPR3 protein concentration was increased in 
chorioamniotic membranes in the presence of hCAM. Additionally, Pontillo et al. 
[97] observed that LPS from Gram-negative bacteria increases expression of the 
NLRP3 inflammasome in trophoblast and decidual stromal cells, suggesting that 
this multiprotein complex could be important in placental immune defense against 
invading pathogens.
4. Conclusion
Inflammation and oxidative stress are important to the success of normal 
pregnancy, and their disruption is closely related with pregnancy complications. 
Regarding inflammatory responses, special receptors of the maternal innate 
immune system are capable of responding to microbial ligands present in amniotic 
fluid during intra-amniotic infection, resulting in an exacerbation of inflamma-
tory mediator production, which is associated with the precocious activation of 
the parturition pathway. Additionally, studies have demonstrated the participation 
of oxidative stress in the physiopathology of PPROM, highlighting the similarity 
between PPROM and term pregnancies in relation to degradation and aging of fetal 
membranes. In this way, PPROM would be a consequence of notable tissue dam-
age resulting from chronic oxidative stress, while PTL would be associated with 
minimal tissue degradation, resulting from acute exposure associated with a better 
antioxidant status. This indicates that exacerbation of the maternal inflammatory 
response and oxidative stress operates in an interdependent way in the pathophysi-
ology of spontaneous preterm birth, including PTL and PPROM.
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Abstract
Early phase clinical research for drug development requires the investigation of 
safety, tolerability and efficacy of novel compounds. The latter is hampered by the 
absence of the disorder in healthy volunteers, which is why challenge models are often 
applied in order to demonstrate ‘proof of pharmacology.’ These challenge models can 
often be translatable from animal work and can inform the drug developer which 
dose, dosing regimen or application frequency should be selected prior to phase II 
studies in the target population. Furthermore, these challenge models represent well-
controlled settings to perform activity screening of the compound. The following skin 
challenge models will be reviewed in this chapter: inflammation induced by Toll-like 
receptor agonists such as imiquimod, KLH challenge, UV-B irradiation and histamine.
Keywords: skin inflammation, immune system, imiquimod, translational model, 
pruritus, drug development
1. Introduction
Drug development programs are well-established and long-lasting processes, 
taking between 10 and 15 years, from discovery to market availability. Clinical trials 
with drug candidates are the final stage in drug development programs [1, 2]. These 
clinical trials are often classified into four stages of experimentation, phase I—IV, 
which are used as a general guideline in clinical trial research for development of a 
new treatment in specific diseases, i.e., skin diseases [3]. In general, safety, toler-
ability and pharmacokinetic properties are assessed in healthy volunteers during 
phase I. The candidate drug will move on to phase II when the initial safety and 
tolerability has been determined. The main aim of phase II is to establish the safety 
and efficacy of the drug in the target population. Phase III studies involve large-
scaling testing to provide more and extended information on the effectiveness of 
the drug and on the benefits and possible adverse events. The last phase, IV, also 
known as the post marketing surveillance trials, is executed after the drug enters 
the market. The main purpose of this monitoring phase is to determine the long-
term effectiveness and patient’s quality of life and cost-effectiveness [4, 5].
Translational research focuses on the transcription of the animal model into 
humans, also known as first-in-human-dose. In general, efficacy, safety and toler-
ability are examined in the early phases of clinical research. However, the absence 
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of the disorder in healthy volunteers may hamper investigation of the above-
mentioned hallmarks of drug development. Inflammation, for example, plays 
an important role in diseases and is often an indication for a certain skin disease. 
Difficulties occur when testing drugs against inflammation in volunteers who do 
not have this condition. Therefore, pharmacological challenge models have been 
established to mimic physiological and pathophysiological conditions of several skin 
diseases. These models distort the physiological condition and lead to temporary 
effects that mimic the pathophysiology of the disease.
Table 1 gives an overview of established skin challenge models.
This approach includes translating basic scientific discoveries into clinical 
applications. Several recent developments in plaque psoriasis are noteworthy, which 
serve as an example of research with many translational aspects [42, 43]. Psoriasis 
is a chronic, inflammatory skin disease that is characterized by erythematous, itchy 
plaques covered by course scales on the extensor surface of the elbows and knees, as 
well as the scalp, dorsal hands and lumbar area. Also, the nails and joints ( psoriatic 
arthritis) can be affected [44, 45]. Psoriasis is a multifactorial disease but the 
Challenge Application Mode of action Condition induced Immune response Reference
Inflammation







Imiquimod Local under 
occlusion
TLR7 agonist Local inflammation Innate + adaptive [9–13]
LPS 
challenge + Al(OH)3
Intra dermal TLR 4 agonist Inflammatory 
response
Innate + adaptive [14, 15]
Cantharidin Paper disc with 
cantharidin
Neutrophils Local inflammation Innate [14, 16]
Injected UV killed 
E. coli







































BCG: Bacillus Calmette-Guérin; LPS challenge: lipopolysaccharide; injected UV killed E. coli: Injected ultraviolet 
killed Escherichia coli; KLH: keyhole limpet hemocyanin; UV-B: Ultraviolet B.
Table 1. 
Overview of human skin challenge models.
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hallmarks of pathophysiological pathways (Th1/Th17) with interleukin-12/23 and 
IL-17 have been clearly established as most important players. Over the last decade 
many new compounds have been in development for psoriasis yielding a total of 
11 registered, targeted monoclonal antibodies today. In these drug development 
programs in vivo models in mice are of great importance for the setup of clinical pro-
grams. These mouse models needed to be made suitable to display certain features of 
psoriasis, since mice are unable to develop psoriasis themselves [10]. This research 
resulted in development of diverse mouse models i.e., spontaneous mutation model, 
genetically engineered model, cytokine injection model and transplantation model. 
All of the mentioned animal approaches represent more or less psoriasis-like cutane-
ous characteristics. Despite expression of psoriasis like features, the models also 
have some limitations including the need for special experimental facilities and lack 
of effectiveness of anti-psoriatic drugs [46–49]. In general, animal models are far 
from perfect especially in terms of pharmaco- and toxicokinetics.
Animals are not able to predict health effects in humans better than humans 
themselves. Monkeys reflects the human being the best, however, even they can 
differ as became clear in 2016. An anti-CD28 antibody caused multiple organ 
failures in six healthy volunteers within hours, despite multiple normal tests in 
monkeys. This shows that animal models may have limited predictability for safety 
in humans. Ethical concerns with regard to need for animal testing may also be a 
factor underlining the need for pharmacological challenge models in humans [50].
This chapter will provide a detailed overview of four different, local inflam-
mation models: inflammation by Toll-like receptor agonists such as imiquimod 
(inflammation), UV-B irradiation (inflammation and pain), histamine provocation 
(itch) and KLH challenge (delayed type hypersensitivity).
2. Imiquimod skin inflammation model
Skin inflammation is a common response of our immune system to penetrating 
pathogens, skin trauma, exposure of xenobiotics, microbes and parasites [51–53]. 
Inflammation is clinically recognizable by erythema, pain, heat and swelling [54]. 
Generally, in inflamed skin, various immune cells, of both the innate and adaptive 
system are involved to combat the pathogens. However, imbalance of these immune 
cells may lead to chronic skin diseases such as psoriasis vulgaris, atopic dermatitis 
and acne vulgaris. Currently, many investigations are addressing the biomolecular 
mechanisms of inflammation; however, the pathophysiology of the skin remains 
complex and needs further investigation [55, 56].
Hence, various models in healthy volunteers were developed that mimic 
inflamed skin conditions [57]. One of the examples is the challenge model 
with topical application of imiquimod, the active ingredient of Aldara cream. 
Imiquimod is a small molecule with a low molecular weight and high lipophilicity 
which is preferable for absorption in the skin after topical administration. This 
small molecule is also a ligand for toll-like receptor seven and eight (TLR), which 
belongs to the class of immunomodulatory agents and is able to induce the produc-
tion of several cytokines (interferon-1 response) with antiviral and tumoricidal 
properties. The mechanism of action of imiquimod is complex and three main 
pathways are required including TLR signaling, inflammasome activation and 
inhibition of the adenosine receptor. However, limited information is available 
on the mechanism of imiquimod on the adenosine receptor. The first pathway 
is TLR dependent and activates nuclear factor kappa B (NF-κB) signaling via 
My-D88, which is important in an early immune response. Herewith, activation of 
c-Junk and IRAK pathways occur which are involved in the production of several 
Translational Studies on Inflammation
28
of the disorder in healthy volunteers may hamper investigation of the above-
mentioned hallmarks of drug development. Inflammation, for example, plays 
an important role in diseases and is often an indication for a certain skin disease. 
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plaques covered by course scales on the extensor surface of the elbows and knees, as 
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BCG: Bacillus Calmette-Guérin; LPS challenge: lipopolysaccharide; injected UV killed E. coli: Injected ultraviolet 
killed Escherichia coli; KLH: keyhole limpet hemocyanin; UV-B: Ultraviolet B.
Table 1. 
Overview of human skin challenge models.
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hallmarks of pathophysiological pathways (Th1/Th17) with interleukin-12/23 and 
IL-17 have been clearly established as most important players. Over the last decade 
many new compounds have been in development for psoriasis yielding a total of 
11 registered, targeted monoclonal antibodies today. In these drug development 
programs in vivo models in mice are of great importance for the setup of clinical pro-
grams. These mouse models needed to be made suitable to display certain features of 
psoriasis, since mice are unable to develop psoriasis themselves [10]. This research 
resulted in development of diverse mouse models i.e., spontaneous mutation model, 
genetically engineered model, cytokine injection model and transplantation model. 
All of the mentioned animal approaches represent more or less psoriasis-like cutane-
ous characteristics. Despite expression of psoriasis like features, the models also 
have some limitations including the need for special experimental facilities and lack 
of effectiveness of anti-psoriatic drugs [46–49]. In general, animal models are far 
from perfect especially in terms of pharmaco- and toxicokinetics.
Animals are not able to predict health effects in humans better than humans 
themselves. Monkeys reflects the human being the best, however, even they can 
differ as became clear in 2016. An anti-CD28 antibody caused multiple organ 
failures in six healthy volunteers within hours, despite multiple normal tests in 
monkeys. This shows that animal models may have limited predictability for safety 
in humans. Ethical concerns with regard to need for animal testing may also be a 
factor underlining the need for pharmacological challenge models in humans [50].
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pathogens, skin trauma, exposure of xenobiotics, microbes and parasites [51–53]. 
Inflammation is clinically recognizable by erythema, pain, heat and swelling [54]. 
Generally, in inflamed skin, various immune cells, of both the innate and adaptive 
system are involved to combat the pathogens. However, imbalance of these immune 
cells may lead to chronic skin diseases such as psoriasis vulgaris, atopic dermatitis 
and acne vulgaris. Currently, many investigations are addressing the biomolecular 
mechanisms of inflammation; however, the pathophysiology of the skin remains 
complex and needs further investigation [55, 56].
Hence, various models in healthy volunteers were developed that mimic 
inflamed skin conditions [57]. One of the examples is the challenge model 
with topical application of imiquimod, the active ingredient of Aldara cream. 
Imiquimod is a small molecule with a low molecular weight and high lipophilicity 
which is preferable for absorption in the skin after topical administration. This 
small molecule is also a ligand for toll-like receptor seven and eight (TLR), which 
belongs to the class of immunomodulatory agents and is able to induce the produc-
tion of several cytokines (interferon-1 response) with antiviral and tumoricidal 
properties. The mechanism of action of imiquimod is complex and three main 
pathways are required including TLR signaling, inflammasome activation and 
inhibition of the adenosine receptor. However, limited information is available 
on the mechanism of imiquimod on the adenosine receptor. The first pathway 
is TLR dependent and activates nuclear factor kappa B (NF-κB) signaling via 
My-D88, which is important in an early immune response. Herewith, activation of 
c-Junk and IRAK pathways occur which are involved in the production of several 
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pro-inflammatory cytokines. The second pathway is TLR independent. Imiquimod 
is able to activate the inflammasome via the NALP3 pathway, which also triggers 
an immune response and leads to production of interleukin-1β (IL-1β, a pro-
inflammatory cytokine) [10, 11, 13, 58–60].
Aldara 5% cream is registered as a topical product that is indicated for the treat-
ment of superficial basal cell carcinoma, actinic keratosis and genital and peri-anal 
warts (condyloma acuminata). Topical administration of imiquimod appears to be 
safe and reasonably tolerated according to the mouse model. This murine imiqui-
mod challenge model has been widely used to examine the mechanisms involved in 
psoriasis vulgaris, since it is simple, inexpensive and develops an acute inflamma-
tory response with psoriasiform features. However, in general, the main limitation 
of murine models is that no single mouse model is able to reflect human disease 
precisely, as the physiology and the pathophysiology of the skin differs in both 
species [61]. Therefore, recently, human studies been conducted that study skin 
inflammation after topical application of imiquimod.
Vinter et al. successfully developed an imiquimod-induced psoriasis- like skin 
inflammation model in humans by applying imiquimod topically under occlu-
sion on non-lesional psoriatic skin of the lower back. A group of patients (n = 7) 
received the treatment and vehicle for 2 days, while the other group (n = 3) received 
the same treatment for 7 days. All the treatments were applied on tape stripped 
skin resulting in perturbation of the skin barrier. After 2 days of treatment with 
imiquimod, a significant upregulation in mRNA expression was observed for the 
pro- inflammatory cytokines tumor necrosis factor a (TNF-a), IL-1β and IL-6, 
whereas TNF-a and IL-6 are keratinocyte driven cytokines. Additionally, a high 
level of IFN-γ and IL-10 was found, the latter has an important role in suppression 
of the inflammatory response in the skin, as it influences the regulatory T-cells. In 
this model, inflammation and psoriasis-like characteristics were induced; however, 
typical psoriasis lesions were not observed and therefore appear to be the main 
limitation of the study.
A different approach to study skin inflammation was established by Van 
der Kolk et al. by applying imiquimod topically to healthy volunteers under 
occlusion. A distinction between the two groups was made. The first cohort 
received a topical treatment for 24, 48 and 72 hours on the intact skin barrier, 
while the second cohort received exactly the same treatment on a compromised 
skin barrier, through tape stripping (Figure 1). In this open label, dose-ranging 
study, erythema and blood perfusion were monitored by means of erythema 
index photo analysis, erythema colorimetry, erythema visual grading and laser 
speckle contrast imaging (LSCI). A dose-dependent increase in erythema was 
observed for all measurements, with a more rapid and pronounced effect in the 
tape stripped group. This model showed no clear differences in erythema inten-
sity between the treatments after 48 and 72 hours, which is in concordance with 
observations in the murine model [9, 13]. Additionally, an increased skin perfu-
sion was found after treatment with imiquimod, however this was only observed 
in the tape stripped cohort. A similar effect was found for the biomarkers in skin 
biopsies. Tape-stripping combined with imiquimod treatment resulted in an 
upregulation of gene expression of CXCL10, MX-A, ICAM-1 and hBD-2 after 48 
and 72 hours. The same results were observed after treatment with imiquimod 
only compared to vehicle, however to a lesser extent. Imiquimod has a three-step 
mechanism, which entails an initial (24 hour), intermediate (24–72 hour) and 
late phase (>72 hour). In the intermediate phase of imiquimod, activation of 
both the innate and adaptive immune response takes place, which is character-
ized by infiltration of neutrophils, lymphocytes, and macrophages, based on the 
findings reported in the review of translational imiquimod skin inflammation 
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models [59]. In addition, histologically, infiltration of CD11+, HLA-DR, CD4+ 
and CD8+ into the dermis was observed. Increased infiltration was more pro-
nounced in the tape stripped cohort, however, no differences were observed 
between 48 and 72 hours of treatment [9].
This chapter focuses mainly on translating skin inflammation into a model that 
can be used in healthy human volunteers. In the past decades, a lot of research 
has been performed in this field; however, murine models remained the gold 
standard. Since skin inflammation plays a crucial role in skin diseases such as 
psoriasis and atopic dermatitis, Vinter et al. established a human counterpart to 
the mouse model of imiquimod- induced psoriasis like skin inflammation [13]. 
Despite the expression of different pro-inflammatory cytokines and the presence 
of psoriasis-like features, typical psoriasis lesions were not observed. However, 
this study formed the base to the inflammation model developed by Van der Kolk 
et al. where imiquimod has been applied under occlusion to challenge the skin. 
This model resulted in expression of certain cytokines and chemokines that are 
involved in activation of innate as well as adaptive immune system. Chemokines 
such as CXCL10 are expressed through activation of keratinocytes in inflamed 
skin. Expression of MX-A, a downstream interferon, which corresponds with the 
activation of plasmacytoid dendritic cells (pDCs), was also upregulated in the tape 
stripped cohort. The presence of interferons reflects the antiviral response, which 
is in concordance with the antiviral characteristics of imiquimod, used for HPV-
induced diseases [62, 63]. Based on these findings, the murine imiquimod skin 
inflammation model was translated to a safe, human model in healthy volunteers. 
Skin erythema, skin perfusion and expression of cytokines had high intensity in 
the tape stripped cohort due to the enhanced transepidermal drug delivery. This 
model is suitable as a challenge model and can be used in drug developmental 
programs where TLR 7 is involved. Currently, several drugs are under development 
targeting TLR7/8 that have anti-tumor characteristics with more than 30 leads to 
be explored within the next years [64, 65].
Figure 1. 
Overview of the treatment schedule. (a) Treatment areas 1, 2 and 3 were treated with 5 mg imiquimod 
respectively for 24, 48 and 72 hours. All treatments were applied under occlusion by a 12 mm Finn chamber. 
(b) Clinical impression of site 3 of the tape stripped cohort after 72 hours of imiquimod treatment [9]. 
Permitted for non-profit use.
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is able to activate the inflammasome via the NALP3 pathway, which also triggers 
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occlusion. A distinction between the two groups was made. The first cohort 
received a topical treatment for 24, 48 and 72 hours on the intact skin barrier, 
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study, erythema and blood perfusion were monitored by means of erythema 
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speckle contrast imaging (LSCI). A dose-dependent increase in erythema was 
observed for all measurements, with a more rapid and pronounced effect in the 
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and 72 hours. The same results were observed after treatment with imiquimod 
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nounced in the tape stripped cohort, however, no differences were observed 
between 48 and 72 hours of treatment [9].
This chapter focuses mainly on translating skin inflammation into a model that 
can be used in healthy human volunteers. In the past decades, a lot of research 
has been performed in this field; however, murine models remained the gold 
standard. Since skin inflammation plays a crucial role in skin diseases such as 
psoriasis and atopic dermatitis, Vinter et al. established a human counterpart to 
the mouse model of imiquimod- induced psoriasis like skin inflammation [13]. 
Despite the expression of different pro-inflammatory cytokines and the presence 
of psoriasis-like features, typical psoriasis lesions were not observed. However, 
this study formed the base to the inflammation model developed by Van der Kolk 
et al. where imiquimod has been applied under occlusion to challenge the skin. 
This model resulted in expression of certain cytokines and chemokines that are 
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stripped cohort. The presence of interferons reflects the antiviral response, which 
is in concordance with the antiviral characteristics of imiquimod, used for HPV-
induced diseases [62, 63]. Based on these findings, the murine imiquimod skin 
inflammation model was translated to a safe, human model in healthy volunteers. 
Skin erythema, skin perfusion and expression of cytokines had high intensity in 
the tape stripped cohort due to the enhanced transepidermal drug delivery. This 
model is suitable as a challenge model and can be used in drug developmental 
programs where TLR 7 is involved. Currently, several drugs are under development 
targeting TLR7/8 that have anti-tumor characteristics with more than 30 leads to 
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3. Models for itch: histamine and cowhage provocation
Itch, interchangeably used as pruritus, is a common skin sensation and 
together with pain are crucial symptoms in many chronic and allergic skin 
diseases. Itch can be induced by mechanical, thermal and chemical stimuli. 
Additionally, itch can lead to impairment of the skin and thereby affect a per-
son’s quality of life. Yosipovitch et al. defined different types of pruritus that 
are involved in chronic itch including pruriceptive, neuropathic, neurogenic 
and psychogenic itch. Skin inflammation, dryness, or other skin damage are the 
main factors causing pruriceptive itch and are found in diseases such as scabies, 
urticaria and insect bite reactions [66, 67]. Neuropathic itch, is usually caused by 
nerve injury and can arise at any point along the afferent pathway of the neu-
rons. This itch is observed for example after a varicella zoster infection or nerve 
trauma. Itch that is originated from activation of the central nervous system is 
called neurogenic itch. The underlying mechanism is complex since it involves 
pruriceptive itch as well. This itch is often observed in visceral disease states such 
as end state renal disease or kidney failure. The last subtype of itch is termed 
psychogenic itch. This type of itch arises with somatization and the delusional 
state of parasitophobia [66–68]. In this chapter, we will focus on pruriceptive itch 
and the translational model for it.
Generally, theories have been proposed that explained the relation between 
itch and pain. Itch is mediated through weak activation of nociceptors and stron-
ger activation would result in weak pain. This is also called, the intensity theory. 
However, further research has elucidated new aspects that explain pruriceptive 
sensory mechanism in the nervous system. This resulted in two main pathways 
including specificity and pattern theories. The specificity theory, explains that there 
are different sets of neuron fibers transferring information to the central nervous 
system which send responsive signals including itch and pain [25, 35]. The pattern 
theory stipulates that many sensory receptors and spinal cord neurons are involved 
in sensation of itch [69]. Although, the neural mechanism of pruritus has been 
investigated extensively, there remains much to be learned. Therefore, studies that 
use chemical agents to induce itch have been designed to study the sensory patterns 
of itch and pain in humans.
One of the most frequently and widely used pruritic agent, that evokes itch, is 
histamine [70]. Originally, histamine is a neurotransmitter that is associated with 
pathological processes such as inflammation, pruritus and vascular leak. Histamine 
is stored in several immune cells, basophils and mast cells and is quickly released 
after stimulation. Stimulation with histamine, triggers the unmyelinated nerve 
fibers, also known as C-fibers. A subset of C-fibers (CMi or CMh) is stimulated 
according the intensity of the stimulus. In case of histamine stimulation, sustained 
response of CMi occurs [71]. Histidine decarboxylase (HDC), an enzyme that is 
responsible for histamine production, increases through stimulation with certain 
mediators that are found in skin lesions of patients with atopic dermatitis. Hence, 
this enhancement is associated with upregulated histamine release and thus with 
increased itch sensitivity [28, 70].
Histamine has been used in literature as an important inflammatory mediator 
that is responsible for vascular and inflammatory effects [33]. In the early 1900s 
the first studies were conducted regarding the potential vascular role of histamine 
in vivo, however, only a couple of years ago a clinical study was conducted that 
investigated the cutaneous inflammatory response in human skin. Falcone et al. 
has developed an easy-to-use model to study the early stages of skin inflamma-
tion. Eighteen (18) subjects with Fitzpatrick skin type II and III received topically 
applied histamine after performing histamine iontophoresis. The subject had to 
33
Pharmacological Challenge Models in Clinical Drug Developmental Programs
DOI: http://dx.doi.org/10.5772/intechopen.85352
rate their perceived itch on visual analog scale (VAS) with 3 being the threshold 
for willingness to scratch the skin. Additionally, different skin assessments were 
performed including trans-epidermal water loss, skin redness and punch biopsy to 
process immunohistochemistry. Itch was observed up to 30 minutes after stimula-
tion with histamine iontophoresis and was above the itch threshold (VAS > 3). 
Immunohistochemistry showed an increase of the epidermal thickness, after 
72 hours of histamine iontophoresis challenge. In summary, this model can be used 
as an in vivo model to provoke local and acute skin inflammation, without having 
an impact on the barrier function. However, no data are available on cell level or 
cytokine expression profiles [29].
As was earlier described, increased production of histamine has been related to 
several skin diseases including atopic dermatitis. In addition, histamine has been 
the main prototypical pruritogen that has been used for experimental purposes. 
The working mechanism of histamine is going via G- protein coupled receptors: H1 
up and till H4. It appears that the H1 and H4 receptors play a role in the histamine 
involved itch response in mice. In humans, the involvement of other receptor 
subtypes (H2 and H3) in itch is not well-examined in literature [31, 32]. Generally, 
the classical anti-histamines bind to H1 receptor and are prescribed in patients 
suffering from atopic dermatitis. However, recent research clarifies that histamine 
pathway is not playing a major role in atopic dermatitis. Also, the clinical use of 
anti-histamines in atopic dermatitis population has been ineffective and question-
able which corroborates these findings [27, 32, 72].
Therefore, there was a need to establish an alternative itch model, relating to 
another pathway. The pruritus pathway has physiological functions such as skin 
barrier homeostasis, inflammation, itch and pain and is the protease-activated 
receptor (PAR) pathway. PARs are classified as G-protein-coupled receptors and 
consist of four members, PAR-1, PAR-2, PAR-3 and PAR-4, whereas PAR-2 pathway 
is mainly associated with skin diseases such as atopic dermatitis [26]. Papoiu et al. 
established a simple human model based on exogenously stimulation of the PAR-2 
pathway in order to provoke itch by applying Cowhage spicules. Additionally, the 
Cowhage model was compared to the traditional histamine iontophoresis model 
and the effect of the combined model (histamine iontophoresis and Cowhage) was 
observed. VAS rating was increased in both atopic dermatitis patients and healthy 
volunteers, the Cowhage and combination model compared to the histamine model, 
resulting in no synergy between the Cowhage and the combined model. This 
finding suggests that Cowhage was the major contributor of itch after stimulation 
of both pathways simultaneously [34]. The Cowhage model is simple and easy to 
use and could serve to study itch related skin diseases such as atopic dermatitis. On 
the other hand, less is known about this pathway and more research is required to 
examine the mechanism behind this model.
In conclusion, two main skin challenge models were described to provoke itch: 
histamine iontophoresis and Cowhage. Both models are suitable to use, however, 
both have a different underlying mechanism to elicit the itch sensation. Evidence-
based, induction of the PAR-2 pathway plays a major role in atopic dermatitis, 
causing pruritus, compared to the histamine model. Therefore, from a therapeutic 
point of view, drugs that inhibit PAR-2 itch pathway, could be promising, leading 
to development of a new treatment for chronic pruritus. Since less is known about 
the underlying cellular mechanism of Cowhage, it would we useful to examine 
biomarker expression, conduct different skin photography assessments and look at 
the skin vascularity flow. Furthermore, an advanced challenge study is required in 
healthy volunteers and patients with atopic dermatitis to examine and monitor the 
inflammation of both models. In addition, the efficacy of anti-histamine agents and 
PAR-2 antagonists could be evaluated as well.
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performed including trans-epidermal water loss, skin redness and punch biopsy to 
process immunohistochemistry. Itch was observed up to 30 minutes after stimula-
tion with histamine iontophoresis and was above the itch threshold (VAS > 3). 
Immunohistochemistry showed an increase of the epidermal thickness, after 
72 hours of histamine iontophoresis challenge. In summary, this model can be used 
as an in vivo model to provoke local and acute skin inflammation, without having 
an impact on the barrier function. However, no data are available on cell level or 
cytokine expression profiles [29].
As was earlier described, increased production of histamine has been related to 
several skin diseases including atopic dermatitis. In addition, histamine has been 
the main prototypical pruritogen that has been used for experimental purposes. 
The working mechanism of histamine is going via G- protein coupled receptors: H1 
up and till H4. It appears that the H1 and H4 receptors play a role in the histamine 
involved itch response in mice. In humans, the involvement of other receptor 
subtypes (H2 and H3) in itch is not well-examined in literature [31, 32]. Generally, 
the classical anti-histamines bind to H1 receptor and are prescribed in patients 
suffering from atopic dermatitis. However, recent research clarifies that histamine 
pathway is not playing a major role in atopic dermatitis. Also, the clinical use of 
anti-histamines in atopic dermatitis population has been ineffective and question-
able which corroborates these findings [27, 32, 72].
Therefore, there was a need to establish an alternative itch model, relating to 
another pathway. The pruritus pathway has physiological functions such as skin 
barrier homeostasis, inflammation, itch and pain and is the protease-activated 
receptor (PAR) pathway. PARs are classified as G-protein-coupled receptors and 
consist of four members, PAR-1, PAR-2, PAR-3 and PAR-4, whereas PAR-2 pathway 
is mainly associated with skin diseases such as atopic dermatitis [26]. Papoiu et al. 
established a simple human model based on exogenously stimulation of the PAR-2 
pathway in order to provoke itch by applying Cowhage spicules. Additionally, the 
Cowhage model was compared to the traditional histamine iontophoresis model 
and the effect of the combined model (histamine iontophoresis and Cowhage) was 
observed. VAS rating was increased in both atopic dermatitis patients and healthy 
volunteers, the Cowhage and combination model compared to the histamine model, 
resulting in no synergy between the Cowhage and the combined model. This 
finding suggests that Cowhage was the major contributor of itch after stimulation 
of both pathways simultaneously [34]. The Cowhage model is simple and easy to 
use and could serve to study itch related skin diseases such as atopic dermatitis. On 
the other hand, less is known about this pathway and more research is required to 
examine the mechanism behind this model.
In conclusion, two main skin challenge models were described to provoke itch: 
histamine iontophoresis and Cowhage. Both models are suitable to use, however, 
both have a different underlying mechanism to elicit the itch sensation. Evidence-
based, induction of the PAR-2 pathway plays a major role in atopic dermatitis, 
causing pruritus, compared to the histamine model. Therefore, from a therapeutic 
point of view, drugs that inhibit PAR-2 itch pathway, could be promising, leading 
to development of a new treatment for chronic pruritus. Since less is known about 
the underlying cellular mechanism of Cowhage, it would we useful to examine 
biomarker expression, conduct different skin photography assessments and look at 
the skin vascularity flow. Furthermore, an advanced challenge study is required in 
healthy volunteers and patients with atopic dermatitis to examine and monitor the 
inflammation of both models. In addition, the efficacy of anti-histamine agents and 
PAR-2 antagonists could be evaluated as well.
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4. Model for inflammation and pain: UV-B skin irradiation
Ultraviolet (UV) radiation is classified as a carcinogenic compound since it has 
the ability to initiate and promote malignant skin tumors. Additionally, increased 
exposure to UV radiation can lead to other skin problems such as inflammation and 
degenerative aging. UV energy is subdivided into three main classes based on physi-
cal properties: UV-A, UV-B and UV-C. UV-B can cause physiological skin alterations 
leading to a cascade of cytokine activation and resulting in an inflammatory response, 
so called “sunburn”. Furthermore, exposure to UV-B is related to the accumulation of 
epidermal keratinocytes and thereby increases the epidermal thickness. UV-B radia-
tion has an additional effect on the skin, it is able to up-regulate the production and 
the accumulation of melanin in the skin and is also linked to cancer susceptibility.
In well-controlled clinical settings, exposure to UV-B is widely used as a human 
and animal challenge model to induce local cutaneous hyperalgesia (pain) and 
inflammation. Primary hyperalgesia is induced after 24 hours and remains for more 
than 48 hours which makes the model suitable for studies where multiple dosing is 
required. The amount of UV-B radiation applied to the skin needs to be adjusted to a 
subject’s skin type, according the classification of Fitzpatrick Skin Type [73, 74].  
Hereafter, prior the start of the challenge, the Minimal Erythema Dose (MED) 
is determined and subsequently a one-, two- or threefold multiple of this dose is 
applied to the skin. After 24 hours, skin inflammation occurs.
This UV model is one of the pain models that can be used as a screening tool 
for early stage clinical drug development. However, in research, the UV model 
is used to examine the effects of anti-analgesic or local anesthetics [75, 76]. 
Recently, an article was published where the UV-B model was one of the models 
that was applied to compare the effects of several analgesic to placebo. The follow-
ing analgesic compounds were investigated in the first part: fentanyl, phenytoin, 
(S)-ketamine and placebo. For the second part of the study imipramine, prega-
balin, ibuprofen and placebo were examined. Different pharmacodynamic (PD) 
assessments were performed which are part of the pain cart including thermal 
grill, thermode testing and UV-B, electrical stimulation test, pressure stimula-
tion and cold pressure test [41]. Whilst, this study was performed to examine 
systemic effects of analgesic compounds, the topical effect of UV-B radiation was 
not determined. One article published the effects of single doses of UV-A, UV-B 
and UV-C on skin blood flow and barrier function by laser-Doppler flowmeter 
and evaporimetry. Radiation with various UV light resulted in skin inflamma-
tion characterized by erythema, however, assessed visually. Visual perception of 
erythema correlated with the increase in blood flow assessed by laser-Doppler 
flowmeter. However, UV radiation has not damaged the skin barrier function, 
since the trans- epidermal water loss was not increased. An exception formed 
the three MED, an increase in blood flow was observed after 2 weeks [38]. This 
study has examined the effects of analgesics on UV-B radiation and other models 
evoking pain, while skin inflammation occurs as well. Only a few in vivo stud-
ies attempted to examine the effect of UV-B radiation on skin inflammation. In 
general, UV-B radiation triggers the production of inflammatory cytokines in 
the human keratinocyte cell line HaCaT, including IL-1, IL-6, IL-8, IL-10 and 
TNF-a, which are leading to alterations of immune cells of the skin [39]. However, 
involvement of immune cells in skin inflammation after UV-B radiation has not 
yet been examined and monitored in healthy volunteers.
For future perspectives, the UV-B challenge model could be applied to induce 
temporarily skin inflammation that could be monitored with additional derma-
tological tests, such as multispectral imaging, thermography and laser speckle 
contrast imaging.
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5. KLH challenge
Challenge models that are described in this chapter, were mostly initiating an 
innate response, except the imiquimod challenge model. However, in auto-immune 
skin diseases, activation of the adaptive immune system is crucial as well as the 
involvement of T-cells [77]. It is quite challenging to evaluate the efficacy of novel 
drugs in healthy volunteers that target T-lymphocytes, since these are in the resting 
phase. Hence, challenge models could provide the desirable solution by activating 
autoreactive T-cell pathways in healthy volunteers. Earlier research investigated 
keyhole limpet hemocyanin (KLH) as a potential immunization candidate for 
studying the cell- mediated immune response [78]. KLH is a large molecule 
(~8000 kDa) consisting of several subtypes and has been widely used in animal and 
human research for more than 40 years to outline cellular and humoral responses 
[79–81]. Additionally, KLH can be used as a carrier protein for cancer vaccines and 
for bladder cancer immunotherapy [20, 82]. Because of the xenogeneic properties 
to the human immune system, KLH is able to promote a reliable primary immune 
response. The following administration routes are known and have been used in 
earlier research—intradermal, subcutaneous, intramuscular and inhalational  
[21, 22, 83–87]. Furthermore, KLH is considered to be clinically safe, since no 
reports are available on significant adverse events as reported in the comprehensive 
review by Harris & Markl. Only mild adverse events were reported including itch, 
rash and mild injection site reactions (soreness) [19, 88]. In summary, single dose 
immunization with KLH evokes a predictable primary T-cell dependent immune 
response. An additional intradermal dose of KLH will result in an additional 
immune response and thereby induces a delayed type IV hypersensitivity reaction 
around the site of injection [78].
Presence of erythema and induration are features of a cell-mediated immune 
response and are generally scored by visual inspection, which is a subjective 
method and may lead to significant interrater variability. Saghari et al. established 
a challenge model to activate T-cells in healthy volunteers after immunization with 
KLH, whereas both the cellular response and the delayed type hypersensitivity are 
objectively quantified. Adaptive immunity was measured by anti-KLH IgM and IgG 
blood serum level titers. Additionally, cutaneous blood perfusion, erythema and 
swelling were objectively measured by respectively laser speckle contrast imaging 
(LSCI), multispectral imaging and colorimetry. An increase in anti-KLH IgM and 
IgG was observed after intramuscular KLH administration compared to placebo. 
This was the case for the cutaneous blood perfusion quantified by LSCI and for 
the erythema and swelling quantified by multispectral imaging and colorimetry. 
So far, none of the studies have quantified induration and erythema response by 
using non-invasive instruments. This model is developed as proof-of-concept to 
determine the feasibility and to quantify the features of cell-mediated response 
[89]. Therefore, the delayed type hypersensitivity model can serve as a candidate to 
study the pharmacological and pharmacodynamic effects of immunomodulators in 
healthy volunteers.
6. Conclusion
Generally, in vivo mice models are a crucial part in pre-clinical drug develop-
mental programs, assessing safety. However, often animal models lack the disease or 
differ in morphological and physiological properties. Ethical concerns with regard 
to animal studies are an additional issue which prompts to search for new solu-
tions. Currently, safety is assessed in healthy volunteers who hamper the disease. 
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Therefore, challenge models that mimic the disease temporarily, could provide 
a possible solution and act as translational models. This chapter has provided an 
overview (Table 1) of various challenge models that are known to initiate skin 
inflammation by triggering the human immune system. First, the human imiqui-
mod challenge model was introduced as a safe and well-tolerated model to study 
temporarily induced skin inflammation by targeting the TLR7/8 receptor. The effect 
on erythema, cutaneous perfusion and biomarker expression was more pronounced 
in the group with the perturbed skin barrier due tape stripping. Nowadays, this 
imiquimod model can be applied to test agents that target TLR7/8 receptor with 
anti-tumor characteristics.
Furthermore, two models for pruritus were described focusing on two different 
mechanisms. The first model used histamine as pruritogen to evoke itch via a subset 
of C-fibers. An upregulation of HDC is associated with an increase in histamine 
release and is found in the lesions of patients suffering from atopic dermatitis. 
Anti-histamines are often prescribed against itch in patients with atopic dermatitis 
even though they are ineffective. Therefore, an alternative model was developed 
targeting the PAR-2 pathway. In this model, itch was initiated by applying Cowhage 
spicules to the forearm of healthy volunteers and patients with atopic dermatitis. 
The itch sensation was based on VAS score and EASI (in patients with atopic derma-
titis), both giving qualitative measures.
Another model that has been described in this chapter is the UV-B radiation 
model, which is used to induce pain stimulus in healthy volunteers. A couple of 
studies elucidates the occurrence of skin inflammation after UV-B radiation. 
However, no research has been done that focuses on skin inflammation in humans 
after using UV-B radiation.
The last model of this chapter triggering neo-antigen, is the KLH challenge 
model in healthy volunteers. KLH caused a delayed type IV immune response. An 
increase in cutaneous blood perfusion, erythema and swelling was observed after 
administration of KLH. This model could be used for proof-of-concept studies.
In general, all the challenge models that have been developed could be optimized 
by assessing pharmacodynamic endpoints focusing on the four pillars imaging, 
biophysical, clinical and cellular/molecular that together constitute a so-called 
‘dermatological toolbox’. For imaging, various tools can be used such as multispec-
tral imaging, 2D/3D imaging, colorimetry and optical coherence tomography. Laser 
speckle contrast imaging, trans-epidermal water loss, thermography, transdermal 
analysis patch and microbiome analyses are able to provide objective information 
on biophysical condition of the skin. For completeness of the derma toolbox it 
is recommended to include the NRS pain/itch or VAS as well as the skin histol-
ogy, immunohistochemistry and mRNA expression. This toolbox will allow us to 
develop and monitor advanced human skin challenge models that will provide a 
more holistic view and to move a step closer towards ‘systems dermatology’.
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Abstract
Obesity is defined as a BMI greater than 25 kg/m2. Once thought to simply be a 
nutritional disorder, obesity has become a major health concern characterized by a 
state of constant low-grade inflammation caused by chronic adiposity. This state of 
inflammation is characterized by circulating inflammatory mediators, such as IL-6, 
leptin, and TNF-α, as well as varying levels of glucose-regulating hormones pro-
duced by obese adipose tissue. When left untreated, obesity can lead to a number of 
diseases including, but not limited to, cardiovascular disease, metabolic syndrome, 
neurodegeneration, type II diabetes mellitus, chronic kidney disease, and infertil-
ity. The distribution of adiposity differs in men and women, and these differences, 
along with the differences in sex hormones and sex hormone levels, can exacerbate 
or attenuate the course of disease pathology. Obesity can also be exacerbated by 
stress, which can worsen disease pathogenesis. In this review, we will explore how 
obesity affects inflammation and disease and how sex can affect the course of these 
diseases.
Keywords: obesity, inflammation, sex differences, estrogen, testosterone
1. Introduction
Approximately 70% of the US adult population is considered overweight or 
obese [1]. Obesity has been associated with an elevated risk of type II diabetes, 
cancer, neurodegeneration, infertility and stress hypertension, and cardiovascular 
disease (CVD)[2, 3]. The increased risk for various health risks is due in part to the 
inflammatory adipokines produced by the adipose tissue itself. Clinically, body 
mass index (BMI) is the most widely used tool to measure adiposity. However, 
BMI measures total mass, including both fat and fat-free (lean) mass, so it is a 
poor indicator of adiposity [2]. Further, the different compartments of fat and 
different types of adipose tissue within these compartments play a major role in 
the overall increased health risks associated with increases in adiposity [4]. Lastly, 
the body composition differs between men and women; men have more lean mass 
than women, whereas women have more fat mass. In this book chapter, we help to 
unravel the differences in adipose-induced inflammation in men and women and 
how these differences may contribute to various pathophysiologies.
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2. Adipose tissue
Adipose tissue is composed of a variety of cells, including adipocytes, macro-
phages, leukocytes, endothelial cells, and fibroblasts. This metabolic tissue and 
the subsets of cells found within this tissue play a role in both the inflammatory 
and hormonal pathways. This has led many to believe that adipose tissue is a novel 
endocrine organ [5].
Classically adipocytes were believed to be either white or brown adipocytes. 
The white adipose tissue (WAT) is the adipose tissue which is often focused on 
in obesity research. The WAT is less metabolically active, is composed primarily 
of stored triglycerides, and produces adipokines which regulate hunger, satiation 
via leptin, breakdown of triglycerides via adiponectin, and insulin sensitivity via 
IL-1 and IL-6 [5]. WAT has also been associated with inflammatory adipokine 
production, including TNF-alpha, MCP-1, resistin, and IL-6 [5]. Interestingly, 
these adipokines become dysregulated in obese states which can further exacer-
bate cellular and systemic dysfunctions [6]. The increase in inflammatory cyto-
kines is a contributing factor to the various pathophysiologies discussed within 
this chapter.
Brown adipose tissue (BAT) is colored brown due to the high mitochondrial 
content. This highly metabolically active tissue also plays a role in thermogenesis, 
classically in neonates, and in lipid breakdown [7]. Key features of BAT include 
the high levels of mitochondria and the presence of uncoupling protein 1 (UCP-
1), which both play a role in the “extraction” of nutrients from free fatty acids 
and triglycerides [8, 9]. Recent studies have shown that BAT is not only found in 
neonates but can also be found in adults. A study conducted in males and females 
using PET-CT scans detected BAT tissue in the fascial plane in the ventral trunk and 
superficial and lateral sternocleidomastoid muscles [10]. Further, this study showed 
that there were differences in BAT mass in males and females, with females having 
more BAT than males. There was also an inverse correlation in BAT detection with 
age and BMI in older patients [10]. The data of this study suggest that shifting WAT 
to BAT also known as “beiging WAT” or increasing BAT production may be an effec-
tive treatment against obesity [11].
3. Sex differences in hormones and adipose tissue
The sex hormones, most notably testosterone (androgen) in males and estrogen 
and progesterone in females, play a role in fat deposition, metabolism, and energy 
balance within their respective sex. We will briefly discuss the specific roles of the 
sex hormones as they relate to adipose tissue. Estrogen has been shown to have both 
anti-inflammatory and antioxidant properties and can regulate metabolism [12]. 
Much of the data supporting estrogen as a protective factor comes from differences 
observed between pre- and postmenopausal women, where women in the pre-
menopausal phase are protected against many cardiometabolic diseases, until they 
reach the menopausal period, where there is an increase in CVDs, inflammation, 
and weight gain [13]. Low testosterone levels in men have also been associated as 
a risk factor for pathophysiologies, including sexual dysfunction, CVD, insulin 
sensitivity, and type II diabetes [14].
Conversely, high levels of estrogen in men and high levels of testosterone in 
women have been shown to have negative effects on weight gain [15]. High levels of 
testosterone, seen in women with polycystic ovarian syndrome (PCOS), or low lev-
els of estrogen seen in postmenopausal women have been linked to increased weight 
gain, specifically in the intra-abdominal fat [16]. Further, in men, testosterone 
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replacement, when there are low levels of testosterone, has been shown to increase 
lean body mass and improve lipid and cholesterol levels [17, 18].
More recent studies have shown that while both estrogen and androgens are 
important for many physiological processes, the estrogen to androgen ratio is 
important in regulating adipose tissue deposition. Interestingly in a study looking 
at the effects of testosterone replacement therapy, men with the lowest levels of 
estrogen (<10 pg./mL) had the largest decrease in body fat reduction after 6 months 
of testosterone therapy [19]. An important step in the production of estrogen is the 
enzyme aromatase, which converts testosterone to estrogen. Both male and female 
aromatase null mice exhibited increased weight gain and obesity-related metabolic 
complications [20]. Together, these data suggest that both estrogen and testosterone 
play an important role in regulating obesity and adiposity.
As stated previously, the body composition differs between men and women. 
Men are more likely to accumulate adipose tissue around the trunk and abdomen, 
whereas women usually accumulate adipose tissue around the hips and thighs  
[21, 22]. Women have a higher percentage of body fat than lean fat when compared 
to men who have the same BMI. Therefore, the health consequences are different 
for each gender at the same BMI [21]. In addition, a higher portion of that fat is 
in the femoral-gluteal region as compared to the abdominal region for men [22]. 
Studies have shown that the relative distribution of fat has a greater impact on 
CVD risks than total excess body fat. The female pattern of fat distribution, around 
the femoral-gluteal area, is relatively protective, compared to the male pattern of 
abdominal fat accumulation [23–25].
Within the abdomen, fat can accumulate in the subcutaneous area, subcutaneous 
adipose tissue (SAT), or, in the deep abdomen, visceral adipose tissue (VAT). Both 
VAT and SAT, in the obese state, produce increased inflammatory cytokines, includ-
ing TNF-α and IL-6, which produce increased levels of leptin and decreased levels 
of adiponectin [26, 27]. These changes can cause further inflammatory cascades, 
including inducing proinflammatory macrophages into the adipose tissue (Figure 1). 
Figure 1. 
The effects of lean vs. obese adipose tissue. A healthy diet and exercise are characterized by lean adipose 
tissue. Lean adipose tissue aids in regulating inflammation by secreting anti-inflammatory cytokines as well 
as secreting high levels of adiponectin which aids in insulin sensitivity [27]. Leaner adipose tissue also secretes 
low levels of leptin and resistin. Conversely, obese adipose tissue release high levels of resistin and leptin 
which promote insulin insensitivity. Obese adipose tissue also exhibits a proinflammatory cytokine profile 
which can lead to diseases such as diabetes and neurodegeneration. Men tend to have a greater ratio of lean 
to obese adipose tissue since they have greater muscle mass compared to women who have more obese adipose 
tissue [28].
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These inflammatory cells exacerbate adipose tissue cytokine production or increase 
disease risks, which can further feed into this cycle.
Multiple studies have also shown that VAT is associated with a higher cardiovas-
cular risk [24, 25]. Since the VAT has primarily been associated with the abdominal 
region, the VAT has historically played a more pathogenic role in male pathology. 
Because of the high rate of obesity in the United States, and the increased VAT 
deposition seen in both men and women, we understand that VAT deposition also 
increases risks in females. Therefore, more therapeutic interventions are needed to 
inhibit VAT deposition in both men and women.
4. Gender-specific differences in aging due to inflammation
Considerable amounts of data indicate that sex-specific differences in both 
acute and chronic inflammatory responses exist between males and females across 
multiple species and that these differences are altered with advancing age. Various 
studies suggest that these sex-specific variances include differences in multiple 
inflammatory biomarkers, including TNF-alpha, IL-6, IL-10, and C-reactive 
protein (CRP)[29]. While it appears clear that variations between the sexes do exist 
and these variations change with aging, the exact fluctuations in inflammatory 
biomarkers, both between sexes and with aging, are not fully elucidated.
Complicating matters is the established role of adipose tissue as a source of both 
pro- and anti-inflammatory cytokines. Leptin, adiponectin, and other cytokines 
synthesized and secreted by adipose tissue have been shown to play a profound role 
in modulating both systemic and localized inflammatory reactions. Adipose tissue 
likely plays a role as a source of pro- and anti-inflammatory cytokines and since, 
as previously described, males and  females accumulate adipose tissue in different/ 
store body fat in different locations, the adipose tissue plays an important role in the 
sex-specific differences in inflammatory responses, especially with aging.
Another complicating factor regarding inflammatory responses between males 
and females is the potential role of steroid hormones in various sex-specific physi-
ological responses, including accumulation and storage of adipose tissue, and 
inflammation. Estrogen has been shown to have potent anti-inflammatory activity 
and cardioprotective effects in females, and as estrogen levels decline with age after 
the onset of menopause, these protective effects of estrogen are minimized [12, 30]. 
While much has been determined, further study into the sex-specific differences 
between males and females, how these levels change over time with aging in a sex-
specific manner, and the role that these levels and their changes play in both acute 
and chronic diseases are warranted.
Many biomarkers of inflammation have been investigated regarding adiposity, 
age, sex, and ethnic variations. The most studied biomarkers include C-reactive 
protein (CRP), interleukin-6 (IL-6), interleukin-10 (IL-10), tumor necrosis factor 
alpha (TNF-alpha). Data from a meta-analysis investigating potential relationships 
between the adipose tissue-derived cytokines leptin and adiponectin and inflam-
matory biomarkers including CRP, IL-6, and TNF-alpha suggested a positive 
correlation between leptin and all three inflammatory biomarkers, whereas there 
was a negative correlation with respect to adiponectin and the biomarkers [31]. 
When adjusted for age, Grassman et al. observed that correlations weakened as the 
age of the participants increased. In contrast to other studies, the authors found no 
significant differences when looking at sex and inflammatory markers in relation 
to adipose tissue. In another study aimed at elucidating mechanisms responsible 
for differences in inflammatory responses across sexes, Wegner et al. found that 
proinflammatory responses to endotoxin in women were greater compared to 
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men, with significantly higher increases in plasma TNF-alpha and IL-6 [32]. 
Interestingly, increases in circulating plasma cortisol levels were also found to be 
significantly elevated in women as compared to men, which could play a role in the 
heightened response.
In contrast Kuo et al. used endotoxin exposure in young (5–6 weeks) versus 
adult (9–10 weeks) male and female mice to investigate relationships in the inflam-
matory responses in these groups [33]. Older male mice showed significantly 
higher levels of pro-inflammatory markers IL-6, IL-10, and TNF-alpha than age-
matched female mice upon stimulation with endotoxin. In younger mice, however, 
they did not find a gender-specific difference in these same biomarkers. An investi-
gation of factors associated with biomarkers of systemic inflammation using age-, 
sex-, and body mass index (BMI)-adjusted linear regression found an age-related 
effect on the markers. They examined multiple factors in relation to inflammatory 
biomarkers including CRP, IL1β, IL6, IL8, and TNFα in adults between the ages of 
50 and 76 years. The results of this study indicated that age influenced circulating 
concentrations of all biomarkers except IL1β, with increasing age being associated 
with higher concentrations of all other biomarkers tested [34]. When they looked 
at sex-specific differences, the results were varied, with CRP and IL-6 levels being 
lower among men.
In looking at sex-specific differences of oxidative stress and inflammation 
with regard to cardiovascular risk factors in Arab populations, Khadir et al. found 
that females had higher levels of reactive oxygen species (ROS) and CRP after 
adjustment for body mass index (BMI) and waist circumference [35]. Conversely, 
males had increased levels of IL-6, IL-8, and TNF-alpha. In order to look at the 
relative impact of central obesity versus general obesity, the authors adjusted for 
age, BMI, and gender and noted that the levels of IL-6, TNF-alpha, and ROS were 
associated with central obesity but not general obesity, further suggesting that 
sex-specific patterns of adipose distribution can potentially account for some of 
the observed sex-specific differences in males versus females. The authors con-
cluded that the relative contribution of inflammation and oxidative stress to CVD 
in Arab populations was linked, at least in part, to gender-specific distributions of 
body fat [35].
5. Sex differences in obesity-induced inflammation in pathology
While it is well known that obesity is a risk factor for many diseases, it is impor-
tant to understand that the chronic state of inflammation associated with obesity 
further exacerbates obesity itself. Therefore, in many cases, obesity and inflamma-
tion increase pathophysiology, and these pathophysiologies further exacerbate the 
inflammation and obesity in a continuous vicious cycle. It is important to under-
stand the role of sex and the sex hormones in this vicious cycle in order for better/
more effective treatments and treatment plans for obese patients with various 
pathophysiologies. Below we describe the role of the sex hormones on obesity-
induced inflammation in metabolic syndrome, CVD, type II diabetes, chronic 
kidney disease (CKD), neurodegeneration, cancer, infertility, and stress.
5.1 Metabolic syndrome
Metabolic syndrome (MetS), also known as syndrome x, is a health condition 
characterized by insulin resistance, glucose intolerance, hypertension, high triglyc-
erides, low HDL cholesterol, abdominal obesity, dyslipidemia, and inflammation 
[36]. The increased incidence of MetS has been linked to obesity and a lack of 
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These inflammatory cells exacerbate adipose tissue cytokine production or increase 
disease risks, which can further feed into this cycle.
Multiple studies have also shown that VAT is associated with a higher cardiovas-
cular risk [24, 25]. Since the VAT has primarily been associated with the abdominal 
region, the VAT has historically played a more pathogenic role in male pathology. 
Because of the high rate of obesity in the United States, and the increased VAT 
deposition seen in both men and women, we understand that VAT deposition also 
increases risks in females. Therefore, more therapeutic interventions are needed to 
inhibit VAT deposition in both men and women.
4. Gender-specific differences in aging due to inflammation
Considerable amounts of data indicate that sex-specific differences in both 
acute and chronic inflammatory responses exist between males and females across 
multiple species and that these differences are altered with advancing age. Various 
studies suggest that these sex-specific variances include differences in multiple 
inflammatory biomarkers, including TNF-alpha, IL-6, IL-10, and C-reactive 
protein (CRP)[29]. While it appears clear that variations between the sexes do exist 
and these variations change with aging, the exact fluctuations in inflammatory 
biomarkers, both between sexes and with aging, are not fully elucidated.
Complicating matters is the established role of adipose tissue as a source of both 
pro- and anti-inflammatory cytokines. Leptin, adiponectin, and other cytokines 
synthesized and secreted by adipose tissue have been shown to play a profound role 
in modulating both systemic and localized inflammatory reactions. Adipose tissue 
likely plays a role as a source of pro- and anti-inflammatory cytokines and since, 
as previously described, males and  females accumulate adipose tissue in different/ 
store body fat in different locations, the adipose tissue plays an important role in the 
sex-specific differences in inflammatory responses, especially with aging.
Another complicating factor regarding inflammatory responses between males 
and females is the potential role of steroid hormones in various sex-specific physi-
ological responses, including accumulation and storage of adipose tissue, and 
inflammation. Estrogen has been shown to have potent anti-inflammatory activity 
and cardioprotective effects in females, and as estrogen levels decline with age after 
the onset of menopause, these protective effects of estrogen are minimized [12, 30]. 
While much has been determined, further study into the sex-specific differences 
between males and females, how these levels change over time with aging in a sex-
specific manner, and the role that these levels and their changes play in both acute 
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Many biomarkers of inflammation have been investigated regarding adiposity, 
age, sex, and ethnic variations. The most studied biomarkers include C-reactive 
protein (CRP), interleukin-6 (IL-6), interleukin-10 (IL-10), tumor necrosis factor 
alpha (TNF-alpha). Data from a meta-analysis investigating potential relationships 
between the adipose tissue-derived cytokines leptin and adiponectin and inflam-
matory biomarkers including CRP, IL-6, and TNF-alpha suggested a positive 
correlation between leptin and all three inflammatory biomarkers, whereas there 
was a negative correlation with respect to adiponectin and the biomarkers [31]. 
When adjusted for age, Grassman et al. observed that correlations weakened as the 
age of the participants increased. In contrast to other studies, the authors found no 
significant differences when looking at sex and inflammatory markers in relation 
to adipose tissue. In another study aimed at elucidating mechanisms responsible 
for differences in inflammatory responses across sexes, Wegner et al. found that 
proinflammatory responses to endotoxin in women were greater compared to 
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men, with significantly higher increases in plasma TNF-alpha and IL-6 [32]. 
Interestingly, increases in circulating plasma cortisol levels were also found to be 
significantly elevated in women as compared to men, which could play a role in the 
heightened response.
In contrast Kuo et al. used endotoxin exposure in young (5–6 weeks) versus 
adult (9–10 weeks) male and female mice to investigate relationships in the inflam-
matory responses in these groups [33]. Older male mice showed significantly 
higher levels of pro-inflammatory markers IL-6, IL-10, and TNF-alpha than age-
matched female mice upon stimulation with endotoxin. In younger mice, however, 
they did not find a gender-specific difference in these same biomarkers. An investi-
gation of factors associated with biomarkers of systemic inflammation using age-, 
sex-, and body mass index (BMI)-adjusted linear regression found an age-related 
effect on the markers. They examined multiple factors in relation to inflammatory 
biomarkers including CRP, IL1β, IL6, IL8, and TNFα in adults between the ages of 
50 and 76 years. The results of this study indicated that age influenced circulating 
concentrations of all biomarkers except IL1β, with increasing age being associated 
with higher concentrations of all other biomarkers tested [34]. When they looked 
at sex-specific differences, the results were varied, with CRP and IL-6 levels being 
lower among men.
In looking at sex-specific differences of oxidative stress and inflammation 
with regard to cardiovascular risk factors in Arab populations, Khadir et al. found 
that females had higher levels of reactive oxygen species (ROS) and CRP after 
adjustment for body mass index (BMI) and waist circumference [35]. Conversely, 
males had increased levels of IL-6, IL-8, and TNF-alpha. In order to look at the 
relative impact of central obesity versus general obesity, the authors adjusted for 
age, BMI, and gender and noted that the levels of IL-6, TNF-alpha, and ROS were 
associated with central obesity but not general obesity, further suggesting that 
sex-specific patterns of adipose distribution can potentially account for some of 
the observed sex-specific differences in males versus females. The authors con-
cluded that the relative contribution of inflammation and oxidative stress to CVD 
in Arab populations was linked, at least in part, to gender-specific distributions of 
body fat [35].
5. Sex differences in obesity-induced inflammation in pathology
While it is well known that obesity is a risk factor for many diseases, it is impor-
tant to understand that the chronic state of inflammation associated with obesity 
further exacerbates obesity itself. Therefore, in many cases, obesity and inflamma-
tion increase pathophysiology, and these pathophysiologies further exacerbate the 
inflammation and obesity in a continuous vicious cycle. It is important to under-
stand the role of sex and the sex hormones in this vicious cycle in order for better/
more effective treatments and treatment plans for obese patients with various 
pathophysiologies. Below we describe the role of the sex hormones on obesity-
induced inflammation in metabolic syndrome, CVD, type II diabetes, chronic 
kidney disease (CKD), neurodegeneration, cancer, infertility, and stress.
5.1 Metabolic syndrome
Metabolic syndrome (MetS), also known as syndrome x, is a health condition 
characterized by insulin resistance, glucose intolerance, hypertension, high triglyc-
erides, low HDL cholesterol, abdominal obesity, dyslipidemia, and inflammation 
[36]. The increased incidence of MetS has been linked to obesity and a lack of 
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physical activity [37]. According to the Centers for Disease Control (CDC), a review 
of the NHANES data shows that as of 2012 more than one-third of US adults were 
considered to have MetS [38]. MetS affects over 30% of people by the time they 
reach age 65, and these statistics are expected to rise in the upcoming years [26]. By 
simply losing 5–10% of body weight, risk of developing metabolic syndrome, CVD, 
and type 2 diabetes is reduced significantly [26]. This emphasizes that prevention, 
rather than treatment, is the key to reducing the prevalence of metabolic syndrome 
in those at risk and those who are pre-symptomatic.
Diagnostic criteria for metabolic syndrome vary among organizations but typi-
cally include blood pressure, a large waist circumference, and the following: high 
levels of triglycerides and blood glucose and low levels of high-density lipoprotein 
cholesterol [26, 37, 39]. Previous diagnoses relied on body mass index; however, this 
has recently shifted to favor waist circumference because of its role in identifying 
central/abdominal obesity [36]. As previously described in this chapter, abdominal/
central obesity, with increased VAT, has been associated with increased risks for 
disease and inflammation.
Interestingly, there is no difference in prevalence of MetS between men and 
women, but there are differences in symptoms among men and women; women are 
more likely to have abdominal obesity, whereas men have more varied symptoms 
[36]. As previously described, intra-abdominal obesity is not classically associ-
ated with women and, therefore, may play a more pronounced role in this gender. 
Further, it has been shown that women throughout their lives have consistently 
higher levels of adiponectin which increases insulin sensitivity and leptin, which 
signals fullness to the brain than males. This implies that the adipose tissue in 
women produces adipokines which play a role in female adipose deposition and 
regulation [40–43].
It is well known that brown adipose tissue (BAT) is characterized by the expres-
sion of UCP-1 which causes an increase in mitochondrial function and metabolism 
[44, 45]. UCP-1 has been linked to the “beiging of WAT” and a more metabolically 
active tissue. Further, in oxidative phosphorylation, genes, responsible for assisting 
in transcriptional activation in the mitochondria, have increased levels of expres-
sion in women [41]. The upregulation of this UCP-1 and increases in oxidative 
phosphorylation genes indicate that women express more metabolically active fat 
mass in comparison to men. Understanding that women have more metabolically 
active fat may help to explain the differing symptoms seen in MetS between men 
and women.
MetS and obesity can induce changes in gene expression. PPAR γ is one of 
the hormone receptors responsible for regulating adipocyte differentiation and 
lipolysis. Genetic SNP predispositions within this receptor, which are found 
in women, have been linked to increased susceptibility for obesity and insulin 
resistance [46] Estrogen can also activate a variety of metabolism genes, which 
play a role in the increased fat metabolism in humans and rodents [44, 47]. 
Women in the postmenopausal period, when estrogen levels have decreased, 
have a higher incidence in central adiposity and a higher risk for developing MetS 
[48]. Contrastingly, throughout life men have larger muscle mass and less free fat 
in organs that are highly metabolically active like the kidneys, liver, and brain. 
Males are more likely than women to experience an increase in incidence of 
diabetes due to decreases in insulin sensitivity [46]. Men also have lower expres-
sion of oxidative phosphorylation genes and brown adipose tissue, as indicated 
by UCP1, compared to women [49]. Taken together, these data support the idea 
that men and women present with different symptoms of metabolic syndrome 
and, therefore, may need different treatments for MetS consistent with these 
symptoms.
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5.2 Cardiovascular disease
According to the American Heart Association, CVD is a term that encompasses 
many conditions including heart disease, heart valve issues, heart failure, and 
stroke. CVD is the leading cause of death for a variety of US ethnic populations 
[50]. Risk factors include metabolic syndrome, high blood lipid and glucose levels, 
high blood pressure, central/abdominal adiposity, low HDL, and high LDL choles-
terol [46]. Further, there are differences in the prevalence of CVD among race, sex, 
and hormone levels [50]. Classically, men have higher levels of CVD than women, 
until women reach the postmenopausal period, the sixth decade of life, where 
women have similar or higher incidence of CVD than males of the same age [50].
Obesity, specifically abdominal adiposity, is a main risk factor for CVD. The 
Framingham Heart Study, a long-term observational study, determined that obesity 
increases cardiovascular disorders by 64% for women and 46% for men [51]. 
Further, Garcia et al. have shown that obesity more greatly impacts women’s risk 
and incidence of CVD than men [52]. Therefore, reducing and preventing obesity 
could be a critical method for mitigating cardiovascular-related disorders in both 
men and women.
Fat accumulation of the neck has been found to be a strong predictor of CVD 
[53]. Fat accumulation is usually estimated via the measuring the neck circumfer-
ence. In contrast to the well-defined and studied compartments and sex differences 
in accumulation with the abdominal fat deposition, less is known about these 
factors in the neck. In one retrospective study, overweight and obese women have 
more subcutaneous neck fat compared to men even after age and BMI matching. 
In the same study, subcutaneous neck fat was associated with higher incidence of 
metabolic risk than intermuscular fat deposits in both sexes [54]. This suggests 
that similar to abdominal fat, women have more subcutaneous fat and men more 
intermuscular fat in the neck.
Obesity creates an inflammatory state of the body that affects heart health. 
However, the overall effects may differ among the sexes based on sex hormone 
activity. Men have a higher overall incidence of death due to CVD [50]. The X 
chromosome in men upregulates the expression of genes responsible for functions 
of cell death mechanisms and cellular trafficking/migration, while the Y chromo-
some is responsible for genes involved in innate immunity activation. Activating 
the innate immune system, specifically the immune cell, the macrophages, induces 
inflammation and increases the risk for developing atherosclerosis [46]. Therefore, 
by inheriting a Y chromosome, men increase their genetic risk for developing 
CVD. Data suggests that testosterone does not confer any protection against obesity, 
inflammation, and CVD [46].
Levels of the sex hormone estrogen do not appear to affect men as severely as 
women [46]. It is hypothesized that the gender difference of varying estrogen levels 
only becomes evident in postmenopausal women who have lower levels of this sex 
hormone. Treatment and prevention methods using statins for CVD have been 
targeted more at men than women, as deemed appropriate by the American Heart 
Association. However, guidelines have recently been tailored to be more gender-
inclusive based on cardiovascular risk factor assessments [52]. Sex differences 
attributed to genetic factors and lifestyle habits lead women to be more susceptible 
to CVD with elevated risk if preventative methods are not taken. Sex differences in 
CVD arise as the result of a combination of effects from various genetic and envi-
ronmental factors.
Another important sex difference in CVD is the effect of the sex hormone 
estrogen. Circulating levels of estrogen fluctuate during a woman’s life span and can 
regulate inflammation. Inflammation increases cardiovascular risk, as indicated 
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physical activity [37]. According to the Centers for Disease Control (CDC), a review 
of the NHANES data shows that as of 2012 more than one-third of US adults were 
considered to have MetS [38]. MetS affects over 30% of people by the time they 
reach age 65, and these statistics are expected to rise in the upcoming years [26]. By 
simply losing 5–10% of body weight, risk of developing metabolic syndrome, CVD, 
and type 2 diabetes is reduced significantly [26]. This emphasizes that prevention, 
rather than treatment, is the key to reducing the prevalence of metabolic syndrome 
in those at risk and those who are pre-symptomatic.
Diagnostic criteria for metabolic syndrome vary among organizations but typi-
cally include blood pressure, a large waist circumference, and the following: high 
levels of triglycerides and blood glucose and low levels of high-density lipoprotein 
cholesterol [26, 37, 39]. Previous diagnoses relied on body mass index; however, this 
has recently shifted to favor waist circumference because of its role in identifying 
central/abdominal obesity [36]. As previously described in this chapter, abdominal/
central obesity, with increased VAT, has been associated with increased risks for 
disease and inflammation.
Interestingly, there is no difference in prevalence of MetS between men and 
women, but there are differences in symptoms among men and women; women are 
more likely to have abdominal obesity, whereas men have more varied symptoms 
[36]. As previously described, intra-abdominal obesity is not classically associ-
ated with women and, therefore, may play a more pronounced role in this gender. 
Further, it has been shown that women throughout their lives have consistently 
higher levels of adiponectin which increases insulin sensitivity and leptin, which 
signals fullness to the brain than males. This implies that the adipose tissue in 
women produces adipokines which play a role in female adipose deposition and 
regulation [40–43].
It is well known that brown adipose tissue (BAT) is characterized by the expres-
sion of UCP-1 which causes an increase in mitochondrial function and metabolism 
[44, 45]. UCP-1 has been linked to the “beiging of WAT” and a more metabolically 
active tissue. Further, in oxidative phosphorylation, genes, responsible for assisting 
in transcriptional activation in the mitochondria, have increased levels of expres-
sion in women [41]. The upregulation of this UCP-1 and increases in oxidative 
phosphorylation genes indicate that women express more metabolically active fat 
mass in comparison to men. Understanding that women have more metabolically 
active fat may help to explain the differing symptoms seen in MetS between men 
and women.
MetS and obesity can induce changes in gene expression. PPAR γ is one of 
the hormone receptors responsible for regulating adipocyte differentiation and 
lipolysis. Genetic SNP predispositions within this receptor, which are found 
in women, have been linked to increased susceptibility for obesity and insulin 
resistance [46] Estrogen can also activate a variety of metabolism genes, which 
play a role in the increased fat metabolism in humans and rodents [44, 47]. 
Women in the postmenopausal period, when estrogen levels have decreased, 
have a higher incidence in central adiposity and a higher risk for developing MetS 
[48]. Contrastingly, throughout life men have larger muscle mass and less free fat 
in organs that are highly metabolically active like the kidneys, liver, and brain. 
Males are more likely than women to experience an increase in incidence of 
diabetes due to decreases in insulin sensitivity [46]. Men also have lower expres-
sion of oxidative phosphorylation genes and brown adipose tissue, as indicated 
by UCP1, compared to women [49]. Taken together, these data support the idea 
that men and women present with different symptoms of metabolic syndrome 
and, therefore, may need different treatments for MetS consistent with these 
symptoms.
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5.2 Cardiovascular disease
According to the American Heart Association, CVD is a term that encompasses 
many conditions including heart disease, heart valve issues, heart failure, and 
stroke. CVD is the leading cause of death for a variety of US ethnic populations 
[50]. Risk factors include metabolic syndrome, high blood lipid and glucose levels, 
high blood pressure, central/abdominal adiposity, low HDL, and high LDL choles-
terol [46]. Further, there are differences in the prevalence of CVD among race, sex, 
and hormone levels [50]. Classically, men have higher levels of CVD than women, 
until women reach the postmenopausal period, the sixth decade of life, where 
women have similar or higher incidence of CVD than males of the same age [50].
Obesity, specifically abdominal adiposity, is a main risk factor for CVD. The 
Framingham Heart Study, a long-term observational study, determined that obesity 
increases cardiovascular disorders by 64% for women and 46% for men [51]. 
Further, Garcia et al. have shown that obesity more greatly impacts women’s risk 
and incidence of CVD than men [52]. Therefore, reducing and preventing obesity 
could be a critical method for mitigating cardiovascular-related disorders in both 
men and women.
Fat accumulation of the neck has been found to be a strong predictor of CVD 
[53]. Fat accumulation is usually estimated via the measuring the neck circumfer-
ence. In contrast to the well-defined and studied compartments and sex differences 
in accumulation with the abdominal fat deposition, less is known about these 
factors in the neck. In one retrospective study, overweight and obese women have 
more subcutaneous neck fat compared to men even after age and BMI matching. 
In the same study, subcutaneous neck fat was associated with higher incidence of 
metabolic risk than intermuscular fat deposits in both sexes [54]. This suggests 
that similar to abdominal fat, women have more subcutaneous fat and men more 
intermuscular fat in the neck.
Obesity creates an inflammatory state of the body that affects heart health. 
However, the overall effects may differ among the sexes based on sex hormone 
activity. Men have a higher overall incidence of death due to CVD [50]. The X 
chromosome in men upregulates the expression of genes responsible for functions 
of cell death mechanisms and cellular trafficking/migration, while the Y chromo-
some is responsible for genes involved in innate immunity activation. Activating 
the innate immune system, specifically the immune cell, the macrophages, induces 
inflammation and increases the risk for developing atherosclerosis [46]. Therefore, 
by inheriting a Y chromosome, men increase their genetic risk for developing 
CVD. Data suggests that testosterone does not confer any protection against obesity, 
inflammation, and CVD [46].
Levels of the sex hormone estrogen do not appear to affect men as severely as 
women [46]. It is hypothesized that the gender difference of varying estrogen levels 
only becomes evident in postmenopausal women who have lower levels of this sex 
hormone. Treatment and prevention methods using statins for CVD have been 
targeted more at men than women, as deemed appropriate by the American Heart 
Association. However, guidelines have recently been tailored to be more gender-
inclusive based on cardiovascular risk factor assessments [52]. Sex differences 
attributed to genetic factors and lifestyle habits lead women to be more susceptible 
to CVD with elevated risk if preventative methods are not taken. Sex differences in 
CVD arise as the result of a combination of effects from various genetic and envi-
ronmental factors.
Another important sex difference in CVD is the effect of the sex hormone 
estrogen. Circulating levels of estrogen fluctuate during a woman’s life span and can 
regulate inflammation. Inflammation increases cardiovascular risk, as indicated 
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by increased levels of C-reactive protein [52]. CRP is both an inflammatory protein 
and an important biomarker of cardiovascular damage. It is hypothesized that 
the higher levels of systemic estrogen, associated with pre-menopausal women, 
have been shown to have a cardioprotective effect and reduce inflammation. The 
Women’s Health Initiative designed a study to determine the possible use of hor-
mone therapy as a preventative measure against CVD in postmenopausal women. 
The initial trials were ended early due by the Data Safety Monitoring Board (DSMB) 
due to the increased incidence of stroke and breast cancer in the estrogen + pro-
gesterone arm of the trial [55]. Further analysis of this randomized control study 
ultimately provided evidence for a concept known as the “timing hypothesis.” This 
hypothesis states that hormone replacement therapy near the onset of menopause, 
within 5 years, may lower the risk for CVD, while MHT treatment in women greater 
than 5 years from menopause is harmful [56]. The timing hypothesis has had an 
important impact in clinical settings [30].
Traditional CVD risk factors that are increased for women include lack of physi-
cal activity, smoking, diabetes, obesity, dyslipidemia, and hypertension. Many of 
these risk factors are highly prevalent in the United States, meaning comorbidities 
are associated with CVD. For example, every two in three adults are overweight or 
obese, highly increasing their risk to develop CVD as well as other conditions [52]. 
These risk factors are preventable and reducible by means of lifestyle changes such 
as eating a healthy diet and maintaining exercise. Some nontraditional risk factors 
for women CVD include the following: depression, autoimmune diseases, treatment 
for breast cancer, hypertensive pregnancy disorders, gestational diabetes, delivering 
a preterm child, and ischemic heart disease [52]. It is hypothesized that women with 
ischemic heart disease have higher mortality rates and worse CVD outcomes than 
men due to insufficient detection and treatment options.
One method to improve adipose deposition detection is through imaging, as 
advancements in technology have allowed for detailed assessment of subcutaneous 
and visceral fat compartments. Computed topography (CT) and magnetic reso-
nance imaging (MRI) are considered the gold standard for detailed assessment of 
body composition. However, these tests are expensive, not readily available, and, in 
the case of CT, associated with a significant dose of radiation. Dual-energy X-ray 
absorptiometry (DXA) is a technique used for osteoporosis screening and more 
readily available and less expensive and has relatively minimal radiation exposure. 
Therefore, it is more often used as it is able to assess body composition, such as 
fat and lean mass, and can quantify VAT and SAT accurately in obese patients 
[57, 58]. Fox et al. examined over 3000 subjects from the Framingham Heart 
Cohort who underwent CT of the abdomen [59]. They demonstrated a significant 
association between abdominal SAT and VAT in men and women and increased 
risk of hypertension, diabetes mellitus type 2, and metabolic syndrome. There 
was a stronger correlation with VAT and most of the cardiovascular risk factors. 
Interestingly, there were significant sex interactions with increasing volumes of SAT 
and VAT. Increasing volumes of SAT and VAT were more strongly and consistently 
associated with higher cardiovascular risks in women than in men [59]. These find-
ings suggest that women who accumulate more VAT have a higher cardiovascular 
risk than men with more VAT.
5.3 Type II diabetes mellitus
Type II diabetes mellitus (TIIDM) is also known as non-insulin-dependent or 
insulin-resistant diabetes and is characterized by high blood glucose, polyuria, 
and polydipsia. The most common risk factors attributed to TIIDM are poor diet 
and lack of exercise but have also been linked to obesity. TIIDM was traditionally 
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been considered a disease of adulthood, but this is rapidly changing since there is 
an increased incidence of TIIDM in children and adolescents [60]. The common 
comorbidities of TIIDM include metabolic syndrome, increased adiposity, and 
inflammatory conditions [37].
Males and females exhibit sex-specific differences in total muscle mass and 
in distribution of muscle that becomes apparent in puberty. Males typically have 
greater total muscle mass and greater in the upper body compared to the lower body 
[61]. Janssen et al. performed whole body MRI in men and women 18–88 years 
of age, and the results of their study suggested that men had significantly higher 
skeletal muscle mass than women relative to total body mass (38% vs. 31%) and that 
the sex differences were greater in the upper body (40%) than lower body (33%) 
[62]. It further showed that with aging, there is an age-associated loss of muscle 
mass, with the greatest loss in the lower body [62].
Skeletal muscle plays an important role in determining glucose homeostasis as 
the muscle mass is responsible for the majority of basal and insulin-stimulated glu-
cose uptake. In addition, impaired insulin activity at the level of the skeletal muscle 
is a central component to the clinical findings associated with TIIDM. The reported 
sex differences in muscle mass emphasize the differences of maintaining muscle 
during aging and could represent an important target in women who are at greater 
risk for sarcopenic obesity given their higher fat and lower muscle mass [63].
Studies have shown that exercise and fasting both present conditions that result 
in lower insulin levels with greater instances of insulin receptor binding. However, 
obese conditions result in greater levels of insulin with low insulin binding. A 
study conducted by Hotamisligil et al. suggests that TNF-a secretion by adipocytes 
decreases insulin-mediated glucose uptake by lowering the usage of glucose by 
fat and muscle tissues [64]. Insulin aids in glucose uptake in conjunction with the 
GLUT4 receptor. However, with the inability of insulin to properly interact with its 
receptor, GLUT4 is unable to take up glucose, and it continues to circulate through-
out the blood [65]. The increased blood glucose and the increased inflammatory 
cytokines produced by the adipose tissue exacerbate TIIDM pathology.
If the levels of adipokines and free fatty acids rise, their presence will result in 
the recruitment of inflammatory cell types such as macrophages. When the inflam-
matory cells are recruited to the adipose tissue, they become activated and release 
additional cytokines such as TNF-alpha and IL-6 to recruit even more inflammatory 
cells. This results in a positive feedback loop that results in a chronic state of inflam-
mation. Inflammation-resolving proteins such as annexin A1 are typically increased 
in obese patients but are inactivated by dysregulated cleavage [66]. Cleavage of 
annexin A1 deactivates the inflammation-resolving properties of the protein, lead-
ing the patient to maintain a chronic state of inflammation [66].
Various estrogen replacement therapy studies have shown that estrogen provides 
anti-inflammatory and antioxidant effects in women [67]. A meta-analysis of 
these studies investigated the effects of replacement therapy on women based on 
the age they start therapy and noted that when women began therapy within 10 
years of entering the postmenopausal phase of life, estrogen provided protective 
anti-inflammatory and antioxidant effects [12]. When women present with TIIDM, 
the benefits of estrogen are also lost regardless of age of onset, and they begin to 
present with the same diseases that are typically more prevalent in postmenopausal 
women [68].
The loss of estrogen protection after TIIDM diagnosis causes the female body 
to be attacked more aggressively compared to men of the same age. Men diagnosed 
with TIIDM have significantly lower levels of testosterone compared to healthy 
men, while women have significantly higher levels of testosterone [69]. These data 
suggest that the sex hormones can regulate TIIDM severity in both men and women.
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by increased levels of C-reactive protein [52]. CRP is both an inflammatory protein 
and an important biomarker of cardiovascular damage. It is hypothesized that 
the higher levels of systemic estrogen, associated with pre-menopausal women, 
have been shown to have a cardioprotective effect and reduce inflammation. The 
Women’s Health Initiative designed a study to determine the possible use of hor-
mone therapy as a preventative measure against CVD in postmenopausal women. 
The initial trials were ended early due by the Data Safety Monitoring Board (DSMB) 
due to the increased incidence of stroke and breast cancer in the estrogen + pro-
gesterone arm of the trial [55]. Further analysis of this randomized control study 
ultimately provided evidence for a concept known as the “timing hypothesis.” This 
hypothesis states that hormone replacement therapy near the onset of menopause, 
within 5 years, may lower the risk for CVD, while MHT treatment in women greater 
than 5 years from menopause is harmful [56]. The timing hypothesis has had an 
important impact in clinical settings [30].
Traditional CVD risk factors that are increased for women include lack of physi-
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and visceral fat compartments. Computed topography (CT) and magnetic reso-
nance imaging (MRI) are considered the gold standard for detailed assessment of 
body composition. However, these tests are expensive, not readily available, and, in 
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was a stronger correlation with VAT and most of the cardiovascular risk factors. 
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and VAT. Increasing volumes of SAT and VAT were more strongly and consistently 
associated with higher cardiovascular risks in women than in men [59]. These find-
ings suggest that women who accumulate more VAT have a higher cardiovascular 
risk than men with more VAT.
5.3 Type II diabetes mellitus
Type II diabetes mellitus (TIIDM) is also known as non-insulin-dependent or 
insulin-resistant diabetes and is characterized by high blood glucose, polyuria, 
and polydipsia. The most common risk factors attributed to TIIDM are poor diet 
and lack of exercise but have also been linked to obesity. TIIDM was traditionally 
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been considered a disease of adulthood, but this is rapidly changing since there is 
an increased incidence of TIIDM in children and adolescents [60]. The common 
comorbidities of TIIDM include metabolic syndrome, increased adiposity, and 
inflammatory conditions [37].
Males and females exhibit sex-specific differences in total muscle mass and 
in distribution of muscle that becomes apparent in puberty. Males typically have 
greater total muscle mass and greater in the upper body compared to the lower body 
[61]. Janssen et al. performed whole body MRI in men and women 18–88 years 
of age, and the results of their study suggested that men had significantly higher 
skeletal muscle mass than women relative to total body mass (38% vs. 31%) and that 
the sex differences were greater in the upper body (40%) than lower body (33%) 
[62]. It further showed that with aging, there is an age-associated loss of muscle 
mass, with the greatest loss in the lower body [62].
Skeletal muscle plays an important role in determining glucose homeostasis as 
the muscle mass is responsible for the majority of basal and insulin-stimulated glu-
cose uptake. In addition, impaired insulin activity at the level of the skeletal muscle 
is a central component to the clinical findings associated with TIIDM. The reported 
sex differences in muscle mass emphasize the differences of maintaining muscle 
during aging and could represent an important target in women who are at greater 
risk for sarcopenic obesity given their higher fat and lower muscle mass [63].
Studies have shown that exercise and fasting both present conditions that result 
in lower insulin levels with greater instances of insulin receptor binding. However, 
obese conditions result in greater levels of insulin with low insulin binding. A 
study conducted by Hotamisligil et al. suggests that TNF-a secretion by adipocytes 
decreases insulin-mediated glucose uptake by lowering the usage of glucose by 
fat and muscle tissues [64]. Insulin aids in glucose uptake in conjunction with the 
GLUT4 receptor. However, with the inability of insulin to properly interact with its 
receptor, GLUT4 is unable to take up glucose, and it continues to circulate through-
out the blood [65]. The increased blood glucose and the increased inflammatory 
cytokines produced by the adipose tissue exacerbate TIIDM pathology.
If the levels of adipokines and free fatty acids rise, their presence will result in 
the recruitment of inflammatory cell types such as macrophages. When the inflam-
matory cells are recruited to the adipose tissue, they become activated and release 
additional cytokines such as TNF-alpha and IL-6 to recruit even more inflammatory 
cells. This results in a positive feedback loop that results in a chronic state of inflam-
mation. Inflammation-resolving proteins such as annexin A1 are typically increased 
in obese patients but are inactivated by dysregulated cleavage [66]. Cleavage of 
annexin A1 deactivates the inflammation-resolving properties of the protein, lead-
ing the patient to maintain a chronic state of inflammation [66].
Various estrogen replacement therapy studies have shown that estrogen provides 
anti-inflammatory and antioxidant effects in women [67]. A meta-analysis of 
these studies investigated the effects of replacement therapy on women based on 
the age they start therapy and noted that when women began therapy within 10 
years of entering the postmenopausal phase of life, estrogen provided protective 
anti-inflammatory and antioxidant effects [12]. When women present with TIIDM, 
the benefits of estrogen are also lost regardless of age of onset, and they begin to 
present with the same diseases that are typically more prevalent in postmenopausal 
women [68].
The loss of estrogen protection after TIIDM diagnosis causes the female body 
to be attacked more aggressively compared to men of the same age. Men diagnosed 
with TIIDM have significantly lower levels of testosterone compared to healthy 
men, while women have significantly higher levels of testosterone [69]. These data 
suggest that the sex hormones can regulate TIIDM severity in both men and women.
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5.3.1 Chronic kidney disease in TIIDM
TIIDM diagnosis increases the risk of kidney stones and hypertension, both of 
which are precursors for CKD [70]. CKD is not usually diagnosed until the patient 
goes to the doctor for a physical, and they are diagnosed with high blood pressure, 
or protein is found in the urine. The Centers for Disease Control has estimated that 
as of 2015, 14% of the US population lives with CKD; of those that live with CKD, 
approximately 22% also have TIIDM.
Recent studies have shown parallels between the obesity epidemic and the onset 
of CKD. Obese patients with CKD are often seen with glomerular scarring, also 
known as glomerulosclerosis. This is now being termed obesity-related glomeru-
lopathy due to its prevalence in obese patients [71]. Development of this condition 
has been related to lipid accumulation in the kidneys which may be a response to 
hyperfiltration if the patient also has TIIDM [71]. Under normal conditions glucose 
is not filtered through the glomerulus. However, if a patient has unregulated TIIDM, 
glucose is constantly being filtered out through the glomerulus, which becomes more 
permeable when blood glucose levels are high. When the glomerulus is constantly 
filtering glucose, the glomerular net becomes weak and more permeable to other 
large molecules such as proteins. This eventually leads to total dysregulation of the 
glomerulus and, ultimately, CKD [72]. Diabetic kidney disease is the leading cause of 
CKD worldwide and affects over 40% of patients diagnosed with TIIDM [73].
The overall increase in adiposity in obesity in patients with TIIDM is also cor-
related with an increase in kidney stone formation. Due to the increased levels of 
circulating adipokines released by the engorged adipocytes, these patients have an 
overall inflamed profile that results in higher levels of oxidative stress that can lead 
to the development of nephrolithiasis or kidney stones. Chronic kidney stone for-
mation can also affect glomerular filtration rate and lead to CKD [70]. This increase 
in oxidative stress further upregulates inflammation in a positive feedback loop that 
can eventually lead to CKD and more serious pathology.
Advanced diabetes-related kidney disease is more prevalent in women than in 
men. However, men have a greater risk of onset. This difference may stem from 
how diabetes negates the protective qualities of estrogen. The effects of TIIDM 
on testosterone are unknown but do not appear to lead to progression of diabetes-
related kidney disease. Women with TIIDM appear to have diabetic kidney disease 
more severely than men [74–76]. Obesity-related CKD that does not coincide with 
metabolic abnormalities is more prominent in men than women [77]. Estrogen may 
prevent kidney dysregulation in women, but these protective effects are negated in 
women with metabolic abnormalities.
5.4 Cancer
Approximately 14% of cancer deaths in men and 20% of cancer deaths in women 
can be attributed to obesity [78]. This can be related to the activation of signal-
ing pathways in adipocytes which lead to secretion of low levels of inflammatory 
cytokines by the adipocytes, thereby leading to low-grade inflammatory responses 
throughout the body in locations where fat is most present [78]. Similarly, obesity 
increases endoplasmic reticulum stress resulting in oxidative stress, the unfolded 
protein response, and the upregulation of additional inflammatory cytokines [78]. 
These different inflammatory mechanisms can all contribute to the formation and 
progression of cancer, making obesity a deadly player in the onset of certain cancers.
The incidence of certain sex-linked cancers, such as breast cancer, may be 
upregulated in obese patients. In women specifically, the dysregulation of hor-
mones that is linked with obesity can exacerbate the onset of breast cancer [79]. 
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Non-sex-linked cancers, such as liver cancer, may also have an increased risk in 
relation to obesity [78]. The obesity-related development of nonalcoholic fatty 
liver disease (NAFLD), nonalcoholic steatohepatitis (NASH), and NASH-related 
cirrhosis are also associated with an increased risk of hepatocellular carcinoma 
[78]. By affecting both sex-linked and non-sex-linked cancers, obesity’s wide range 
of potential effects on tumor initiation and progression could contribute to an 
increased prevalence of cancer in obese patients.
A meta-analysis of cohort studies done by Larsson and Wolk found that obese 
individuals had an 89% increased risk of liver cancer [80]. However, the relative 
risk for liver cancer was significantly higher in men than in women, indicating that 
there may be hormone-dependent mechanisms at play [80]. Secretion of proinflam-
matory cytokines including IL-6, IL-8, IL-10, and IL-17 by hypertrophic adipocytes 
triggers an inflammatory cascade in the liver [81]. Damage induced by these inflam-
matory mediators can cause carcinogenesis. Further, the AMPK-TORC1 pathway 
that regulates autophagy is decreased by obesity and hypernutrition [81]. The 
decrease in the autophagy pathway causes a decrease in the clearance of damaged 
cellular organelles which can further induce inflammation and carcinogenesis.
Obesity may be a driving force in sex-related cancers such as prostate cancer 
and breast cancers in men and women. In women, obesity is related to a higher 
incidence of pre-menopausal triple-negative breast cancers, while ER-positive 
breast cancers had a higher incidence among postmenopausal women [82]. This 
is suggested in that breast cancer progression in pre-menopausal obese women is 
not affected by high amounts of systemic estrogen. However, in postmenopausal 
women, with normally low circulating estrogen levels, the incidence in ER-positive 
breast cancer increases. Additionally, the obesity associated risk with triple-neg-
ative breast cancer in postmenopausal women is inversely associated with obesity 
[82]. Among men, obesity and BMI are strong risk factors for male breast cancer 
[83]. Studies have shown that male breast cancer tumors show an increase in the 
estrogen and progesterone receptors [84]. The hormone aromatase, produced by the 
adipose tissue, plays a role in increasing estrogen levels by converting testosterone 
into estrogen and can therefore exacerbate breast cancer in obese men.
In summary, studies have indicated that there are sex-related differences in 
relation to obesity and the onset of cancer, specifically in response to breast cancers. 
Low-grade inflammation as a result of obesity seems to be an underlying cause of 
the disruption of important protective pathways, contributing to the initiation and/
or progression of cancer.
5.5 Neurodegeneration
Neurodegeneration involves the gradual breakdown of the nervous system and 
causes anxiety, dysphoria, apathy, disinhibition, and euphoria [85]. Alzheimer’s 
disease, (AD) the most common neurodegenerative disease and the sixth leading 
cause of death in the United States, is the cause of death in one in three seniors 
living in the United States [86]. It is estimated that 5.7 million Americans are 
affected by Alzheimer’s, two-thirds of which are women [86]. Currently AD is the 
only unpreventable, untreatable disease of the top 10 leading causes of death in the 
United States [86]. While the cause of Alzheimer’s may be unknown, research has 
shown strong links between neurodegeneration and obesity.
AD and other dementias occur more commonly in women than in men world-
wide suggesting that there may be some sex-specific hormonal influences to the 
progression of the disease [87]. Although the specific hormonal influences are not 
known, men may have a certain ability to protect themselves against the severity of 
neurodegeneration, or women may simply lose their ability to do so. As awareness 
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[83]. Studies have shown that male breast cancer tumors show an increase in the 
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adipose tissue, plays a role in increasing estrogen levels by converting testosterone 
into estrogen and can therefore exacerbate breast cancer in obese men.
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Low-grade inflammation as a result of obesity seems to be an underlying cause of 
the disruption of important protective pathways, contributing to the initiation and/
or progression of cancer.
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Neurodegeneration involves the gradual breakdown of the nervous system and 
causes anxiety, dysphoria, apathy, disinhibition, and euphoria [85]. Alzheimer’s 
disease, (AD) the most common neurodegenerative disease and the sixth leading 
cause of death in the United States, is the cause of death in one in three seniors 
living in the United States [86]. It is estimated that 5.7 million Americans are 
affected by Alzheimer’s, two-thirds of which are women [86]. Currently AD is the 
only unpreventable, untreatable disease of the top 10 leading causes of death in the 
United States [86]. While the cause of Alzheimer’s may be unknown, research has 
shown strong links between neurodegeneration and obesity.
AD and other dementias occur more commonly in women than in men world-
wide suggesting that there may be some sex-specific hormonal influences to the 
progression of the disease [87]. Although the specific hormonal influences are not 
known, men may have a certain ability to protect themselves against the severity of 
neurodegeneration, or women may simply lose their ability to do so. As awareness 
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increases, TIIDM is becoming recognized as a contributor to the risk of developing 
AD [88]. The widespread association between TIIDM and neurodegenerative dis-
eases may eventually wind up providing a link between the two. With the expected 
population diagnosed with diabetes reaching 573 million within 12 years by the 
World Health Organization, research into the implications of diabetes and other 
overnutrition illness is becoming essential [89].
Neurodegeneration related to over nutrition has been shown to have profound 
implications on the functionality of the central nervous system and cerebral func-
tions in particular. Recently, the IKK-beta/NF-kappaB pathway has been shown 
to be triggered by overnutrition, leading to inflammation of the hypothalamus 
and other CNS peripheral tissues [90]. This is critical because the hypothalamus is 
responsible for regulating functions such as energy balance as well as controlling 
some metabolic activities related to the sympathetic and parasympathetic nervous 
systems [90]. This inflammation due to overnutrition has been deemed “metabolic 
inflammation” [90].
A diet that is high in fat may contribute to the progression of neurodegeneration 
through increased fatty acid uptake. Saturated fatty acids cause activation of the 
immune system through Toll-like receptor 4 (TLR4), leading to the production of 
cytokines by astrocytes [91]. This thereby induces an inflammatory response that 
could lead to damage of the hypothalamus. Additionally, loss of normal function 
of the TLR4 increases and encourages diet-induced obesity [91]. This positive 
feedback loop would encourage inflammation while also sustaining the nutrient- 
and fat-rich environment in which it was produced. Microglia, macrophages in the 
brain, produce inflammasomes in diseased states such as obesity and TIIDM [91]. 
Therefore, any inflammation already pre-existing in the body due to obesity would 
only encourage self-damaging signaling cascades. These processes hijack the body’s 
natural defense mechanisms to further the progression of neurodegeneration.
Advanced glycation end products, or AGEs, are markers of carbonyl stress due to 
oxidative stress, and their formation is irreversible and leads to protein deposits and 
amyloidosis [92]. Unnatural amyloid deposits in critical areas of the central nervous 
system can result in irregularities of normal functioning, and AGE formation seems 
to occur early in the stages of plaque formation in connection with AD [92]. AGE 
leads to a release of free radicals that are associated with the oxidation of sugars which 
eventually can lead to site-specific attacks of proteins and lipid peroxidation [92]. 
Additionally, when AGEs induce the expression of AGE cell surface receptors (RAGE), 
superoxide radicals and hydrogen peroxide are released, further contributing to cyto-
toxic effects on cells and inflammation [92]. The combination of these effects continues 
to incite an inflammatory response and furthers the progression of the neurodegenera-
tive diseases and other neurological damages. These findings support the claim that 
hyperglycemia-derived AGEs constitute a crucial link between diabetes and AD [91].
Diabetes mellitus may serve as a very relevant risk factor for AD. This link may 
be due to the existence of insulin resistance in both patients affected by TIIDM and 
in neural cells [93]. Insulin receptors activate receptor tyrosine kinases which in 
turn phosphorylate insulin receptor subtypes 1 and 2 [93]. The interaction of these 
receptors with Src domains allows for several protective processes to occur and 
promote cellular division and longevity of healthy cells [93]. Cells that are deficient 
in this receptor, or that cannot express sufficient amounts, are subsequently at risk 
for diminished functioning capabilities. Furthermore, insulin specifically binds to 
the respective receptors to initiate different functions, so the expression of both 
receptors is vital to cellular functioning [93]. In the brain, the highest levels of 
insulin are found in the hypothalamus, temporal lobe, and cerebellum [93]. A lack 
of the protecting effects of insulin may explain why the hypothalamus is classically 
inflamed in conditions of obesity.
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Obesity-associated low-grade inflammation seems to be an underlying cause in 
the progression of neurodegenerative diseases, specifically AD. While there seem 
to be sex-related differences in the relationship between neurodegeneration and 
obesity, more research is needed to identify what the exact cause is. Nevertheless, 
the correlation between neurodegeneration, TIIDM, and obesity is apparent, and 
further research is needed to elucidate this mechanism.
5.6 Infertility
Infertility is defined as the inability of a couple to conceive after 12 months or 
more of regular, unprotected sex [94]. There can be many causes of infertility, but an 
emerging comorbidity and risk factor is obesity. Obesity can affect reproduction and 
development by altering sex hormones, sex cells, and different genes within the sex 
cells. These alterations can be found in both men and women; however, the effects 
differ slightly. Both sexes exhibit an increase of the androgen sex hormone [95, 96]. 
Obese men and women are also shown to produce less sex cells overall [97]. A 2015 
epidemiological study found that over 100 genes that were related to infertility were 
also related to obesity [95, 96]. Furthermore, genes that support sex cell matura-
tion and function have been shown to be altered with an increase in adiposity [98]. 
Maintaining a healthy body weight can help normalize these factors of reproduction, 
while obesity can cause reproductive alterations that can result in infertility.
5.6.1 Males
Infertility in males is linked to decreased viable sperm count, sperm motility, 
or supporting sex hormones. When compared to men with a normal body mass 
index (BMI) of 20–25 kg/m2, obese men with a BMI greater than 25 kg/m2 showed a 
decrease in concentration of the number of sperm per milliliter of ejaculatory fluid, 
a decrease in total sperm count in millions, and a decrease in healthy sperm cells 
[97]. Successful conception rates have been directly related to sperm counts; greater 
sperm counts correlate to an increased chance of conception, and in addition to 
sperm count, obesity-induced epigenetic modifications play a role in sperm-egg 
interaction [97]. Increased obesity-induced DNA methylation and decreased DNA 
acetylation affect sperm cell gene expression [99]. This change can inhibit a success-
ful fertilization by altering embryogenesis, and this can lead to a failed pregnancy 
or problems in embryo development.
In males, onset of obesity correlates with an increase in estrogen and a decrease 
in supporting sex hormones such as testosterone, sex hormone-binding globulin 
(SHBG), and inhibin B [97]. SHBG is mainly produced in the liver and primar-
ily functions by binding to and transporting sex steroids throughout the blood. 
Decreased SHBG protein levels have been linked to metabolic and endocrine 
disorders and obesity [100]. Obesity has been correlated with low secretion levels 
of luteinizing hormone (LH) from the pituitary gland, which induces testosterone 
release from the Leydig cells. In a healthy male, after testosterone secretion, a 
majority of the steroid would bind to SHBG and then travel to various androgen 
receptors throughout the male body, with small levels being converted to estrogen 
via aromatase. However, obese patients tend to have a greater aromatase activity 
and therefore have higher levels of estrogen than nonobese men [99]. An increase in 
metabolism of free testosterone to estrogen can lead to decreased testicular sensitiv-
ity to LH, further leading to high estrogen and low testosterone levels [99]. This cre-
ates a negative feedback loop, ultimately leading to a decrease in sperm production.
Inhibin B is a glycoprotein produced by Sertoli cells that aids in regulating 
follicle-stimulating hormone (FSH) in a negative feedback manner [101]. When 
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only encourage self-damaging signaling cascades. These processes hijack the body’s 
natural defense mechanisms to further the progression of neurodegeneration.
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amyloidosis [92]. Unnatural amyloid deposits in critical areas of the central nervous 
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further research is needed to elucidate this mechanism.
5.6 Infertility
Infertility is defined as the inability of a couple to conceive after 12 months or 
more of regular, unprotected sex [94]. There can be many causes of infertility, but an 
emerging comorbidity and risk factor is obesity. Obesity can affect reproduction and 
development by altering sex hormones, sex cells, and different genes within the sex 
cells. These alterations can be found in both men and women; however, the effects 
differ slightly. Both sexes exhibit an increase of the androgen sex hormone [95, 96]. 
Obese men and women are also shown to produce less sex cells overall [97]. A 2015 
epidemiological study found that over 100 genes that were related to infertility were 
also related to obesity [95, 96]. Furthermore, genes that support sex cell matura-
tion and function have been shown to be altered with an increase in adiposity [98]. 
Maintaining a healthy body weight can help normalize these factors of reproduction, 
while obesity can cause reproductive alterations that can result in infertility.
5.6.1 Males
Infertility in males is linked to decreased viable sperm count, sperm motility, 
or supporting sex hormones. When compared to men with a normal body mass 
index (BMI) of 20–25 kg/m2, obese men with a BMI greater than 25 kg/m2 showed a 
decrease in concentration of the number of sperm per milliliter of ejaculatory fluid, 
a decrease in total sperm count in millions, and a decrease in healthy sperm cells 
[97]. Successful conception rates have been directly related to sperm counts; greater 
sperm counts correlate to an increased chance of conception, and in addition to 
sperm count, obesity-induced epigenetic modifications play a role in sperm-egg 
interaction [97]. Increased obesity-induced DNA methylation and decreased DNA 
acetylation affect sperm cell gene expression [99]. This change can inhibit a success-
ful fertilization by altering embryogenesis, and this can lead to a failed pregnancy 
or problems in embryo development.
In males, onset of obesity correlates with an increase in estrogen and a decrease 
in supporting sex hormones such as testosterone, sex hormone-binding globulin 
(SHBG), and inhibin B [97]. SHBG is mainly produced in the liver and primar-
ily functions by binding to and transporting sex steroids throughout the blood. 
Decreased SHBG protein levels have been linked to metabolic and endocrine 
disorders and obesity [100]. Obesity has been correlated with low secretion levels 
of luteinizing hormone (LH) from the pituitary gland, which induces testosterone 
release from the Leydig cells. In a healthy male, after testosterone secretion, a 
majority of the steroid would bind to SHBG and then travel to various androgen 
receptors throughout the male body, with small levels being converted to estrogen 
via aromatase. However, obese patients tend to have a greater aromatase activity 
and therefore have higher levels of estrogen than nonobese men [99]. An increase in 
metabolism of free testosterone to estrogen can lead to decreased testicular sensitiv-
ity to LH, further leading to high estrogen and low testosterone levels [99]. This cre-
ates a negative feedback loop, ultimately leading to a decrease in sperm production.
Inhibin B is a glycoprotein produced by Sertoli cells that aids in regulating 
follicle-stimulating hormone (FSH) in a negative feedback manner [101]. When 
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spermatogenesis appears to be elevated based on activity of the hypothalamic-
pituitary-gonadal hormone (HPG), this indicates a high sperm count due to FSH 
secretions. Inhibin B will regulate FSH levels based on HPG status which modu-
lates sperm concentration. An inhibin B study found that a negative correlation 
between sperm count and inhibin B was revealed [101]. Inhibin B activity is high 
when sperm count is concentrated; infertile men often have very low levels of 
inhibin B; this relationship indicates further exacerbation of infertility and low 
sperm count. Decreased gonadal function in obese men has been characterized 
by lower levels of inhibin B even though FSH levels remain similar before and 
after weight loss [102]. Therefore, while obese males have similar levels of FSH to 
nonobese males, the high aromatase activity converts much of the testosterone to 
estrogen, thereby inhibiting spermatogenesis and decreasing fertility [103].
Lastly, in healthy males, the scrotum usually is about 2–3°C lower than body 
temperature, which is essential for sperm storage, health, and motility [104]. 
Obesity can also result in increased scrotum temperatures which can lead to infertil-
ity [104]. The changes associated with obesity-induced infertility can be circum-
vented by weight loss [104]. Staying healthy and maintaining a moderate BMI can 
help regulate hormone and sex cell secretions and promote fertility.
5.6.2 Females
Obesity in females can lead to infertility by decreasing oocyte quality, altering 
ovulation, and affecting developmental factors. The mitochondria and mitochon-
drial oxidative phosphorylation are essential to oocyte maturation, fertilization, 
and implantation [105]. It has been shown that mice lacking the mitochondrial 
replication protein, TFAM, are embryonic lethal and reduced levels of TFAM cause 
decreased fertility [106]. The effects of high-fat diet (HFD) on obesity are summa-
rized in Grindler et al. but briefly show that HFD-induced obesity alters mitochon-
drial function and mitochondrial membrane potential, increases reactive oxygen 
species, and decreases mitochondrial DNA copy number in oocytes which indicates 
damaged and unhealthy oocytes [105]. Regular diets with less fat would minimize 
mitochondrial dysfunction and oxidative damage to oocytes and keep them viable.
Menstrual abnormalities contributing to infertility like anovulation are seen 
in obese women [107]. SAT plays a role in regulating anovulation, whereas VAT 
plays more of a role in proinflammatory secretions [108]. Regulating fat intake 
can improve chances of conception by regulating menstrual cycles and oocyte 
development. Further, the proinflammatory secretions from VAT create a positive 
feedback loop causing more inflammation and more ovulation complications. The 
changes in ovulation and the increased levels of inflammatory cytokines exacer-
bate infertility in females.
Regulation of the follicular environment is necessary for oocyte development, 
and obesity changes the follicular environment and consequently the oocyte gene 
expression which contribute to infertility [109]. Leptin is typically elevated in obese 
patients and can cause negative changes to the follicular environment. Interestingly, 
women with higher BMI have higher levels of lactate, triglycerides, and CRP and 
decreased levels of SHGB in their follicular fluid, compared to normal-weight 
women, which can be linked to decreased oocyte viability and an inhospitable 
environment for oocyte development [109]. In addition, the same decrease in 
SHBG seen in obese men was seen in obese women [109]. This decrease in SHBG 
expression would lead to decreased transport of estrogen and thereby decreased 
oocyte development. This suggests that secretions from adipose tissues could be 
contributing to decreased oocyte function. Further, when oocytes were extracted 
from women of BMIs considered normal, overweight, and obese, fewer oocytes 
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were obtained from the women in the obese category with a BMI of greater than 
30 kg/m2 [109]. Taken together this data indicates that obesity impairs oocyte 
development.
The increase in C-reactive protein suggests that systemic inflammation can 
also affect fertility and oocyte development [109]. High amounts of inflammatory 
secretions such as C-reactive protein seen in obese women contribute to decreased 
fertility. Obesity-induced inflammation presents damaging effects to oocytes and 
contributes to infertility. Obesity decreases chances of healthy oocyte fertilization 
and implantation. Couples will have a better chance at conception and successful 
pregnancy if a healthy weight is maintained.
5.7 Stress
Obesity and stress cause a vicious positive feedback loop to cause more obesity 
and stress. Outside stressors activate the sympathetic nervous system and the 
hypothalamic-pituitary-adrenal (HPA) axis. When these systems are dysregulated 
by continuous stress, the hyperactivity causes health issues, such as obesity [110]. 
Under normal conditions, the HPA axis is needed to maintain energy and metabolic 
homeostasis through modulating hormones such as insulin and leptin [111]. When 
activated, the sympathetic nervous system will cause secretion of epinephrine and 
norepinephrine from the adrenal gland, and the HPA axis will release cortisol. 
Negative feedback mechanisms inhibit the HPA axis from continuously secreting 
cortisol and maintaining alterations in metabolism [112]. Homeostatic fluctuation 
of the HPA axis controls metabolism; however, stress and inflammation alter this 
feedback loop and contribute to metabolic dysfunction.
Obesity-induced inflammation has also been correlated with an increase in 
the HPA axis function. Cortisol can increase leptin levels and inhibit leptin from 
suppressing appetite, or cortisol can induce neuropeptide Y release, which stimu-
lates fat growth [110]. Therefore, cortisol can increase fat deposition. The origin 
of cortisol, from stress or normal homeostatic activation, and the obesity status 
play a role in fat deposition. For example, stress-induced increases in cortisol levels 
cause women to gain more weight compared to non-stressed women with the 
same cortisol levels. Further, elevated cortisol levels in overweight women cause 
increased weight gain at a faster pace than women with average weight and similar 
elevated cortisol levels [110]. The correlation between cortisol and weight gain in 
men appears to be related more to weight gain than to increases in cortisol levels, 
and the increased cortisol production seen in men could be further stimulated by 
the inflammatory cytokines secreted in fat tissues [110]. Together, this data suggests 
gender differences in cortisol-induced adiposity.
Stress can affect choice of food intake differently in males and females by 
modulating appetite. While most individuals were seen to eat less in high stress, 
individuals were seen to eat more in continuous low or moderate stress levels [113]. 
This suggests that prolonged moderate stress could contribute more to obesity 
than high stress in a shorter time period. Not only does stress increase appetite for 
some people, but it also affects food choice. Individuals under stress were seen to 
increase the intake of higher-calorie “comfort foods” in replacement of vegetables 
[111]. These findings support the role of stress-induced weight gain in chronically 
stressed people.
Ideas of self-image, ideal weight, or body shape also lead to increased stress. 
The ideas of normal or desired body image are found everywhere and are often 
unrealistic and idealized. The role of weight-based stigmas and how they differ 
in males and females offer inconclusive results [114]. In a recent study by Sattler 
et al., weight-based stigmas in obese population caused weight gain and a decreased 
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activated, the sympathetic nervous system will cause secretion of epinephrine and 
norepinephrine from the adrenal gland, and the HPA axis will release cortisol. 
Negative feedback mechanisms inhibit the HPA axis from continuously secreting 
cortisol and maintaining alterations in metabolism [112]. Homeostatic fluctuation 
of the HPA axis controls metabolism; however, stress and inflammation alter this 
feedback loop and contribute to metabolic dysfunction.
Obesity-induced inflammation has also been correlated with an increase in 
the HPA axis function. Cortisol can increase leptin levels and inhibit leptin from 
suppressing appetite, or cortisol can induce neuropeptide Y release, which stimu-
lates fat growth [110]. Therefore, cortisol can increase fat deposition. The origin 
of cortisol, from stress or normal homeostatic activation, and the obesity status 
play a role in fat deposition. For example, stress-induced increases in cortisol levels 
cause women to gain more weight compared to non-stressed women with the 
same cortisol levels. Further, elevated cortisol levels in overweight women cause 
increased weight gain at a faster pace than women with average weight and similar 
elevated cortisol levels [110]. The correlation between cortisol and weight gain in 
men appears to be related more to weight gain than to increases in cortisol levels, 
and the increased cortisol production seen in men could be further stimulated by 
the inflammatory cytokines secreted in fat tissues [110]. Together, this data suggests 
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Stress can affect choice of food intake differently in males and females by 
modulating appetite. While most individuals were seen to eat less in high stress, 
individuals were seen to eat more in continuous low or moderate stress levels [113]. 
This suggests that prolonged moderate stress could contribute more to obesity 
than high stress in a shorter time period. Not only does stress increase appetite for 
some people, but it also affects food choice. Individuals under stress were seen to 
increase the intake of higher-calorie “comfort foods” in replacement of vegetables 
[111]. These findings support the role of stress-induced weight gain in chronically 
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Ideas of self-image, ideal weight, or body shape also lead to increased stress. 
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desire to exercise in females more than males [114]. Females with weight-associated 
stigmas had less motivation to participate in physical activities, while males had 
more motivation to exercise [114]. These stigmas can cause increases in stress levels 
and cortisol release and may actually have a negative impact on exercise and weight 
loss in obese patients. The idea that this weight stigma differentially affects males 
and females is important to understand, in order to effectively motivate overweight 
and obese males and females to exercise and to lose weight. This data suggests that 
the stress of ideal body image can also negatively affect stress-induced adiposity.
Stress and obesity combined contribute to fat growth, changes in appetite, and 
additional stress. The negative self-image, depression, or anxiety that obese people 
have provides the stress for prolonged HPA axis activation and increased adiposity.
6. Conclusion
Obesity plagues approximately 70% of US adults. Obese adipose tissue is 
responsible for releasing proinflammatory cytokines throughout the body as well 
as dysregulating glucose-regulating hormones. Chronic obese adiposity puts the 
body in a state of chronic inflammation which leads to numerous diseases includ-
ing CVD, TIIDM, MetS, cancer, neurodegeneration, and infertility (Figure 2). 
Sex differences play a role in regulating the prevalence of disease, causing 
sexual dimorphism in diseases and disease pathogenesis in men than women. 
The role of the sex hormones, estrogen, and testosterone should be further 
explored in order to most effectively treat obese patients and their numerous 
pathophysiologies.
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Figure 2. 
The relationship between obesity, inflammation, and disease. Obesity, inflammation, and chronic diseases cause 
a vicious cycle, each exacerbating the other. Inflammatory cytokines and adipokines are produced systemically 
and by adipocytes, respectively, and play a role in exacerbating disease states. Prevalence of disease caused by 
inflammation and obesity varies between men and women, and sex differences may be due to the proposed 
protective nature of the primary female sex hormone, estrogen.
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Abstract
Portal hypertensive inflammation is associated with chronic liver diseases. The 
three successive and overlapping systemic inflammatory phenotypes, i.e., neuro-
genic, immune, and endocrine, which characterize the wound-healing response, are 
expressed by the portal venous system upon liver injury. The diverse functions of 
hepatic stellate cells in homeostasis and inflammation indicate the versatile nature 
of these mesenchymal-derived cells, which could adopt numerous phenotypes 
according to the interstitial microenvironmental characteristics. Consequently, 
these inflammatory phenotypes could represent the reexpression of two extra-
embryonic functional axis, i.e., coelomic-amniotic and trophoblastic-vitelline, 
whose coupling in the portal system would induce a gastrulation-related pheno-
type. Therefore, hepatic stellate cells and liver-specific mesenchymal cells could 
recapitulate and couple these abovementioned extra-embryonic phenotypes during 
portal hypertension. These hepatic cellular population, thanks to their potential 
ability to integrate and reexpress functions showing analogies to extra-embryonic 
functions, display characteristics of stem/progenitor cells. In this way, during the 
development of portal hypertension, hepatic stellate cells not only could reexpress 
extra-embryonic functions, but also could adapt themselves in order to induce a 
gastrulation-related process in the space of Disse. Hence, by understanding the 
ontogenic interactions between hepatic stellate cells and the host inflammatory 
response in portal hypertension, it is possible to design effective therapeutic and 
prophylactic strategies to avoid or reverse wound-like hypertensive response.
Keywords: liver fibrosis, extra-embryonic functions, inflammation, wound-healing, 
portal hypertension
1. Introduction
Portal hypertension is a frequent complication of chronic liver disease [1]. At 
the same time, cirrhosis represents the final stage of chronic liver disease due to any 
cause [2]. Cirrhosis can be defined as an advanced stage of fibrosis involving the 
formation of the regenerative nodule of the parenchyma surrounded and separated 
by fibrotic septa, a scenario also characterized by significant changes in hepatic 
angioarchitecture [3–5].
The cause-effect relationship existing between inflammation and fibrotic 
processes is so narrow that the term “inflammatory fibrosis” [6] appropriately 
describes multiple fibrotic diseases, including local conditions, such as wound 
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healing [7] and liver cirrhosis [5]. Therefore, the chronic activation of the wound-
healing response represents the driving force for progressive fibrosis, eventually 
leading to liver cirrhosis and hepatic failure [5].
2. The wound-healing response
Knowledge relating to wounding repair and healing comprises a significant 
fraction of the science of surgery and its specialties [8]. Wound healing is an 
obligatory sequence of events starting with inflammation due to a variety of 
stimuli [9]. In lower vertebrate tissues, regeneration can restore injured organs and 
even severe limbs or other body segments [10]. However, in higher vertebrates, tis-
sue repair consists of a fibroproliferative response that usually results in a fibrotic 
scar [10, 11]. Regenerating vertebrates, such as zebrafish and salamanders, offer 
a unique example where wounds are not only resolved without the formation of a 
fibrotic scar, but also the wound tissue executes tissue patterning equivalent to the 
original process of embryonic development to restore lost tissue [11, 12].
Scarring is a frequent consequence of full-thickness mammalian wound healing 
[10, 13]. However, the mid-gestation fetus is capable of regenerative healing with 
wound healing indistinguishable from surrounding skin [14, 15]. Current therapies 
to minimize scarring in postnatal wound have attempted to recapitulate singular 
aspects of the fetal regenerative phenotype and have met with varying degrees of 
clinical success [14].
Cutaneous wound repair is an integration of dynamic interactive processes involv-
ing soluble mediators, formed blood elements, extracellular matrix, and parenchymal 
cells [10]. These processes follow a specific time sequence which is classically grouped 
into three interrelated phases: inflammation, proliferation with tissue formation, and 
tissue remodeling [16, 17]. In brief, coagulation and inflammatory cells are crucial to 
the initial inflammatory phase. Neutrophils and macrophages enter the fibrin-rich 
zone. In addition to phagocyte pathogens and tissue debris, these cells secrete a mul-
titude of chemokines, cytokines, and growth factors. Granulation tissue—composed 
of macrophages, fibroblasts, and endothelial cells—is the hallmark of the prolifera-
tive phase. Reepithelization is essential for the reestablishment of tissue integrity 
[18]. During the remodeling phase, formation of granulation tissue ceases through 
apoptosis of the responsible cells. With maturation of the wound, the type III collagen 
deposited during the proliferative phase is slowly degraded and replaced with stron-
ger type I collagen. Furthermore, the wound undergoes a contractile response and 
reduces the surface area of the scar [19].
3. The systemic wound-healing phenotypes
From a general point-of-view, the wound-healing response could be considered 
as a systemic inflammatory response in the body, which appears to develop through 
the expression of three successive and overlapping phenotypes, the neurogenic, 
immune, and endocrine [20]. The above-mentioned phenotypes, which character-
ize the evolution of the systemic inflammatory response to the injury, are focused 
and integrated within the interstitial space of the injured tissue or organ [7, 21, 22].
3.1 The neurogenic inflammatory phenotype
The systemic inflammatory response begins with an immediate pathological neu-
romuscular response that includes sensitive impairments like stress sensation, pain, 
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analgesia, and motor alterations. In particular, these motor alterations are harm-
ful to the skeletal muscle (fight-to-flight and withdrawal reflexes), myocardium 
(tachycardia), and vascular smooth muscle (vasoconstriction and vasodilation), 
which induces systemic and local hemodynamic impairments, including blood flow 
redistribution and ischemia-reperfusion [21, 22]. A common and basic pathogenic 
mechanism of this complex neuromuscular response would be sudden hydroelectro-
lytic alterations [20–22]. Consequently, there is increasing evidence that the systemic 
inflammatory response is actually associated with abnormal ion transport [23].
The ischemia-reperfusion phenomenon, which causes oxidative and nitrosative 
stress, could be responsible for exudation and the progression of interstitial edema 
in the injured tissues or organs [21]. While edema is being produced, the lymphatic 
circulation is activated [20, 22]. Since the inflammatory interstitium is initially 
hypoxic and shows metabolic anaerobic acidosis, mainly due to the accumulation of 
acid by-products including lactate, the hypoxic and acid environment could repre-
sent an ideal stem cell niche [24].
In the early evolutionary period of the neurogenic stress response, the 
hypothalamic-pituitary-adrenocortical, sympathetic-adrenal-medullary, and 
renin-angiotensin-aldosterone axes, with the secretion of catecholamines, 
glucocorticoids, and mineralocorticoids in the circulation, are activated [25, 26]. 
Chromaffin vesicles in adrenal medullary chromaffin cells also store granins, 
which can function as prohormones giving rise to bioactive peptides, some with 
potent antimicrobial activity [27]. Consequently, these substances are selectively 
accumulated in the interstitial space of the tissues suffering from ischemia-
reperfusion because endothelial permeability is increased, especially in the 
post-capillary venules [7, 20–22] (Table 1 and Figure 1).
3.2 The immune inflammatory phenotype
The immune inflammatory phenotype corresponds to the intermediate phase of 
systemic wound-healing response to injury. In this phase, the tissue or organ which 
has previously suffered ischemia-reperfusion is infiltrated by inflammatory cells 
and even by bacteria [22]. This infiltration occurs in an edematous oxygen-poor 
environment [7, 21].
Today, the inflammatory bone marrow-related response is considered both a key 
and complementary arm of the stress response [7, 22]. The inflammatory activation 
of the bone marrow stem cell niche indicates the stimulation of the hematopoi-
etic stem cells (HSCs) and the mesenchymal stem cells (MSCs), which are both 
multipotent stem cells [28, 29]. HSCs are the progenitors of all blood and immune 
cells that infiltrate all the tissues and organs that have been previously primed by 
oxidative and nitrosative stress [22]. Inflammatory signaling molecules, including 
chemokines, interferons, tumor necrosis factor-alpha, and toll-like receptors appear 
to stimulate HSC proliferation in the short term [30]. In turn, interferon gamma 
mediates HSC stimulation in response to chronic inflammation [31].
This immune phenotype could be characterized by enzymatic stress related to 
intracellular digestion, i.e., autophagy [32], phagocytosis, and antigen presentation 
[21, 22]; and extracellular digestion, i.e., fermentation [20], all of which favor tissue 
tropism [7, 20]. In addition, macrophages and dendritic cells also take advantage 
of the lymphatic circulation activation. Macrophages migrate within the lymphatic 
circulation until reaching the lymph nodes where they activate lymphocytes [7, 33].
The cells that infiltrate the interstitium in the inflamed tissues and organs, thanks 
to the open microcirculatory system, acquire metabolic characteristics that transform 
them into tissues with great functional autonomy. Thus, leukocytes express adreno-
ceptors, catecholamines [34, 35], serotonin [36], pro-opiomelanocortin (POMC) 
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Translational Studies on Inflammation
72
peptides [37], and cholinergic activity [38]. Perhaps, these are the reasons why the 
stress response axis can be retrieved by the immunocytes participating in the inflamed 
interstitium of tissues and organs, where the corticotrophin-releasing hormone (CRH), 
adrenocorticotrophin (ACTH)-like and biogenic amines are present [37].
MSCs are usually derived from bone marrow, but can also be isolated from 
adipose and other tissues [29]. MSCs act through complex interactions with the 
endogenous cells and tissues, and they may function in the multiple mechanisms of 
tissues [39]. MSCs in the wound bed contribute to the generation of a high-quality 
well-vascularized granulation tissue; they enhance reepithelialization of the wound 
and attenuate the formation of fibrotic scar tissue [39, 40]. Bone marrow-derived 
MSCs secrete molecules that inhibit the effector function of immune cells and are 
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During the expression of the immune phenotype, the acute-phase reaction 
becomes more prominent and exhibits diverse pathophysiological changes, includ-
ing pyrexia, leukocytosis, and dramatic changes in the plasmatic concentrations 
of acute-phase proteins [43, 44]. Acute-phase proteins are circulating biomark-
ers of inflammation and are defined as either positive or negative, depending on 
whether they increase or decrease during the inflammatory response [43]. Positive 
acute-phase proteins are synthesized by hepatocytes in response to IL-6 as part of 
the innate immune response [45]. Positive acute-phase proteins include proteins 
of the coagulation-fibrinolysis system (fibrinogen, prothrombin, factor VIII, 
Von-Willebrand factor, complement factors plasminogen), protease inhibitors 
(alpha-1-antitrypsin, alpha-1-antichymotrypsin), transport proteins (ceruloplas-
min, hemopexin, haptoglobin), and lipid transport proteins (serum amyloid A and 
serum amyloid P) [43, 44]. However, C-reactive protein is the main human acute-
phase protein and one of the more sensitive markers of inflammation [44, 46].
Negative acute-phase proteins including albumin invade the interstitium of the 
injured tissues or organs through its plasmatic storage [21]. In turn, a pivotal func-
tion of the positive acute-phase proteins increases the availability of cellular free 
cholesterol. In particular, it has been suggested that acute-phase serum amyloid A is 
part of a systemic response to injury to recycle and reuse cholesterol from destroyed 
and damaged cells [47]. In this case, the recycling of cholesterol during serious 
injury could play an important role in survival [47]. In fact, the predominance 
of the lipid metabolism with accumulation of cholesterol in the inflamed tissue 
could be attributed to its role as a precursor molecule of many hormones, including 
Figure 1. 
The systemic wound-healing phenotypes. N: the neurogenic phenotype with sensitive and motor functions 
including ischemia-reperfusion and edema. A niche is created that can host stem cell-like cells. This interstitial 
niche accumulates molecules from the neuroendocrine stress response of the organism. I: the immune 
phenotype is associated with acute-phase response and an inflammatory bone marrow-related response, i.e., 
hematopoietic stem cells and mesenchymal stem cells. E: the endocrine phenotype. Formation of a new tissue 
that could execute a regenerative role or a reparative role through fibrosis. A: angiogenesis; AG: adrenal gland; 
BMA: bone marrow; CNS: central nervous system; DAMP: damage-associated molecular pattern; E: edema; 
ER: epithelial regeneration; EV: post-capillary vascular endothelium; F: fibrosis; GT: granulation tissue; L: 
lymphocyte; Le: leukocyte; Mo: macrophages; M: myofibroblast; MN: monocyte; MSC: mesenchymal stem cell; 
PAMP: pathogen-associated molecular pattern; PMN: polymorphonuclear neutrophil leukocyte; SC: stem cells.
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peptides [37], and cholinergic activity [38]. Perhaps, these are the reasons why the 
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aldosterone, corticoids, progesterone, androgens, and estrogens [48] and even 
vitamin D [49] (Table 1 and Figure 1).
3.3 The endocrine inflammatory phenotype
It could be proposed that the expression of this inflammatory phenotype 
represents a metamorphosis through the creation of a pseudo-tissue made by a 
provisional parenchyma, with stem-like cells, and leukocytes, associated with 
a provisional stroma, i.e., coagulation and complement systems-related, which 
is finally transformed into a definitive tissue [50]. There is scattered evidence 
supporting the hypothesis that mononuclear phagocytes interact with cells with 
progenitor or “bona fide” stem cell properties, and that this interplay may contrib-
ute to repair and remodeling [51]. Even, it has been hypothesized that the immune 
system could create overriding signals that push the mesenchyme toward scarring 
rather than regeneration [52].
It has been proposed that the focus of the systemic phenotypes, neurogenic and 
immune, on the interstitial space of the injured tissue could be completed in two 
steps [7]. First, the upregulated neurogenic phenotype, characterized by systemic 
cardiovascular, hemodynamic, and hydroelectrolytic alterations, could favor the 
development of an interstitial niche with appropriate biochemical properties for 
the recruitment of cells with stem cell properties [7, 53]. In turn, the upregulated 
immune phenotype could mediate the inflammatory bone marrow response with 
an acute-phase reaction and a lipid metabolic switch linked to steroid synthesis [7]. 
Finally, the progressive polarization and integration of the functions that character-
ize both systemic inflammatory functions phenotypes, i.e., neurogenic and immune, 
in the injured tissue would condition the evolution of the tissue repair [7, 54].
The new tissue, a proliferative inflammatory mesenchyma, could execute a 
regenerative role or by default, repair through fibrosis [54, 55]. If so, several days 
after injury, a subset of wound fibroblasts can differentiate into myofibroblasts, 
which is responsible for repopulating the wounded area in parallel to angiogenesis, 
thus forming the granulation tissue [21]. Macrophages, fibroblasts, and blood 
vessels move into the wound space as a unit, suggesting an interdependence of these 
cells during the tissue repair [10, 51].
However, the dominating cell in this phase is the fibroblast, which fulfills 
different functions, such as the production of collagen and extracellular matrix 
substances, i.e., fibronectin, glycosaminoglycans, and proteoglycans [13]. Fibrosis 
is generally preceded by robust angiogenesis and vascular regression suggesting that 
the vascular apoptotic burden may be important to the fibrotic outcome [56, 57]. 
Recruited bone marrow mesenchymal cells could also transdifferentiate into epithe-
lial cells [58] (Figure 1).
Therefore, the wound-healing response could be viewed as a successive and 
overlapping of systemic phenotypes, i.e., neurogenic and immune, which are 
coupled in the wounded area in order of reconstructing the injured tissue by regen-
eration or, by default, repairing it by fibrosis.
4. Inflammatory phenotypes and recapitulated ontogeny
Inflammation could recapitulate ontogeny by reexpressing two hypothetical 
extra-embryonic axes, i.e., exocoelomic-amniotic and trophoblastic-yolk sac in the 
interstitial space of the injured tissue [7, 22, 54]. If so, the inflammatory response 
could represent the postnatal debut of ancestral biochemical mechanisms that were 
used for normal embryonic development [22].
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After fertilization, the first stage of embryogenesis is the zygote, which 
undergoes cleavage by mitosis. When the morula stage is reached, the embryo 
establishes polarity. The cells bind tightly to each other, forming a compact sphere 
or blastocyst, with two cell layers. The outermost layer becomes the trophoblast, 
giving rise to the placenta. The inner cells become the inner cell mass, giving rise 
to the embryo and the remaining structures, including the exocoelomic cavity, the 
amnion, yolk sac, and allantois [59]. The extra-embryonic coelom or exocoelomic 
cavity surrounds the blastocyst, which is composed of two structures, the amnion 
and the primary yolk sac. At the end of the fourth week of gestation, the develop-
ing exocoelomic cavity splits the extra-embryonic mesoderm into two layers, the 
somatic mesoderm, lining the trophoblast, and the splanchnic mesoderm, covering 
the secondary yolk sac and the embryo [60] (Figure 2).
The hypothetical recapitulation of these initial phases of the embryonic devel-
opment during the early inflammatory response would imply the expression of 
functions similar to the extra-embryonic exocoelomic-amniotic and trophoblastic-
yolk sac structures [22]. Accordingly, the exocoelomic-amniotic phenotype could 
be adopted by the inflamed interstitium that subsequently induces the accumulation 
of fluid with similar characteristics to coelomic and amniotic fluids in an environ-
ment with low pH and oxygen [60–62]. In essence, interstitial edema with high 
levels of proteins, in particular albumin, as well as electrolytes, metals, amino 
acids, antioxidants, cytokines, growth factors, and cholesterol-derived hormones 
would be produced in the inflammatory exudate [60–65]. In addition, the amnion 
is an embryonic functional axis with strong neural potential [66]. Amnion-derived 
multipotent progenitor cells secrete a unique combination of cytokines and growth 
factors, called the amnion-derived cellular cytokine solution, which establishes a 
connection between mesenchymal and epithelial cells during embryo development 
[67]. Furthermore, pluripotent stem cells within the amniotic fluid could be a new 
source for stem cell research [68] (Figure 2).
In turn, during trophoblast differentiation, trophoblast cells exhibit intense 
phagocytic activation leading to events as diverse as engulfment and destruction 
of extracellular material and the production of inflammatory mediators that may 
modulate both the immune response [69] and trophoblast invasiveness [70]. The 
wall of the secondary yolk sac in mammals is formed by an external mesothelial 
layer facing the exocoelomic cavity, a vascular mesenchyme and an endodermal 
layer facing the yolk sac cavity [60]. The formation of blood islands in the mes-
enchymal layer promotes the development of hematopoiesis and angiogenesis. 
Hemangioblasts found in these blood islands could generate blood cells through 
intermediate progenitors called hemogenic endothelial cells [71]. From the sixth 
week of gestation, the secondary yolk sac appears as a cystic structure covered 
by numerous superficial small vessels [60]. The mesothelial and endodermal 
layers have absorptive functions and are active in endocytosis/digestion [72]. In 
addition, the endodermal layer in the source of several proteins including acute-
phase proteins, such as prealbumin, albumin, transferrin, and α1-antitrypsin 
[73], as well as α-fetoprotein, which is produced by both the adult and fetal 
liver [60, 71]. A major function of the yolk sac is carbohydrate, protein, and 
lipid accumulation for embryo nutrition (vitellum) [74]. The yolk sac, therefore, 
provides lipids and lipid-soluble nutrients to embryos during the early phases of 
development [74].
It could be considered that the trophoblastic-yolk sac-related phenotype could 
favor the regulation of lipid metabolism genes [75], the hematopoietic-cell derived 
control with recruitment of immune cells and the induction of an angiogenic 
switch [71] to enable new tissue immunological tolerance during the inflamma-
tory response [22]. In addition, through the synthesis and release of acute-phase 
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proteins, this extra-embryonic phenotype could reduce oxidative, nitrosative, and 
enzymatic stress, activate the complement-coagulation system, regulate the lipid 
metabolism [74], and favor phagocytosis [69, 70, 72], a specific form of endocytosis 
primarily associated with nutrition in unicellular organisms and with innate and 
adaptive immunity in mammals [69] (Figure 2).
The molecular and cellular contribution made by the above-mentioned extra-
embryonic membranes, i.e., coelomic-amniotic and trophoblast-yolk sac to the 
intra-embryonic mesoderm, could be essential for embryo development and 
organogenesis [76]. Moreover, these primitive extra-embryonic structures can be 
internalized by the embryo at the early developmental stages [76]. Consequently, 
the hypothesized reexpression of the functions made by these extra-embryonic 
membranes during the postnatal life, when an inflammatory process is produced, 
could be a key process needed to repair the injured organism [7, 22, 54].
Both the coelomic-amniotic and trophoblast-yolk sac phenotypes reexpressed 
during the inflammatory response would therefore contribute to the formation of 
new tissue by regeneration and/or by scarring. Therefore, these two extra-embry-
onic phenotypes could act on the injured interstitium in a similar fashion as they act 
during embryonic development, using similar mechanisms [7, 22].
The hypothesized comparison between the coelomic-amniotic and trophoblastic-
yolk sac phenotypes with the neurogenic and immune inflammatory phenotypes, 
respectively, would explain that the interstitial integration of both pathological axes 
in the injured tissues and organs could finally induce a gastrulation-like process [54] 
(Figure 3). It could be accepted that the above-mentioned extra-embryonic pheno-
types are internalized during gastrulation to create the intra-embryonic mesoderm 
[76]. Gastrulation is the first major shape change of the developing embryo. In this 
development phase, the three embryogenic germ layers, i.e., ectoderm, mesoderm, 
and endoderm, are delineated [37]. Afterward, mesenchymal-epithelial transitions 
occur to create a secondary epithelium as part of somitogenesis. Then commitment 
and diversification of cells forming mesoendodermal structures are produced [77, 
78]. The concept that fibroblasts are simple residual embryonic mesenchymal cells 
explains the incorrect and often interchangeable substitution of the term fibroblast 
for mesenchymal cell [78]. The vast arrangement of the mesenchyma, in the extra- and 
intra-embryonic structures, suggests an important role of the mesenchyma in orches-
trating embryo development. In addition, mesenchymal stem cells are a versatile 
group of cells derived from mesodermal progenitors and can be found in several fetal 
and adult tissues [28–39].
Figure 2. 
The recapitulated extra-embryonic functions in the portal hypertensive inflammatory response. Inflammation 
could recapitulate ontogeny by reexpressing two hypothetical extra-embryonic axes: the exocoelomic-amniotic 
axis and the trophoblastic-yolk sac axis in the interstitial space of the injured tissue. The interstitial integration 
of both pathological axes into the injured tissues and organs could finally induce a gastrulation-like process, 
which contributes to develop a new tissue by regeneration and/or by scarring. A: amnion; EC: exocoelomic 
cavity; T: trophoblast; Y: yolk sac.
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5.  The portal hypertensive inflammatory response: an ontogenic 
recapitulation
The portal venous system includes all veins that carry blood from the abdominal 
part of the alimentary tract, spleen, pancreas, and gallbladder to the liver [79]. The 
fetal architecture of the afferent portal venous circulation of the liver is acquired 
between the fourth and sixth week. At the end of this process, the portal venous 
system is formed from several distinct segments of the previous extra-embryonic 
vitelline veins. The efferent venous vessels of the liver also derive from the extra-
embryonic vitelline veins [80].
The right and left paired vitelline veins transport blood from the yolk sac to 
the heart [80]. Hence, this type of circulation will be maintained and represented 
by the portal venous system; although, in this case, the blood transport is from 
the abdominal part of the alimentary tract, including the microbiome, spleen, 
pancreas, and gallbladder to the heart, but after passing through the liver [79]. 
Therefore, the portal venous system allows for the spatial distribution of different 
splanchnic functions and their coordinated integration that also is essential for the 
physiological functioning of the organism.
The existence of hyperpressure in the portal venous system induces the impair-
ment of the splanchnic functions that, in addition are aggravated by the associ-
ated progression of the liver disease [81]. It could be hypothesized that chronic 
hemodynamic, vascular, and metabolic changes in portal hypertension could have 
an inflammatory origin, most probably subsequent to splanchnic inflammation 
[81–83]. Since, it has been proposed that the inflammatory response could reca-
pitulate ontogeny by reexpressing the two hypothetical extra-embryonic axes, i.e., 
coelomic-amniotic and trophoblastic-yolk sac, in the interstitial space of the injured 
tissue [7, 22, 54], the splanchnic alterations related to portal hypertension could 
be also attributed to a recapitulation of the embryonic functions of the tissues and 
organs whose venous drainage is made for the portal system.
In this case, the splanchnic changes related to portal hypertension would rep-
resent the ontogenic recapitulation of the coelomic-amniotic-related (neurogenic 
inflammatory phenotype) and trophoblastic-yolk sac-related (immune inflam-
matory phenotype) functions. These functions would induce a gastrulation-like 
process (endocrine inflammatory phenotype), which would remodel it, since they 
are coupled into the interstitium of the splanchnic organs and tissues.
Figure 3. 
The reexpression of the two hypothetical extra-embryonic axes. The exocoelomic-amniotic axis and the 
trophoblastic-yolk sac axis in the interstitial splanchnic space; i.e., the gut-liver axis. The interstitial activation 
of these two extra-embryonic axes induce a gastrulation-like process, which causes portal fibrosis and steatosis 
in the liver while in the gastrointestinal tract an excessive angiogenic response is produced. BP: biliary 
proliferation; E: enterocyte; F: fibrosis; Fi: fibroblasts; G: goblet cell; KC: Kupffer cell; H: hepatocyte; HSC: 
hepatic stellate cell; IC: Ito cell; Le: leukocyte; Mo: macrophages; MF: myofibroblasts; SC: stem cells.
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resent the ontogenic recapitulation of the coelomic-amniotic-related (neurogenic 
inflammatory phenotype) and trophoblastic-yolk sac-related (immune inflam-
matory phenotype) functions. These functions would induce a gastrulation-like 
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The reexpression of the two hypothetical extra-embryonic axes. The exocoelomic-amniotic axis and the 
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6.  The reexpresion of the coelomic-amniotic-related phenotype in portal 
hypertension
Portal hypertension could evolve with the reexpression of the coelomic-amniotic 
phenotype, which begins with a pathological neuromuscular response that includes 
sensitive impairment, like unconscious stress sensation with autonomic dysfunc-
tion, and motor alterations including liver vasoconstriction (ischemia) and gut 
vasodilation (reperfusion) [1, 83]. It is noteworthy that although the mesenteric 
and the hepatic vascular beds share alterations in the same vasoactive pathways, 
they are not working in parallel [1]. Unlike the vasoconstriction in the intrahepatic 
vasculature, the alimentary tract vasculature undergoes a progressive vasodila-
tion. In turn, the splanchnic vasodilation produces systemic hypotension, vascular 
underfilling, stimulation of endogenous vasoactive systems, including the renin-
angiotensin-aldosterone system with save of Na+ and water, plasma volume expan-
sion, and increased cardiac index (hyperkinetic syndrome) [2, 79].
It is accepted that the hyperkinetic syndrome plays a key role in the pathogenesis 
of renal dysfunction and ascites in chronic liver disease [83]. Therefore, a basic 
pathogenic mechanism of this complex neurovascular response would be chronic 
hydroelectrolytic alterations [81].
The central nervous system has an initial and important influence in the evolu-
tion of portal hypertension. Chronic liver disease and portal hypertension can 
stimulate the hypothalamic-pituitary-adrenal axis and produce chronic secondary 
autonomic dysfunction [84] associated with a decreased response to vasoconstric-
tors, which may be caused by an increased concentration of vasodilators, including 
vasodilating peptides [85]. Chronic secondary autonomic dysfunction produces 
orthostatic hypotension, fatigue, gastrointestinal mobility disorders, with delayed 
gastric emptying, and prolonged transit times [84]. In addition, the central nervous 
system can influence immune function by stimulating the hypothalamic-pituitary-
adrenal axis. It can also activate specific pathways within the sympathetic nervous 
system, which mainly damps down the immune phenotype triggered by the inflam-
matory splanchnic response [86].
The later evolution of the portal hypertensive syndrome is possibly determined 
by increased endothelial permeability in the gut-liver axis, which is secondary to a 
complex neurovascular response, that it also produces interstitial edema [81]. The 
increased hydrostatic pressure should preferentially drive fluid into the lymphatics, 
thus increasing mesenteric lymph flow [87, 88] and resulting in dilation of cistern 
chili [89]. It is accepted that when the high-output state of the mesenteric lymph 
circulation is overwhelmed, excess lymph is collected in the peritoneal cavity 
leading to ascites [87] and in 0.5–1% of cirrhotic patients even chylous ascites [90]. 
It has been proposed that decompensation related to severe hepatic insufficiency 
would induce an acute-on-chronic inflammatory response [81]. In this case, the 
splanchnic interstitium, the mesentery lymph, and the peritoneal mesothelium seem 
to create an inflammatory axis that produces ascites [91, 92].
Ascitic fluid formation is a not well-known pathogenic mechanism. However, 
ascitic fluid is a bioactive medium containing electrolytes, with high levels of 
sodium and proteins including albumin and enzymes, as well as cells including 
leukocytes [93]. Some of these characteristics make it similar to another bioac-
tive medium, the amniotic fluid [94, 95]. Amniotic fluid, the protecting liquid 
contained in the amnion cavity, is an essential component for fetal development 
and maturation during pregnancy [95–97]. The hypothetical comparison of 
amniotic and ascitic fluid characteristics would make it worthwhile to reapproach 
the role of peritoneal mesothelial cells in the etiopathogeny of ascites in the portal 
hypertensive syndrome [81]. The functional comparison of amniotic and ascitic 
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fluids would imply that in the decompensated portal hypertensive syndrome, the 
abdominal mesothelium acquires properties of the amniotic membrane or amnion. 
This hypothesis would imply several suggestions. For example, the intestine and, 
by extension, the liver, could not benefit from the supposed trophic properties of 
the ascitic fluid, given that peritoneal cavity-gastrointestinal tract pathway does 
not exist [91, 92]. In this way, the ascitic fluid could have therapeutic actions if it is 
administered by the enteral route in the cirrhotic patients [91, 92].
The interstitial edema in the gut-liver axis could be considered as the space 
where the battle of inflammation develops. In particular, during the intestinal 
inflammatory response secondary to portal hypertension the interstitial space 
increases in size as a consequence of successive infiltration suffered by plasmatic 
molecules, blood cells, and bacteria. The impairment of the lymph pumping and 
lymphangiectasia also collaborate in producing splanchnic edema [98, 99]. There 
is increased intestinal epithelial permeability associated with the endothelial 
post-capillary permeability in patients with chronic liver disease [100]. Findings of 
increased endotoxin and bacterial DNA in blood in patients with cirrhosis support 
the relevance of the increased intestinal epithelial permeability observed in these 
patients with portal hypertension [99, 100].
Liver and biliary tract diseases are common extra-intestinal manifestations for 
inflammatory bowel diseases, including gut microbiota alterations [101–105]. This 
is why the etiopathogenic participation of the intestinal inflammatory response 
cannot be excluded from the pathology produced in the hepatic parenchyma in 
the cases of portal hypertension. In particular, this pathophysiological mechanism 
occurs when portal hypertension leads to increased permeability of the sinusoidal 
endothelium that, in turn, causes edema in the interstitial space of Disse [106]. 
It is evident that the space of Disse has a connection to the interstitial space of 
the portal tract or space of Mall [98]. Therefore, it is likely that fluid filtered 
out of the inflamed sinusoids into the space of Disse flows through the channel 
traversing the limiting plate to reach the interstitial space of the portal tracts [98]. 
Interestingly enough, it was found that superphysiological or pathological levels 
of interstitial flow could induce fibroblast motility as well as drive myofibroblast 
differentiation and matrix alignment [106]. Hence, fibroblasts appear to be highly 
sensitive to interstitial flow and heightened flow could drive myofibroblast differ-
entiation and extracellular matrix remodeling that recapitulates certain patho-
logical features of cirrhosis [107]. Besides, in cases of endotoxemia, this increased 
interstitial flow would collaborate in the production of edema in the space of 
Disse. In addition, endotoxemia favors the intrahepatic lymph stasis, which may 
be caused by a reduction in the pumping activity of the extra-hepatic and the 
intrahepatic large lymph vessels [108]. In turn, the edematous interstitial space of 
Disse could show analogies to typical stem cell niches to retain mesenchymal stem 
cells or stem-like cells as well as to influence their cellular fate [109]. In this sense, 
the edematous space of Disse could serve as a niche of the hepatic stellate cells 
because of their mesodermal origin [109].
7.  The reexpression of the trophoblastic-yolk sac-related phenotype in 
portal hypertension
An array of functions made up by the secondary yolk sac seems to be expressed 
by the organism when it suffers portal hypertension. In rats with prehepatic portal 
hypertension, the reexpression of this extra-embryonic phenotype by the splanchnic 
tissues and organs is coupled with the upregulation of the immune cells [2, 110, 111], 
as well as with the development of dyslipidemia and hepatic steatosis [112, 113]. 
Translational Studies on Inflammation
78
6.  The reexpresion of the coelomic-amniotic-related phenotype in portal 
hypertension
Portal hypertension could evolve with the reexpression of the coelomic-amniotic 
phenotype, which begins with a pathological neuromuscular response that includes 
sensitive impairment, like unconscious stress sensation with autonomic dysfunc-
tion, and motor alterations including liver vasoconstriction (ischemia) and gut 
vasodilation (reperfusion) [1, 83]. It is noteworthy that although the mesenteric 
and the hepatic vascular beds share alterations in the same vasoactive pathways, 
they are not working in parallel [1]. Unlike the vasoconstriction in the intrahepatic 
vasculature, the alimentary tract vasculature undergoes a progressive vasodila-
tion. In turn, the splanchnic vasodilation produces systemic hypotension, vascular 
underfilling, stimulation of endogenous vasoactive systems, including the renin-
angiotensin-aldosterone system with save of Na+ and water, plasma volume expan-
sion, and increased cardiac index (hyperkinetic syndrome) [2, 79].
It is accepted that the hyperkinetic syndrome plays a key role in the pathogenesis 
of renal dysfunction and ascites in chronic liver disease [83]. Therefore, a basic 
pathogenic mechanism of this complex neurovascular response would be chronic 
hydroelectrolytic alterations [81].
The central nervous system has an initial and important influence in the evolu-
tion of portal hypertension. Chronic liver disease and portal hypertension can 
stimulate the hypothalamic-pituitary-adrenal axis and produce chronic secondary 
autonomic dysfunction [84] associated with a decreased response to vasoconstric-
tors, which may be caused by an increased concentration of vasodilators, including 
vasodilating peptides [85]. Chronic secondary autonomic dysfunction produces 
orthostatic hypotension, fatigue, gastrointestinal mobility disorders, with delayed 
gastric emptying, and prolonged transit times [84]. In addition, the central nervous 
system can influence immune function by stimulating the hypothalamic-pituitary-
adrenal axis. It can also activate specific pathways within the sympathetic nervous 
system, which mainly damps down the immune phenotype triggered by the inflam-
matory splanchnic response [86].
The later evolution of the portal hypertensive syndrome is possibly determined 
by increased endothelial permeability in the gut-liver axis, which is secondary to a 
complex neurovascular response, that it also produces interstitial edema [81]. The 
increased hydrostatic pressure should preferentially drive fluid into the lymphatics, 
thus increasing mesenteric lymph flow [87, 88] and resulting in dilation of cistern 
chili [89]. It is accepted that when the high-output state of the mesenteric lymph 
circulation is overwhelmed, excess lymph is collected in the peritoneal cavity 
leading to ascites [87] and in 0.5–1% of cirrhotic patients even chylous ascites [90]. 
It has been proposed that decompensation related to severe hepatic insufficiency 
would induce an acute-on-chronic inflammatory response [81]. In this case, the 
splanchnic interstitium, the mesentery lymph, and the peritoneal mesothelium seem 
to create an inflammatory axis that produces ascites [91, 92].
Ascitic fluid formation is a not well-known pathogenic mechanism. However, 
ascitic fluid is a bioactive medium containing electrolytes, with high levels of 
sodium and proteins including albumin and enzymes, as well as cells including 
leukocytes [93]. Some of these characteristics make it similar to another bioac-
tive medium, the amniotic fluid [94, 95]. Amniotic fluid, the protecting liquid 
contained in the amnion cavity, is an essential component for fetal development 
and maturation during pregnancy [95–97]. The hypothetical comparison of 
amniotic and ascitic fluid characteristics would make it worthwhile to reapproach 
the role of peritoneal mesothelial cells in the etiopathogeny of ascites in the portal 
hypertensive syndrome [81]. The functional comparison of amniotic and ascitic 
79
The Wound-Healing Portal Hypertensive Response
DOI: http://dx.doi.org/10.5772/intechopen.84689
fluids would imply that in the decompensated portal hypertensive syndrome, the 
abdominal mesothelium acquires properties of the amniotic membrane or amnion. 
This hypothesis would imply several suggestions. For example, the intestine and, 
by extension, the liver, could not benefit from the supposed trophic properties of 
the ascitic fluid, given that peritoneal cavity-gastrointestinal tract pathway does 
not exist [91, 92]. In this way, the ascitic fluid could have therapeutic actions if it is 
administered by the enteral route in the cirrhotic patients [91, 92].
The interstitial edema in the gut-liver axis could be considered as the space 
where the battle of inflammation develops. In particular, during the intestinal 
inflammatory response secondary to portal hypertension the interstitial space 
increases in size as a consequence of successive infiltration suffered by plasmatic 
molecules, blood cells, and bacteria. The impairment of the lymph pumping and 
lymphangiectasia also collaborate in producing splanchnic edema [98, 99]. There 
is increased intestinal epithelial permeability associated with the endothelial 
post-capillary permeability in patients with chronic liver disease [100]. Findings of 
increased endotoxin and bacterial DNA in blood in patients with cirrhosis support 
the relevance of the increased intestinal epithelial permeability observed in these 
patients with portal hypertension [99, 100].
Liver and biliary tract diseases are common extra-intestinal manifestations for 
inflammatory bowel diseases, including gut microbiota alterations [101–105]. This 
is why the etiopathogenic participation of the intestinal inflammatory response 
cannot be excluded from the pathology produced in the hepatic parenchyma in 
the cases of portal hypertension. In particular, this pathophysiological mechanism 
occurs when portal hypertension leads to increased permeability of the sinusoidal 
endothelium that, in turn, causes edema in the interstitial space of Disse [106]. 
It is evident that the space of Disse has a connection to the interstitial space of 
the portal tract or space of Mall [98]. Therefore, it is likely that fluid filtered 
out of the inflamed sinusoids into the space of Disse flows through the channel 
traversing the limiting plate to reach the interstitial space of the portal tracts [98]. 
Interestingly enough, it was found that superphysiological or pathological levels 
of interstitial flow could induce fibroblast motility as well as drive myofibroblast 
differentiation and matrix alignment [106]. Hence, fibroblasts appear to be highly 
sensitive to interstitial flow and heightened flow could drive myofibroblast differ-
entiation and extracellular matrix remodeling that recapitulates certain patho-
logical features of cirrhosis [107]. Besides, in cases of endotoxemia, this increased 
interstitial flow would collaborate in the production of edema in the space of 
Disse. In addition, endotoxemia favors the intrahepatic lymph stasis, which may 
be caused by a reduction in the pumping activity of the extra-hepatic and the 
intrahepatic large lymph vessels [108]. In turn, the edematous interstitial space of 
Disse could show analogies to typical stem cell niches to retain mesenchymal stem 
cells or stem-like cells as well as to influence their cellular fate [109]. In this sense, 
the edematous space of Disse could serve as a niche of the hepatic stellate cells 
because of their mesodermal origin [109].
7.  The reexpression of the trophoblastic-yolk sac-related phenotype in 
portal hypertension
An array of functions made up by the secondary yolk sac seems to be expressed 
by the organism when it suffers portal hypertension. In rats with prehepatic portal 
hypertension, the reexpression of this extra-embryonic phenotype by the splanchnic 
tissues and organs is coupled with the upregulation of the immune cells [2, 110, 111], 
as well as with the development of dyslipidemia and hepatic steatosis [112, 113]. 
Translational Studies on Inflammation
80
Prehepatic portal hypertension is one factor determining bacterial intestinal trans-
location to mesenteric lymph nodes [111, 114]. In addition, the increased presence 
of mast cells in the hypertrophied mesenteric lymph nodes [115] would not only col-
laborate in the production of mesenteric adenitis [111], but also would constitute a 
source of inflammatory mediators located between the intestine and systemic blood 
circulation [116]. The mesenteric lymph nodes are key structures involved in the 
gut-associated lymphoid tissue (GALT) [117]. GALT constitutes the largest lymphoid 
organ of the body, and its activation in portal hypertensive enteropathy results in the 
release of several inflammatory mediators. These mediators would be transported by 
the intestinal lymph nodes to the pulmonary circulation inducing an inflammatory 
phenotype and later to the systemic circulation [91, 118, 119].
In response to bacterial translocation, gut epithelial cells release chemokines that 
induce the recruitment of dendritic cells to the mucosae [100, 114]. Once activated, 
mature intestinal dendritic cells can induce and prime mucosal and mesenteric 
lymph nodes, B and T cells [100, 114]. After maturation, these B and T cells are 
released into the blood stream and, due to surface expression of the specific homing 
markers, home back to reside within the lamina propria [114]. In addition, aberrant 
intestinal T lymphocytes homing to the liver may contribute to trigger immune 
hepatic damage [100]. Moreover, data from the literature indicate a relationship 
between the gut microbiota and the intestinal stem cells. Thus, lipopolysaccharide-
sensitive cell types can be seen within bone marrow-derived cells which are 
involved in the development of inflammation in the adipose tissue of obese and 
type 2-diabetic mice [120]. Intestinal epithelial cells not only produce and release 
mediators affecting immune cells, but they also respond to factors produced by the 
subjacent immune cells [121]. In addition to the damage of intestinal epithelial cells, 
intestinal epithelial barrier dysfunction can result from loss of junctional complex 
integrity with increased paracellular permeability [100].
Nowadays, there have been various reports suggesting the role of gut flora and 
bacterial translocation in the pathogenesis of portal hypertension and chronic 
liver disease [101, 102, 122]. Translocated bacterial products could activate Kupffer 
cells through pattern recognition receptors such as toll-like receptors (TLRs) and 
NOD-like receptors (NLRs). Recent studies suggested that TLR4 signaling can be 
activated not only by pathogen-associated molecular patterns (PAMPs), but also 
by some endogenous ligands or damage-associated molecular patterns (DAMPs), 
which are released from damaged cells [123, 124]. In turn, activated Kupffer cells 
significantly increase their release of oxidative and nitrosative stress species and 
proinflammatory cytokines, including chemokines [101].
Chemokine expression by Kupffer cells, hepatic stellate cells, and sinusoidal 
endothelial cells drive the migration of immune cells populations [125]. In par-
ticular, CXCL12 (SDF-1α), which binds to the CXCR4 receptor, regulates several 
pathological responses. CXCL12 is crucial in early embryogenesis, hematopoiesis, 
and angiogenesis, as well as maintenance of the bone marrow stem cell niche 
[125]. In addition, the liver with its dual arterial and venous blood supply has a 
low oxygen tension, which has worsened during portal hypertension leading to 
hypoxic environment that could stimulate CXCL12 production with recruitment of 
immune cells [125].
Hepatic macrophages hold a central position in the pathogenesis of chronic liver 
injury. Resident hepatic macrophages or self-renewing embryo-derived local mac-
rophages, i.e., Kupffer cells, appear essential for initiating inflammatory response 
while infiltrating bone marrow-derived macrophages originated from circulating 
monocytes are linked to chronic inflammation and fibrogénesis [126]. However, 
after local differentiation into resident macrophages they could restore liver integ-
rity and then are termed restorative macrophages [126].
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In the yolk sac, the blood islands are generated by mesodermal cell aggregates 
that differentiate into both hematopoietic and endothelial cells [127]. The simulta-
neous appearance of these two lineages suggests the existence of a common ances-
tral precursor for endothelial and hematopoietic cells: the hemangioblast [128]. In 
addition, the embryo could generate their definitive hematopoiesis from a hemo-
genic endothelium derived from a transient mesenchymal population [126, 127]. 
This close physiological ontogenic association between hematopoiesis and angio-
genesis could persist during the pathophysiological response that produces portal 
hypertension. In this case, during the evolution of portal hypertensive pathology, 
the gut-liver axis could recapitulate the functions derived from the mesenchymal-
angiogenic-hematopoietic axis that form the blood islands in the yolk sac [125, 127].
It has been suggested that mast cells could mediate the pathogenic relation-
ship between portal hypertension and the angiogenic hyperactivity that occurs in 
experimental portal hypertension, particularly in the alimentary tract [110, 115]. 
The formation of new blood vessels is a key mechanism in the pathogenesis of por-
tal hypertension [129]. Although the precise mechanisms by which the angiogene-
sis-associated response in portal hypertension is modulated remain to be defined, 
several mediators produced by mast cells are involved in angiogenesis [110]. This 
is the reason why it has been proposed that the angiogenic hyperactivity occur-
ring in portal hypertension could mainly be mediated by mast cells [110, 115]. In 
addition, the exceeding angiogenesis through the neoformed collateral circulation 
allows portal blood flow to directly reach the systemic circulation [79]. However, 
the morphological vascular alterations stand out in the chronic portal hypertensive 
enteropathy [130]. The exacerbated angiogenesis produced in the intestinal wall 
during the evolution of portal hypertension is similar to the process of vasculo-
genesis that occurs in the extra-embryonic membranes [131]. More explicitly, the 
endothelial cells of the blood islands expand to cover the entire yolk sac creating a 
vascular network known as the capillary plexus [131], the precursor of the vitelline 
veins which, in turn, are the embryonic origin of the portal system [80].
From an ontogenic point of view, vitellogenesis plays a vital role in providing lipids 
and lipid-soluble nutrients to embryos [132]. The ability to transport fat in the form of 
lipoproteins through the circulatory system by eukaryotes is one of the most significant 
functions right from the beginning of existence [133]. Thus, the evolutionary advance-
ment of storing energy in the form of fat has provided organisms with enormous 
advantages for adapting to environmental and developmental changes [134].
We have previously shown that prehepatic portal hypertension in the rat induces 
liver steatosis and causes changes in lipid and carbohydrate metabolisms similar to 
those produced in chronic inflammatory conditions described in metabolic syn-
drome in humans [112, 113, 135]. It has been suggested that in experimental pre-
hepatic portal hypertension, the liver could constitute a kind of yolk sac in which 
the animal carries out a pathological deposit of lipids [81, 92]. Prehepatic portal 
hypertension in the rat, both in short- (1 month) and in the long-term (1 year), pro-
duces hepatic accumulation of triglycerides and cholesterol [112, 113]. Nonetheless, 
the mechanisms by which portal hypertension could induce liver steatosis are not 
finally understood [135] (Figure 4).
Inflammation, and the concomitant acute-phase response, induces marked 
changes in the lipoprotein profile [136]. Thus, in the prehepatic portal hypertensive 
rat, liver steatosis is associated with the plasmatic increase of low density lipopro-
tein (LDL) and lipopolysaccharide binding protein (LBP) as well as a reduction of 
high-density lipoproteins (HDL) [135]. In turn, hepatic steatosis might play a key 
role in the pathogenesis of cardiovascular disease through the systemic release of 
several inflammatory mediators and/or through the production of insulin resistance 
and atherogenic dyslipidemia [137, 138].
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Gut microbiota could alter nutrient absorption, energy homeostasis, and intes-
tinal permeability, with a translocation of bacteria-derived products to the liver. It 
could also cause hepatocellular inflammation and nonalcoholic fatty liver disease 
(NAFLD) [105, 139]. Western diet seems to cause dysbiosis, i.e., vitellogenic micro-
biome, which affects host gastrointestinal metabolism and contributes to higher 
incidences of metabolic syndrome, including NAFLD [139, 140]. Genetics might 
also modulate the spectrum of liver disease and its progression [141]. In turn, when 
portal hypertension coexists, the factors previously mentioned would represent an 
associated risk factor for the development of NAFLD and metabolic syndrome.
In portal hypertension, cholesterol synthesis could play a key role during the 
hypothesized reexpression of the vitellogenic phenotype. The liver plays a central 
role in cholesterol metabolism. Hepatocytes not only express a number of different 
lipoprotein receptors that enable them to take up cholesterol, but also synthesized 
cholesterol de novo within the liver [142, 143]. In addition, to these input pathways, 
the liver secretes cholesterol by two routes, the first, within triglyceride-rich very 
low density lipoprotein (VLDL) to supplying peripheral cells with fatty acids, fat 
soluble vitamins, and cholesterol. And, secondly, the liver releases cholesterol into 
bile, either directly as free cholesterol or after conversion into bile acids [142].
Cholesterol is used locally to synthesize glucocorticoids and mineralocorticoids, 
which could regulate microcirculatory functions and immune cell activation [144]. 
Perhaps, the ability of local corticosteroid synthesis is upregulated in the inflamed 
tissue due to the metabolic and functional needs of the neoformed tissue includ-
ing angiogenesis in portal hypertension [7, 22]. Moreover, the pro-inflammatory 
Figure 4. 
Histopathological images of rat liver with long-term portal hypertension (3 months). The liver presents 
diffuse steatosis (superior) and portal fibrosis (inferior) as the result of splanchnic and systemic inflammatory 
responses. This inflammatory process could be proposed as the representation of the recapitulated extra-
embryonic functions in the splanchnic area when portal hypertension is developed.
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and anti-inflammatory functions of androgens and estrogens and progesterone, 
respectively, suggest that endogenous sex steroids may influence immune func-
tions [145–147] and, therefore, the evolution of the portal inflammatory response. 
In particular, estrogen has been shown to be effective in animal models of portal 
hypertension with cirrhosis by suppressing hepatic fibrosis and relaxing the hepatic 
sinusoid, and could reverse the severity of hyperdynamic circulation and the vas-
cular hyporeactivity of the mesenteric arteries in portal hypertensive rats without 
cirrhosis [148].
Hence, it could be proposed that within the splanchnic impairments related 
to portal hypertension, the stimulation of the angiogenic-hematopoietic axis, 
the cellular and bacterial interstitial infiltration of the tissues and organs and the 
acute-phase-response, including dyslipidemia and hepatic steatosis (vitellogenic 
phenotype), seem to recall the functions characteristic of the secondary yolk sac 
during embryo development.
In this sense, the microvesicles, released from practically all cells including 
mesenchymal stem cells [149], would collaborate in inducing the recapitula-
tion of extra-embryonic functions during the evolution of portal hypertension. 
Microvesicles contain lipids, proteins, RNA, and micro-RNAs and could act as 
vectors of information that regulate the function of target cells [150]. Microvesicles 
from inflammatory cells are suspected to be involved in various diseases. In particu-
lar, microvesicles probably enhance portal hypertension by contributing to splanch-
nic vasomotor alterations and angiogenesis [151].
8.  Coupling extra-embryonic phenotypes to induce a gastrulation-like 
liver phenotype
In the current review, we propose that during the evolution of portal hyperten-
sion different extra-embryonic functions, such as the coelomic-amniotic and the 
trophoblastic-yolk sac or vitelline function, would be successively recapitulated. 
If so, the inflammatory conditions that characterize portal hypertension could 
actually represent the reexpression of extra-embryonic mechanisms that have been 
already used during the early phases of embryonic development. In this way, the 
pathophysiological mechanisms involved in the above-mentioned inflammatory 
response could represent the recapitulation of the extra-embryonic functions, 
which collaborate together to make an embryo-like tissue from gastrulation [7, 54] 
(Figure 3).
The liver stands out among other organs since its persistent injury usually results 
in the chronic activation of inflammation and the wound-healing response [7, 152]. 
Development of the liver during early embryogenesis may share similarities with 
pathophysiological processes seen in adulthood, such as acute liver injury and liver 
regeneration, but also in liver fibrosis [152–154]. The increasing knowledge of the 
extra-hepatic involvement typical of this fibrotic liver disease, however, suggests 
that this wound healing process is associated with a complex systemic pathogenesis 
[155]. Portal hypertension is the major hemodynamic complication of a variety of 
diseases that obstruct portal blood flow, including liver cirrhosis [79]. Portal hyper-
tension in the cirrhotic patient could be associated with hyperkinetic syndrome, 
increased total blood volume by sodium and water retention [155], endothelial 
dysfunction [81, 83, 156] in the splanchnic and systemic circulation [81, 83, 119], 
esophageal varices, ascites, encephalopathy, and hepatorenal syndrome [157].
The severe systemic complications of the portal hypertension syndrome 
accompanying the wound-healing liver reaction could be based on some metabolic 
similarities that can be established with the extra-embryonic coelomic-amniotic 
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Figure 5. 
Schematic representation of the systemic inflammatory response in portal hypertension in order to produce 
a systemic wound-healing phenotype. By means of two inflammatory phenotypes expression; i.e., neurogenic 
(CNS and AG) and immune (BMA), into the interstitial injured splanchnic area, an endocrine phenotype 
could be induced, that ultimately would causes a wound-like response. Thus, fibrosis and angiogenesis will be 
produced in the splanchnic area. A: angiogenesis; AG: adrenal gland; B: bile; BMA: bone marrow; BP: biliary 
proliferation; CHS: cholestasis; CNS: central nervous system; E: enterocyte; ES: endothelial sinusoid; G: goblet 
cell; HSC: hepatic stellate cell; IC: Ito cell; KC: Kupffer cell; Le: leukocyte; Mo: macrophages; M: myofibroblast; 
Mi: microbiome; SC: stem cells; SD: space of Disse.
and trophoblastic-yolk sac functions playing the leading role during embryonic 
development [7]. Thus, the confluence of these two extra-embryonic axes in the 
injured liver could favor a gastrulation-like response in which fibrogenesis could 
predominate [7, 22, 54]. Therefore, the wound-healing liver reaction that charac-
terizes the cirrhotic process could have properties comparable to an embryo and, 
in particular, with its initial evolutive phase, namely gastrulation [22]. If so, the 
gastrulation-related process with neoformation of a reparative tissue could be based 
on the recapitulation of the developmental process of the intra-embryonic mesen-
chyme [158].
The interstitial space of Disse could be schematically represented like an area 
fundamentally surrounded by a sinusoidal endothelium. Inside this endothelium, 
an inflammatory response is developed, which is made up by the hepatic stellate 
cell. In turn, the liver interstitial inflammation would be activated by means of the 
reexpression of extra-embryonic functions by the host organism, which provides 
molecules and cells selectively to the inflamed interstitial space through the sinusoi-
dal endothelium [22] (Figures 3 and 5).
Hepatic stellate cells are liver-specific mesenchymal cells located in the space 
of Disse between the sinusoidal endothelial cells and hepatic epithelial cells 
[159]. Hepatic stellate cells also known as Ito cells, fat-storing cells, vitamin 
A-storing cells, or lipocytes, store excess vitamin A as retinyl esters in lipid drop-
lets within their cytoplasm [159, 160]. In pathological conditions, hepatic stellate 
cells upon activation lose the vitamin A-containing lipid droplets and produce 
large amounts of collagen [160]. Therefore, modulation of vitamin A-containing 
lipid droplets has been suggested to have a therapeutic impact on the develop-
ment of liver fibrosis [160] (Table 2). Hepatic stellate cells are known to express 
both mesenchymal and neural lineage markers [161, 162]. Moreover, during 
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liver injury, stellate cells activate into alpha smooth muscle actin-expressing 
contractile myofibroblasts, which increase vascular resistance thereby promot-
ing portal hypertension [163, 164]. Mesodermal mesenchymal cells including 
hepatic stellate cells are the major source of myofibroblasts [164]. In this sense, 
activated-hepatic stellate cells also strengthen the immune response through the 
production of a wide array of cytokines and chemokines [4]. Finally, hepatic stel-
late cells are able to adopt a fibrogenic phenotype and participate in extracellular 
matrix remodeling [163] (Figure 4).
Kupffer cells activate hepatic stellate cells via paracrine mechanisms, likely 
involving the profibrotic and mitogenic cytokines TGF-β and PDGF [165, 166]. 
Early deposition of an extracellular matrix in the subendothelial space of Disse 
causes capillarization of the sinusoid, diminished liver function, and contributes 
to the perpetuation of hepatic stellate cell activation [159, 160, 167]. Liver fibro-
genesis is not only sustained by a heterogenic population of profibrogenic hepatic 
myofibroblasts [3, 4], but also includes mesothelial-related capsular fibrosis [167]. 
Mesothelial cells have a phenotype intermediate between epithelial cells and 
mesenchymal cells and these both type of cells could then undergo myofibroblastic 
transdifferentiation. Upon liver injury, it has been demonstrated that mesothe-
lial cells participate in capsular fibrosis of the liver surface via differentiation to 
hepatic stellate cells and myofibroblasts [167]. In portal hypertension, the forma-
tion of a fibrotic scar tissue in the liver is associated with the development of an 
excessive gastrointestinal angiogenic response [110]. Therefore, the two principal 
components for creating granulation tissue, i.e., fibroplasia and angiogenesis, are 
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distributed along the portal axis. In essence, the portal venous system continues 
playing a key role as a spatial delivery of functions in pathological situations.
9. Conclusion
The diverse functions of hepatic stellate cells in homeostasis and inflammation 
indicate the versatile nature of these mesenchymal-derived cells, which could adopt 
numerous phenotypes according to the interstitial microenvironmental character-
istics [163]. Therefore, these hepatic cellular population, thanks to their potential 
ability to integrate and reexpress functions showing analogies to extra-embryonic 
functions, display characteristics of stem/progenitor cells [109]. In this way, during 
the development of portal hypertension, hepatic stellate cells not only could reex-
press extra-embryonic functions but also could adapt themselves in order to induce 
a gastrulation-related process in the space of Disse. Therefore, by understanding 
the ontogenic interactions between hepatic stellate cells and the host inflammatory 
response in portal hypertension, it is possible to design effective therapeutic and 
prophylactic strategies to avoid or reverse wound-like hypertensive response.
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Abstract
Inflammatory bowel disease (IBD) is a group of intestinal disorders that cause 
prolonged inflammation of digestive tract. Chronic inflammation results in Crohn’s 
disease (CD) and ulcerative colitis (UC). There is a disruption of homeostasis of 
various regulatory factors, for example, cohesive functioning of intestinal epithelial 
barrier, macrophages, and cellular mediators such as cytokines and chemokines. 
Natural products derived from plants based on traditional system of medicine have 
exhibited efficacy for UC and CD in experimental models and clinical trials. In the 
present review, current developments of natural products and herbs for the treat-
ment of IBD in the context of Indian traditional medicine have been highlighted. 
Two classes of Ayurvedic formulation, fermented preparations (Asava and Arishta) 
and Ghrita (preparations involving butter), are employed for the maintenance of 
intestinal disorders. Here, we discuss mainly about the fermented preparations, 
their main constituents, and correlations with modern findings. The way these 
fermented formulations are processed also affects the extraction of constituents 
in them. So, the correlation between the chemistry of the plant material (their 
constituents as well) with the IBD was done. These correlations may serve as a step 
forward to reduce the gap between modern system of medicine and traditional 
system of medicine.
Keywords: inflammatory bowel disease, traditional system of medicine,  
fermented preparations, gallotannins, ellagitannins
1. Introduction
Inflammatory bowel disease (IBD) is the intestinal disorder induced by chronic 
gastrointestinal inflammation. Crohn’s disease (CD) and ulcerative colitis (UC) 
are global health problems, with the highest incidence and a prevalence rate of 
0.5–1.0% in Europe [1]. The incidence of IBD is increasing dramatically in Asian 
countries, especially in China. There is rising incidence and prevalence of inflam-
matory bowel disease in India, topping the Southeast Asian (SEA) countries [2]. 
IBD is relatively complex disease that involves numerous factors such as commensal 
flora, genetic factors, immune system dysfunction, and environmental risk factors 
[3]. The human gastrointestinal tract serves as the first-line sensor, and defense 
against external environment stimuli is exposed to the external environment, 
particularly to bacterial antigens released from resident microbiota. It is the chronic 
inflammation in the intestinal surface that first leads to the development of UC, 
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which can progress into CD and/or colon cancer [3]. Advances have been achieved 
in understanding the pathogenesis of IBD in the past few years, yet exact mecha-
nisms remain to be elucidated. Patients usually suffer from severe pain, diarrhea, 
abscesses, fistulas, abdominal pain, and stenosis. Thus the development of effective 
treatments and/or reducing the symptoms of patients with IBD is urgently needed. 
The current mainstream management of IBD includes antibiotics, corticosteroids, 
thiopurines, anti-tumor necrosis factor (TNF) antibodies, and aminosalicylates 
[2]. They have severe side effects such as diarrhea, nausea, vomiting, headache, 
and osteoporosis when used for the long term. One-third of CD patients undergo 
surgery after long-term use of these mainstream treatments [4].
The Indian System of Medicine which mainly comprises of Ayurveda (meaning 
the science of life) is one of the oldest systems of medicine in India. This system of 
using natural resources for better health was developed through the experimenta-
tion and experiences of day-to-day lifestyle of Indian people. Evolution of Ayurveda 
and plant-based remedies for health care through day-to-day life experiences is a 
part of cultural heritage of India. There is class of Ayurveda fermented prepara-
tions called Asava and Arishta mainly intended for intestinal disorders. These weak 
alcoholic preparations are more appreciated because of their quick action and high 
preserving qualities. These preparations are made by soaking the drugs, either 
powder form or in the form of decoction in a solution of sugar or jaggery, as the 
case may be for a specified period of time, during which it undergoes fermentation. 
It facilitates dissolution of active principles and acts as a preservative. For Arishta 
preparation, the drugs mentioned in the text are coarsely powdered, and the decoc-
tion is prepared by boiling the plant material in a specified volume of water till it is 
reduced to one-fourth of the original volume. The decoction is filtered using muslin 
cloth. Jaggery as prescribed in formula is added and dissolved. Drugs indicated as 
prakshepa dravyas (plant material added after preparing decoction) are finely pow-
dered and added. At the end Woodfordia fruticosa (Dhataki pushpa) if mentioned 
is added. The container is then sealed and kept for fermentation and monitored 
regularly. After the fermentation is over, the fluid is decanted without disturbing 
the sediment. The decanted preparation is then kept for maturation for 2 weeks. 
The fine particles in the decanted preparation settle down (Figure 1) [5, 6].
The present review mainly discusses the fermented preparations used in 
Ayurveda for the intestinal disorders and correlates the constituents used for the 
same. For the preparation of formulations in ancient times, mainly decoctions were 
used, and then they were preserved by some processing methods, as fermenta-
tion in the case of Asava and Arishta. During the making of formulations, it is the 
water-soluble ingredients that are mainly extracted to water, and during fermenta-
tion they are transformed fit for the body to be absorbed and are medicinally active. 
The formulations (Parthadyarishta, Abhayarishta, and Jirakadyarishta) have shown 
certain chemical changes during fermentation due to which the desired marker 
constituents in the decoction are transformed: polyphenolics to their monomeric 
counterparts and glycosides to their respective aglycones [7–9]. HPLC analysis 
of the selected formulations revealed that it is the polyphenolics which are easily 
decocted into water and they form the major constituent of these liquid oral for-
mulations. There is also a breakdown of high molecular weight polyphenolics into 
the low molecular weight phenolics as evident from the quantitative analysis of the 
formulations. The changes in marker concentrations during fermentation also affect 
the antioxidant activity of the decoction and formulation [7–9]. Major constituents 
in these formulations based on their analysis have revealed the presence of polyphe-
nolics (gallotannins and ellagitannins), flavonoids, 5- HMF, and phenolic glyco-
sides, and constituents of jaggery formed the major constituents in the formulation. 
These constituents are correlated with modern finding in next section.
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2.  Major constituents present in fermented preparations and correlation 
with inflammatory bowel disease
2.1 Gallotannins
Gallotannins are a major constituent of plant materials used for the preparation 
of fermented preparation Abhayarishta. The pericarp of Terminalia chebula fruit 
is used in the preparation which is rich in hydrolyzable tannins and is reported to 
contain the following constituents: chebulic acid (1), gallic acid (2), ethyl gallate 
(3), polygalloyl derivatives (4–6), chebulinic acid (7), chebulanin (7a), chebulagic 
acid (8), terchebin (9), and terchebulin (10). During the making of formulation, 
pericarp powder is boiled in water till the volume is reduced to one- fourth, and 
this process mainly decocts the hydrolyzable tannins. During fermentation these 
gallotannins are fermented to their monogalloyl and digalloyl derivatives (5) and 
other counterparts (chebulic acid (1) in case of T. chebula). The fermented counter-
parts in case of their preparations have shown more antioxidant activity [7]. They 
may have very good effect on IBD also as have shown to good inflammatory agents. 
For example, chebulic acid (1) inhibits TNF-α, TNF-α, IL-1β, and IL-6 as well as 
enhances antioxidant detoxification defensing mediators such as HO-1 and NQO1 
expression, through ERK/Nrf2 signaling in HUVEC [10, 11]. It may be noted that 
tannins in case of T. chebula are of chebuloyl derivative [12], and during fermenta-
tion 7, 7a, and 8 will be hydrolyzed in acidic conditions to chebulic acid (1). It is also 
one of the major constituents in the formulation Abhayarishta [7]. Other constitu-
ents formed in final processed formulation during fermentation were monogalloyl 
derivatives and digalloyl derivative. This could be attributed to the presence of free 
galloyl group at anomeric carbon that makes chebulinic acid (7) and chebulagic acid 
(8) susceptible for cleavage [13]. Moreover, the amount of chebulinic acid (7) in 
decoction was found to be less (which is normally 2–4% of total dry weight of plant 
material). The reason for this may be the possible hydrolysis of the chebulinic acid 
(7) during boiling (as simple boiling resulted in hydrolysis) or less extraction of 
the same due to its hydrophobic properties resulting from free galloyl groups [13]. 
Ethyl gallate (3) and gallic acid (1) were formed as hydrolytic products and etha-
nolysis of tannic acid (Figures 2 and 3). These fermentation products had better 
Figure 1. 
Method of preparation of fermented preparations in Ayurveda.
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radical scavenging activity [7], and among them gallic acid (1) has shown to induce 
ROS-dependent apoptosis and inhibited the growth of colon cancer cells [14]. These 
formulations are used as nutraceuticals in the Indian subcontinent [15], and the 
constituents present in the formulation (or formed during the fermentation) have 
good anti-inflammatory properties as discussed above.
2.2 Ellagitannins
Ellagitannins are the other major phytoconstituents that are extracted during the 
boiling/maceration with water. This is mainly due to the presence of hexahydroxy-
diphenic (HHDP) moiety in ellagitannins [13]. Their extractability in water is more 
than the gallotannins. Terchebulin (9), punicalagin (10), and punicalin (11) are the 
major ellagitannins present in decoction and are fermented to increase concentration of 
ellagic acid in the final formulation [7, 12]. Studies have shown that there is formation 
Figure 2. 
Structures of compound present in T. chebula (1–14).
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of urolithin A, B, and C by human gut microbiota when an ellagitannin-rich diet was 
given, and also these urolithins significantly inhibited TNF-α production. The most 
potent urolithin A inhibition was observed at nanomolar concentrations (at 0.625 μM 
29.2 ± 6.4% of inhibition). Urolithin C was the only compound inhibiting IL-6 produc-
tion (at 0.625 μM 13.9 ± 2.2% of inhibition) [16]. These studies clearly indicate that 
ellagitannin-rich plant material extract has a good effect on gut microbiota. A combina-
tion of the ellagitannin metabolites found in the colon, urolithins and ellagic acid, at 
concentrations achievable in the intestine after the consumption of pomegranate, was 
able to moderately improve the inflammatory response of colon fibroblasts and suggest 
that consumption of ellagitannin-containing foods has potential beneficial effects on 
gut inflammatory diseases [17]. Effectiveness of polyphenols in dysbiosis and colon-
related diseases mainly depends on their stability, absorption, and bioavailability and 
the gut microbiota composition [18]. Encapsulation technologies could be promising 
tools to improve bioavailability and bio-accessibility of polyphenols. In recent studies, 
several micro- and nano-encapsulation systems have been proposed for specific delivery 
of individual polyphenols or mixtures of polyphenols (food ingredients) in the gut [19].
2.3 Flavonoid glycosides and aglycones
Flavonoid glycosides and phenolic glycosides are the other class of phytocon-
stituents that are extracted in substantial amount during the boiling of plants 
during preparation of formulation. These were evident when formulations like 
Figure 3. 
Possible changes during fermentation in Abhayarishta.
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Jirakadyarishta and Parthadyarishta were analyzed for standardization purpose [8, 
9]. The chemical constituents that are present in cumin seeds (major plant material 
in Jirakadyarista) are water-soluble flavonoid glycosides luteolin 4′-O-glucoside 
7-O-galacturonoside (15), apigenin-7′-digalactouronoside (16), luteolin 
7-O-glucoside (17), apigenin 7-O-glucoside (18), flavonoid aglycones luteolin (19), 
apigenin (20), sesquiterpene lactone glucosides, cuminoside A (21) and cuminoside 
B (22), cumic acid (23), cuminyl alcohol (24), glycosides of 2-C-methyl-D erythri-
tol, alkyl glucosides, and various monoterpene glycosides [20–25].
RP-HPLC analysis of the decoction and the final processed formulation revealed 
that luteolin 4′-O-glucoside 7-O-galactouronoside (15) and luteolin 4´-O-glucoside 
7-O-galactouronoside (16a) were the two major constituents of the decoction of 
C. cyminum. Selective hydrolysis of 7-O-glucosides of luteolin and apigenin during 
fermentation resulted in an increase in the amount of luteolin and apigenin in the 
final processed formulation. The 4′-O-glucoside-7-O-galacturonide of luteolin and 
galacturonide derivative of apigenin was not hydrolyzed during fermentation [9]. 
An increase in luteolin and apigenin concentration is also good for the gut health as 
recent studies have shown that flavonoids participate in the regulation of intestinal 
tight junction barrier integrity and that this regulation may partially contribute to the 
flavonoid-mediated biological effects on our health [26]. Dietary flavonoids are often 
transformed before absorption, and this transformation modulates their biological 
activity. Health benefits from this aglycone consumption should be attributed to their 
bioactive metabolites and also to the modulation of the intestinal bacterial population 
[27]. Flavonoids are the major constituents in the formulation, and various beneficial 
actions of flavonoids at the GI have been demonstrated through various reports, for 
example, (i) protection of the intestinal epithelium against pharmacological insults and 
food toxins and (ii) modulation of the activity of enzymes involved in lipid and carbo-
hydrate absorption. Thus, they maintain the intestinal barrier integrity and modulate 
the secretion of gut hormones and finally modulate the GI tract immune system. They 
also have been shown to exert potential anti-colorectal cancer activity by shaping 
microbiota composition and function. The understanding of the mechanisms mediat-
ing the effects of flavonoids on the intestine (and its microbiota) is further required for 
the widespread recommendations of increasing the intake of plant bioactives [28].
Further, the addition of Woodfordia fruticosa for augmenting fermentation 
also adds flavonoid glycosides to the formulation in major quantity, as evident 
in the studies done on Parthadyarishta, where flavonoid aglycones quercetin and 
kaempferol were produced as fermentation products from flavonoid glycosides of 
Woodfordia fruticosa [8]. Thus these flavonoid glycosides and aglycones are present 
in substantial quantity in these formulations and have well-reported protective 
actions against the IBD through various mechanisms.
2.4 5-Hydroxymethyl furfuraldehyde (5-HMF)
5-Hydroxymethyl furfuraldehyde, 5-HMF (25), is another major constituent 
which is ought to be present in this class of formulation as per the analysis done for 
the selected formulations. 5-HMF is also present in decoction of fruits and flowers 
(V. vinifera and M. indica) used for preparation of fermented preparations. Another 
source for 25 in final processed formulation is jaggery and honey which is added in a 
substantial amount to augment fermentation (Figures 1 and 4). 5 -HMF is the major 
compound extracted during boiling and forms the major constituent in the formula-
tion and is also reportedly formed under acidic conditions from fructose [29]. There 
was an enormous increase in amount of 5-HMF (25) in formulation as compared 
with decoction. The concentration of 25 needs proper monitoring in this class of 
formulations as recent reports suggest it to be genotoxic and cytotoxic [30].  
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Further, Maillard reaction product components, namely, 5-hydroxymethyl furfural 
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Jirakadyarishta and Parthadyarishta were analyzed for standardization purpose [8, 
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compound extracted during boiling and forms the major constituent in the formula-
tion and is also reportedly formed under acidic conditions from fructose [29]. There 
was an enormous increase in amount of 5-HMF (25) in formulation as compared 
with decoction. The concentration of 25 needs proper monitoring in this class of 
formulations as recent reports suggest it to be genotoxic and cytotoxic [30].  
107
Review and Implications of Traditional Indian Medicine for Inflammatory Bowel Disease
DOI: http://dx.doi.org/10.5772/intechopen.89465
Further, Maillard reaction product components, namely, 5-hydroxymethyl furfural 
and 5-hydroxymethyl-2-furoic acid (HMFA), were shown to have bioactive poten-
tial, especially in regard to suppressing oxidative stress and inflammation in IFN-
γ- and PMA-induced Caco-2 cells [31]. 5-Hydroxymethyl furfural (HMF)–cysteine 
adduct, 1-dicysteinethioacetal–5-hydroxymethyl furfural (DCH), promoted the 
growth of Lactobacillus, Tyzzerella, Enterobacter, and Streptococcus and also increased 
Figure 4. 
Water-soluble constituents in cumin Cuminum cyminum seeds.
Figure 5. 
5-HMF(25) as major constituent in fermented preparation.
Translational Studies on Inflammation
108
the ratio of Firmicutes/Bacteroidetes and promoted the growth of Akkermansia, 
Shigella, and Escherichia while inhibiting the growth of Lactobacillus [32]. Thus these 
reports are suggestive of their usage in controlling IBD (Figure 5).
2.5 Bioactives present in jaggery
Jaggery constitutes a major part in this class of formulation. It is also used very 
frequently in other class of Ayurvedic formulations. Jaggery is traditionally made 
Figure 6. 
Flavonoid glycosides in sugarcane juice: (27–38).
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by boiling sugarcane juice to solid [33]. A review of chemistry of sugarcane juice 
and its products reveals that they are rich in phenolics, phenolic glycosides, and  
flavonoid glycosides (Figure 6), namely, diosmetin-8-C-glucoside (26), 
tricin-7-O-neohesperidoside (27), 4′,5′-dimethoxy-luteoline-8-C-glucoside (28), 
tricin-7-O-rhamnosylgalacturonide (29), tricin-7-O-glucoside (30), schaftoside 
(31), isoschaftoside (32), vitexin (33), and orientin (34). Four minor flavones 
swertisin (35), tricin-7-O-neohesperoside-4’-O-rhamnoside (36), tricin-7-O-
methylglucuronate-4’-O-rhamnoside (37), and tricin-7-O-methylglucuronide (38) 
were isolated and identified from sugarcane juice [34–39]. There are health benefits 
from phenolic consumption, mainly attributed to their bioactive metabolites and 
also to the modulation of the intestinal bacterial population. Phenolic contents of 
the herbal preparation can be increased as a consequence of fermentation, and a 
positive correlation between polyphenols and the antioxidant activities of herbs has 
been well demonstrated. This is in agreement with evidence showing fermentation-
mediated enhancement of the pharmacological properties and therapeutic effica-
cies of herbal formulations against a number of diseases including obesity and 
inflammation [27].
3. Conclusions
From the evidences cited above, it is very clear that herbal formulations and 
their analysis for the presence of bioactive constituents are important as far as 
their efficacy is concerned. Three formulations have been cited, and major con-
stituents present in them have proven to be good agents for IBD. Natural products 
and herbal medicine formulas have exhibited efficacy in preclinical evaluation, 
improved symptoms, and decreased medical costs for IBD patients. The compo-
nents of natural products and herbs are complex and have multiple mechanisms 
of action that may synergize to produce their overall efficacy. Intensive studies 
based on murine models of IBD and human studies are required for evaluating 
the efficacy of natural products and herbal medicine as an alternative treatment 
for IBD. Thus identification of the active component(s) and optimization of the 
dosage and development of treatment protocol(s) are of primary importance. The 
modern hyphenated techniques having high-throughput technologies shall enable 
the identification of the effective ingredient(s) and reveal the mechanisms of 
action of natural products and herbs in treating IBD. Natural products and herbal 
formulations (as co-adjuvants) with existing medications may also provide new 
therapy options for IBD patients.
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Immuno-oncology is a young and growing field in cancer therapy. It  stimulates 
immune system to target and attack the tumor or inhibiting the immune response. 
Recent findings in cancer immunotherapy has revealed that the immune system 
can control many cancers across various histologies, producing durable responses 
in a way which not seen with many small molecule drugs. Advances in understand-
ing the role and molecular mechanisms of immunotherapy are revolutionizing 
 clinical practice in cancer treatment. Immunotherapy is being intensively explored 
with the aim of improving primary response rates or prolonging overall survival. 
The purpose of this chapter is to review the different aspect of immunotherapy 
including blockade of immunological checkpoints, immuno-oncology and imaging 
biomarkers, immune response, therapeutic resistance and combination therapy, 
while several additional immuno-therapeutic strategies are also highlighted.
Keywords: immune response, immunotherapy, immuno-oncology, cancer
1. Introduction
Cancer plays a serious role in public health bother. Global demographic features 
increase the predicted incidence of cancer in the coming decades. Annually, cancer 
is expected to reach 420 million new cases by 2025. Female breast cancer, colorectal, 
prostate, and lung are often diagnostic cancers in Europe, while lung cancer is the 
leading explanation for cancer and death worldwide [1]. The increasing informa-
tion of biology and tumors over the past 15 years has considerably modified the 
pattern of cancer. Throughout the past decades, immune therapy has been used as a 
promising approach to the treatment of a broad variety of human cancers. But these 
methods such as chemotherapy and radiotherapy seem to be effective enough due 
to the problems including low target property, drug resistance, severe side effects 
and immuno-therapies induce host immune system to promote a response against 
tumors [2]. An important feature of Immunotherapy is to kill malignant tumors 
whereas healthy tissues not damaged. The issue of immunotherapy is to expand 
strategies that effectively and securely enhance anti-tumor responses. A few current 
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leading explanation for cancer and death worldwide [1]. The increasing informa-
tion of biology and tumors over the past 15 years has considerably modified the 
pattern of cancer. Throughout the past decades, immune therapy has been used as a 
promising approach to the treatment of a broad variety of human cancers. But these 
methods such as chemotherapy and radiotherapy seem to be effective enough due 
to the problems including low target property, drug resistance, severe side effects 
and immuno-therapies induce host immune system to promote a response against 
tumors [2]. An important feature of Immunotherapy is to kill malignant tumors 
whereas healthy tissues not damaged. The issue of immunotherapy is to expand 
strategies that effectively and securely enhance anti-tumor responses. A few current 
cancer immunotherapy methods tested for their effectiveness include cytokine 
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treatment, cell-receptor cell transfer, cancer vaccines and monoclonal antibodies 
(mAbs). The most encouraging of these approaches are those that are specific T-cell 
stimulants that are capable of long-term tumor immunity [3]. The activity and 
regulation of T-cell is vital for the development of the tumor, since T-cells have the 
ability to remove cancerous cells [4].
2. Checkpoint blockade in immuno-oncology therapy
Checkpoint inhibitors are immune synapses which decrease the function of 
T-lymphocyte [5]. They are against autoimmunity and systemic inflammations. 
These mechanisms help tumor to escape from immune detection [2, 5]. The most 
frequent useful checkpoint inhibitor is checkpoint inhibitor mAbs, anti-cytotoxic 
T lymphocyte-associated protein 4 (CTLA-4) and anti-programmed cell death 
protein 1 (PD-1) [6, 7]. Checkpoint inhibitors invigorate immune system and per-
suade tumors. However, stimulation of cancerous T-cell proliferation can provide 
non-Hodgkin lymphoma (NHL) [2, 8]. Complication of checkpoint inhibitors is 
an autoimmune disease. Due to PD-1 or CTLA-4 illustrates beneficial result on 
advanced-stage melanoma [2, 9]. So, cytotoxic T lymphocyte antigen-4 and B7.1 
are the most frequent targets in Immunotherapy. They can manage the interaction 
between T-cell and dendritic cells [1, 10].
2.1 PD-1
PD-1 is a receptor which is increased by T-cells during peripheral activation. 
PD-1 blockade down regulates the activity of intramural T regulatory cells [10]. 
Tumors can evade from immune system by inhibiting PD-1. Also, PD-1 is expressed 
by other immune cells such as lymphocyte B, natural killer (NK) cells and den-
dritic cells [4, 11–13]. PD-L1 has two ligands including PD-L1 (B7-H1) and PD-L2 
(B7-H2). These two ligands expressed by inflammation and tumors tissues [4, 14]. 
Also, these ligands are expressed on antigen presenting cell (APCs). In addition, 
tumor tissues express these ligands [13]. PD-1 reduces the activity of T-cells later 
than CTLA-4. So, PD-1 influences on immune response during the chronic inflam-
mation. PD-1 is important for the monitoring of Tregs suppressor performance 
[4]. CD80 or B7-1 is linked to PD-L1. Bidirectional interactions can inhibit PD-L1 
and B7-1. Evading of PD-1 from immune diagnosis is so important [13]. Overall, 
PD-L1 in cancer is related to poor prognosis and larger tumor size and reduction in 
cytotoxic activity [4, 15, 16]. But, PD-1 can stop NHL by diminishing the prolifera-
tion of cancerous T-cells [15]. PD-L2 only can regulate the responses of Th2. But, 
PD-L2 is not selected as a target in cancer. PD-L2 does not have strong relation 
with survival. However, PD-L1 has the most potent influence and anti-tumor Th1 
responses [4, 9]. PD-L1 is a useful ligand to manage several cancers like melanoma, 
non-small cell lung cancer (NSCLC) and kidney cancer [9].
2.2 CTLA-4
Cytotoxic T lymphocyte antigen 4 (CTLA-4) is a glycoprotein that exists on the 
surface of T cells [1]. When T-cells activation is regulated in its early stage, T-cells 
in central lymph nodes express CTLA-4. CTLA-4 which is expressed by regulatory 
T cells (Tregs) can control the activated lymphocyte’s proliferation in the lymph 
nodes. CTLA-4 plays a role in joining to B7·1 and B7·2 and involves with CD28. So, 
CTLA-4 can discontinue the activation and production of T cells. Anti-CTLA-4 
decreases the Tregs cell to promote the proliferation of T cells [2, 10].
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2.3 CD73
The investigations on anti-CD73 or anti-adenosine phase 1 found that they could 
effectively provoke immune response and improve the functions of first genera-
tion immune checkpoint inhibitors [17]. CD73 in Triple-negative breast cancer 
have poor prognosis [18]. Estrogen receptor (ER) negative has poor prognosis as 
well. CD73 in ER positive has no prognostic value. Stages I–III have good prognosis 
[19]. CD73 in B-cell acute lymphoblastic leukemia is a marker of minimal residual 
disease. B-cell chronic lymphocytic leukemia expresses CD73 as a marker of 
aggressiveness. CD73 is associated with CD38 and ZAP70 expression; two markers 
of disease progression in B-cell chronic lymphocytic leukemia [18, 20, 21]. CD73 in 
glioblastoma multiform (GBM) has poor prognosis [17]. CD73 is associated with 
limited metastatic potential in melanoma [17]. High-grade serous CD73 expression 
shows poor prognosis in ovarian cancers. However, CD73 expression indicated good 
prognosis in Epithelial ovarian cancer [17].
3. First group of immunotherapy medication
3.1 Ipilimumab (Yervoy)
Ipilimumab is a fully human immunoglobulin G1 (IgG1) monoclonal. It up 
regulates T-cell activation by targeting CTLA-4 and is used in phase 2 data for 
tumor response and safety by logistic regression models. Ipilimumab dosage is 
about 0.3, 3, and 10 mg/kg every 3 weeks for maximum four doses. About 10 mg/
kg doses of Ipilimumab are more effective than 3 mg/kg in metastatic melanoma. 
However, 10 mg/kg doses of Ipilimumab have more serious side effects [1, 22, 23]. 
Clinical efficacy of Ipilimumab shows strong improvement on survival. Its response 
rate is 9–18% in phase III clinical trial in patients with NSCLC. Also, treatment 
scenario for Ipilimumab is pretreated and its control arm is Docetaxel. Response 
rate in patient with melanoma in phase 3 trial is p100 10.9 mo vs. 1.5 mo. Treatment 
scenario for Ipilimumab is pretreated in management of melanoma [1].
3.2 Tremelimumab
Tremelimumab is fully humanized IgG2 antibody and its target cell is T 
lymphocyte. Tremelimumab affects T lymphocyte by targeting CTL-4 and is an 
immune checkpoint inhibitor in hepatocellular carcinoma (HCC) clinical trials 
[1]. The effect of Tremelimumab has recently been studied in combination with 
Durvalumab on HCC. The response rate of this combination on HCC was approxi-
mately 25%. In phase 3 on metastatic melanoma, Tremelimumab can increase over-
all survival in comparison to chemotherapy [10]. It is given every 3 weeks for the 
management of melanoma and has 10% response rate [1]. Another study on phase 
1 clinical trial has shown that the combination of Tremelimumab and CP-893,870 
(a CD40-agonist mAb) provides the 27% objective response rate and 26 months 
overall survival. Also this combination provides 8% complete response rate [2].
3.3 Pembrolizumab (Keytruda)
Pembrolizumab is a humanized IgG4 monoclonal antibody against PD-1. It has 
only influence on tumors express programmed death-ligand 1 (PD-L1) [4, 24]. 
Pembrolizumab is recommended for the management of advance melanoma along 
with Ipilimumab. The recommended dosage is 2 mg/kg each 3 weeks in phase 1 
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clinical trial in patient with metastatic melanoma [1, 4, 24]. Also, Pembrolizumab 
is suggested for the treatment of metastatic NSCLC [4]. This drug has been studied 
in various cancer including gastric/gastroesophageal junction cancer (phase III), 
NSCLC (phase III), squamous cell carcinoma of the head and neck (SCCHN) 
(phase III), urothelial cancer (phase III), colorectal carcinoma (phase II), gastric/
gastroesophageal junction cancer (phase II), GBM Merkel cell carcinoma (phase 
II), Hodgkin lymphoma (HL) and NHL (phase II). Pembrolizumab is one of the 
most important immune checkpoint inhibitors in HCC clinical trials. Response 
rate of Pembrolizumab is about 25 vs. 4% in patients with melanoma in phase 
II clinical trial. Also its control arm is investigator’s choice chemotherapy. Also, 
using Pembrolizumab, as first line in treatment of melanoma, has 33.7 vs. 11.9% 
response rate in phase 3 clinical trial [23]. A recent study shows the saturations of 
Pemberolizumab is reached to 95% by dosage of 1 mg/kg every 3 week. Some studies 
revealed that reaching to complete achievement of the goal is 64% by 1 mg/kg each 
3 week. However, complete achievements ≥2 mg/kg (such as 10 mg/kg) is higher 
90% [25]. Later study has found that Pembrolizumab illustrates equivalence in 
exposure at dosage body weight-based 2-mg/kg each 3 week. But, Nivolumab does 
not have equality in exposure at indefinite quantity of two hundred mg each 3 weeks 
[24, 26]. Pembrolizumab clearance decreases about 20% after first injection. But this 
clearance is not clinically important [24, 27]. Common side effects of Pembrolizumab 
are fatigue, pruritus, and decreased appetite. Recent study in lung cancer patients 
shows 50% of tumors cell has PD-L1 receptors. In addition, Pembrolizumab has 
45.2% response rate in patients who has PD-L1 receptors. But, objective response rate 
is 19.4% through all patients with metastatic lung cancer [27].
3.4 Blinatumomab (connecting bi-specific antibodies)
Blinatumomab is approved for CD19+ B-cell malignancies and its pre-clinical 
finding has strong in-vitro cytolytic activity. Blinatumomab’s pharmacokinetics has 
clear kinetics and can trigger T lymphocytes to reach tumors cell. One of the recent 
studies on Blinatumomab shows that its clinical efficacy has high response rates, 
and its safety has moderate to severe toxicity [23].
3.5 Nivolumab (Optivo)
Nivolumab is a human immunoglobulin G4 (IgG4) monoclonal antibody that 
targets PD-1. Nivolumab target cell is T lymphocyte and is accepted in cancer with 
expressing PD-L1 and also without expressing PD-L1 [4]. Nivolumab dosage is 
about 1–10 mg/kg. Also non-clinical data recommends 0.3 mg/kg as initial dose. 
Low-immunogenic tumor types needed higher Nivolumab dosage. For instance, 
beneficial dosage for melanoma and renal cell carcinoma (immunogenic tumors) is 
1–10 mg/kg (1 mg/kg each 2 week) [26]. However, higher dosage (3 and 10 mg/kg 
each 2 week) needs for NSCLC. Thus, lower dose level can have longer progression-
free survival in immunogenic tumor types. Nivolumab is approved for both PD-L1 
expressers [24, 28]. Recent studies indicate that Nivolumab has increased the 
survival in patients with melanoma [28, 29]. Nivolumab has 25–40% response 
rate with long lasting response (2 years) in patients with melanoma. Another 
study in phase III trial has shown Nivolumab has increased survival in comparison 
with chemotherapy in patients with advance melanoma and advance NSCLC [4]. 
Nivolumab should be selected 3 mg/kg each 2 week as monotherapy dose for differ-
ent type of tumors to improve survival [30]. The investigation exhibited that there 
was a linear relationship between Nivolumab pharmacokinetics and the dose range. 
For renal cell carcinoma, metastatic melanoma and NSCLC, suggested dosage is 
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240 mg IV every 2 week depends on population pharmacokinetics analyses and 
response analyses of dose and exposure [31]. Also, Nivolumab is prescribed for 
renal cell carcinoma due to second choice. Pharmacometrics has main role in chang-
ing body weight based on dosage to flat dosage. The advantages of using a flat dose 
include removing excess material waste, the convenience of health care providers, 
and reducing worries about the exact dose in patients with weight fluctuations. 
Combination of Nivolumab and Ipilimumab are used in the management of 
melanoma [28]. Nivolumab are investigated in different types of tumors including 
gastric cancer (phase III), GBM (phase III), acute myeloid leukemia (AML) (phase 
II), anal canal (phase II), cervical cancer (phase II), colon cancer (phase II), HL, 
NHL (phase II), nasopharyngeal carcinoma (phase II), pancreatic cancer (phase II) 
[4]. Nivolumab is one of important Immune checkpoint inhibitors in HCC clinical 
trials. Nivolumab’s pre-clinical findings has moderate effect and its clinical efficacy 
has a strong influence on improvement of survival. It is used for the first line treat-
ment of melanoma in phase 3 clinical trial. Nivolumab’s control arm is Dacarbazine. 
Melanoma response rate of Nivolumab is approximately 40 vs. 13.9%. Nivolumab 
is used in treatment of NSCLC as pretreated with response rate about 32 vs. 11% in 
phase 3 clinical trial and the control arm is investigator’s choice chemotherapy [1].
3.6 Atezolizumab
Atezolizumab is a humanized Fc-engineered IgG1 monoclonal and binds to PD-L1. 
Atezolizumab promote neither activate antibody-dependent cell-mediated cytotoxic-
ity (ADCC) nor complement-dependent cytotoxicity (CDC). Also, Atezolizumab 
blocks the interaction with PD-1 and B7.1 receptors on tumor cells. Recent study 
shows that the best dosage for metastatic urothelial carcinoma and metastatic NSCLC 
is 1200 mg every 3 weeks. Also later study on dose-escalation in phase 1 indicates 
dosage of Atezolizumab is about 0.01–20 mg/kg based on body weights [32].
3.7 Durvalumab
Durvalumab is a humanized Fc-engineered IgG1 monoclonal and binds to 
PD-L1. Durvalumab promote neither ADCC nor CDC, and avoids the ability of 
toxicity caused by it does not have attraction to joining PD-L2. Recommended dos-
age of Durvalumab is 10 mg/kg each 2 weeks in carcinoma of urothelial. Proposed 
concentration in metastatic urothelial carcinoma is about 50 μg/mL. Recommended 
fixed dosage regimen of Durvalumab is 1500 mg every 4 week or 750 mg every 
2 week. This regimen indicates similar overall pharmacokinetic exposure based on 
body weight [33].
3.8 Avelumab
Avelumab is a fully human IgG1 monoclonal antibody and has short half-
life for about 3.9–4.1 days compare to Nivolumab which is about 12–20 days, 
Pembrolizumab with half-life of 14–22 days, and Atezolizumab with half-life of 
21 days. Avelumab shows the reduction in clearance similar to Nivolumab and 
Pembrolizumab during long treatments. The investigation of avelumab on meta-
static Merkel cell carcinoma after 1 year of follow up has shown that avelumab can 
be effective in treating advance Merkel cell carcinoma due to 33.0% overall response 
rate (ORR) and 11.4% to complete response rate. The dosage is used in that study 
was 10 mg/kg every 2 weeks. Also, studies in phase 1 have shown that this drug can 
also be effective in patients with platinum-refractory metastatic urothelial carci-
noma cancer due to 17.3% ORR [24, 34–38].
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clinical trial in patient with metastatic melanoma [1, 4, 24]. Also, Pembrolizumab 
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240 mg IV every 2 week depends on population pharmacokinetics analyses and 
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4. Second group of immunotherapy medication
Next-generation of novel therapeutic target include VISTA, LAG-3, TIGIT, and 
TIM-3 inhibitors. Also, another potential checkpoint is p-selectin glycoprotein 
ligand-1 (PSGL-1) which regulates T-cell responses in tumor microenvironment 
(TME). CTLA-4 and PD-1 are co-target receptors which they are responsible for 
supporting overall immune self-tolerance. However, TIGIT, LAG-3, and TIM-3 
receptors influence on NK and CD8+ T-cell. Treg cell suppressive influence and 
improving CD8+ and NK cell activity inside malignancy tissues is revoked by 
synergizing their corresponding blockade. Thus, synergizing of first- and second 
generation inhibitors provoke immune system to have beneficial response against 
malignancies [2, 39–41].
4.1 T-cell immunoglobulin-3 (Tim-3)
Tim-3 is expressed on IFNγ producing CD4+ T helper 1 (Th1) and CD8+ T 
cytotoxic 1 (Tc1) T-cells. Also, Tim-3 is expressed on Treg cells and on innate 
immune cells (DC, NK cells, and monocytes). Co-inhibition of Tim-3 and PD-1 is 
more beneficial than PD-1 alone inhibition in anti-tumor effector functions. Tim-3 
shows the dysfunction of CD8+ T-cells in cancers. Co-inhibition in Tim-3 and PD-1 
has greater effects in managing melanoma, NSCLC, and NHL [37].
4.2 T-cell immunoglobulin and ITIM domain (TIGIT)
T-cell immunoglobulin and ITIM domain (TIGIT) Ligand (CD155 and CD112) 
are expressed in tumors cells. Negative TIGIT up regulate anti-tumors activities. 
Dysfunctional phenotype among CD8+ TILs is produced by co-expression of CD8 plus 
TIGIT+ TILs with PD-1, Tim-3, and Lag3. Co-inhibition of TIGIT with PD-1 increased 
proliferation, cytokine production, and degranulation In CD8+ TILs from melanoma 
patients [37]. Moreover, TIGIT synergies with Tim-3 to improve anti-tumor responses. 
So, both co-inhibition of TIGIT with PD-1 or TIGIT with Tim-3 induce anti-tumor 
effects. In addition, TIGIT are expressed on tumor infiltrating Treg. Restrictive 
phenotype of Treg cell is provided by the TIGIT+ Treg in tissues with malignancy cells. 
Notably, CD8+ T-cell function (direct suppression) and promotion of Treg function 
(indirect suppression) can suppress anti-tumor immunity by TIGIT [37].
4.3 B-cell and T-cell lymphocyte attenuator (BLTA)
B-cell and T-cell lymphocyte attenuator (BTLA) is an immunoglobulin-like mole-
cule expressed on different cells such as on B-cells, T-cells, NK cells, and APCs. BLTA 
is a section of CD28 family. BLTA plays a major role in early T-cell regulation and 
provides early T-cell response gene. Combination of BLTA and herpes virus entry 
mediator (HVEM) induces reduction of T-cell proliferation and cytokine produc-
tion. Melanoma cells are expressed HVEM. The combination of BTLA and HVEM 
inhibits the expansion and IFNγ production. Also, BLTA is related to restricted T-cell 
expansion. Inhibition of BTLA, PD-1, and TIM3 together increase IL-2. Inhibition of 
BTLA, PD-1, and TIM3 can restore T-cell dysfunctions. After the BTLA and HVEM 
interconnections, T-cell activation and level of IFNγ decreases [13].
4.4 V-domain Ig suppressor of T-cell activation (VISTA)
V-domain Ig suppressor of T-cell activation (VISTA) is a powerful suppressor of 
T-cell [13] which is expressed by hematopoietic tissues and infiltrating leukocytes. 
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VISTA is predominantly found on leukocytes inside tumors and myeloid hemato-
poietic section 140. Like PD-L1, it promotes suppression of CD4 and CD8. VISTA 
also has long-lasting kinetics which can induce the reduction of cytokine produc-
tion such as IL-10, TNF-alpha, and IFNγ. VISTA inhibition increase the frequency 
of tumor-infiltrating effector T-cells by combining to a specific antibody. Thus this 
combination inhibit tumor growth. VISTA can increase overall survival by combin-
ing to an agonistic CD40 antibody, TLR agonists, and tumor antigen peptides [13].
4.5 CD160
CD160 is a glycosyl-phosphatidyl-inositol (GPI) which is expressed on CD8þ 
T-cells, NK cells, and NK-T cells. CD160 inhibition induces T-cell proliferation and 
cytokine production 147. Also, CD160 is a ligand for HVEM. The combination of 
CD160 and HVEM promote the suppression of T-cells. So, CD160 is an inhibitory 
checkpoint for T-cells [13].
4.6 CD244
CD244 is a immunoglobulin which can regulate and activates the lymphocytes. 
In addition, CD244 can stimulate both T-cell and NK cells. NK cytotoxicity is inhib-
ited opposed the expression of CD48 by CD244. CD244 can provide both suppres-
sion and activation of T-cell by cross linking, related to CD244 level of expression 
and adaptation of intracellular molecule. Recent study shows that CD244, LAG-3, 
and PD-1 is reduced in tumor-infiltrating antigen-specific CD8þ T-cells by herpes 
virus glycoprotein (GD) adjutant vaccine [13].
5. Passive immuno-therapy
With the exception of immuno-suppressants, many other important thera-
pies are developing immunization that can be divided into active or inactive 
Immunotherapy with respect to host immunity when detecting anti-tumor 
responses. Active immuno-therapies have correlation with capacity of  
anti-tumor attack of T-cell. However, passive Immunotherapy includes inherent 
anti-tumor properties of adaptive T-cell therapy [1, 41].
5.1 Tumor-targeting monoclonal antibodies (mAbs)
MAbs have different effects on immune cells. First, mAbs can change the recep-
tor’s signaling role which malignant cells expressed them. Second, they neutralize 
the signals which malignant cells or stromal components or neoplastic lesion 
provided them. MAbs identify cancer cells due to tumor associated antigen (TAA) 
expression which expressed by transformed cells [39, 42]. Another anti-cancer 
immuno-therapies against activatory checkpoint receptors include anti-CD137 or 
anti-CD40 which are being tested in clinical trials [1]. MAbs Cetuximab blocks 
signaling pathways which determine neoplastic cells’ survival or progression. Also 
Cetuximab is approved for the treatment of head and neck cancer. In addition, 
it is used in managing colorectal carcinoma [9, 39, 43, 44]. Naked mAbs such as 
Tigatuzumab activates murderous receptors of malignant cells. Gemtuzumab 
ozogamicin is an anti-CD33 Calicheamicin. Gemtuzumab ozogamicin binds to a 
TAA-specific mAbs. It use for acute myeloid leukemia patients [38]. CD20-specific 
mAb Rituximab is complement-dependent cytotoxicity. Rituximab is activated 
by TAA-specifics mAbs. Also, naked TAA-specific mAbs activates ADCC and 
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antibody-dependent cellular phagocytosis [39, 45, 46]. A recent study shows that 
Rituximab has beneficial influence on chronic lymphocytic leukemia, and NHL  
[39, 46, 47]. Blinatumomab is a CD19- and CD3 bispecific T-cell engagers (BiTE) 
which is chimeric proteins includes of two single-chain changeable fragments from 
mAbs. BiTE has two fragments, one of them target a TAA and another target T-cell 
surface antigen. Blinatumomab is approved for treatment of B-cell acute lympho-
blastic leukemia. MAbs and BiTE should be considered active immuno-therapeutic 
or passive immun0-therapeutics. This implying depends on host immune responses. 
For example, Cituximab can block epidermal growth factor receptor (EGFR) 
signaling and also can induce ADCC. In addition, Cituximab can mediate the effects 
of immuno-stimulatory [39, 48]. Bevacizumab is approved for management of 
glioblastoma multiform, cervical carcinoma, renal cell carcinoma, and lung cancer 
due to anti-angiogenesis effects. But, Bevacizumab induces tumor infiltration via 
lymphocyte B and lymphocyte T. In addition, Bevacizumab blocks CD4+ CD25+ 
FOXP3+ regulatory T-cells [39, 48, 49].
5.2 Summary of anti mAbs indications
Alemtuzumab’s indication is chronic lymphocytic leukemia. Bevacizumab’s 
indications are colorectal carcinoma, lung carcinoma, renal cell carcinoma. 
Brentuximab vedotin indications are anaplastic large cell lymphoma and 
HL. Blinatumomab indication is acute lymphoblastic leukemia. Catumaxomab 
indications are malignant ascites in patients with epithelial cell adhesion molecule 
(EPCAM) + cancer. Cetuximab indications are head and neck cancer and colorectal 
carcinoma. Denosumab indications are breast carcinoma, prostate carcinoma, and 
bone giant cell tumors. Gemtuzumab ozogamicin indication is acute myeloid leuke-
mia. Ibritumomab tiuxetan indication is NHL. Panitumumab indication is colorec-
tal carcinoma. Pertuzumab indication is breast carcinoma. [38]. Obinutuzumab 
indication is chronic lymphocytic leukemia. Ofatumumab indication is chronic 
lymphocytic leukemia. Ramucirumab indications are gastric or gastroesophageal 
junction adenocarcinoma. Rituximab indications are chronic lymphocytic leukemia 
and NHL. Siltuximab indication is Multicentric Castleman’s disease. Tositumomab 
indication is NHL, and Trastuzumab indications are breast carcinoma, gastric or 
gastroesophageal and junction adenocarcinoma [38].
5.3 Oncolytic viruses
Oncolytic viruses have potential anti-neoplastic effects and can inherent cyto-
pathic effects. Productive viral infection up regulates the mortal overcharge of 
cellular metabolism. Oncolytic viruses are lethal for host cells due to endogenous 
or exogenous gene products, and are approved by US food and drug administration 
(FDA) [39, 50].
5.4 Oncorine H101
Oncorine H101 is oncolytic viruses. Oncorine indication is head and neck cancer. 
The mechanism of action is selective lysis of malignant cells [38].
6. Immune oncology biomarker and immune response
Biomarkers have different purpose and are seen as a pre-existing anti-
tumor in certain developing tumors. Also, response to immune treatments can 
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provide specific biomarkers [48]. When blockade of the PD-1/PD-L1 checkpoint 
response increase, PD-L1 expression can be seen in the TME. The high level 
expression of PD-L1 is related with a higher response rate and its expression 
increases survival [48]. Immunotherapy can exacerbate tumor lymphocytes 
(TILs), which illustrates antitumor immune response [48]. CD8 T-cells are 
associated with tumor regression after stopping of PD-1/L1 in melanoma 
metastasis. Increased immunogenicity of a tumor shows an increasing of tumor 
mutational load and neoantigen [49]. High mutational burdens increase survival 
than low load. Mutational load and neoantigens have been shown in many type 
of advance tumors including melanoma, NSCLC, and colorectal carcinoma. 
The investigations on colorectal carcinoma illustrate higher tumor-infiltrating 
lymphocytes and smokers response which is better than nonsmokers (adenocar-
cinomas) [1]. Immuno-stimulatory or immune inhibitory cytokines existence in 
the microscopic environment of the tumor forecast susceptibility or resistance. 
There are several methods for research in the microscopic environment of the 
tumor including immuno-histochemistry, immuno-fluorescence, whole-exome 
sequencing, transciptome analysis, proteomics, flow cytometry and others [48]. 
Type I interferon-based transcriptomic signatures has beneficial effect in meta-
static melanoma. However, it may originally be used for other types of tumors 
[1]. Several investigations on PD-1/PD-L1 checkpoints indicate that TME PD-L1 
(TME cell types express PD-L1) expression is significantly related with response 
[29]. Tumors with negative PD-L1 are resistance to therapy since tumor or 
immune cell must have PD-L1 for immune checkpoint therapy [29]. Alone PD-L1 
(B7-H1) expression cannot adequately predict the Immunotherapy response. So, 
adding PD-L1 with another parameters (CD8+ T-cells or an IFNγ gene signature) 
improves predictive value [48].
6.1 Imaging biomarker
There are two main approaches for imaging in clinical oncology including 
anatomic and functional imaging. Anatomic change fluorescence and biolumi-
nescence are the most useful imaging techniques. In addition, magnetic resonance 
imaging (MRI) improves contrast and increase resolution of anatomic images. 
Also, MRI can improve range of functional measure. Dynamic contrast-enhanced 
MRI can indicate tumor perfusion and permeability of cell membrane. Diffusion-
weighted MRI demonstrates the access of drug by parameters such as rate and 
distance of water molecule. Recent study evaluates immunotherapy by using 
cells labeled with either super paramagnetic iron oxide particles or perfluoro-
carbon nanoemulsions in MRI-based cell follow [51, 52]. Detecting biochemical 
markers in tumors is possible by single-photon emission computed tomography 
(SPECT) and PET. These two mature imaging techniques has beneficial effects 
such as high-resolution images, the potential to quantify metabolic activity for 
corrects attraction of therapeutic influences [52]. The investigations on lym-
phoma and solid tumors shows that 18F-FDG-PET imaging which is oncologic 
nuclear imaging is very useful for disease response evaluations. But, there are 
few important problem with 18F-FDG-PET such as the distinction between 
neoplasm and infectious or inflammatory processes. SPECT provide high resolu-
tion similar to PET. However, beneficial advantage of SPECT in comparison with 
PET is ubiquity of SPECT cameras, reduced cost structure, increased logistics for 
imaging caused by longer half-lives of the radionuclides, and a greater number of 
radionuclides available for labeling. 99mTc-methyldiphosphonate (99mTc-MDP) 
is the most useful SPECT agents in imaging of advance osteoblastic bone cancer. 
Real metastases are not detected by bone scan, while the reaction of the skeleton 
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Biomarkers have different purpose and are seen as a pre-existing anti-
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provide specific biomarkers [48]. When blockade of the PD-1/PD-L1 checkpoint 
response increase, PD-L1 expression can be seen in the TME. The high level 
expression of PD-L1 is related with a higher response rate and its expression 
increases survival [48]. Immunotherapy can exacerbate tumor lymphocytes 
(TILs), which illustrates antitumor immune response [48]. CD8 T-cells are 
associated with tumor regression after stopping of PD-1/L1 in melanoma 
metastasis. Increased immunogenicity of a tumor shows an increasing of tumor 
mutational load and neoantigen [49]. High mutational burdens increase survival 
than low load. Mutational load and neoantigens have been shown in many type 
of advance tumors including melanoma, NSCLC, and colorectal carcinoma. 
The investigations on colorectal carcinoma illustrate higher tumor-infiltrating 
lymphocytes and smokers response which is better than nonsmokers (adenocar-
cinomas) [1]. Immuno-stimulatory or immune inhibitory cytokines existence in 
the microscopic environment of the tumor forecast susceptibility or resistance. 
There are several methods for research in the microscopic environment of the 
tumor including immuno-histochemistry, immuno-fluorescence, whole-exome 
sequencing, transciptome analysis, proteomics, flow cytometry and others [48]. 
Type I interferon-based transcriptomic signatures has beneficial effect in meta-
static melanoma. However, it may originally be used for other types of tumors 
[1]. Several investigations on PD-1/PD-L1 checkpoints indicate that TME PD-L1 
(TME cell types express PD-L1) expression is significantly related with response 
[29]. Tumors with negative PD-L1 are resistance to therapy since tumor or 
immune cell must have PD-L1 for immune checkpoint therapy [29]. Alone PD-L1 
(B7-H1) expression cannot adequately predict the Immunotherapy response. So, 
adding PD-L1 with another parameters (CD8+ T-cells or an IFNγ gene signature) 
improves predictive value [48].
6.1 Imaging biomarker
There are two main approaches for imaging in clinical oncology including 
anatomic and functional imaging. Anatomic change fluorescence and biolumi-
nescence are the most useful imaging techniques. In addition, magnetic resonance 
imaging (MRI) improves contrast and increase resolution of anatomic images. 
Also, MRI can improve range of functional measure. Dynamic contrast-enhanced 
MRI can indicate tumor perfusion and permeability of cell membrane. Diffusion-
weighted MRI demonstrates the access of drug by parameters such as rate and 
distance of water molecule. Recent study evaluates immunotherapy by using 
cells labeled with either super paramagnetic iron oxide particles or perfluoro-
carbon nanoemulsions in MRI-based cell follow [51, 52]. Detecting biochemical 
markers in tumors is possible by single-photon emission computed tomography 
(SPECT) and PET. These two mature imaging techniques has beneficial effects 
such as high-resolution images, the potential to quantify metabolic activity for 
corrects attraction of therapeutic influences [52]. The investigations on lym-
phoma and solid tumors shows that 18F-FDG-PET imaging which is oncologic 
nuclear imaging is very useful for disease response evaluations. But, there are 
few important problem with 18F-FDG-PET such as the distinction between 
neoplasm and infectious or inflammatory processes. SPECT provide high resolu-
tion similar to PET. However, beneficial advantage of SPECT in comparison with 
PET is ubiquity of SPECT cameras, reduced cost structure, increased logistics for 
imaging caused by longer half-lives of the radionuclides, and a greater number of 
radionuclides available for labeling. 99mTc-methyldiphosphonate (99mTc-MDP) 
is the most useful SPECT agents in imaging of advance osteoblastic bone cancer. 
Real metastases are not detected by bone scan, while the reaction of the skeleton 
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to metastases can be found [52, 53]. Also, another SPECT agents which they 
are useful for different cancers including using 123I-metaiodobenzylguanidine 
(123I-MIBG) in neuroblastoma, using 111In-pentreotide in patients with neuro-
endocrine tumors, and 123I-sodium iodide (NaI) for thyroid distinction between 
expected post immuno-therapeutic results. The most frequent use of PET agent 
is 18F-fluorothymidine (18F-FLT) which is a marker for proliferation of the cells. 
18F-fluorothymidine (18F-FLT) improves the differentiation between tumors and 
false positive rate associated to infections and inflammations [52]. 18F-FLT has 
some limitations in comparison with 18F-FDG-PET such as reduction in signal 
to background ration. Also, 18F-FLT shows background structures such as bone 
marrow, which cannot show the activity of the tumors and reduces the identifica-
tion of tumors. Furthermore, 18F-FlT gathers in area of infection and inflamma-
tion lesser than 18F-FDG [54].
7. Immune response
Genomic factors play an important role in responding to Immunotherapy. 
Across several mechanisms, viral proteins have influence on intercommunication 
alongside T-cells and malignancy. For example anti-tumor cytotoxic activity of the 
NK cells is increased by hidden cytomegalovirus [55]. In addition, PD-L1 expres-
sion is provoked by EBV in NHL and other EBV+ cancers [53]. one of the most 
responsive cancer to checkpoints inhibitor is HL. Also, HL has high level of PD-L1 
expression. PD-L1 expression is reduced in HPV+ tumors; But, T-cell infiltration 
is increased in HPV+ tumors. Therefore, an important biological biomarkers for 
Immunotherapy is the presence of viral proteins [56]. Recent study shows that 
Merkel-cell polyomavirus positive tumors have higher PD-L1 expression (71 vs. 
25%). Response rate in virus positive tumor is about 65 vs. 44% higher than virus 
negatives tumors [48].
8. Combination therapy
Combination therapy can increase response rate, efficacy and improve multiple 
components of T-cell anti-tumor responses. It has been reported that, Nivolumab + 
Ipilimumab are beneficial against melanoma. But, this combinations may have 
many serious side effects such as hepatitis, colitis, pneumonia. Bevacizumab com-
bine with interferon-alpha to manage renal cancer. The combination of Elotuzumab 
and Dexamethasone and Lenalidomide is useful to control multiple myeloma  
[7, 59]. Combination of Nivolumab and Pembrolizumab is prescribed for managing 
squamous and non-squamous NSCLC [4, 33].
8.1 Binary checkpoint inhibition
Combination of Nivolumab (anti-PD-1) and Ipilimumab (anti-CTLA-4) provide 
total two-year survival in 79% of cases in metastatic melanoma. Also this combina-
tion has 53% objective response rate in metastatic melanoma. Recent study shows 
combinations of Nivolumab and Ipilimumab has 61% objective response rate. 
However, Ipilimumab alone has 11% objective response rate. Totally, recent study 
shows 22% remission [2]. Also, later investigations shows that the combination of 
anti-PD-1 and CTLA-4 stimulate T-cell more than anti-CTLA-4 alone. In combina-
tion of PD-1, CTLA-4 and VISTA blockade checkpoint is demonstrated the stimula-
tion of T-cell [2].
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8.2 Checkpoint inhibitor and mAbs
Combination of Tremelimumab (anti-PD-1) and a CD40-agonist mAb has 27% 
objective response rate, 26 months overall survival. T-cell antigen 4-1BB is targeted 
by mAb’s, and improves T-cell stimulation [57]. Combination of 4-1BB agonists with 
PD-1 blockade has notable results in rejection in murine model with colon adenocar-
cinoma. This combination therapy led to increase the level of IFNγ-producing CD8+ 
and CD4+ T-cells in comparison with monotherapies. Efficacy of OX40 agonist is 
decreased by PD-1 inhibitions. Also, PD-1 blockade causes reduction of CD4+ and 
CD8+ lymphocyte infiltration and causes 30% breast tumors remissions [58].
8.3 Epigenome regulator
Epigenome regulator is coupled with checkpoint inhibitor, and includes an 
inhibitor of histone deacetylases (HDAC) or DNA methyl-transferase (DNMT). 
HADC typically associated with the cancer process [59]. Immune checkpoint 
management mechanisms contain covalent modifications, microRNAs (miRNAs), 
and long noncoding RNAs (lncRNAs), and histone modifications. DNA methyla-
tion and histone acetylation have the most effects in management of growth and 
activation of T lymphocyte. Inhibition of HDAC promotes tumor death. Inhibition 
of HDAC provokes tumor death by different pathway such as reactive oxygen species 
(ROS) and apoptosis. HDAC inhibitor is prescribed for different type of malignan-
cies including leukemia, gastric carcinoma, NSCLC. HDAC inhibitors have several 
complications including lymphopenia, leukopenia, neutropenia, and thrombocy-
topenia. Combination therapy of HDAC and DNMT inhibitors with other immuno-
logical agents is used for more efficacy. For example, Entinostat is combined with 
Nivolumab and Ipilimumab for managing metastatic breast cancer. Also, Entinostat 
with Pembrolizumab is used for solid tumors, metastatic uveal melanoma and 
NSCLC. Mocetinostat and Durvalumab are used for managing solid tumors [60–62].
8.4 Selective therapy with checkpoint inhibitor
Checkpoint blockers coupled with receptor and non-receptor tyrosine kinases 
(TK) play major roles in tumorigenesis. The angiogenesis provides growth factor 
VEGF and restricts T-cell infiltration through the tumor endothelium. In addition, 
angiogenesis promotes myeloid-derived suppressor cells (MDSCs) and Treg cells 
inside tumors. Combination of Bevacizumab (a VEGF inhibitor) with Ipilimumab 
can control 67% in metastatic melanoma. In addition, this combination can induce 
T-cell activation inside tumors with approving toleration level. It is currently 
attempting to coordinate anti-PD-1/PD-L1 MABs with VEGF inhibitor for even 
greater effectiveness [60]. Imatinib (TKI) with an anti-CTLA-4 mAb decrease Treg 
cell. Tumor volume is decreased 50% by CTLA-4 and Indoleamine 2,3-dioxygenase 
(IDO) blockade combination during 80 days [60]. Tumor volume is decreased 50% 
by CTLA-4 and IDO blockade combination during 80 days [60]. Combination of 
PD-1 and IDO blockades has favorable effects on advanced melanoma [2].
8.5 Adaptive T-cell therapy (ACT) with checkpoint inhibitor
Adaptive T-cell therapy induces anti-tumor stimulation. CD19-specifics chi-
meric antigen receptor (CAR) T-cell therapies provide 90% revocation of which 
67% of them have response following 6 months in acute lymphoblastic leukemia 
patients. In addition, more than 53% complete response rate has shown in B-cell 
lymphoma [61].
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8.6 Nanoscale coordination polymer (NCP) with checkpoint inhibitor
Combination of anti-PD-l1 (Pembrolizumab) and nanoscale coordination poly-
mer (NCP) combination increase CD8+ T-cells in tumors. Survival rate is increased 
by antiPD-1 checkpoint inhibitors and agonistic anti-OX40 antibodies. Anti-OX40 
antibodies encourage the stimulation of elevated T-cell due to increased release of 
IFNγ and increased CD8+/Treg cell ratio [59]. It has recently been shown that pre-
sentation of antigen is increased by synthetic polymeric nanoparticle PC7A. Also, 
flexible nanovaccin platform carry antigens to lymph nodes. The combination of 
PD-L1 inhibitor and laser light and gold nanostars, which they are called photo-
dermal nanotherapy, can manage advance metastatic bladder malignancy [2].
9. Conclusion
Immunology has changed the way of cancer treatments and control. Primitive 
immunotherapy with checkpoint inhibitors provides beneficial results. However, 
the combination of checkpoint inhibitor with other immune target agents provide 
new generation of immune-oncology treatments. Knowledge about immunologi-
cal checkpoints, immuno-oncology biomarkers, immune response, therapeutic 
resistance and combination therapy helps us in the process of cancer diagnosis/
follow-up, and imaging during immunotherapy helps to better understand the 
patients’ immune response.
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Abstract
Toll-like receptor-4 (TLR4) is a powerful pathway best known for inducing 
inflammation in response to bacteria-produced lipopolysaccharide. TLR4 is also 
activated by endogenous ligands produced by host-damaged cells and a chemo-drug 
paclitaxel. Under normal conditions, TLR4 is expressed mainly in macrophages and, 
at a lower level, in epithelial, endothelial, and stromal cells. Activated TLR4 signifi-
cantly increases inflammatory cytokines and enhances cell proliferation, migration, 
invasion, and survival. While these functions in normal cells are essential for host 
defense and tissue repair, TLR4 overexpression in malignant cells promotes tumor 
growth and metastasis. This is because pro-oncogenic effects of activated TLR4 in 
tumor cells are amplified by similar event in TLR4-positive tumor-associated 
cells including endothelial cells and their mobilized progenitors. The collective 
activation of multiple cell types within the tumor promotes chemoresistance and 
metastasis. Here, we summarize the current knowledge of the TLR4 pathway and 
its functional outcomes in normal and tumor cells. We also discuss its underap-
preciated role in supporting tumor progression through vascular activation and 
recruitment of endothelial progenitors. The review considers several open questions 
regarding the impact of TLR4-mediated pro- and antitumor effects, structural 
requirements for recognition of the TLR4 complex, and a potential contribution of 
chemotherapy to tumor spread.
Keywords: Toll-like receptor-4, paclitaxel chemotherapy, tumor growth,  
tumor blood and lymphatic vessels, metastasis
1. Introduction
Human Toll-like receptor-4 (TLR4) was discovered in 1997 through a bioinfor-
matics approach based on the homology of similar Toll protein found in Drosophila 
[1, 2]. Drosophila Toll protein-mediated protection against fungus infection was the 
first clue suggesting the role of mammalian TLR4 in activation of the immune system. 
The complex of TLR4 and its co-receptors is the primary sensor and responder to 
lipopolysaccharides (LPS), the major constituents of membranes of Gram-negative 
bacteria [3]. Based on exquisite sensitivity to LPS and high level of TLR4 expression 
in macrophages, it was initially thought that the main function of this protein is 
restricted to an inflammatory response aimed at eradication of microbial pathogens. 
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Human Toll-like receptor-4 (TLR4) was discovered in 1997 through a bioinfor-
matics approach based on the homology of similar Toll protein found in Drosophila 
[1, 2]. Drosophila Toll protein-mediated protection against fungus infection was the 
first clue suggesting the role of mammalian TLR4 in activation of the immune system. 
The complex of TLR4 and its co-receptors is the primary sensor and responder to 
lipopolysaccharides (LPS), the major constituents of membranes of Gram-negative 
bacteria [3]. Based on exquisite sensitivity to LPS and high level of TLR4 expression 
in macrophages, it was initially thought that the main function of this protein is 
restricted to an inflammatory response aimed at eradication of microbial pathogens. 
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Subsequent studies, however, discovered intricate interactions of TLR4 with multi-
tude of other molecules besides LPS suggesting a much broader role in homeostasis, 
tissue repair, and longevity in addition to the immune defense. These functions of 
TLR4 directly relate to cancer initiation, progression, and response to therapy.
2. Basic structure of TLR4 gene and protein
Human TLR4 gene contains four exons, and it is located in the long arm of 
chromosome 9 [4]. TLR4 is Type-1 transmembrane protein belonging to the family 
of Toll-like receptors consisting of 10 members in humans and 12 proteins in mice 
[5]. TLR4 protein is composed of an extracellular domain, a C-terminal leucine-rich 
repeat (LRR) domain, and a single transmembrane sequence connected to an intracel-
lular Toll/IL-1 receptor (TIR) region that conveys signaling [5]. LRR and TIR domains 
are responsible for ligand recognition and signal transduction, respectively [6].
3. TLR4 expression in normal organs
The main cell types that express TLR4 under normal conditions are cells of innate 
immunity including monocytes [7], macrophages [8], neutrophils [9], and dendritic 
cells [10]. In addition, TLR4 is also found in T cells [11] and B lymphocytes [12] albeit 
at lower level. Osteoclasts, macrophage-like cells in the bone marrow, also express 
TLR4 [13]. Embryonic stem cells [14] as well as adult hematopoietic-myeloid [15], 
lymphoid [15], mesenchymal [16], blood vascular endothelial [17], and lymphatic 
endothelial [18] progenitors all express TLR4 and signaling components of this 
pathway. Among non-hematopoietic cells, TLR4 is expressed in blood vascular [19] 
and lymphatic [20] endothelia as well as at low concentration in fibroblasts [21], 
keratinocytes [22], and epithelial cells of most normal organs including the colon 
[23], intestine [24], ovary [25], kidney [26], and lungs [27]. Professional phagocytes 
and their myeloid precursors express the greatest amount of TLR4 and exhibit the 
most pronounced response to its ligands [28]. The level and composition of TLR4 
signal-transducing molecules vary among different cell types, particularly between 
myeloid and epithelial cells [29]. However, all positive cells share the basic traits of 
this pathway such as responsiveness to LPS reflected by activation of transcription 
factors of the NF-κB family and production of inflammatory cytokines. During 
inflammation, TLR4-expressing normal cells significantly increase secretion of 
inflammatory mediators [25, 30] due to co-upregulated TLR4 [31], its intracellular 
adapters [32], and co-receptors [10] which enhances cooperation among the path-
way’s components. Likewise, malignant TLR4-positive cells express much higher 
levels of inflammatory proteins as compared with their normal counterparts [33, 34].
4. Physiological functions of TLR4 in normal organs
In order to understand the full impact of TLR4 on cancer progression, it is useful 
to be familiar with its physiological role in normal organs. The main function of 
TLR4 in normal cells is restoration of tissue homeostasis perturbed by either patho-
gens or sterile injury. Response to pathogens is dictated by its ability to recognize 
and respond to LPS [3] and other microbial [35] and non-bacterial [36] lipids. The 
bacterial lipid-containing products are collectively called pattern-associated molecu-
lar patterns (PAMPs). Recognition of PAMPs triggers upregulation of inflammatory 
proteins that mediate proliferation [37], chemotactic migration [38], and survival 
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[39] of innate immunity cells, all of which is necessary for their division, mobiliza-
tion to infected tissue, and cytoprotection against bacterial toxins and stresses of 
inflamed environment. LPS also induces differentiation of myeloid progenitors 
resulting in rapid maturation of dendritic cells and their superior antigen presenta-
tion to T lymphocytes necessary for eradication of invading pathogens [40].
Another broad panel of TLR4-activating molecules are called damage-associated 
molecular patterns or DAMPs. These molecules are produced by severely damaged 
or dying cells [41, 42]. The TLR4 responsiveness to this class of activators creates 
regenerative environment that helps to repair the injured tissue by replacing its lost 
or damaged components. This function of TLR4 is equally critical for long-term 
survival of the entire organism as the ability to generate pathogen-destroying cells. 
Therefore, in this situation TLR4 activates local and bone marrow (BM)-derived 
myeloid (BMDM) progenitors wired to differentiate the required cell types that 
replenish the damaged tissue. Not surprisingly, TLR4-expressing macrophages 
derived from BMDM progenitors dominate the late stages of wound healing acting 
to restore post-injury homeostasis, including rebuilding of functional vasculature 
[43]. In parallel to systemic effect, local epithelial and stromal cells activated by 
TLR4 produce copious amounts of chemotactic factors to recruit these progenitors 
while also being induced to divide, migrate, and re-populate the wounded area.
Given the TLR4 role in homeostasis, it is not surprising that it activates and 
induces differentiation of BM-derived progenitors from myeloid and lymphoid 
lineages [15], mesenchymal stem cells [16], blood vascular endothelial progenitors 
[17], lymphatic endothelial progenitors [18], and local tissue epithelial stem cells [14]. 
Chemokines recruiting these progenitors are produced by local stroma and epithe-
lium as demonstrated by TLR4-dependent upregulation of a variety of cytokines in 
inflamed fibroblasts [42], hepatic stellate cells [44], as well as intestinal [45], alveolar 
[27], ovarian [25], and renal [26] epithelial cells. In addition to production of chemo-
kines, TLR4 activation of epithelial cells increases their division [46] and survival [47] 
similarly to its effects on immune and hematopoietic cells described above. Tissue 
infiltration by immune cells and BM progenitors is facilitated by increased vascular 
permeability [48, 49] and upregulation of cell adhesion proteins that facilitate leuko-
cyte-endothelial interactions [50]. These two major events permitting recruitment of 
BM-regenerating cells are induced by TLR4 activation of blood vascular endothelium 
[51] and vessel-supporting pericytes [52]. Lastly, TLR4 activation of lymphatic endo-
thelial cells [20, 53] is essential for collection of tissue-mobilized macrophages from 
the inflamed tissue followed by their transportation to locoregional lymph nodes. 
Lymphatic-mediated removal of macrophages and dendritic cells from the affected 
site helps in resolving the inflammation and mounting the adaptive immune response 
through antigen presentation to T cells in the local nodes. Simultaneous activation of 
TLR4 in epithelium, stroma, endothelium, BM, and immune organs ensures tissue 
recovery in a coordinated and timely manner. TLR4 plays a central role in this process 
by coordinating epithelial cytokine release and activation, production of new cells in 
the BM, their recruitment to injured tissue, and resolution of residual inflammation 
that collectively promote tissue repair [54, 47]. While all these processes are essential 
for homeostasis, similar TLR4 activities in the context of cancer result in devastat-
ing outcomes including protection of tumor cells against anticancer drugs and their 
improved ability to generate and invade newly formed vessels.
5. TLR4 expression in malignant tumors
Although TLR4 expression was initially thought to be restricted to hematopoietic 
cells, subsequent studies discovered functional TLR4 in a variety of normal epithelial 
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cells [25, 26]. Malignant transformation amplifies TLR4 expression while typically 
preserving its functionality [55]. In fact, constitutive expression of epithelial TLR4 
might contribute to development of cancer if persistently activated by pathogenic 
and environmental ligands which leads to vicious cycles of self-propagating inflam-
mation. For instance, TLR4 interaction with H. pylori products in normal gastric 
epithelium might lead to chronic gastritis and progression into gastric intestinal 
metaplasia [56]. Analysis of cell lines from other organs also consistently showed 
substantial upregulation of TLR4 in tumor cells compared with their normal counter-
parts. Protein, mRNA, and functional activity of the TLR4 pathway have been dem-
onstrated in tumor lines derived from many human epithelial lines including breast 
[33, 57], ovarian [58, 59], lung [60], prostate [61, 62], head and neck [63], hepatic 
[64], gastric [65], and pancreatic [66] cancers. It is also expressed in melanoma [67], 
glioblastoma [68], and various lines derived from hematopoietic malignancies [69]. 
Mouse tumor cell lines from a variety of tissues replicate these findings [70, 71].
TLR4 expression is not only limited to cultured tumor cell lines but is also 
detected in malignant cells in clinical human cancers. Moreover, the majority 
of clinical studies showed that TLR4 expression strongly correlates with poor 
prognosis due to increased tumor size [72], stage [73], loss of differentiation [74], 
chemoresistance [73, 75], venous invasion [72], lymph node metastasis [72, 75–78], 
recurrence [79], and shorter patient survival [77, 80] (Table 1). A recently pub-
lished meta-analysis examining data from 15 independent encompassing analyses 
of different tumors from 1294 patients found strong associations (P-values 0.001–
0.05) between TLR4 expression and reduced overall and disease-free survival [81]. 
Collectively, these studies demonstrate high expression of TLR4 in a variety of 
human solid tumors suggesting it plays a prominent role in inflammation-fueled 
cancer progression and metastasis.
6. Signal transduction and intracellular pathways induced by TLR4
Given the emerging evidence for the TLR4 pro-tumorigenic role (Table 1), it is 
important to understand the basic steps in this pathway, its positive and negative 
molecular regulators, as well as biochemical requirements for intracellular signal 
transduction in both normal myeloid and malignant epithelial cells. The best 
understanding of this pathway is derived from the studies of macrophages activated 
by LPS. Initiation of a signal cascade is mediated through recruitment of adapters 
interacting with the TIR domain of TLR4. Upon ligand-induced oligomerization 
of TLR4, the TIR domain recruits myeloid differentiation factor-88 (MyD88) that 
forms heterodimers with Mal (MyD88 adapter-like) partner, a protein specific for 
TLR4 pathway [89]. Upon binding to TIR, MyD88-Mal complex recruits mem-
bers of the IL-1R associated kinase (IRAK) family, IRAK1 and IRAK4 [90]. Once 
phosphorylated, IRAK1/4 dissociates from the complex and recruits TNF recep-
tor associate factor-6 (TRAF6), an E3 ubiquitin ligase and a critical mediator of 
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cells [25, 26]. Malignant transformation amplifies TLR4 expression while typically 
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Mouse tumor cell lines from a variety of tissues replicate these findings [70, 71].
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recurrence [79], and shorter patient survival [77, 80] (Table 1). A recently pub-
lished meta-analysis examining data from 15 independent encompassing analyses 
of different tumors from 1294 patients found strong associations (P-values 0.001–
0.05) between TLR4 expression and reduced overall and disease-free survival [81]. 
Collectively, these studies demonstrate high expression of TLR4 in a variety of 
human solid tumors suggesting it plays a prominent role in inflammation-fueled 
cancer progression and metastasis.
6. Signal transduction and intracellular pathways induced by TLR4
Given the emerging evidence for the TLR4 pro-tumorigenic role (Table 1), it is 
important to understand the basic steps in this pathway, its positive and negative 
molecular regulators, as well as biochemical requirements for intracellular signal 
transduction in both normal myeloid and malignant epithelial cells. The best 
understanding of this pathway is derived from the studies of macrophages activated 
by LPS. Initiation of a signal cascade is mediated through recruitment of adapters 
interacting with the TIR domain of TLR4. Upon ligand-induced oligomerization 
of TLR4, the TIR domain recruits myeloid differentiation factor-88 (MyD88) that 
forms heterodimers with Mal (MyD88 adapter-like) partner, a protein specific for 
TLR4 pathway [89]. Upon binding to TIR, MyD88-Mal complex recruits mem-
bers of the IL-1R associated kinase (IRAK) family, IRAK1 and IRAK4 [90]. Once 
phosphorylated, IRAK1/4 dissociates from the complex and recruits TNF recep-
tor associate factor-6 (TRAF6), an E3 ubiquitin ligase and a critical mediator of 
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TLR2 and TLR4 signaling [91]. Polyubiquitination mediated by TRAF6 activates 
MAP3 kinases and TGF-beta associated kinase (TAK1) [92]. MAP3K activation 
leads to stimulation of p38/JNK pathways, whereas TAK1 together with TAB1/2 
kinases phosphorylates the inhibitor of cytosolic NF-κB complex leading to release 
and nuclear translocation of NF-κB p65/p50 heterodimers [92]. This initiates the 
canonical NF-κB cascade resulting in transcription of a broad panel of inflamma-
tory and pro-survival genes. This is amplified by genes transcribed by AP-1, CREB, 
and Sp1, factors activated through the parallel p38/JNK cascade.
Independently of MyD88 pathway, viruses and some TLR4 ligands also activate 
TIR domain-containing adapter inducing interferon-beta protein (TRIF) that is 
associated with TRIF-related adapter molecule (TRAM). TRIF also activates NF-κB; 
however, the expression level and the composition of the downstream transcribed 
genes are distinct from the MyD88-dependent activation. For instance, TRIF specifi-
cally activates IRF3 factor that induces robust transcription of antiviral interferons 
necessary to fight viral infections as opposed to classic MyD88-NF-κB targets such as 
TNFα and IL-6 that are predominantly upregulated after exposure to bacterial LPS.
7. Role of co-receptors in activation of TLR4
One persistent misconception in the cancer research literature is that TLR4 
directly binds LPS and other activating ligands. However, it has been firmly 
established that TLR4, as a single protein, has very low affinity to LPS. Triggering 
the TLR4 pathway by LPS in monocytes and macrophages requires at least four 
co-receptors: myeloid differentiation protein-2 (MD2), CD14, and CD11b bound 
to CD18 (a complex of integrins known as Mac-1). Secreted MD2 binds to and 
stabilizes extracellular portion of TLR4 which creates a highly specific site for LPS 
recognition [93]. Intracellular MD2 also aids cytosolic trafficking of TLR4 from 
Golgi to the plasma membrane [94]. Physical interaction among MD2, LPS, and 
TLR4 has been shown in multiple elegant studies employing a combination of high-
resolution structural analyses, phenotype comparison in genetically modified mice, 
and other rigorous approaches [95] that show a critical role of MD2 in LPS recogni-
tion by TLR4 in either mouse or human cells.
Likewise, the essential role of CD14 has been shown by physical binding of 
CD14 to lipid A portion of LPS using crystal structure analyses [35] and resonance 
energy transfer [96] as well as by hypo-responsiveness to LPS in mice lacking 
CD14 [97] or in the presence of CD14-blocking antibodies [7]. The function of 
CD14 is to accept a monomer of LPS from a blood-circulating LPS-binding protein 
and transfer it to a pre-made pocket in the MD2/TLR4 complex [98]. The absence 
of CD14 from TLR4-/MD2-positive cells results in a 1000-fold reduced sensitiv-
ity to LPS compared with cells expressing this protein [99]. The involvement of 
CD11b/CD18 in reactivity to LPS is somewhat less certain although some studies 
using a point mutation identified a specific LPS-binding site in CD18 integrin 
[100]. Additional studies showed lack of cytokine production in Mac-1-deficient 
mice [101] and other deficiencies in TLR4 signaling upon treatment with anti-
CD11b or anti-CD18 antibodies in vivo [9]. While some studies suggested that 
optimal signaling requires LPS engagement with TLR4/MD2 complex and Mac-1, 
others found lesser requirements for CD11b/CD18 [102]. This issue, therefore, 
remains unresolved as well as the mechanisms of TLR4 signal transduction 
induced by various endogenous ligands dissimilar from LPS. Importantly, very 
few structural studies were performed in TLR4-expressing normal or tumor epi-
thelial cells that might have entirely different requirements for TLR4 co-receptors 
and signal transduction than macrophages. Tumor epithelial cells are unlikely 
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to express myeloid-specific CD14 and CD11b and might not uniformly express 
MyD88, MD2, and other TLR4 pathway essential proteins. How exactly TLR4 
transmits the multitude of functional effects in the epithelial cell context is largely 
unknown.
8. LPS is the most rigorously confirmed TLR4 agonist
The best-studied ligands of TLR4 are various LPS molecules expressed in Gram-
negative bacteria. The basic structure of LPS includes a lipid A component with 
4–6 fatty acyl chains, an oligosaccharide core, and covalently attached O-antigen 
polysaccharide side chain [103]. The presence of phosphates in the lipid A and 
oligosaccharides confers the highly negative charge to LPS enabling its reactivity 
with cationic bactericidal host molecules such as beta-defensins [104]. CD14 binds 
the lipid A portion of LPS leaving acyl chains exposed to an LPS-binding site on the 
TLR4/MD2 complex. The presence of six acyl chains (as opposed to five or four) 
confers the best potency in activating TLR4 [105], presumably because the four acyl 
chains perfectly fit the hydrophobic cavity in MD2 [106] and the other two chains 
support the complex and promote its oligomerization [107]. This structural require-
ment illustrates the exquisite specificity of the binding site in the TLR4/MD2 com-
plex to LPS raising reservations about the potential suitability of this complex for 
binding alternative ligands [95]. A functional and some structural evidence exists 
demonstrating TLR4-dependent cell activation triggered by lipid-like molecules 
(e.g., lipoteichoic acid [108], minimally oxidized LDL [109], and free saturated 
fatty acid palmitate [110]) whose binding might be supported by a hydrophobic site 
on CD14. Among other proposed TLR4-activating ligands, some structural evidence 
exists for a chemotherapeutic drug paclitaxel (PXL) [95, 101] and endogenous 
ligands HMGB1 [111] and S100A8 [112]. At the present, mechanisms by which other 
functional TLR4 ligands induce signal transduction are largely unknown.
9.  Chemotherapeutic drug paclitaxel as a TLR4 ligand and a promoter of 
tumor growth and metastasis
For cancer researchers, a TLR4 stimulating effect of PXL is of special signifi-
cance. This is because PXL and the entire class of its derivatives known as taxanes 
are widely used as anticancer cytotoxic drugs against a variety of human malig-
nancies [113]. Resistance, however, occurs frequently [114], and the underlying 
mechanisms are poorly understood. PXL, the active component of all taxanes, 
exerts its cytotoxic action via binding to microtubules leading to their over-
stabilization which results in apoptotic death of dividing cells [115]. The pro-
survival effects of activated TLR4 pathway can explain many attributes associated 
with PXL chemoresistance including activation of NF-κB [116], phosphorylation 
of Bcl-2 and Bcl-XL [117], and resultant evasion of apoptosis [33, 58] in spite of 
continuous therapy.
Despite somewhat limited direct evidence confirming physical interactions of 
PXL with the TLR4 complex, there is overwhelming functional evidence for PXL 
activation of the TLR4 pathway in malignant human and mouse cells (Table 2). 
The early studies demonstrated that wild-type (WT) mice with functional TLR4 
injected with PXL upregulated nearly an identical panel of inflammatory cytokines 
as those injected with LPS [3]. That was in sharp contrast to myeloid cells from 
TLR4-deficient mice that failed to respond to either molecule [118]. Mice lack-
ing MyD88, the major intracellular adapter of TLR4, also did not respond to LPS 
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TLR2 and TLR4 signaling [91]. Polyubiquitination mediated by TRAF6 activates 
MAP3 kinases and TGF-beta associated kinase (TAK1) [92]. MAP3K activation 
leads to stimulation of p38/JNK pathways, whereas TAK1 together with TAB1/2 
kinases phosphorylates the inhibitor of cytosolic NF-κB complex leading to release 
and nuclear translocation of NF-κB p65/p50 heterodimers [92]. This initiates the 
canonical NF-κB cascade resulting in transcription of a broad panel of inflamma-
tory and pro-survival genes. This is amplified by genes transcribed by AP-1, CREB, 
and Sp1, factors activated through the parallel p38/JNK cascade.
Independently of MyD88 pathway, viruses and some TLR4 ligands also activate 
TIR domain-containing adapter inducing interferon-beta protein (TRIF) that is 
associated with TRIF-related adapter molecule (TRAM). TRIF also activates NF-κB; 
however, the expression level and the composition of the downstream transcribed 
genes are distinct from the MyD88-dependent activation. For instance, TRIF specifi-
cally activates IRF3 factor that induces robust transcription of antiviral interferons 
necessary to fight viral infections as opposed to classic MyD88-NF-κB targets such as 
TNFα and IL-6 that are predominantly upregulated after exposure to bacterial LPS.
7. Role of co-receptors in activation of TLR4
One persistent misconception in the cancer research literature is that TLR4 
directly binds LPS and other activating ligands. However, it has been firmly 
established that TLR4, as a single protein, has very low affinity to LPS. Triggering 
the TLR4 pathway by LPS in monocytes and macrophages requires at least four 
co-receptors: myeloid differentiation protein-2 (MD2), CD14, and CD11b bound 
to CD18 (a complex of integrins known as Mac-1). Secreted MD2 binds to and 
stabilizes extracellular portion of TLR4 which creates a highly specific site for LPS 
recognition [93]. Intracellular MD2 also aids cytosolic trafficking of TLR4 from 
Golgi to the plasma membrane [94]. Physical interaction among MD2, LPS, and 
TLR4 has been shown in multiple elegant studies employing a combination of high-
resolution structural analyses, phenotype comparison in genetically modified mice, 
and other rigorous approaches [95] that show a critical role of MD2 in LPS recogni-
tion by TLR4 in either mouse or human cells.
Likewise, the essential role of CD14 has been shown by physical binding of 
CD14 to lipid A portion of LPS using crystal structure analyses [35] and resonance 
energy transfer [96] as well as by hypo-responsiveness to LPS in mice lacking 
CD14 [97] or in the presence of CD14-blocking antibodies [7]. The function of 
CD14 is to accept a monomer of LPS from a blood-circulating LPS-binding protein 
and transfer it to a pre-made pocket in the MD2/TLR4 complex [98]. The absence 
of CD14 from TLR4-/MD2-positive cells results in a 1000-fold reduced sensitiv-
ity to LPS compared with cells expressing this protein [99]. The involvement of 
CD11b/CD18 in reactivity to LPS is somewhat less certain although some studies 
using a point mutation identified a specific LPS-binding site in CD18 integrin 
[100]. Additional studies showed lack of cytokine production in Mac-1-deficient 
mice [101] and other deficiencies in TLR4 signaling upon treatment with anti-
CD11b or anti-CD18 antibodies in vivo [9]. While some studies suggested that 
optimal signaling requires LPS engagement with TLR4/MD2 complex and Mac-1, 
others found lesser requirements for CD11b/CD18 [102]. This issue, therefore, 
remains unresolved as well as the mechanisms of TLR4 signal transduction 
induced by various endogenous ligands dissimilar from LPS. Importantly, very 
few structural studies were performed in TLR4-expressing normal or tumor epi-
thelial cells that might have entirely different requirements for TLR4 co-receptors 
and signal transduction than macrophages. Tumor epithelial cells are unlikely 
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to express myeloid-specific CD14 and CD11b and might not uniformly express 
MyD88, MD2, and other TLR4 pathway essential proteins. How exactly TLR4 
transmits the multitude of functional effects in the epithelial cell context is largely 
unknown.
8. LPS is the most rigorously confirmed TLR4 agonist
The best-studied ligands of TLR4 are various LPS molecules expressed in Gram-
negative bacteria. The basic structure of LPS includes a lipid A component with 
4–6 fatty acyl chains, an oligosaccharide core, and covalently attached O-antigen 
polysaccharide side chain [103]. The presence of phosphates in the lipid A and 
oligosaccharides confers the highly negative charge to LPS enabling its reactivity 
with cationic bactericidal host molecules such as beta-defensins [104]. CD14 binds 
the lipid A portion of LPS leaving acyl chains exposed to an LPS-binding site on the 
TLR4/MD2 complex. The presence of six acyl chains (as opposed to five or four) 
confers the best potency in activating TLR4 [105], presumably because the four acyl 
chains perfectly fit the hydrophobic cavity in MD2 [106] and the other two chains 
support the complex and promote its oligomerization [107]. This structural require-
ment illustrates the exquisite specificity of the binding site in the TLR4/MD2 com-
plex to LPS raising reservations about the potential suitability of this complex for 
binding alternative ligands [95]. A functional and some structural evidence exists 
demonstrating TLR4-dependent cell activation triggered by lipid-like molecules 
(e.g., lipoteichoic acid [108], minimally oxidized LDL [109], and free saturated 
fatty acid palmitate [110]) whose binding might be supported by a hydrophobic site 
on CD14. Among other proposed TLR4-activating ligands, some structural evidence 
exists for a chemotherapeutic drug paclitaxel (PXL) [95, 101] and endogenous 
ligands HMGB1 [111] and S100A8 [112]. At the present, mechanisms by which other 
functional TLR4 ligands induce signal transduction are largely unknown.
9.  Chemotherapeutic drug paclitaxel as a TLR4 ligand and a promoter of 
tumor growth and metastasis
For cancer researchers, a TLR4 stimulating effect of PXL is of special signifi-
cance. This is because PXL and the entire class of its derivatives known as taxanes 
are widely used as anticancer cytotoxic drugs against a variety of human malig-
nancies [113]. Resistance, however, occurs frequently [114], and the underlying 
mechanisms are poorly understood. PXL, the active component of all taxanes, 
exerts its cytotoxic action via binding to microtubules leading to their over-
stabilization which results in apoptotic death of dividing cells [115]. The pro-
survival effects of activated TLR4 pathway can explain many attributes associated 
with PXL chemoresistance including activation of NF-κB [116], phosphorylation 
of Bcl-2 and Bcl-XL [117], and resultant evasion of apoptosis [33, 58] in spite of 
continuous therapy.
Despite somewhat limited direct evidence confirming physical interactions of 
PXL with the TLR4 complex, there is overwhelming functional evidence for PXL 
activation of the TLR4 pathway in malignant human and mouse cells (Table 2). 
The early studies demonstrated that wild-type (WT) mice with functional TLR4 
injected with PXL upregulated nearly an identical panel of inflammatory cytokines 
as those injected with LPS [3]. That was in sharp contrast to myeloid cells from 
TLR4-deficient mice that failed to respond to either molecule [118]. Mice lack-
ing MyD88, the major intracellular adapter of TLR4, also did not respond to LPS 
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or PXL [119]. Treatment with PXL faithfully reproduced all known events in the 
LPS-inducing cascade including dual activation of MyD88 and TRIF pathways 








Human In vitro PXL induced degradation of IkappaB 
alpha followed by activation of NF-κB 
and MAPK
[126]
Renal Human In vitro PXL activated ERK1/2 and induced 
Bcl-2 and EGFR
[127]
Breast Human In vitro Only PXL-responsive tumor lines 
showed marked increase in AP-1 and 
NF-κB binding to IL-8 promoter
[128]
Breast Human In vitro &  
In vivo
Curcumin, an inhibitor of NF-κB, 
blocked PXL-dependent upregulation 
of pro-survival, proliferative and 
angiogenic proteins including MMP9 
& VEGF-A
[129]
Prostate Human In vitro Docetaxel increased tumor cell survival 
by activating PI3K/AKT pathway and 
TLR4 silencing reduced this effect
[61]
Breast Human Tumor 
xenografts 
in mice
PXL therapy induced NF-κB, Bcl-2, and 
VEGF-A, and anti-VEGF-A antibody 
blocked this effect
[130]
Various Human In vitro In a cell-based screening of 1,280 
compounds, PXL was identified as one 







Pre-operative taxane therapy increased 
COX2, PGE2 and microvessel density 
in patients
[132]
Breast Human In vitro 
& models 
in vivo
PXL upregulated cytokines mainly in 
TLR4-positive tumor lines; an anti-
TLR4 antibody blocked this effect
[33]
Breast Human Clinical 
study
Taxane chemotherapy increased 
circulating angiogenic factors and 
endothelial cell progenitors in patients
[133]
Breast Human & Mouse Tumor 
models in 
mice
Taxane chemotherapy increased 
circulating CSF1 and tumor homing of 
BM pro-vascular myeloid cells
[134]
Breast Human Clinical 
study
Neoadjuvant taxane therapy increased 
angiogenesis in patients, possibly 
through VEGF-A and Notch pathways
[135]
Breast Human Tumor 
xenografts 
in mice
TLR4-positive tumors responded 
to PXL by increasing cytokines, 
homing of myeloid pro-vascular cells, 
lymphangiogenesis, and metastasis to 
lymph nodes
[136]
Breast Human & Mouse In vitro PXL induced differentiation of 
lymphatic endothelial progenitors in 
TLR4-positive BM myeloid precursors
[18]
Breast Human & Mouse Tumor 
models 
in vivo
Docetaxel increased tumor lymphatic 
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[33, 118, 122]; signaling through PI3K/pAKT [61, 121, 123] and activation of MAP 
kinases [119], p38 [124], JNK [123], ERK1/2 [33, 125], AP-1, and STAT3 [116]; and 
transcription of inflammatory genes and pro-survival factors [33, 118].
PXL-induced upregulation of inflammatory, promitotic, and pro-survival 
genes is evidenced by transcriptional analyses of drug-treated human cancer 
lines from breast [33, 122, 136], ovarian [58, 121], prostate [61], lung [116, 138], 
and melanoma [139] origins. Upregulation of these genes is evidenced as early 
as 6 hours posttreatment [138] which eliminates the possibility that this is a 
secondary effect resulting from cell death. Inhibition of IRAK1, an intracellular 
kinase whose phosphorylation is required for TLR4-dependent activation of 
NF-κB [90], in breast cancer lines suppressed an inflammatory response to PXL 
concomitant with decreased chemoresistance in vivo [122]. Correlation with 
chemoresistance was also recorded in an independent study that employed two 
different models of isogenic TLR4-negative and TLR4-positive lines [33, 136]. 
Mediation of PXL signaling through TLR4 is also suggested by studies with TAK-
242 (also known as CLI-095), a TLR4-specific inhibitor that blocks interactions 
between the TIR domain and intracellular adapters [140]. Breast carcinoma cells 
pre-treated with TAK-242 reduced PXL-induced expression of inflammatory 
cytokines by nearly 90% [33]. Multiple studies showed that PXL effects on tumor 
epithelial or immune cells are largely TLR4-dependent since silencing TLR4 by 
siRNAs or blocking its actions by specific antibodies or sequence-based peptide 
inhibitors significantly reduced both NF-κB activation and subsequent molecular 
(e.g., cytokine upregulation) and cellular (e.g., division and migration) activities 
[33, 61, 121].
While the notion of PXL sharing the TLR4 pathway with LPS is generally 
accepted, the molecular basis for physical TLR4 recognition by PXL is still a matter 
of debate, particularly in the context of nonmyeloid cells. CD14 was reported to 
play a minimal role in transmission of PXL signals [141], and it is typically absent in 
normal and tumor epithelial cells. PXL was reported to bind to CD18 [101], but the 
partner for the Mac-1 complex, CD11b, is typically absent from non-hematopoietic 
cells such as tumor cells from epithelial malignancies. The requirement for MD2 
turned out to be particularly contentious as several studies reported an exclusive 
specificity of mouse but not human MD2 in supporting PXL-induced signaling 
[142, 143]. The implication would be that PXL affects only cells from the mouse 
specie, but this contradicts extensive evidence demonstrating functional LPS-
mimetic effects of PXL on human tumor cells (Table 2) and normal monocytes 
[18]. One group found that PXL does bind to human TLR4/MD2 complex but acts 
as an antagonist [143]. However, this is inconsistent with increased migration, 
invasion, and other activities of human tumor cells [62, 144] as well as with direct 
stimulating effects on multiple signaling pathways [122]. It should be noted that 
two studies that identified PXL as an inhibitor of TLR4 were performed in HEK-
293 cells, a human embryonic kidney line immortalized by adenovirus A5 which 
caused substantial deviations from the epithelial phenotype including expression 
of neuron-specific genes [145]. HEK-293 cell line was very useful for identification 
of structural components of the TLR4 complex but might not necessarily reflect the 
biology of human tumor cells due to differences in organ origin (many responders 
are derived from tissues other than kidney), stemness status (embryonic vs. adult), 
and unique genetic changes caused by virus. The latter could lead to significant 
differences in expression of TLR4 co-receptors and other regulatory proteins. In 
general, the majority of structural studies with PXL have been performed with 
either HEK-293 or macrophages. It therefore remains to be established whether 
the same mechanisms control PXL interactions with the TLR4 complex in human 
epithelial neoplastic cells.
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[33, 118, 122]; signaling through PI3K/pAKT [61, 121, 123] and activation of MAP 
kinases [119], p38 [124], JNK [123], ERK1/2 [33, 125], AP-1, and STAT3 [116]; and 
transcription of inflammatory genes and pro-survival factors [33, 118].
PXL-induced upregulation of inflammatory, promitotic, and pro-survival 
genes is evidenced by transcriptional analyses of drug-treated human cancer 
lines from breast [33, 122, 136], ovarian [58, 121], prostate [61], lung [116, 138], 
and melanoma [139] origins. Upregulation of these genes is evidenced as early 
as 6 hours posttreatment [138] which eliminates the possibility that this is a 
secondary effect resulting from cell death. Inhibition of IRAK1, an intracellular 
kinase whose phosphorylation is required for TLR4-dependent activation of 
NF-κB [90], in breast cancer lines suppressed an inflammatory response to PXL 
concomitant with decreased chemoresistance in vivo [122]. Correlation with 
chemoresistance was also recorded in an independent study that employed two 
different models of isogenic TLR4-negative and TLR4-positive lines [33, 136]. 
Mediation of PXL signaling through TLR4 is also suggested by studies with TAK-
242 (also known as CLI-095), a TLR4-specific inhibitor that blocks interactions 
between the TIR domain and intracellular adapters [140]. Breast carcinoma cells 
pre-treated with TAK-242 reduced PXL-induced expression of inflammatory 
cytokines by nearly 90% [33]. Multiple studies showed that PXL effects on tumor 
epithelial or immune cells are largely TLR4-dependent since silencing TLR4 by 
siRNAs or blocking its actions by specific antibodies or sequence-based peptide 
inhibitors significantly reduced both NF-κB activation and subsequent molecular 
(e.g., cytokine upregulation) and cellular (e.g., division and migration) activities 
[33, 61, 121].
While the notion of PXL sharing the TLR4 pathway with LPS is generally 
accepted, the molecular basis for physical TLR4 recognition by PXL is still a matter 
of debate, particularly in the context of nonmyeloid cells. CD14 was reported to 
play a minimal role in transmission of PXL signals [141], and it is typically absent in 
normal and tumor epithelial cells. PXL was reported to bind to CD18 [101], but the 
partner for the Mac-1 complex, CD11b, is typically absent from non-hematopoietic 
cells such as tumor cells from epithelial malignancies. The requirement for MD2 
turned out to be particularly contentious as several studies reported an exclusive 
specificity of mouse but not human MD2 in supporting PXL-induced signaling 
[142, 143]. The implication would be that PXL affects only cells from the mouse 
specie, but this contradicts extensive evidence demonstrating functional LPS-
mimetic effects of PXL on human tumor cells (Table 2) and normal monocytes 
[18]. One group found that PXL does bind to human TLR4/MD2 complex but acts 
as an antagonist [143]. However, this is inconsistent with increased migration, 
invasion, and other activities of human tumor cells [62, 144] as well as with direct 
stimulating effects on multiple signaling pathways [122]. It should be noted that 
two studies that identified PXL as an inhibitor of TLR4 were performed in HEK-
293 cells, a human embryonic kidney line immortalized by adenovirus A5 which 
caused substantial deviations from the epithelial phenotype including expression 
of neuron-specific genes [145]. HEK-293 cell line was very useful for identification 
of structural components of the TLR4 complex but might not necessarily reflect the 
biology of human tumor cells due to differences in organ origin (many responders 
are derived from tissues other than kidney), stemness status (embryonic vs. adult), 
and unique genetic changes caused by virus. The latter could lead to significant 
differences in expression of TLR4 co-receptors and other regulatory proteins. In 
general, the majority of structural studies with PXL have been performed with 
either HEK-293 or macrophages. It therefore remains to be established whether 
the same mechanisms control PXL interactions with the TLR4 complex in human 
epithelial neoplastic cells.
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10.  Endogenous ligands of TLR4 released from damaged and necrotic 
cells
The class of endogenous ligands comprises more than 30 molecules that share 
no structural resemblance within the members of the group and either LPS or 
PXL. The list of proposed endogenous TLR4 ligands includes a variety of structur-
ally dissimilar molecules ranging from high-mobility group box-1 (HMBG1) [146] 
to S100A8 [27, 147] and fibronectin [148]. Alternative names for endogenous ligands 
are DAMPs mentioned above [41], danger factors [42], and alarmins [149]. The 
current concept suggests that DAMPs normally segregated into cytosol or intracel-
lular compartments are secreted upon exposure to inflammatory cytokines [146] or 
passively released from damaged or necrotic cells [71]. Soluble DAMPs then activate 
receptors of innate immunity such as TLR2, TLR4, and RAGE that are charged not 
only with protection against pathogens but also with restoration of homeostasis 
[41]. This is an appealing concept that fits well with well-established activation of 
TLR4 during sterile injury [150] and remodeling of wounded tissue or tumor [151]. 
It might also explain activation of TLR4 in cancers developed at sterile anatomic sites 
and, particularly, during cytotoxic therapy that produces massive cell death.
DAMP-mediated activation of the TLR4 pathway in tumor cells has been shown 
by numerous independent studies using genetically modified mice with absent or 
mutated TLR4 [152], blocking anti-TLR4 antibodies [153], specific inhibitors [152], 
and gain- of-function or loss-of-function approaches [153]. For instance, anti-TLR4 
antibody reduced HMGB1-induced proliferation of mouse lung carcinoma cells [154]. 
HMGB1-dependent recruitment of c-Kit+ progenitors [155], angiogenesis [156], and 
lymphangiogenesis [157] was significantly reduced in TLR4 −/− non-tumor-bearing 
mice suggesting similar outcomes in the presence of tumor. HMGB1-induced angio-
genesis was also shown in study with UV-damaged keratinocytes in which the released 
factor increased inflammation, cell proliferation, and migration of melanoma cell 
toward the endothelial monolayer [144]. All effects were reduced in TLR4- and 
MyD88-deficient mice as well as in the presence of TAK-242, a specific peptide inhibi-
tor of TLR4 signal transduction [144]. Consistent with this finding, HMGB1 released 
from necrotic skin cells enhanced inflammation and recruitment of BM myeloid cells 
and promoted tumor formation, all of which were reduced in TLR4 null mice [158]. 
Overexpression of HMGB1 in hepatic carcinoma correlated with tumor invasion, and 
knockdown of this protein suppressed metastasis [159]. Chemotherapy that produces 
massive necrosis and hence release of HMGB1 and other pro-inflammatory intracel-
lular factors was shown to enhance tumor relapse and metastasis in a model of colon 
cancer [71]. A variety of tumor- and metastasis-promoting effects have also been 
reported for other endogenous TLR4 ligands including S100A8/A9 [152], SAA3 [147], 
hyaluronic acid [153], heat-shock proteins [68, 160], and peroxiredoxin-1 [161].
While the existing functional evidence strongly supports DAMP activation of 
the TLR4 pathway, the question remains whether these factors are truly ligands 
for TLR4 or ancillary molecules that stabilize its membrane complex or potentiate 
intracellular signaling. This uncertainty stems from structural dissimilarity between 
LPS and many TLR4-activating molecules; a potential risk by LPS contamination 
of recombinant factors produced in Gram-negative bacteria [162]; and lack of clear 
structural evidence for physical interaction with TLR4 or MD2 proteins for some 
ligands [95]. That said, binding of mammalian cell-produced, endotoxin-free SAA3 
and S100A8 to TLR4/MD2 complex was shown by surface plasmon resonance [163], 
and binding of HMGB1 to the same complex was demonstrated by a point muta-
tion in Cys106 that severely reduced the HMGB1 capacity to activate TLR4 [111]. 
Determination of other ligands as binding partners, amplifiers [164], or assistants 
might need to be resolved in the future studies.
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11.  Cellular and molecular consequences of TLR4 activation in the 
context of cancer
TLR4 is a powerful pathway that simultaneously enhances several key cell 
functions including differentiation, proliferation, migration, invasion, and survival. 
On molecular level, the hallmark of TLR4 stimulation is strong upregulation of 
inflammatory cytokines that act as autocrine and paracrine activators of the first cell 
responders to TLR4 ligands and nearby stroma, respectively, as well as systemic alert 
signals for immune organs. In tumors, parallel TLR4 activation of neoplastic and 
immune cells often results in “double-edge sword” effects [165] due to conflicting 
functional implications for each cell type. An antitumor effect of TLR4 activation 
of dendritic cells (DC) is evident by enhanced maturation [166], migration [167], 
improved antigen presentation [168], better activation of cytotoxic T cells  
[168], and increased tumor cell death [169]. However, induction of similar pro-
mitotic, survival, and migratory functions in malignant and tumor-associated cells 
has a pro-tumorigenic effect. TLR4 agonists are often proposed to be used clinically 
for enhancing antitumor therapy [170]; however, it is worth considering both local 
and systemic consequences of TLR4 activation. The effects on host immune and 
hematopoietic cells are not straightforward as improved DC functions are coun-
terbalanced by increased generation of myeloid-derived suppressor cells [171] that 
inhibit antitumor responses. TLR4 activation of BM immature myeloid cells leads to 
generation of provascular progenitors [17, 18] that increase tumor vessel formation 
and metastasis [136, 172]. Lung recruitment of the host BM-derived myeloid cells 
by TLR4 ligands SAA3 in combination with S100A8/A9 has been shown to create a 
pulmonary pre-metastatic niche, thus ensuring successful establishment of tumor 
lesions in distant organs [147]. Likewise, TLR4 activation of T cells may enhance 
their immunosuppressive effects [173] rather than anticancer activities. In our stud-
ies performed in tumor-bearing immunocompetent and immunodeficient mice, we 
often observe a transiently reduced growth upon injection of TLR4-differentiated 
myeloid progenitors. However, tumor growth resumes at later stages along with 
substantial increase in lymph node metastasis which correlates with injection 
of myeloid-derived progenitors [18]. These studies suggest that development of 
either TLR4-suppressing or TLR4-activating therapeutic strategies should take 
into account the impact of modulators on all TLR4-positive cells at both tumor and 
systemic organs.
12. Direct functional effects of TLR4 on tumor cells
Most solid tumors that originated from epithelial, neuronal, and skin cells do 
not exhibit the same level of responsiveness to LPS as myeloid cells. Nevertheless, 
functionally, TLR4 activation of tumor cells largely reproduces the known effects 
in cells of innate immunity. On molecular level, this includes MyD88-dependent 
activation of NF-κB [33, 71, 174], MAPK [75], PI3K/AKT [61, 175], ERK1/2 [176], 
c-Jun [69], p38 [75, 176, 177], and other pathways that collectively upregulate 
inflammatory cytokines [174, 178], metalloproteases [179], and pro-survival 
factors [59, 180]. Among multiple LPS-induced cytokines in cancer cells are par-
ticularly important angiogenic factor VEGF-A [55, 60, 181], immunosuppressive 
TGF-beta [60, 182], and a variety of chemokines recruiting BM-derived myeloid 
cells [34, 178] that promote tumor progression through their own mechanisms. On 
a cellular level, TLR4 activation increases tumor cell proliferation [69, 177, 183], 
migration [64, 175], invasion [159], and survival [58, 176, 184] that collectively 
results in resistance to therapy [58, 61, 69, 136, 183]. Some studies also reported 
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11.  Cellular and molecular consequences of TLR4 activation in the 
context of cancer
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On molecular level, the hallmark of TLR4 stimulation is strong upregulation of 
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functional implications for each cell type. An antitumor effect of TLR4 activation 
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not exhibit the same level of responsiveness to LPS as myeloid cells. Nevertheless, 
functionally, TLR4 activation of tumor cells largely reproduces the known effects 
in cells of innate immunity. On molecular level, this includes MyD88-dependent 
activation of NF-κB [33, 71, 174], MAPK [75], PI3K/AKT [61, 175], ERK1/2 [176], 
c-Jun [69], p38 [75, 176, 177], and other pathways that collectively upregulate 
inflammatory cytokines [174, 178], metalloproteases [179], and pro-survival 
factors [59, 180]. Among multiple LPS-induced cytokines in cancer cells are par-
ticularly important angiogenic factor VEGF-A [55, 60, 181], immunosuppressive 
TGF-beta [60, 182], and a variety of chemokines recruiting BM-derived myeloid 
cells [34, 178] that promote tumor progression through their own mechanisms. On 
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migration [64, 175], invasion [159], and survival [58, 176, 184] that collectively 
results in resistance to therapy [58, 61, 69, 136, 183]. Some studies also reported 
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increased stemness due to expansion of cancer stem cells [153, 183]. Additional 
effects include induction of epithelial-mesenchymal transition (EMT) [66, 180] 
and evasion of immunosurveillance [183], both of which might reflect TLR4-
activated macrophage properties enabling tissue repair and resilience against 
pathogen-produced toxins. Undoubtedly, combination of these effects profoundly 
impacts tumor growth, chemoresistance, and metastasis.
While it is not possible to discuss all relevant reports due to very extensive 
literature on the subject, it is worthwhile to highlight several general points. First, 
the majority of reports showed a significant increase in oncogenic and metastatic 
potential of tumor cells treated with TLR4 ligands, whereas a minority described 
an opposite effect [185]. This suggests that in most situations, although both 
pro- and antitumor effects are induced by TLR4 signaling, the former might be 
prevailing over the latter. Second, the pro-oncogenic effects have been observed 
across the entire tumor source spectrum including breast [136, 174, 175], ovarian 
[58, 121], prostate [61, 62, 184], lung [55, 70], pancreatic [186], colon [176, 180], 
colorectal [75, 78], and hepatocellular [159, 177] carcinoma lines as well as glioma 
[183], myeloma [69], and melanoma [144] cells. This indicates a widespread role 
of TLR4 signaling in human solid cancers which should be considered by clinical 
therapeutic strategies. Third, TLR4 pathway activated by PXL [33, 58, 62], LPS 
[175, 184], or other ligands [154] equally affects mouse [178] and human [33, 58] 
cancer cells. This point is important not only because of the widespread use of 
mice for modeling human cancers but also because of a lingering debate whether 
PXL-dependent activation is restricted to mouse cells [142, 187]. Evidence from 
multiple studies demonstrating PXL-dependent activation of human tumor 
cells (Table 2; reviewed in [188]) indicates that this is not a case. Lastly, media-
tion through the TLR4 protein by PXL and endogenous ligands has been shown 
by many approaches including RNA interference [61, 62], anti-TLR4 blocking 
antibodies [33, 189], TLR4-specific inhibitors [33, 144], as well as use of TLR4−/− 
mice [30, 144, 158] and isogenic tumor lines with differential TLR4 expression 
[33]. Although the studies of alternative TLR4 ligands would still benefit from 
stronger structural evidence for direct recognition of the TLR4 complex, the 
combined functional evidence derived from multiple independent studies cannot 
be dismissed. The currently available data show mainly a pro-tumorigenic impact 
of TLR4 expressed in human and mouse cancer cells resulting from exposure to 
LPS or TLR4 alternative ligands.
13.  Importance of TLR4-induced autocrine loops in normal myeloid cell 
physiology and tumor pathology
One important function of the TLR4 pathway in macrophages during pathogenic 
invasion is to amplify the signaling to hasten proliferation and survival of resident 
macrophages as well as recruitment of BM-derived myeloid cells to the septic site. 
Macrophages effectively achieve this goal by establishing autocrine loops through 
coincided upregulation of secreted cytokines and corresponding membrane-
inserted receptors. This positive reinforcement ensures sustained expression of 
downstream targets necessary for prolonged survival, resilience, and heightened 
activities of immune cells. For instance, LPS-upregulated IL-1 and IL-18 are 
co-expressed with their receptors that signal through the MyD88 pathway in addi-
tion to TLR4 [190] which doubles the outcomes of the combined signaling [191]. 
LPS-induced co-expression of IL-8, TNF alpha, and other cytokines with their 
receptors was reported to amplify macrophage functions by enhancing activation of 
NF-κB [39] and STAT1 [192]. This pattern is mimicked by TLR4-positive tumor cells 
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activated by either LPS [178] or PXL [33]. In our study with TLR4-expressing breast 
carcinoma lines, we observed that PXL-induced transcription of multiple cytokines 
was coordinated with upregulation of matching receptors evident by parallel 
elevation of CXCL2/CXCR2, CCL20/CCR6, and CSF1/CSF1R pairs [33]. Similarly to 
positive reinforcement in activated macrophages, signaling through these addi-
tional pathways in tumor cells significantly increased expression of pro-survival 
proteins such as pAKT and ERK1/2 [33]. These findings highlight a cytoprotective 
program naturally induced by TLR4 in macrophages and reproduced by tumor cells 
that might represent a key mechanism underlying tumor evasion of apoptosis and 
resistance to therapy.
14.  Indirect pro-oncogenic effects of TLR4 mediated by cells in the 
tumor microenvironment (TME)
TME has profound effects on tumor progression [193, 194]. Some of the pro-
oncogenic and pro-metastatic effects of TLR4 are mediated by TME cells such as 
macrophages, fibroblasts, smooth muscle cells, and pericytes as well as endothe-
lium lining blood and lymphatic vessels. Macrophages are natural responders to 
TLR4 ligands having the highest expression of this receptor. Under inflammatory 
conditions, TLR4 is further upregulated by LPS [31] and cytokines [195] through 
positive feedback loops. Tumor-associated macrophages (TAMs) are well-known 
promoters of metastasis through secretion of growth-promoting cytokines, prote-
ases [196], and immunosuppressive factors [197]. TAMs are also significant source 
for lymphangiogenic factors that increase lymphatic density and metastasis [198]. 
Importantly, TAMs from TLR4-deficient mice have a significantly reduced capacity 
to activate NF-κB leading to deficient production of angiogenic and inflammatory 
factors that promote tumor growth [55].
Cancer-associated fibroblasts (CAFs) are another cell type found in most 
solid tumors but particularly pronounced in pancreatic [199], colorectal [200], 
and breast [201] cancers. Inflamed human and mouse fibroblasts express TLR4/
MD2 complex and respond to TLR4 ligands [202]. Deletion of TLR4 prevents 
fibrosis in vivo [202] suggesting that CAF-expressed TLR4 might play a non-
redundant role in tumor pathology. This is, indeed, supported by several studies. 
TLR4 expression in CAFs in human colorectal cancer was associated with high 
recurrence rate and poor patient survival [200]. CAFs associated with breast 
cancer were identified as a main source of HMGB1 that activated neighboring 
TLR4-positive tumor cells [203]. Functional TLR4 was also found to be expressed 
in another TME component, tumor-recruited mesenchymal stem cells (MSC), 
which was evidenced by LPS-activated NF-κB, PI3K and IRF1, and upregulation 
of downstream cytokines [204]. High level of TLR4 was also detected in human 
pericytes that are ontogenically related to MSC [52]. When activated by either 
LPS or HMGB1, pericytes upregulated classic NF-κB genes including cytokines 
and cell adhesion molecules (CAMs) such as VCAM-1 and ICAM-1. The latter 
greatly increase leukocyte adhesion to pericyte monolayer [52] which might play 
a key role in transmigration of blood-circulating immune cells and hematopoietic 
progenitors through the vascular barrier and infiltration of the tumor interstitium. 
Tumor-recruited cells harbor BM-derived myeloid-suppressive cells that promote 
immuno-evasion [205] as well as provascular progenitors that expand tumor vas-
culature [206, 207]. Both of these TME populations are known to advance tumor 
progression. Collectively, these studies illustrate a prominent role of TLR4 signal-
ing in cross-talk of various TME compartments that propagate circuits supporting 
tumor-associated and malignant cells.
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15. Role of TLR4 in tumor angiogenesis and lymphangiogenesis
Although majority of studies have been focused on myeloid cells, it is difficult to 
overstate the functional impact of the TLR4 pathway on vasculature. Blood ves-
sels are the first responders to circulating septic molecules, and lymphatic vessels, 
among other functions, help mounting the adaptive immune response by collecting 
pathogenic antigens from the infected tissue and delivering them to regional lymph 
nodes. Blood vascular endothelial cells (BEC) and lymphatic endothelial cells (LEC) 
from human [19, 208] and mouse [50] origins express TLR4 and are naturally 
equipped to sense and respond to TLR4 ligands [49, 209]. Endothelial cells (EC) 
from both large [208] and microvessels [19] express TLR4 and accessory molecules 
for ligand recognition [32] and intracellular signaling [49, 209, 210]. The TLR4 
specificity of endothelial response to LPS and other ligands has been documented 
using mice with deleted receptor [50], ectopic overexpression of nonfunctional 
protein [19], siRNA [211], and anti-TLR4 monoclonal antibodies [19].
Similarly to myeloid cells, activation of endothelial TLR4 results in NF-κB-
mediated upregulation of inflammatory cytokines [19] that includes prominent 
expression of angiogenic factors VEGF-A and PDGF-BB [212]. Along with this 
shared pattern, EC also display a distinct response to TLR4 activation such as high 
upregulation of transcription factor FOXC2 and induction of DLL4-Notch signal-
ing [210] regulating vascular sprouting [213]. Likewise, CAM upregulation, which 
is detected in all TLR4-activated cells, is particularly pronounced in endothelium 
[212]. TRAF6, the key regulator of the TLR4 pathway, also mediates endothelial-
specific responses, e.g., disruption of the vascular barrier [48, 49]. The resultant 
increase in vascular permeability combined with CAM upregulation strongly 
promotes recruitment of blood-circulating cells [50, 155] many of which (e.g., 
BM-derived immature myeloid cells) have potent independent effects on generation 
of tumor vessels [206]. Indeed, microvessel density in clinical human pancreatic 
cancers was found to be strongly associated with TLR4 expression [211]. A puta-
tive endogenous ligand of TLR4, peroxiredoxin-1, was shown to increase tumor 
growth by promoting tumor vasculature [161]. These studies support the concept 
that TLR4 activation of tumor endothelium promotes vascular formation through 
direct induction of angiogenic factors and sprouting and, indirectly, by facilitating 
transmigration of blood-circulating tumor-promoting immune cells.
Whereas tumor angiogenesis is indispensable for expansion of tumor mass, it 
might be less relevant to metastasis than lymphatic vessels that have invasion-prone 
discontinuous basement membrane [214] and are naturally equipped to transport 
cells to regional lymph nodes [215]. Hematogenous metastasis typically occurs 
later from the blood vessels in the lymphatic lesions as has recently been shown 
in several mouse models [216, 217]. Cell trafficking to lymph nodes is mediated 
exclusively by tumor-associated lymphatic vessels, and increase in density of these 
vessels is directly associated with metastasis in breast [218] and many other human 
cancers [188]. Functional TLR4 is highly expressed in LEC as evidenced by sub-
stantial upregulation of NF-κB-dependent chemokines that recruit macrophages 
from inflamed tissue to the lymphatic vessels leading to the draining nodes [20]. 
The absence of TLR4 significantly reduces lymphatic vessel formation resulting 
in increased edema and decreased transport through the lymphatic channels [53]. 
Paclitaxel, a potent mimetic of LPS, promotes lymphangiogenesis in breast cancer 
models concomitant with highly elevated lymphatic metastasis and, subsequently, 
increased recurrence [136]. Collectively, these studies present strong evidence for 
TLR4-dependent promotion of metastasis through activation of both blood and 
lymphatic endothelia in the tumor.
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16.  Indirect provascular effects of TLR4 through differentiation of 
BM-derived endothelial progenitors and their recruitment to tumors
One often overlooked aspect of systemic TLR4 signaling is its tremendous 
impact on differentiation and recruitment of BM-derived provascular progenitors. 
Angiogenesis and lymphangiogenesis are tightly regulated in adult organism and, 
with few exceptions (e.g., wound healing and a female reproductive cycle), are 
induced only during sustained unresolved inflammation or cancer. The latter are one 
and the same because all solid tumors have a persistent inflammatory component. 
Physiologically, any increase in tissue mass or remodeling is accompanied by expan-
sion of blood and lymphatic vessels necessary to serve the new vascular bed. TLR4 
responds to this host default program not only by activating local endothelium but 
also by inducing differentiation of provascular progenitors from early BM precursors.
In all vertebrates, embryonic stem cells derived from hemogenic endothelium 
express TLR4-NF-κB pathway that is necessary and sufficient to create hemato-
poietic stem/progenitor cells [15]. The latter give rise to both immune and vascular 
endothelial cells [219, 220]. Adult mesenchymal [16, 204] and hematopoietic stem 
cells express functional TLR4 as evidenced by LPS-induced self-renewal and their 
differentiation into appropriate lineages. Both blood vascular [17, 221] and lym-
phatic endothelial [18] progenitors vigorously respond to LPS [17] and other TLR4 
ligands [221] by increasing proliferation, migration, and expression of transcription 
factors that control their differentiation into endothelial-like cells. When ligands 
are present systemically (e.g., released from necrotic tumors and during bolus PXL 
chemotherapy), TLR4-induced differentiation of BM progenitors occurs in parallel 
with upregulation of TLR4-dependent CCL2, CCL20, and other chemokines that 
recruit these progenitors to tumor [136, 174, 178, 222]. In experimental models, 
mobilization of genetically traceable BM-derived provascular progenitors increased 
tumor angiogenesis [172], whereas recruitment of myeloid-derived lymphatic 
endothelial progenitors (M-LECP) substantially increased tumor lymphangiogen-
esis [136] and lymphatic metastasis [18]. Taken together, these studies demonstrate 
how TLR4-induced differentiation of BM endothelial precursors and upregulation 
of tumor chemokines act in concert to increase blood and lymphatic networks that 
ultimately promote metastasis.
While both LPS and PXL can expand provascular progenitors, the latter is more 
pertinent to oncology due to widespread use of taxanes in clinical practice. PXL 
is an active component of all taxanes including widely clinically used docetaxel 
and nab-paclitaxel. Although counterintuitive, the new concept of chemotherapy-
driven metastasis mediated by the TLR4-PXL axis [188, 223, 224] is substantiated 
by ample evidence from clinical studies. A single dose of PXL to breast cancer (BC) 
patients doubles the blood level of inflammatory cytokines [225]. An independent 
study of BC patients before and after PXL therapy confirmed these data and further 
demonstrated in mice that PXL significantly increases tumor recruitment of 
BM-derived progenitors [226]. An additional study in BC patients found that PXL 
increased mobilization of myeloid-derived progenitors by >300% [227]. A separate 
analysis conducted before and after taxane therapy in BC patients showed a > five-
fold increase in tumor-infiltrating myeloid cells and subsequent metastasis [228]. 
Similar extent of tumor enrichment by CD11b+/CD14+ myeloid cells concomitant 
with enhanced metastasis was shown in a large study of patients (N = 699) treated 
by taxanes [134]. Tumor recruitment of these cells was strongly associated with 
lymphatic metastasis that doubled in taxane-treated compared with untreated 
patients [134]. In experimental models, PXL treatment increased angiogenesis 
and metastatic properties in tumor cells [229]. We recently showed that PXL 
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how TLR4-induced differentiation of BM endothelial precursors and upregulation 
of tumor chemokines act in concert to increase blood and lymphatic networks that 
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and nab-paclitaxel. Although counterintuitive, the new concept of chemotherapy-
driven metastasis mediated by the TLR4-PXL axis [188, 223, 224] is substantiated 
by ample evidence from clinical studies. A single dose of PXL to breast cancer (BC) 
patients doubles the blood level of inflammatory cytokines [225]. An independent 
study of BC patients before and after PXL therapy confirmed these data and further 
demonstrated in mice that PXL significantly increases tumor recruitment of 
BM-derived progenitors [226]. An additional study in BC patients found that PXL 
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and metastatic properties in tumor cells [229]. We recently showed that PXL 
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chemotherapy increased differentiation of BM hematopoietic-myeloid precur-
sors into lymphatic progenitors [18], tumor mobilization of these progenitors, 
intratumoral lymphangiogenesis, and enhanced metastasis to lymph nodes [18, 
136]. Broader recognition of this emerging concept should help in developing novel 
approaches to combat metastasis such as targeting TLR4-dependent BM differentia-
tion and tumor recruitment of provascular myeloid cells.
Figure 1. 
Activation of TLR4 in tumor cells and tumor microenvironment. TLR4 is overexpressed in malignant cells 
and in a variety of host cells within the tumor mass including endothelial cells, fibroblasts, pericytes, immune 
cells, and various progenitors recruited by TLR4-dependent chemokines to tumor inflammatory environment. 
TLR4 is activated mainly by endogenous ligands released from all expressing cells due to necrotic death induced 
by pathological surroundings as well as by taxane chemotherapy due to direct activation of the receptor and, 
indirectly, through increase of endogenous ligands from dead and damaged cells. Following, TLR4 signaling leads to 
upregulation of inflammatory cytokines, pro-survival and migratory factors, and proteases that disrupt extracellular 
matrix. This collectively increases not only tumor growth but also its metastatic potential due to enhanced vascular 
invasion and resistance to cytotoxic therapies. Metastasis is also enhanced because of direct activating effects on 
tumor endothelium as well as recruitment of provascular progenitors that aid in generation of new vessels.
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17.  Summary of TLR4-dependent mechanisms that specifically promote 
metastasis
Among multitude of pro-oncogenic effects of TLR4, those that specifically 
affect metastasis relate first and foremost to acquisition of traits normally restricted 
to inflamed macrophages, that is, enhanced migration, invasion, proliferation, 
and survival (Figure 1). However, this is strongly supplemented by effects on 
TLR4-expressing cells in the tumor environment from which most relevant are 
BEC and LEC. Undoubtedly, expansion of angiogenesis and lymphangiogenesis 
confers direct enhancement of tumor spread through these channels which may 
occur independently of TLR4 expression in tumor cells. Additionally, the ability 
to expand BM provascular and stromal progenitors and recruit them to tumor by 
chemokines—a specific property of inflamed macrophages—substantially sup-
ports new vessel and stroma formation. Importantly, the newly acquired properties 
enabled by the TLR4 signaling are further enhanced by endogenous factors released 
due to spontaneous necrotic death and chemotherapeutic treatments. Under 
these conditions, PXL, as an activator of TLR4, takes a special place because of its 
pro-inflammatory effects through release of endogenous ligands due to tumor cell 
kill as well through direct action on the TLR4 complex. Ultimately, these processes 
occur in parallel at tumor and systemic, mainly immune organs, sites. TLR4-
positive tumor cells have a pro-metastatic advantage by coordinating generation 
of new transporting channels and enhanced migratory/invasive potential as well 
as the enhanced capacity to survive in the circulation and at new sites (Figure 1). 
TLR4-negative tumor cells might have a reduced metastatic potential due to the 
absence of direct stimulating effects, but they are still benefited from the regenera-
tive tumor environment that is strongly supported by inflammation orchestrated by 
TLR4. Taking into account a comprehensive systemic view on tumor and chemo-
therapy effects on TLR4-mediated activities should facilitate the rational develop-
ment of new anti-metastatic strategies.
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The scope of this chapter is to review the significant effect that nanomedicine 
has had in the treatment of inflammatory diseases. Nanotechnology has been widely 
studied in the last decade and proved to be an encouraging strategy in the health-
care system and the medical field. This novel technology provides a vast number 
of nanomaterials and tools that could actually diagnose and treat different inflam-
matory disorders and conditions. An enormous amount of in vivo and in vitro 
research was conducted by many groups to validate the positive contribution that 
nanoparticles have in regard to the treatment of inflammation and its associated 
illnesses. This contribution is due to the fact that nanoparticles could be modulated 
to pass through metabolic barriers and specifically targeted to deliver drugs to the 
required sites without affecting healthy cells and tissues. This makes them a promis-
ing therapeutical choice for the treatment of inflammatory diseases in the future.
Keywords: nanoparticles, inflammation, nanomedicine, drug delivery, 
nanotechnology
1. Introduction
Along with the advances in drug development recently, a new technology has 
gained a lot of attention in the last decades; this technology is nanotechnology 
[1]. Pharmaceutical industries have become increasingly interested in nanomedi-
cine, due to the huge advantages this technology provides. Nanomedicine is the 
application of nanotechnology to diagnose and treat biological systems in health 
and disease [2]. Nanomedicine has led to the development of powerful tools for 
biological and medical research; these developments include targeted drug deliv-
ery, implantable materials for tissue engineering, and creating nanoscale probes 
for medical diagnostics and tracking cell movements [3]. At times of infection or 
injury, inflammation plays a very important role in protecting the injured tissue 
from further infection by starting the healing process [4]. It does this by increas-
ing blood flow to the damaged tissue, which increases the activity of the cells 
and makes the tissue appear red, hot, and swelling. So, inflammation is actually 
the body’s own response to any damage occurred in the body, which makes it an 
important part of the healing process. However, if inflammation occurs by mistake, 
for example, in autoimmune diseases where the body attacks itself or if the inflam-
mation stays too long, even after the infection or injury had passed, then this could 
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cause an inflammatory disease. Therefore, short periods of inflammation, such 
as with an allergic reaction or with an infection, are generally fully treatable and 
leave no long-term problems. On the other hand, if inflammation lasts more than 
several months or years, then it is particularly severe and may cause lasting damage 
to the affected area or organ, for example, deformed joints. Although, there are an 
extensive number of medications that are available for the treatment of acute and 
chronic inflammation in the market. However, scientists have recently started to 
guide their research toward nanomedicine treatments for inflammatory diseases. 
Many researches have been studied in vivo and in vitro regarding the treatment of 
inflammatory diseases with different kinds of nanoparticles. The results of most of 
the studies reveal a lot of promising and very successful developments. The focus 
of this chapter is to provide an overview in nanotechnology contribution in treating 
inflammatory diseases.
2. Inflammation
When a body is injured or attacked by microbial organisms such as bacteria, 
viruses, or fungi, the immune system is signaled for invaders by the process of 
inflammation. Inflammation is simply the body’s mechanism of defending itself 
by responding to stimuli to repair and heal any signs of damaged cells or tissues. 
That’s why inflammation is an important part of the immune system’s physiologi-
cal response, without which, infections and injuries could become fatal. However, 
if the inflammatory process is not working as it should be, it can turn into a 
disease. Inflammatory diseases include a massive number of disorders and condi-
tions [4–6]. Examples include allergy, asthma, glomerulonephritis, hepatitis, and 
inflammatory bowel disease [5]. Chronic inflammation has been linked to certain 
diseases such as heart disease or stroke and may also lead to autoimmune disor-
ders, such as rheumatoid arthritis or cancer [4].
2.1 Causes of inflammation
An infection or injury affecting the body will most probably trigger a number of 
physical reactions by the immune system that will eventually cause inflammation 
[5]. On the other hand, inflammation in any part of the body does not necessarily 
mean that there is a microbial infection.
The most common causes of inflammation are:
• Pathogens like viruses, bacteria, or fungi
• Injuries like external cuts or wounds
• Chemicals or radiation affecting the lungs or body
Diseases or conditions that can cause inflammation:
• Cystitis: an inflammation of the bladder
• Bronchitis: an inflammation of the bronchi in the lungs
• Otitis media: an inflammation in the middle ear
• Dermatitis: an inflammation of the skin
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2.2 Kinds of inflammation
2.2.1 Acute inflammation
Acute inflammation is a short-term response with localized effects that means it 
works at a specific place where the problem exists. It usually occurs after an injury 
or wound on the skin, a sprained ankle, or a sore throat due to a bacterial infection. 
It starts rapidly, and symptoms are usually severe, but they subside in a couple of 
days or weeks. During an acute inflammation episode, the blood vessels in the area 
affected dilate, and therefore blood flow increases, and the white blood cells cover 
the injured area to promote healing. This response is what causes the injured area to 
turn red and become swollen [5].
2.2.2 Chronic inflammation
Chronic inflammation is a long-term response; it’s mostly a persistent, low-level 
inflammation that can last for months or even a lifetime [7]. Inflammation begins 
as a defensive process in which the body is ready to protect itself from harmful 
pathogens or chemicals that were exposed to the body for a long period of time. 
However, sometimes, this defense mechanism can become uncontrolled, and hence, 
damage to vital organs, nervous and musculoskeletal systems, and blood vessels 
could occur. In some diseases the immune system might attack its own normal cells 
mistaking it for a foreign organism or pathogen, such as in autoimmune disorders, 
causing harmful inflammatory responses.
Chronic inflammatory diseases include:
• Rheumatoid arthritis, where many joints throughout the entire body are perma-
nently inflamed
• Psoriasis, a chronic skin disease
• Inflammations of the bowel such as ulcerative colitis
• Active hepatitis
2.3 Signs and symptoms of inflammation
Signs and symptoms of inflammation can be uncomfortable, but they show 
that the body is trying to heal itself. They vary in severity and intensity depending 
whether the inflammation is acute or chronic. The most important signs that may 
indicate an acute inflammation are [5, 6]:
• Redness: this occurs because the capillaries in the area are filled with more 
blood than usual.
• Heat: this occurs because more blood flows to the affected area, and this makes 
it feel warm to the touch.
• Swelling: this is caused by a buildup of fluid.
• Pain: this is due to the release of chemicals during inflammation that stimulate 
nerve endings, making the area more sensitive to the touch.
• Immobility: there may be some loss of function in the region of the inflammation.
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Not all of the signs must occur simultaneously; some might appear before the 
others. Some inflammations, however, could occur silently without any symptoms, 
especially when the inflammation is deep inside the body such as in an internal 
organ. The loss of function symptom, for example, is when you cannot breathe 
properly if you have asthma, when an inflamed arm or leg is difficult to move 
or when the sense of smell is lost during a nasal allergy. Inflammation does not 
necessarily start exactly when a person has been infected by a virus or bacteria, but 
it actually begins when the body starts to fight against the harmful stimulus or the 
infection.




• Joint, chest, or abdominal pain
• Rash
• Fever
When people have inflammation, they will feel pain, discomfort, distress, and 
stiffness in the inflamed area, depending on the severity of the inflammation; the 
type of pain varies. Although inflammation, in most cases, does indicate that the 
immune system is working properly, the symptoms are still an unpleasant feeling 
and usually need treatment to ease the pain.
2.4 Treatments of inflammation
The treatment of inflammatory disorders must rely on targets present in the 
diseased tissues [8]. To achieve the desired therapeutic effect on inflammatory 
cells, high drug doses will be required which sometime can induce unwanted 
effects on healthy tissues. The main anti-inflammatory drugs are either steroidal 
such as betamethasone, prednisone, and dexamethasone or nonsteroidal anti-
inflammatory drugs (NSAIDS) such as aspirin, ibuprofen, and naproxen [4]. 
NSAIDs are available in low doses over the counter mostly to treat the pain associ-
ated with inflammation, while higher doses of NSAIDs and steroidal medication 
are available as prescription medications [5]. Both are used to treat acute and 
chronic inflammatory diseases. However, their prolonged use is associated with 
a lot of side effects. Steroidal drugs can cause adrenal atrophy, fluid retention, 
thinning of bones which can lead to osteoporosis, and increased risk of infection 
or injury. NSAIDS can cause peptic ulcers, allergies, high blood pressure, or liver 
and kidney problems. Thus, the search for new anti-inflammatory agents is getting 
popular with the objective to obtain greater safety, better efficacy, and a more 
economical way to treat inflammation [5].
Nanomedicine has grown rapidly due to the need for improved therapies for 
inflammatory, developmental, infectious, and degenerative nervous system dis-
orders [9]. These disorders are a significant burden due to the increased number 
of people affected, disease severity, and financial cost. Therefore, the need for 
an improved diagnosis and treatment is urgent. Nanotechnology has been widely 
studied in the last decade and proved to be an encouraging strategy in the health-
care system and the medical field. This novel technology provides a vast number 
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of nanomaterials and tools that could actually diagnose and treat different inflam-
matory disorders and conditions. This chapter focuses on the current and future 
potential of nanomedicine to positively treat inflammatory disorders.
3. Nanotechnology
The last decade has been a tremendous growth for nanotechnology; it encom-
passes different scientific disciplines. This field aims at designing materials with new 
functions and beneficial properties at the nanometer level [10]. The nanomaterials 
designed are mostly any shape with a size in the range of 1–100 nm [11]. The huge and 
unique advantages that nanoparticles (NPs) offer made them an important research 
in the medical field, which created a new field called nanomedicine [12]. They can 
be used for the prevention, diagnosis, and treatment of many diseases, due to their 
very small size and large surface area. In addition to their easy preparation, NPs can 
be used to encapsulate and protect drugs, genes, or proteins in which they are carry-
ing from degradation, thus, enhancing their biodistribution and allowing sustained 
release [13]. They also improve the bioavailability of hydrophobic molecules and can 
be modulated for site-specific targeting, hence, decreasing the side effects of drugs. 
Moreover, their unique ability to pass through the physiological barriers and intercel-
lular spaces through different mechanisms due to their small size is an important 
property in the treatment of different kinds of diseases such as brain disorders [13]. In 
many cases nowadays, current treatments are simply inadequate to decrease disease 
progression or even remove symptoms and signs of inflammation [9]. However, 
nanoparticles can solve such problems, for example, increasing drug penetration into 
sites of active microbial infection while decreasing its side effects by working as drug 
carriers. In recent years, the goal for nanoparticle development was for the treatment, 
detection, and prevention of inflammatory and infected sites [14–16].
Different types of nanocarriers are available, and they are fabricated and chosen 
depending on different aspects such as the kind of application, what is carried by 
the nanoparticles whether it’s a drug or gene, way of administration, materials 
used, and method of fabrication. Types of nanoparticles include, but not limited 
to, polymeric nanoparticles, solid lipid nanoparticles (SLNs), liposomes, metallic 
nanoparticles, and dendrimers [1]. Below are the different types of nanoparticles 
that are mostly used.
3.1 Polymeric nanoparticles
Polymeric nanoparticles are made from natural or artificial biodegradable and 
biocompatible polymers; they represent a promising formulation for drug delivery 
[17]. They work as carriers to control drug release and target specific locations. 
When compared to conventional formulations, polymeric nanoparticles can 
increase the solubility of the drug, hence, increasing its absorption and reducing the 
therapeutic dose. Furthermore, these nanoparticles are stable and safe. Polymeric 
nanoparticles can be fabricated using various methods of synthesis, according to 
their intended application. They can be designed as nanocapsules or nanospheres 
and range from 10 to 1000 nm in diameter, differing in their composition and 
structural organization [1]. A nanocapsule has a polymeric membrane surround-
ing an oily core in which the active ingredient can be adsorbed to the membrane 
and/or dissolved in the oily core. Nanospheres, on the other hand, are made only 
from a polymeric structure, where the active constituent is adsorbed or retained. 
Polymeric materials that have been used extensively for nanoparticles include poly-
lactic-acid (PLA) and poly-lactic-co-glycolic acid (PLGA) [1, 18].
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Not all of the signs must occur simultaneously; some might appear before the 
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it actually begins when the body starts to fight against the harmful stimulus or the 
infection.
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unique advantages that nanoparticles (NPs) offer made them an important research 
in the medical field, which created a new field called nanomedicine [12]. They can 
be used for the prevention, diagnosis, and treatment of many diseases, due to their 
very small size and large surface area. In addition to their easy preparation, NPs can 
be used to encapsulate and protect drugs, genes, or proteins in which they are carry-
ing from degradation, thus, enhancing their biodistribution and allowing sustained 
release [13]. They also improve the bioavailability of hydrophobic molecules and can 
be modulated for site-specific targeting, hence, decreasing the side effects of drugs. 
Moreover, their unique ability to pass through the physiological barriers and intercel-
lular spaces through different mechanisms due to their small size is an important 
property in the treatment of different kinds of diseases such as brain disorders [13]. In 
many cases nowadays, current treatments are simply inadequate to decrease disease 
progression or even remove symptoms and signs of inflammation [9]. However, 
nanoparticles can solve such problems, for example, increasing drug penetration into 
sites of active microbial infection while decreasing its side effects by working as drug 
carriers. In recent years, the goal for nanoparticle development was for the treatment, 
detection, and prevention of inflammatory and infected sites [14–16].
Different types of nanocarriers are available, and they are fabricated and chosen 
depending on different aspects such as the kind of application, what is carried by 
the nanoparticles whether it’s a drug or gene, way of administration, materials 
used, and method of fabrication. Types of nanoparticles include, but not limited 
to, polymeric nanoparticles, solid lipid nanoparticles (SLNs), liposomes, metallic 
nanoparticles, and dendrimers [1]. Below are the different types of nanoparticles 
that are mostly used.
3.1 Polymeric nanoparticles
Polymeric nanoparticles are made from natural or artificial biodegradable and 
biocompatible polymers; they represent a promising formulation for drug delivery 
[17]. They work as carriers to control drug release and target specific locations. 
When compared to conventional formulations, polymeric nanoparticles can 
increase the solubility of the drug, hence, increasing its absorption and reducing the 
therapeutic dose. Furthermore, these nanoparticles are stable and safe. Polymeric 
nanoparticles can be fabricated using various methods of synthesis, according to 
their intended application. They can be designed as nanocapsules or nanospheres 
and range from 10 to 1000 nm in diameter, differing in their composition and 
structural organization [1]. A nanocapsule has a polymeric membrane surround-
ing an oily core in which the active ingredient can be adsorbed to the membrane 
and/or dissolved in the oily core. Nanospheres, on the other hand, are made only 
from a polymeric structure, where the active constituent is adsorbed or retained. 
Polymeric materials that have been used extensively for nanoparticles include poly-
lactic-acid (PLA) and poly-lactic-co-glycolic acid (PLGA) [1, 18].
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3.2 Solid lipid nanoparticles
Solid lipid nanoparticles (SLNs) are colloidal carrier systems that contain highly 
purified triglycerides, composed mainly of lipids. These structures are produced 
from solid lipids and are stabilized by surfactants. They combine the advantages 
of other colloidal systems such as liposomes and polymeric nanoparticles, in their 
biodegradability, biocompatibility, and low toxicity [19]. SLNs can be produced on 
a large scale; they have high physicochemical stability and offer good protection 
against drug degradation [1, 19]. Their size ranges from 50 to 1000 nm and may be 
used in the pharmaceutical field for the delivery of drugs using different routes of 
administration such as oral and parenteral routes [1].
3.3 Liposomes
Liposomes for drug delivery are spherical small-sized vesicles composed of natural 
or synthetic lipid bilayers, separated by an aqueous medium in their core [1, 2, 17]. 
Hydrophilic substances are encapsulated inside the aqueous compartment, while 
lipophilic substances are adsorbed or incorporated in the lipid bilayers. Liposomes are 
classified according to their surface charge, size, lipid composition, and method of 
preparation. The surface charge could be anionic, cationic, or neutral. According to 
the size and number of lamellae, liposomes can be classified as small, large, or giant 
and oligo-, uni- or multi-lamellar, respectively [1]. Liposomes have helped decrease the 
side effects of different drugs such as anticancer and antifungal drugs, simultaneously 
with improving their efficacy [2]. Liposomal drug delivery preparations have also been 
studied in various chronic inflammatory diseases. This is a promising approach since it 
limits the side effects of anti-inflammatory drugs on healthy tissues [2].
3.4 Metallic nanoparticles
Metallic nanoparticles comprise a class of materials that are made from metals 
such as titanium, gold, and platinum. They exhibit remarkable optical and elec-
tronic properties, which make them very useful in the medical field [20]. These 
nanoparticles are ranged in size from 1 to 100 nm, and they can be fabricated and 
modulated with several functional groups, due to their high surface area to volume 
ratio that allows them to be conjugated with antibodies, ligands, and vehicles for 
gene drug delivery and diagnostic imaging [17, 19, 21]. Moreover, metallic nanopar-
ticles have the potential to carry large doses of drugs and increase their circulatory 
half-life [19]. Examples of metallic nanoparticles used in research nowadays include 
but are not limited to gold, silver, zinc oxide, and iron nanoparticles.
3.5 Dendrimers
Dendrimers, one of the most interesting classes of nanoparticles, are synthetic 
polymers with repetitively branched molecules ranging in size from 1 to 100 nm 
[22]. Dendrimers are radially symmetrical molecules with well-defined and 
homogeneous structure consisting of treelike branches [23]. A typical dendrimer 
is composed of different parts; it is composed of a central core surrounded by 
repeated units that start from the inside and grow outward like branches with 
multiple peripheral functional groups [24]. The functional groups have a high 
degree of molecular uniformity and could be adjusted in size, valency, solubility, 
and biodegradation [17]. The dendrimers have very high stability and huge surface 
area, which made them gain a lot of interest and have a wide number of applications 
in the biomedical field.
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4. Contribution of nanoparticles in inflammatory diseases
Pharmacists, physicians, and patients have long desired better pharmaceutical 
formulations to improve drug efficacy, reduce toxicity, and reduce the costs of 
preparation and treatment [2]. The conventional treatments available for inflamma-
tory diseases involve nontargeted treatment options with extensive adverse effects. 
However, nanodrug delivery has shown, in many studies over the years, a numerous 
number of promising approaches for delivery of therapeutic agents, and most of 
them proved to reduce side effects and toxicity, increase a drug’s bioavailability and 
effectiveness at the site, and reduce cost. The focus of this section is to highlight 
the contribution of several nanoparticle applications that have made an immediate 
major impact in the treatment of different inflammatory disorders.
4.1 Rheumatoid arthritis
Rheumatoid arthritis (RA) is the most common inflammatory disease and is 
the major cause of disability of the joints [13, 17, 25]. This disease is associated with 
progressive disability, systemic complications, and socioeconomic costs [13, 17]. 
To deliver drugs to the target site directly is still a major problem nowadays. Thus, 
bounding drugs to carriers, like nanoparticles, can make cell-specific targeting 
become more achievable. The drugs available conventionally for the treatment of 
RA include three main groups; these are disease-modifying antirheumatic drugs 
(DMARDs), steroids, and anti-inflammatory drugs such as NSAIDS. Discussed 
below are examples for the contribution of nanoparticles to each group.
In one study scientists explored the use of multifunctional nanoparticles in the 
treatment of RA that involves small synovial joints. This study used near-infrared 
(NIR) light technology along with the nanoparticles [25]. In this study methotrex-
ate (MTX), which is a DMARD, was loaded to a PLGA polymer-gold (Au) half shell 
nanoparticle. Then arginine-glycine-aspartic acid (RGD) peptide was conjugated to 
the surface of the Au NP forming a multifunctional NP (RGD-MTX-PLGA-Au). The 
RGD peptide was used as a targeting moiety for inflammation, the Au half shell was 
used to generate heat, and MTX was used for the treatment of RA. The NPs were 
injected into collagen-induced arthritic (CIA) mice. They were effectively deliv-
ered and accumulated in the inflamed joints due to RGD peptides. After delivery, 
heat was generated upon NIR exposure due to Au, and the MTX was then rapidly 
released from PLGA nanoparticles. The application of this multifactorial NP in 
CIA mice had better therapeutic efficacy with a much smaller dose of MTX, when 
compared to conventional treatment [25]. These results demonstrate that the tar-
geted NPs treatment is a useful and effective strategy for increasing the therapeutic 
efficacy and decreasing side effects of drugs used in the treatment of RA.
Steroids have been used for the treatment of chronic inflammatory disorders 
for decades [26]. Normally, to reach efficacious concentrations in the blood, they 
are frequently injected in high doses due to their rapid clearance from the body. 
However, the chronic use of corticosteroids is associated with severe side effects 
such as osteoporosis, hypertension, and weight gain. Therefore, current corticoste-
roids should have active targeting, controlled release and retention in the inflamed 
tissue. This could be done using engineered nanomaterials as delivery vehicles. In 
one study, glucocorticoids were loaded into liposomes to prolong the drug circula-
tion time and change drug distribution. As a consequence, number of injections 
and doses were reduced while still achieving similar efficacy to that of free gluco-
corticoid in rat models of rheumatoid arthritis [26].
Nano-carriers that were also successful in delivering anti-inflammatory drugs 
were PAMAM dendrimers [17, 26]. In one study, they have been used to deliver 
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indomethacin to reduce inflammation in the rat model of arthritis. The polyethyl-
ene glycol (PEG) dendrimers were functionalized with folate as a targeting ligand 
to target only activated macrophages, since folate receptor is expressed on activated 
macrophages only and not on resting ones. This folate-PEG-PAMAM dendrimer 
was loaded with indomethacin to study its anti-inflammatory effect. This conjuga-
tion resulted in a 10–20-fold increase in drug loading efficiency and was found to 
release indomethacin in the joints in a sustained manner [17].
4.2 Dermatitis
Dermatologic therapy is mainly aimed to prevent or decrease inflammation in 
the skin. Topical corticosteroids are the keystone of dermatologic therapy and have 
been used for various inflammatory conditions for their treatment or prevention 
[11]. Corticosteroids are often prescribed, though their use can carry significant 
side effects, as mentioned earlier.
In several studies, SLN corticosteroid formulations showed increased penetra-
tion compared to its traditional counterparts, resulting in penetration beyond the 
epidermis and into the dermis [11]. Moreover, SLN provide the added benefit of 
sustained release, which is a desirable feature for controlling concentration of drug 
in tissue over time; these properties may improve side effect profiles and dosing 
schedules of drugs.
NSAIDs are another main drug used in the treatment of inflammatory diseases 
because of their excellent anti-inflammatory and analgesic actions [10]. However, 
NSAIDs are associated with serious adverse effects. Therefore, whenever possible, 
drugs are used topically for dealing with local inflammatory diseases. Topical oint-
ments that contain NSAIDs nanoparticles were studied for skin penetration, safety, 
and anti-inflammatory effects in animal models of acute and chronic inflammation. 
In one study, two ointments, one with normal NSAIDs and the other containing 
NSAIDs in nanoform, were compared [10]. Following the application of both, the 
study revealed that NSAID in the nanoform had increased penetration of the drug 
into the skin compared with the normal NSAID, suggesting a higher local activity 
of NSAID nanoform when applied to the skin. In chronic inflammation model, both 
formulations decreased foot swelling in a time-dependent manner. However, the 
healing rate at 7 days of post treatment was significantly higher following treat-
ment with NSAID nanoform compared with the normal NSAID [10]. Moreover, 
the concentration of NSAID nanoform was much lower than those required of the 
normal NSAID. Hence, the potency of the nanoformulations is much higher than 
normal treatment [10]. NSAID nanoformulations are expected to be the basis for 
new dermatological products, due to their effective treatment and low side effects.
Another major dermatological product that is used by many consumers is 
sunscreen. Sunscreens are important tools for skincare and the first line of choice 
for the prevention of inflammation caused by ultraviolet (UV) rays. UV filters 
are crucial for the prevention of sunburn and UV-induced mutations that may 
lead to skin cancer. Inorganic UV filters such as titanium oxide (TiO2) and zinc 
oxide (ZnO) have been used in sunscreen formulations for a long time, and they 
are effective in protecting against both UVA and UVB rays. Despite that, TiO2 and 
ZnO filters leave an opaque white residue on the skin, which limits its use by many 
customers [11]. However, by reducing TiO2 and ZnO sizes to the nanoscale, the 
production of translucent products is possible rather than the white coarse raw 
material. It has been shown that sunscreens using particles between 40 and 60 nm 
are capable of providing good transparency without weakening UVA and UVB 
protection [27]. Although there has been some concern about the use of nanoma-
terials in sunscreens, there is no indication that the use of TiO2 or ZnO holds any 
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danger, and studies showed that nanoparticle preparations do not penetrate past the 
stratum corneum [28]. Therefore, further study is still needed to fully evaluate the 
safety of these filters and fully prove their safety.
4.3 Asthma
Asthma is a chronic inflammatory condition characterized by narrowing and 
swelling of the airways with extra production of mucus, which makes it difficult for 
the person to breathe [29]. Theophylline is a drug that had been used conventionally 
worldwide for the treatment of allergic asthma for several years [30]. Although it’s 
still widely prescribed, its use has decreased due to the use of inhaled glucocorti-
coids instead. Moreover, theophylline has severe side effects due to its low therapeu-
tic window, such as nausea, headache, and cardiac arrhythmias, which limits its use. 
The adsorption of theophylline to chitosan nanoparticles, modified by the addition 
of thiol groups, was studied in vivo using mouse models of allergic asthma [29].
Chitosan is a polymer derived from chitin that has been used for nanodrug 
delivery due to its beneficial properties such as biocompatibility, biodegradability, 
and bio-adhesiveness [31]. The mice were treated intranasally with theophylline 
alone, chitosan nanoparticles alone, or theophylline adsorbed to chitosan nanopar-
ticles [29]. The effects of theophylline on cellular infiltration, histopathology 
of lung sections, and apoptosis of lung cells were investigated to determine the 
effectiveness of theophylline chitosan NPs as a drug-delivery vehicle for theophyl-
line. Intranasal delivery of theophylline conjugated nanoparticles augmented the 
anti-inflammatory effects of the drug compared to theophylline administered alone 
[29]. Thus, the clinical effects of theophylline in treating asthma could be enhanced 
through the use of nanodrug delivery system. Nasal drug delivery is indeed a 
promising technique because of the large surface area in the nose, high blood flow, 
avoidance of first-pass metabolism, and the quick onset of pharmacological activity. 
Furthermore, it is reasonable to point out that the bioavailability, adsorption, and 
residence time of drugs administered through the nasal route would be increased 
using drug delivery carriers such as nanoparticles [32].
4.4 Inflammatory bowel disease
Ulcerative colitis (UC) and Crohn’s disease (CD) are the two major types of 
inflammatory bowel disease (IBD). IBD is a chronic but relapsing inflammatory 
disorder of the gastrointestinal tract [33]. UC is characterized by inflammation 
that is limited to the colon, while CD involves any part of the gastrointestinal 
tract. Abdominal pain, diarrhea, and rectal bleeding are frequent symptoms 
in patients suffering from IBD [33]. For years, the conventional treatment 
of IBD consisted of anti-inflammatory medications, such as corticosteroids, 
aminosalicylates, and immune suppressants. However, these drugs have several 
side effects due to their unspecific targeting upon administration. A promising 
strategy toward IBD treatment would be to selectively target the inflamed colonic 
tissue in order to decrease side effects and increase therapeutic efficacy of the 
drug administered.
In one study they used mesalamine, an anti-inflammatory medication used 
conventionally to treat UC, in a nanoparticle formulation [34]. Free mesalamine 
undergoes rapid and almost complete systemic absorption from the intestine, 
which causes side effects and drug loss, lowering the therapeutic effect of the 
medication. The drug then undergoes extensive metabolism. Therefore, it is 
important to deliver mesalamine (5ASA) locally to the colon, in order to reduce 
the systemic drug absorption and thus slow down the metabolism. The drug 
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was loaded with indomethacin to study its anti-inflammatory effect. This conjuga-
tion resulted in a 10–20-fold increase in drug loading efficiency and was found to 
release indomethacin in the joints in a sustained manner [17].
4.2 Dermatitis
Dermatologic therapy is mainly aimed to prevent or decrease inflammation in 
the skin. Topical corticosteroids are the keystone of dermatologic therapy and have 
been used for various inflammatory conditions for their treatment or prevention 
[11]. Corticosteroids are often prescribed, though their use can carry significant 
side effects, as mentioned earlier.
In several studies, SLN corticosteroid formulations showed increased penetra-
tion compared to its traditional counterparts, resulting in penetration beyond the 
epidermis and into the dermis [11]. Moreover, SLN provide the added benefit of 
sustained release, which is a desirable feature for controlling concentration of drug 
in tissue over time; these properties may improve side effect profiles and dosing 
schedules of drugs.
NSAIDs are another main drug used in the treatment of inflammatory diseases 
because of their excellent anti-inflammatory and analgesic actions [10]. However, 
NSAIDs are associated with serious adverse effects. Therefore, whenever possible, 
drugs are used topically for dealing with local inflammatory diseases. Topical oint-
ments that contain NSAIDs nanoparticles were studied for skin penetration, safety, 
and anti-inflammatory effects in animal models of acute and chronic inflammation. 
In one study, two ointments, one with normal NSAIDs and the other containing 
NSAIDs in nanoform, were compared [10]. Following the application of both, the 
study revealed that NSAID in the nanoform had increased penetration of the drug 
into the skin compared with the normal NSAID, suggesting a higher local activity 
of NSAID nanoform when applied to the skin. In chronic inflammation model, both 
formulations decreased foot swelling in a time-dependent manner. However, the 
healing rate at 7 days of post treatment was significantly higher following treat-
ment with NSAID nanoform compared with the normal NSAID [10]. Moreover, 
the concentration of NSAID nanoform was much lower than those required of the 
normal NSAID. Hence, the potency of the nanoformulations is much higher than 
normal treatment [10]. NSAID nanoformulations are expected to be the basis for 
new dermatological products, due to their effective treatment and low side effects.
Another major dermatological product that is used by many consumers is 
sunscreen. Sunscreens are important tools for skincare and the first line of choice 
for the prevention of inflammation caused by ultraviolet (UV) rays. UV filters 
are crucial for the prevention of sunburn and UV-induced mutations that may 
lead to skin cancer. Inorganic UV filters such as titanium oxide (TiO2) and zinc 
oxide (ZnO) have been used in sunscreen formulations for a long time, and they 
are effective in protecting against both UVA and UVB rays. Despite that, TiO2 and 
ZnO filters leave an opaque white residue on the skin, which limits its use by many 
customers [11]. However, by reducing TiO2 and ZnO sizes to the nanoscale, the 
production of translucent products is possible rather than the white coarse raw 
material. It has been shown that sunscreens using particles between 40 and 60 nm 
are capable of providing good transparency without weakening UVA and UVB 
protection [27]. Although there has been some concern about the use of nanoma-
terials in sunscreens, there is no indication that the use of TiO2 or ZnO holds any 
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danger, and studies showed that nanoparticle preparations do not penetrate past the 
stratum corneum [28]. Therefore, further study is still needed to fully evaluate the 
safety of these filters and fully prove their safety.
4.3 Asthma
Asthma is a chronic inflammatory condition characterized by narrowing and 
swelling of the airways with extra production of mucus, which makes it difficult for 
the person to breathe [29]. Theophylline is a drug that had been used conventionally 
worldwide for the treatment of allergic asthma for several years [30]. Although it’s 
still widely prescribed, its use has decreased due to the use of inhaled glucocorti-
coids instead. Moreover, theophylline has severe side effects due to its low therapeu-
tic window, such as nausea, headache, and cardiac arrhythmias, which limits its use. 
The adsorption of theophylline to chitosan nanoparticles, modified by the addition 
of thiol groups, was studied in vivo using mouse models of allergic asthma [29].
Chitosan is a polymer derived from chitin that has been used for nanodrug 
delivery due to its beneficial properties such as biocompatibility, biodegradability, 
and bio-adhesiveness [31]. The mice were treated intranasally with theophylline 
alone, chitosan nanoparticles alone, or theophylline adsorbed to chitosan nanopar-
ticles [29]. The effects of theophylline on cellular infiltration, histopathology 
of lung sections, and apoptosis of lung cells were investigated to determine the 
effectiveness of theophylline chitosan NPs as a drug-delivery vehicle for theophyl-
line. Intranasal delivery of theophylline conjugated nanoparticles augmented the 
anti-inflammatory effects of the drug compared to theophylline administered alone 
[29]. Thus, the clinical effects of theophylline in treating asthma could be enhanced 
through the use of nanodrug delivery system. Nasal drug delivery is indeed a 
promising technique because of the large surface area in the nose, high blood flow, 
avoidance of first-pass metabolism, and the quick onset of pharmacological activity. 
Furthermore, it is reasonable to point out that the bioavailability, adsorption, and 
residence time of drugs administered through the nasal route would be increased 
using drug delivery carriers such as nanoparticles [32].
4.4 Inflammatory bowel disease
Ulcerative colitis (UC) and Crohn’s disease (CD) are the two major types of 
inflammatory bowel disease (IBD). IBD is a chronic but relapsing inflammatory 
disorder of the gastrointestinal tract [33]. UC is characterized by inflammation 
that is limited to the colon, while CD involves any part of the gastrointestinal 
tract. Abdominal pain, diarrhea, and rectal bleeding are frequent symptoms 
in patients suffering from IBD [33]. For years, the conventional treatment 
of IBD consisted of anti-inflammatory medications, such as corticosteroids, 
aminosalicylates, and immune suppressants. However, these drugs have several 
side effects due to their unspecific targeting upon administration. A promising 
strategy toward IBD treatment would be to selectively target the inflamed colonic 
tissue in order to decrease side effects and increase therapeutic efficacy of the 
drug administered.
In one study they used mesalamine, an anti-inflammatory medication used 
conventionally to treat UC, in a nanoparticle formulation [34]. Free mesalamine 
undergoes rapid and almost complete systemic absorption from the intestine, 
which causes side effects and drug loss, lowering the therapeutic effect of the 
medication. The drug then undergoes extensive metabolism. Therefore, it is 
important to deliver mesalamine (5ASA) locally to the colon, in order to reduce 
the systemic drug absorption and thus slow down the metabolism. The drug 
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was covalently bound to a NP matrix polymer. Experiments in mice with colon 
inflammation showed a distinct retention of the mesalamine inside the NP 
matrix, which allowed efficient colonic targeting and slowed down the release of 
the drug. This approach elevated the selectivity of the drug toward the inflamma-
tion site by decreasing the rapid drug release in the proximal intestine after oral 
administration [34].
Nano-drug delivery represents a promising approach in inflammatory disorders, 
mostly due to their accumulation in the inflamed regions [33]. In another study, 
the drug release was triggered by the sensitivity of polymer to pH during gastroin-
testinal (GI) transit. Scientists combined PLGA nanoparticles with pH-triggered 
polymer, to provide both specific accumulation in inflamed tissue and selective 
drug release in the colon [33]. They used curcumin (C) as the drug of choice to 
treat IBD, which is known for decades for its anti-inflammatory, antioxidant, 
antimicrobial, anticarcinogenic, and hepato-protective effects. Anti-inflammatory 
effects of C have been studied in several diseases before, such as Alzheimer’s 
disease, Parkinson’s disease, multiple sclerosis, and cerebral injury [35]. However, 
we must note that raw C is known for its poor solubility and thus low bioavailability. 
Moreover, it has a high rate of metabolism and rapid elimination. Thus, an IBD-
specific delivery system is needed to protect C from fast degradation. This study 
aimed to evaluate the effects of C loaded in polymeric pH-sensitive nanoparticles 
in the treatment of IBD. They were also compared to a C suspension to assess the 
selectivity and specific delivery of C to the colon. The negative charge of the surface 
of nanoparticles attracted them to positively charged ulcerated tissues [36]. Hence, 
C-NPs exhibited suitable physicochemical characteristics, due to their small size 
and opposite surface charge, for colonic delivery. In vitro studies reported that 
encapsulated C was found to cross through the epithelial barrier better than C 
suspension [33].
4.5 Alzheimer’s disease
AD is a type of chronic low-level inflammation that mainly affects the elderly 
[37]. It’s considered as a progressive and devastating neurodegenerative disorder 
that is characterized by cognitive deterioration and decline in the quality of the 
patient’s life [38]. An enormous amount of in vivo and in vitro research was con-
ducted by many groups to study the effect of NPs on the treatment of AD. The 
following are some examples of nanomaterials that are intended to target the brain 
and treat AD:
Albumin NPs loaded with tacrine, which was an AD medication previously, 
was synthesized and administered through the intranasal route of sheep to avoid 
the first-pass metabolism of the drug and deliver it rapidly to the brain. Due to 
the small size and large surface area of albumin NPs, the delivery of tacrine was 
improved through the mucosa to the brain. This research was tested on sheep nasal 
mucosa in permeation cell [39].
Dendrimers, as mentioned earlier, are globular macromolecular structures with 
a densely packed surface. It was found that dendrimers could block the aggrega-
tion of Amyloid β (Aβ), which is one of the causes of AD. This is by binding to the 
protofibrils and fibrils, therefore preventing the cytotoxic effect of Aβ plaques. In 
one study it was suggested that conjugated and unconjugated dendrimers had the 
ability to separate Aβ deposits in vitro [40].
Gold (Au) NPs were designed to dissolve the Aβ aggregates by the use of local 
thermal energy at a molecular level and preventing further aggregation. When Au 
NPs attach to Aβ aggregates and a weak microwave field is applied, they produce 
thermal energy which dissolve the aggregation and prevent them from reforming. 
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Au NPs are known to have the advantage of large surface area, biocompatibility, and 
small size which make them very suitable in this application [41].
Polymeric NPs such as PLGA have great biocompatibility and biodegradabil-
ity properties. They have the ability to encapsulate different kind of drugs and 
transport them to the brain by surface modification. For example, curcumin has 
been encapsulated by PLGA in several studies. This formulation was found to be a 
potential candidate for the treatment of AD due to the great properties of curcumin 
as mentioned earlier. Curcumin was found to bind to the Aβ plaques and disaggre-
gating them, due to its anti-amyloid property, which makes this C-NP formulation a 
very promising drug in the treatment of AD [41].
5. Future directions
Anti-inflammatory effects of engineered nanomaterials can be intentionally 
achieved. This is by modulating the nanoparticle physicochemical properties and 
by using nanoparticles as carriers for anti-inflammatory agents. However, struc-
ture activity relationship (SAR) studies are needed to further improve this area 
of nanotechnology. Despite the huge amount of benefits that nanoparticle holds 
as drug carriers, there are still some disadvantages [13]. For example, NPs might 
generate toxicity due to their small size, which widen the biodistribution of the 
drug in the body. Hence, increasing the drugs’ potency, which although beneficial, 
also might affect the immune response of the body and trigger toxicity. Moreover, 
clinical researchers have mentioned some negative factors, such as high cost and the 
difficulty of scaling-up processes [1]. Therefore, future nanodrug delivery studies 
are recommended, and these studies should focus on toxicity and on identifying 
key elements like dose, route of administration, physicochemical properties, and 
composition that might provoke toxicity. Understanding what makes the same 
nanoparticle beneficial in one model and toxic in another model is critical. This will 
aid drug delivery formulation scientists in choosing appropriate nanoparticle carri-
ers and will clearly enhance the rapidly growing field of nanodrug delivery.
6. Conclusion
Most drugs available nowadays are limited by their poor solubility, number of 
side effects, frequent dosing, and nonspecific delivery. Therefore, scientists have 
shifted their research to using nanoparticles for the delivery of drugs to avoid 
those limitations. NPs are now studied to deliver two or more drugs simultaneously 
for combination therapy, aiming to decrease frequency of dosing and number 
of medications a patient is receiving and thus increasing compliance. The main 
advantage of using NPs is that they could be modulated and specifically targeted 
to match the need. Therefore, the production of nanomaterials as drug delivery 
carriers can offer new opportunities to provide more focused and precise treat-
ment of inflammatory diseases and improve the potential therapeutic effective-
ness of available medications [17]. We covered in this chapter the advantages of 
nanotechnology in the medical field and the different kinds of NPs available. We 
also mentioned different kinds of inflammatory diseases such as arthritis, asthma, 
and Alzheimer’s disease and how nanoparticles were able to positively contribute 
in their treatment. Despite the many technical, regulatory, and legal challenges, 
the development of these technologies on a large scale would face, there is no doubt 
that there is enough desire to overcome these challenges to improve the quality of 
life and benefit the society [2].
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was covalently bound to a NP matrix polymer. Experiments in mice with colon 
inflammation showed a distinct retention of the mesalamine inside the NP 
matrix, which allowed efficient colonic targeting and slowed down the release of 
the drug. This approach elevated the selectivity of the drug toward the inflamma-
tion site by decreasing the rapid drug release in the proximal intestine after oral 
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Nano-drug delivery represents a promising approach in inflammatory disorders, 
mostly due to their accumulation in the inflamed regions [33]. In another study, 
the drug release was triggered by the sensitivity of polymer to pH during gastroin-
testinal (GI) transit. Scientists combined PLGA nanoparticles with pH-triggered 
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drug release in the colon [33]. They used curcumin (C) as the drug of choice to 
treat IBD, which is known for decades for its anti-inflammatory, antioxidant, 
antimicrobial, anticarcinogenic, and hepato-protective effects. Anti-inflammatory 
effects of C have been studied in several diseases before, such as Alzheimer’s 
disease, Parkinson’s disease, multiple sclerosis, and cerebral injury [35]. However, 
we must note that raw C is known for its poor solubility and thus low bioavailability. 
Moreover, it has a high rate of metabolism and rapid elimination. Thus, an IBD-
specific delivery system is needed to protect C from fast degradation. This study 
aimed to evaluate the effects of C loaded in polymeric pH-sensitive nanoparticles 
in the treatment of IBD. They were also compared to a C suspension to assess the 
selectivity and specific delivery of C to the colon. The negative charge of the surface 
of nanoparticles attracted them to positively charged ulcerated tissues [36]. Hence, 
C-NPs exhibited suitable physicochemical characteristics, due to their small size 
and opposite surface charge, for colonic delivery. In vitro studies reported that 
encapsulated C was found to cross through the epithelial barrier better than C 
suspension [33].
4.5 Alzheimer’s disease
AD is a type of chronic low-level inflammation that mainly affects the elderly 
[37]. It’s considered as a progressive and devastating neurodegenerative disorder 
that is characterized by cognitive deterioration and decline in the quality of the 
patient’s life [38]. An enormous amount of in vivo and in vitro research was con-
ducted by many groups to study the effect of NPs on the treatment of AD. The 
following are some examples of nanomaterials that are intended to target the brain 
and treat AD:
Albumin NPs loaded with tacrine, which was an AD medication previously, 
was synthesized and administered through the intranasal route of sheep to avoid 
the first-pass metabolism of the drug and deliver it rapidly to the brain. Due to 
the small size and large surface area of albumin NPs, the delivery of tacrine was 
improved through the mucosa to the brain. This research was tested on sheep nasal 
mucosa in permeation cell [39].
Dendrimers, as mentioned earlier, are globular macromolecular structures with 
a densely packed surface. It was found that dendrimers could block the aggrega-
tion of Amyloid β (Aβ), which is one of the causes of AD. This is by binding to the 
protofibrils and fibrils, therefore preventing the cytotoxic effect of Aβ plaques. In 
one study it was suggested that conjugated and unconjugated dendrimers had the 
ability to separate Aβ deposits in vitro [40].
Gold (Au) NPs were designed to dissolve the Aβ aggregates by the use of local 
thermal energy at a molecular level and preventing further aggregation. When Au 
NPs attach to Aβ aggregates and a weak microwave field is applied, they produce 
thermal energy which dissolve the aggregation and prevent them from reforming. 
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Au NPs are known to have the advantage of large surface area, biocompatibility, and 
small size which make them very suitable in this application [41].
Polymeric NPs such as PLGA have great biocompatibility and biodegradabil-
ity properties. They have the ability to encapsulate different kind of drugs and 
transport them to the brain by surface modification. For example, curcumin has 
been encapsulated by PLGA in several studies. This formulation was found to be a 
potential candidate for the treatment of AD due to the great properties of curcumin 
as mentioned earlier. Curcumin was found to bind to the Aβ plaques and disaggre-
gating them, due to its anti-amyloid property, which makes this C-NP formulation a 
very promising drug in the treatment of AD [41].
5. Future directions
Anti-inflammatory effects of engineered nanomaterials can be intentionally 
achieved. This is by modulating the nanoparticle physicochemical properties and 
by using nanoparticles as carriers for anti-inflammatory agents. However, struc-
ture activity relationship (SAR) studies are needed to further improve this area 
of nanotechnology. Despite the huge amount of benefits that nanoparticle holds 
as drug carriers, there are still some disadvantages [13]. For example, NPs might 
generate toxicity due to their small size, which widen the biodistribution of the 
drug in the body. Hence, increasing the drugs’ potency, which although beneficial, 
also might affect the immune response of the body and trigger toxicity. Moreover, 
clinical researchers have mentioned some negative factors, such as high cost and the 
difficulty of scaling-up processes [1]. Therefore, future nanodrug delivery studies 
are recommended, and these studies should focus on toxicity and on identifying 
key elements like dose, route of administration, physicochemical properties, and 
composition that might provoke toxicity. Understanding what makes the same 
nanoparticle beneficial in one model and toxic in another model is critical. This will 
aid drug delivery formulation scientists in choosing appropriate nanoparticle carri-
ers and will clearly enhance the rapidly growing field of nanodrug delivery.
6. Conclusion
Most drugs available nowadays are limited by their poor solubility, number of 
side effects, frequent dosing, and nonspecific delivery. Therefore, scientists have 
shifted their research to using nanoparticles for the delivery of drugs to avoid 
those limitations. NPs are now studied to deliver two or more drugs simultaneously 
for combination therapy, aiming to decrease frequency of dosing and number 
of medications a patient is receiving and thus increasing compliance. The main 
advantage of using NPs is that they could be modulated and specifically targeted 
to match the need. Therefore, the production of nanomaterials as drug delivery 
carriers can offer new opportunities to provide more focused and precise treat-
ment of inflammatory diseases and improve the potential therapeutic effective-
ness of available medications [17]. We covered in this chapter the advantages of 
nanotechnology in the medical field and the different kinds of NPs available. We 
also mentioned different kinds of inflammatory diseases such as arthritis, asthma, 
and Alzheimer’s disease and how nanoparticles were able to positively contribute 
in their treatment. Despite the many technical, regulatory, and legal challenges, 
the development of these technologies on a large scale would face, there is no doubt 
that there is enough desire to overcome these challenges to improve the quality of 
life and benefit the society [2].
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Exploring Epigenetic Drugs in 
the Regulation of Inflammatory 
Autoimmune Diseases
Cristian Doñas, Alejandra Loyola and Mario Rosemblatt
Abstract
During recent years, numerous studies have shown that epigenetics, heritable 
changes that do not involve alterations in the DNA sequence, play an important role 
in the development, function, and regulation of the immune system as well as in the 
onset and progress of autoimmune diseases. For that reason, in the following chap-
ter, we will review some of the most important concepts about epigenetics and how 
they modulate the development and function of immune cells, specifically macro-
phages, dendritic cells, and T cells. Moreover, we will review the role of epigenetics 
on autoimmune diseases, as well as the use of pharmacological modulation of the 
epigenetic machinery, as an innovative way to approach a potential new treatment 
or improve the current treatments of autoimmune diseases.
Keywords: epigenetic, DNA methylation, histone modification, autoimmunity, 
therapy
1. Introduction
Conrad Waddington introduced the epigenetic term in 1942, and it was 
defined as the causal interactions between genes and their products that allow 
for phenotypic expression [1]. Currently, this term has been refined to collective 
heritable changes in phenotype due to processes that arise independent of DNA 
sequence [2]. The epigenetic information is transferred during cellular division 
and includes DNA methylation, post-translational modifications of histones such 
as acetylation and methylation, and non-coding RNA. The transcriptional effects 
of epigenetic regulation are multidimensional, including on/off gene regulation, 
maintenance of transcriptional status, and responsiveness or no-responsiveness 
to external stimuli.
Increasing interest in the study of epigenetic processes has emerged because 
changes in these mechanisms have been linked to the onset and/or development of 
several human diseases such as cancer, autoimmune diseases, and systemic meta-
bolic disorders. For that reason, many epigenetic clinical trials are on the horizon. 
Here, we will examine some of the basic concepts about DNA methylation, post-
translational modifications of histones, and their effect on development, differen-
tiation, and effector function in antigen-presenting cells (i.e., dendritic cells and 
macrophages) and T cells. Finally, we will summarize the epigenetic changes found 
in immune cell populations and how some of the epigenetic modifications affect the 
most prevalent autoimmune diseases such as systemic lupus erythematosus (SLE),  
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rheumatoid arthritis (RA), multiple sclerosis (MS), and inflammatory bowel 
diseases (IBD). Finally, we will address how “epigenetic drugs” can be used to 
modulate these immunological changes.
2. A brief introduction to epigenetics
The classical concept of heritable information is that phenotypic characteris-
tics are transmitted from parental cell to their offspring by genetic information 
[3]. However, several examples of heritable phenotypic variation cannot be fully 
explained by Mendelian genetics. In this context, epigenetic modifications such 
as covalent chemical modifications on the DNA, histone post translational modi-
fications, and diverse no-coding RNAs can explain the inheritance of specific 
phenotypes that genetics cannot explain [4]. Those modifications occur in the 
nucleosome, the fundamental building block of eukaryotic chromatin, that consist 
of 147 base pairs of DNA wrapped twice around a histone octamer formed by two 
subunits of each of the core histones H2A, H2B, H3, and H4 [5]. A variety of modi-
fying enzymes are responsible of the generation, maintenance, and removal of 
DNA methylation and histone modifications. Enzymes involved in the generation of 
those marks are called “writers,” whereas enzymes involved in the removal of them 
are called “erasers”; the proteins able to bind to the marks are called “readers.” Here, 
will provide a summary of the function and factors involved in these modifications.
2.1 DNA methylation
This modification occurs mostly in CpG dinucleotides and consists of the 
transfer of a methyl moiety from S-adenosylmethionine (SAM) to the 5 position 
of cytosines. DNA methylation in a gene regulatory region or in its coding region 
correlates with repression of gene expression (Figure 1). This reaction is catalyzed 
by DNA methyltransferases (DNMTs) (Figure 2). DNMTs comprise two families 
that are functionally and structurally distinct. Dnmt1 maintains DNA methylation 
patterns during DNA replication and repair, while Dnmt3a and Dnmt3b establish 
de novo CpG methylation patterns [6]. Methylated DNA is recognized by methyl-
CpG-binding proteins (MBPs) (Figure 2), which bind to the methylated DNA and 
Figure 1. 
Epigenetic marks associated to regulation of transcription. DNA methylation and histone modifications induce 
changes on chromatin structure leading to effects on transcriptional activity. On the left, DNA methylation and 
histone modifications such as the trimethylation of lysine 9 of H3 (H3K9me3) and the trimethylation of lysine 27 
of H3 (H3K27me3) induce the chromatin compaction, making the DNA relatively inaccessible to DNA-binding 
proteins such as transcription factors (TFs) and RNA polymerase II (RNAPII) causing a transcriptional 
repression. On the right, histone modifications such as histone acetylation, H3K4me3 and H3K36me3, induce 
an open chromatin making the DNA to remain accessible to DNA-binding proteins such as TFs and RNAPII 
generating a state of active transcription.
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initiate the silencing of chromatin through the recruitment of other factors. These 
MBP proteins include MeCP2 and MBD1-4 [7]. On the other hand, DNA demethyl-
ation is catalyzed by ten-eleven translocation (TET) proteins (Figure 2) [8].
2.2 Histone modifications
Over 60 different modifications have been detected on histones. Histone amino-
terminal tails are the most frequent target of modifications, including acetylation, 
methylation, phosphorylation, ubiquitination, sumoylation, and ADP-ribosylation. 
These modifications, which regulate a variety of functions, including cell cycle, 
DNA repair, and transcription, has led to the “histone code hypothesis” that 
postulates that a combination of different modifications may result in distinct and 
consistent cellular outcomes [9].
2.3 Acetylation
Histone acetylation consists of the transfer of an acetyl group from acetyl-CoA 
to the lysine 1-amino groups on the N-terminal tail of histones. Acetylation can 
occur on specific lysines on H3, H4, H2A, and H2B. Acetylation of histones is 
considered a hallmark of transcriptionally active regions (Figure 1) [9]. Histone 
acetylation is catalyzed by histone acetyltransferases (HATs) (Figure 2), which 
are also known as lysine acetyltransferases (KATs). They are divided into three 
families based on sequence conservation: GNAT (GNC5/PCAF), MYST (KAT6-8), 
and p300/CBP families [10]. In addition to neutralize the positive charge normally 
present on histones, hence reducing affinity between histone and DNA, lysine 
acetylation generates binding sites for specific protein-protein interaction domains, 
such as the bromodomain and tandem PHD domains that facilitate chromatin 
decompaction (Figure 2) [11, 12]. On the other hand, four distinct families of his-
tone deacetylases (HDAC) have been described (Figure 2). The classes I, II, and IV 
are considered classical HDACs and require zinc to catalyze the reaction, whereas 
Figure 2. 
Writer, readers, and erasers of epigenetic marks. A representative model of epigenetic writers, readers, and erasers 
and their function. Writers such as DNMT, HAT, KMT, and PRMT carry out the epigenetic modification on DNA 
and histone tails, while erasers such as TET, HDAC, and KDM remove those modifications. Proteins containing 
specific domains such as MBP, Bromodomain, PHD, MBT, and Tudor are able to “read” these epigenetic marks and 
promote either transcriptional activation or repression.
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the class III is NAD-dependent enzymes of the Sirtuin family. HDACs are involved 
in multiple signaling pathways and are present in numerous repressive chromatin 
complexes [13, 14].
2.4 Methylation
Histone methylation occurs through the covalent addition of methyl group(s) 
from the donor SAM to arginine and lysine. Arginine can be mono- and dimethyl-
ated (symmetrically or asymmetrically), whereas lysine can be mono-, di- and 
trimethylated. Methylation mark on histones can be related to activation or repres-
sion of gene expression, depending on the residue that is modified (Figure 1) [9]. 
For example, methylation of lysine 4 of H3 (H3K4) is linked to the initiation of 
transcription [15], H3K36 methylation correlates to transcriptional elongation [16], 
whereas methylation of H3K79 is implicated both in transcriptional activation and 
elongation [17]. Three lysine methylation sites are correlated to transcriptional 
repression: H3K9, H3K27, and H4K20 [10, 18].
In the case of arginine methylation, asymmetric and symmetric dimethylations on 
arginine have an opposite role on gene expression. For example, asymmetric methyla-
tion on H4R3 produced by PRMT1 (protein arginine methyltransferase 1) promotes 
active transcription [19], whereas symmetric methylation on the same residue (H4R3) 
produced by the enzyme PRMT5 leads to transcriptional repression [20].
In addition, studies have shown that during early development some of the genes 
that are not expressed have both repressive (H3K27me3) and permissive (H3K4me3) 
marks on their promoters, forming the so-called bivalent domains. At the time 
when the differentiation process occurs, bivalent domain genes are resolved by get-
ting rid of either the active or repressive mark. Therefore, these bivalent domains 
are thought to keep genes repressed at a certain developmental window but poised 
for activation in another developmental stage [21].
The enzymatic addition of methyl groups to histone lysine residues is mediated 
by lysine methyltransferases (KMT) (Figure 2) [22]. KMTs have a high degree of 
enzymatic specificity. For example, SUV39H1 and SUV39H2 convert H3K9me1 to 
H3K9me3, while G9a produces H3K9me2 [23]. In addition, some “writers” are able 
to produce all of the methylation status on a histone residue such as Ezh2 (Enhancer 
of zeste homolog 2) on H3K27 [24]. Methylated histone lysine residues can bind to 
several protein domains, including PHD, Tudor, and WD40 domains (Figure 2). 
Each domain recognizes specific methylated residues. For example, H3K4me3 is 
recognized by PHD domains, while WD40 domain recognizes several trimethylated 
lysine residues associated with repressive marks [25]. Histone lysine demethylase 
(KDM) removes methylation on specific histone lysine residues (Figure 2). These 
enzymes are divided into two families with distinct enzymatic mechanisms: the 
FAD-dependent amine oxidase family comprises two members, LSD1 and LSD2, 
while the iron- and α–ketoglutarate-dependent Jumonji C (JmjC) family comprises 
more than 30 members [26].
In the case of arginine methylation, the addition of methyl groups is mediated 
by arginine methyltransferases (PRMTs) (Figure 2). PRMTs are divided into three 
types: type I enzymes including PRMT1-4, 6, 8 and CARM1 generate asymmetric 
dimethylarginine, whereas type II enzymes such as PRMT5 generate symmetric 
dimethylarginine [27]. Tudor domains are one of the best-characterized domains 
that recognize methylated arginines (Figure 2) [28]. JMJD6 and JMJD1B have 
proved to serve as arginine demethylases [29].
Notably, DNA methylation cross-talks with histone modifications. In this 
context, DNA methylation correlates with the absence of activating marks, such as 
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methylation on H3K4, and the presence of repressive marks, such as H3K9 meth-
ylation. H3K4 methylation has been suggested to protect gene promoters from de 
novo DNA methylation. On the other hand, methylated CpG can recruit HDACs to 
deacetylate histones around the methylated CpG [30].
3.  Epigenetic regulation of immune cell development, function, and effector 
function
3.1 Epigenetic regulation of macrophage development
CCAAT enhancer-binding protein (C/EBP) is a key transcription factor in the 
development of granulocyte-monocyte progenitors that it is not expressed on 
hematopoietic stem cells (HSCs). However, the gene promoter that encodes this 
transcription factor (Cebpa) has a “poised” status on HSCs, thus possessing both 
repressive and activating marks. After the commitment to myeloid cell develop-
ment, the repressive modification H3K27me3 is removed from the Cebpa locus, 
while the permissive mark H3K4me3 remains, inducing Cebpa gene expression 
[31]. Afterward during myeloid development, the dosage of the transcription 
factors PU.1 versus C/EBP regulates the macrophage or neutrophil lineage deci-
sion, whereas high PU.1 dosage favors macrophage development. PU.1 recruits both 
DNA demethylases (TET2) and methyltransferases (Dnmt3b) to modulate DNA 
methylation, facilitating or repressing gene expression, respectively. In contrast, 
DNA methylation mediated by Dnmt1 is critical for preventing premature differ-
entiation of HSCs [32].
3.2 Epigenetic regulation of macrophage polarization and function
Stimuli and microenvironmental variables induce the polarization of macro-
phages into M1 or M2 phenotypes. Classical activation is mediated by proinflam-
matory cytokines such as TNF-α and toll-like receptor (TLR) ligands triggering 
differentiation to a M1 phenotype. M1 macrophages have host-defense activities 
that result in pathogen death and are characterized by high expression of proin-
flammatory cytokines (TNFα, IL-1β, IL-12), antimicrobial molecules, and oxygen 
reactive species [33]. Studies have shown that regulatory regions of TLR target 
genes are poised for induction by master transcription factors. Under steady 
state conditions, those promoters have permissive histone modifications such as 
H3K4me3 and acetylated H3, and their enhancers are enriched on H3K4me1 [33, 
34]. In addition, poised promoters of genes involved in eliminating the infection are 
primed for a strong and rapid response by IFN-β [35]. However, macrophages under 
steady state also have the repressive modifications such as H3K9me3, H3K27me3, 
and H4K20me3 at those loci, limiting effector gene expression in the absence of 
TLR ligands. Upon TLR activation, repressive histone methylations are removed by 
inducing histone demethylases such as JMJD3 [36, 37].
The alternative activation of macrophages occurs in the presence of type 2 cyto-
kines, such as IL-4 and IL-13, driving them towards the M2 phenotype that plays 
an essential role in tissue repair and the resolution of inflammation [33]. In this con-
version, the IL-4/Stat6 signaling induces the expression of the histone demethylase 
JMJD3 that binds to genes required for M2 differentiation [38]. JMJD3 removes the 
repressive H3K27me3 mark from the regulatory regions of M2-activating genes such 
as Irf4 [39]. In contrast, HDAC3, which is a positive regulator of M1 polarization, 
has been shown to repress M2 programs [40].
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the class III is NAD-dependent enzymes of the Sirtuin family. HDACs are involved 
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marks on their promoters, forming the so-called bivalent domains. At the time 
when the differentiation process occurs, bivalent domain genes are resolved by get-
ting rid of either the active or repressive mark. Therefore, these bivalent domains 
are thought to keep genes repressed at a certain developmental window but poised 
for activation in another developmental stage [21].
The enzymatic addition of methyl groups to histone lysine residues is mediated 
by lysine methyltransferases (KMT) (Figure 2) [22]. KMTs have a high degree of 
enzymatic specificity. For example, SUV39H1 and SUV39H2 convert H3K9me1 to 
H3K9me3, while G9a produces H3K9me2 [23]. In addition, some “writers” are able 
to produce all of the methylation status on a histone residue such as Ezh2 (Enhancer 
of zeste homolog 2) on H3K27 [24]. Methylated histone lysine residues can bind to 
several protein domains, including PHD, Tudor, and WD40 domains (Figure 2). 
Each domain recognizes specific methylated residues. For example, H3K4me3 is 
recognized by PHD domains, while WD40 domain recognizes several trimethylated 
lysine residues associated with repressive marks [25]. Histone lysine demethylase 
(KDM) removes methylation on specific histone lysine residues (Figure 2). These 
enzymes are divided into two families with distinct enzymatic mechanisms: the 
FAD-dependent amine oxidase family comprises two members, LSD1 and LSD2, 
while the iron- and α–ketoglutarate-dependent Jumonji C (JmjC) family comprises 
more than 30 members [26].
In the case of arginine methylation, the addition of methyl groups is mediated 
by arginine methyltransferases (PRMTs) (Figure 2). PRMTs are divided into three 
types: type I enzymes including PRMT1-4, 6, 8 and CARM1 generate asymmetric 
dimethylarginine, whereas type II enzymes such as PRMT5 generate symmetric 
dimethylarginine [27]. Tudor domains are one of the best-characterized domains 
that recognize methylated arginines (Figure 2) [28]. JMJD6 and JMJD1B have 
proved to serve as arginine demethylases [29].
Notably, DNA methylation cross-talks with histone modifications. In this 
context, DNA methylation correlates with the absence of activating marks, such as 
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methylation on H3K4, and the presence of repressive marks, such as H3K9 meth-
ylation. H3K4 methylation has been suggested to protect gene promoters from de 
novo DNA methylation. On the other hand, methylated CpG can recruit HDACs to 
deacetylate histones around the methylated CpG [30].
3.  Epigenetic regulation of immune cell development, function, and effector 
function
3.1 Epigenetic regulation of macrophage development
CCAAT enhancer-binding protein (C/EBP) is a key transcription factor in the 
development of granulocyte-monocyte progenitors that it is not expressed on 
hematopoietic stem cells (HSCs). However, the gene promoter that encodes this 
transcription factor (Cebpa) has a “poised” status on HSCs, thus possessing both 
repressive and activating marks. After the commitment to myeloid cell develop-
ment, the repressive modification H3K27me3 is removed from the Cebpa locus, 
while the permissive mark H3K4me3 remains, inducing Cebpa gene expression 
[31]. Afterward during myeloid development, the dosage of the transcription 
factors PU.1 versus C/EBP regulates the macrophage or neutrophil lineage deci-
sion, whereas high PU.1 dosage favors macrophage development. PU.1 recruits both 
DNA demethylases (TET2) and methyltransferases (Dnmt3b) to modulate DNA 
methylation, facilitating or repressing gene expression, respectively. In contrast, 
DNA methylation mediated by Dnmt1 is critical for preventing premature differ-
entiation of HSCs [32].
3.2 Epigenetic regulation of macrophage polarization and function
Stimuli and microenvironmental variables induce the polarization of macro-
phages into M1 or M2 phenotypes. Classical activation is mediated by proinflam-
matory cytokines such as TNF-α and toll-like receptor (TLR) ligands triggering 
differentiation to a M1 phenotype. M1 macrophages have host-defense activities 
that result in pathogen death and are characterized by high expression of proin-
flammatory cytokines (TNFα, IL-1β, IL-12), antimicrobial molecules, and oxygen 
reactive species [33]. Studies have shown that regulatory regions of TLR target 
genes are poised for induction by master transcription factors. Under steady 
state conditions, those promoters have permissive histone modifications such as 
H3K4me3 and acetylated H3, and their enhancers are enriched on H3K4me1 [33, 
34]. In addition, poised promoters of genes involved in eliminating the infection are 
primed for a strong and rapid response by IFN-β [35]. However, macrophages under 
steady state also have the repressive modifications such as H3K9me3, H3K27me3, 
and H4K20me3 at those loci, limiting effector gene expression in the absence of 
TLR ligands. Upon TLR activation, repressive histone methylations are removed by 
inducing histone demethylases such as JMJD3 [36, 37].
The alternative activation of macrophages occurs in the presence of type 2 cyto-
kines, such as IL-4 and IL-13, driving them towards the M2 phenotype that plays 
an essential role in tissue repair and the resolution of inflammation [33]. In this con-
version, the IL-4/Stat6 signaling induces the expression of the histone demethylase 
JMJD3 that binds to genes required for M2 differentiation [38]. JMJD3 removes the 
repressive H3K27me3 mark from the regulatory regions of M2-activating genes such 
as Irf4 [39]. In contrast, HDAC3, which is a positive regulator of M1 polarization, 
has been shown to repress M2 programs [40].
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3.3 Epigenetic regulation of trained and tolerized macrophages
Trained and tolerized states of macrophages have been recognized as the 
immunological “memory” of innate immunity. During those states, macrophages 
have a robust and specific response upon a secondary challenge. Macrophages 
derived from monocytes treated with β-glucan, called trained macrophages, show 
an enhanced inflammatory status. β-glucan challenge showed stable changes in 
H3K4me3 at promoters of proinflammatory cytokines such as Tnf, Il6, and Il18, 
while no changes were observed in H3K27me3 [41]. In addition, H3K4me1 mark per-
sists at enhancers after a pathogen challenge, contributing to the faster and stronger 
induction of multiple genes upon restimulation of trained macrophages [42].
In contrast, monocytes-derived macrophages pretreated with LPS produced less 
proinflammatory mediators such as IL-6 and TNFα upon challenge with certain toll-like 
receptor agonist(s). At the same time, anti-inflammatory molecules such as IL-10 and 
TGF-β show an increased expression following a secondary challenge compared to 
non-tolerized macrophages. H3K4me3 was induced in macrophages at both proinflam-
matory and anti-inflammatory gene promoters. However, “tolerized” macrophages 
treated with LPS induce a rapid and selective loss of H3K4me3 at proinflammatory gene 
promoters maintaining the mark on anti-inflammatory gene promoters. In this context, 
H4 acetylation was found on both group of genes in naïve macrophages but was reacety-
lated only on promoters of proinflammatory genes in tolerized macrophages [43, 44].
Additionally, the transcription factor ATF7 controls genes involved on immune 
response such as Tnf, Ccl3, and Cxcl2 in unstimulated macrophages by recruiting the 
lysine methylase G9a and promoting H3K9me2 on these promoters. LPS treatment in 
trained macrophages induces phosphorylation of ATF7 via p38, leading to ATF7 release 
from chromatin with the concomitant removal of G9a and a decrease of the repressive 
H3K9me2 mark on the promoter of target genes. This partially disrupted chromatin 
structure leads to enhanced resistance to pathogens in trained macrophages [45].
3.4 Epigenetic regulation of DC development
The permissive mark H3K4me3 is confined to promoters of progenitor genes in 
multipotent progenitors (MPP) and in common dendritic cell progenitors (CDP), while 
H3K4me1 is found in their enhancers. H3K27me3 was observed at promoters of pro-
genitor genes in conventional DCs (cDC) and plasmacytoid DCs (pDC). Conversely, 
H3K4me3 and H3K4me1 in cDCs and pDC were observed at promoter and enhancer of 
DC-specific genes, while H3K27me3 was seen in progenitors [46, 47].
3.5 Epigenetics and DC function
Few studies have investigated the role of epigenetic modifications on DC 
function. Genome-wide DNA methylation analysis showed rapid and active 
demethylation at thousands of loci on DCs exposed to the pathogenic bacterium 
Mycobacterium tuberculosis (MBT) [48].
Our own studies have shown that under steady state conditions Il6 and tgfb1 
promoters have a bivalent status on splenic DCs and that treatment of DCs with 
LPS induces H3K4me3, decreasing H3K27me3 on the Il6 promoter, while it decreases 
H3K4me3 and increases H3K27me3 on the tgfb1 promoter. Contrary, the use of GSK-J4, 
a specific inhibitor of the H3K27me3 histone demethylase JMJD3, reverses this bivalent 
status and promotes DCs with tolerogenic functions in LPS-treated DCs [49].
Patients who survive sepsis have significant deficiencies in their immune response. 
One study found that these deficiencies are explained at least in part because post-
septic DCs exhibit a significant and chronic suppression of IL-12. Whereas normal 
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DCs showed a high H3K4me3 and low H3K27me2 at both Il12p35 and Il12p40 promot-
ers, suggesting a permissive chromatin structure poised for expression on exposure 
to stimuli, post-septic DCs showed a significant decreased H3K4me3 and increased 
H3K27me2 levels. In addition, post-septic DCs fail to recruit histone methyltransfer-
ases to Il12 promoter [50].
Several studies have shown that histone deacetylase inhibitors such as valproic 
acid and MS-275 inhibit Cd40, Cd80, and Cd86 expression as well as proinflam-
matory cytokines such as Il6, Il12, and Tnf. All these studies suggest that histone 
acetylation is a key player in the modulation of DC function [51, 52].
3.6  Epigenetic regulation of B cell development and immunoglobulin gene 
recombination
The main function of these cells is the production of antibodies. They can also 
act as APC for T cells. Many epigenetic changes have been described during B cell 
development, differentiation, and effector function. PAX5 is an essential transcrip-
tion factor in B-cell differentiation and maintenance as it induces B-cell-specific 
genes, while repressing genes of other lineages. The permissive marks H3K9ac, 
H3K4me2, and H3K4me3 are important to mediate PAX5 transactivation [53]. 
Epigenetic marks also regulate immunoglobulin gene recombination at several 
levels. For example, H3K4me2 on immunoglobulin genes is correlated with V(D)
J recombination, whereas methylation on H3K9 and H3K27 is inversely correlated 
with the efficiency of V(D)J recombination [54, 55]. DNA methylation and histone 
acetylation inhibits and enhances the V(D)J recombination, respectively [56, 57]. 
Furthermore, hypermutation required to produce antibody diversity in V(D)J 
recombination is mediated by activation-induced cytidine deaminase (AID). DNA 
methylation as well as hypoacetylation on H3 suppresses Aicda gene expression 
(encoding AID) [58]. Upon activation of B cells, Aicda gene is DNA demethylated 
and the locus becomes enriched in H3K4me3 and H3K9ac/K14ac [58].
3.7 Epigenetic regulation of plasma cell and memory B cell
B cell differentiation into antibody-secreting plasma cells (PC) is initiated by 
external stimuli. PCs are derived from either germinal center (naïve B cell) or 
memory B cells. Blimp-1, a key transcription factor required for PC differentiation, 
inhibits Bcl6, Pax5, and Spib expression by binding to the promoters of these genes 
and recruiting HDAC to decrease histone acetylation [59] and G9a to induce H3K9me3 
[60]. On the other hand, memory B cells quickly react to a second challenge with the 
same antigen, thereby providing humoral immune protection. Finally, the differ-
entiation of naïve B cells to PC or memory B cells associates with changes in DNA 
methylation in an DNMT3a-dependent manner [61].
3.8 Epigenetic regulation of early T cell development
Initial commitment of hematopoietic precursors to the T-cell phenotype is trig-
gered by Notch signaling. During this process, B-cell transcription factors Pax5 and 
Ebf1 are repressed by H3K27me3 marks. The myeloid regulatory gene, Cebpa, is kept 
silent by a bivalent status (H3K27me3 and H3K4me3), while the erythroid gene, EpoR, 
is repressed via H3K27me3 [62]. Activation of T-cell-associated genes is strongly 
and temporally correlated with histone acetylation, although DNA methylation also 
regulates early T-cell development. DNA demethylation has been observed in many 
essential T-cell regulators, including genes that encode TCR components such as CD3 
molecules and key developmental genes such as Runx3, Rorc, Ikaros, Rag, and Lck [63].
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Trained and tolerized states of macrophages have been recognized as the 
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derived from monocytes treated with β-glucan, called trained macrophages, show 
an enhanced inflammatory status. β-glucan challenge showed stable changes in 
H3K4me3 at promoters of proinflammatory cytokines such as Tnf, Il6, and Il18, 
while no changes were observed in H3K27me3 [41]. In addition, H3K4me1 mark per-
sists at enhancers after a pathogen challenge, contributing to the faster and stronger 
induction of multiple genes upon restimulation of trained macrophages [42].
In contrast, monocytes-derived macrophages pretreated with LPS produced less 
proinflammatory mediators such as IL-6 and TNFα upon challenge with certain toll-like 
receptor agonist(s). At the same time, anti-inflammatory molecules such as IL-10 and 
TGF-β show an increased expression following a secondary challenge compared to 
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H4 acetylation was found on both group of genes in naïve macrophages but was reacety-
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Additionally, the transcription factor ATF7 controls genes involved on immune 
response such as Tnf, Ccl3, and Cxcl2 in unstimulated macrophages by recruiting the 
lysine methylase G9a and promoting H3K9me2 on these promoters. LPS treatment in 
trained macrophages induces phosphorylation of ATF7 via p38, leading to ATF7 release 
from chromatin with the concomitant removal of G9a and a decrease of the repressive 
H3K9me2 mark on the promoter of target genes. This partially disrupted chromatin 
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The permissive mark H3K4me3 is confined to promoters of progenitor genes in 
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H3K4me1 is found in their enhancers. H3K27me3 was observed at promoters of pro-
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H3K4me3 and H3K4me1 in cDCs and pDC were observed at promoter and enhancer of 
DC-specific genes, while H3K27me3 was seen in progenitors [46, 47].
3.5 Epigenetics and DC function
Few studies have investigated the role of epigenetic modifications on DC 
function. Genome-wide DNA methylation analysis showed rapid and active 
demethylation at thousands of loci on DCs exposed to the pathogenic bacterium 
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Our own studies have shown that under steady state conditions Il6 and tgfb1 
promoters have a bivalent status on splenic DCs and that treatment of DCs with 
LPS induces H3K4me3, decreasing H3K27me3 on the Il6 promoter, while it decreases 
H3K4me3 and increases H3K27me3 on the tgfb1 promoter. Contrary, the use of GSK-J4, 
a specific inhibitor of the H3K27me3 histone demethylase JMJD3, reverses this bivalent 
status and promotes DCs with tolerogenic functions in LPS-treated DCs [49].
Patients who survive sepsis have significant deficiencies in their immune response. 
One study found that these deficiencies are explained at least in part because post-
septic DCs exhibit a significant and chronic suppression of IL-12. Whereas normal 
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DCs showed a high H3K4me3 and low H3K27me2 at both Il12p35 and Il12p40 promot-
ers, suggesting a permissive chromatin structure poised for expression on exposure 
to stimuli, post-septic DCs showed a significant decreased H3K4me3 and increased 
H3K27me2 levels. In addition, post-septic DCs fail to recruit histone methyltransfer-
ases to Il12 promoter [50].
Several studies have shown that histone deacetylase inhibitors such as valproic 
acid and MS-275 inhibit Cd40, Cd80, and Cd86 expression as well as proinflam-
matory cytokines such as Il6, Il12, and Tnf. All these studies suggest that histone 
acetylation is a key player in the modulation of DC function [51, 52].
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The main function of these cells is the production of antibodies. They can also 
act as APC for T cells. Many epigenetic changes have been described during B cell 
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tion factor in B-cell differentiation and maintenance as it induces B-cell-specific 
genes, while repressing genes of other lineages. The permissive marks H3K9ac, 
H3K4me2, and H3K4me3 are important to mediate PAX5 transactivation [53]. 
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J recombination, whereas methylation on H3K9 and H3K27 is inversely correlated 
with the efficiency of V(D)J recombination [54, 55]. DNA methylation and histone 
acetylation inhibits and enhances the V(D)J recombination, respectively [56, 57]. 
Furthermore, hypermutation required to produce antibody diversity in V(D)J 
recombination is mediated by activation-induced cytidine deaminase (AID). DNA 
methylation as well as hypoacetylation on H3 suppresses Aicda gene expression 
(encoding AID) [58]. Upon activation of B cells, Aicda gene is DNA demethylated 
and the locus becomes enriched in H3K4me3 and H3K9ac/K14ac [58].
3.7 Epigenetic regulation of plasma cell and memory B cell
B cell differentiation into antibody-secreting plasma cells (PC) is initiated by 
external stimuli. PCs are derived from either germinal center (naïve B cell) or 
memory B cells. Blimp-1, a key transcription factor required for PC differentiation, 
inhibits Bcl6, Pax5, and Spib expression by binding to the promoters of these genes 
and recruiting HDAC to decrease histone acetylation [59] and G9a to induce H3K9me3 
[60]. On the other hand, memory B cells quickly react to a second challenge with the 
same antigen, thereby providing humoral immune protection. Finally, the differ-
entiation of naïve B cells to PC or memory B cells associates with changes in DNA 
methylation in an DNMT3a-dependent manner [61].
3.8 Epigenetic regulation of early T cell development
Initial commitment of hematopoietic precursors to the T-cell phenotype is trig-
gered by Notch signaling. During this process, B-cell transcription factors Pax5 and 
Ebf1 are repressed by H3K27me3 marks. The myeloid regulatory gene, Cebpa, is kept 
silent by a bivalent status (H3K27me3 and H3K4me3), while the erythroid gene, EpoR, 
is repressed via H3K27me3 [62]. Activation of T-cell-associated genes is strongly 
and temporally correlated with histone acetylation, although DNA methylation also 
regulates early T-cell development. DNA demethylation has been observed in many 
essential T-cell regulators, including genes that encode TCR components such as CD3 
molecules and key developmental genes such as Runx3, Rorc, Ikaros, Rag, and Lck [63].
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3.9  Epigenetics on the regulation of terminal differentiation and effector functions 
of CD4+ and CD8+ T cells
The lineage choice between CD4 and CD8 T cells is defined by the transcrip-
tion factors ThPOK and Runx. ThPOK activity is necessary and sufficient for CD4 
lineage commitment, and its function is abrogated in the presence of the histone 
deacetylase HDAC1. Runx1 and Runx3 or their common obligatory dimerization 
partner, Cbfβ, is necessary for the development of CD8 T cells. ThPOK and Runx 
factors are mutual repressors [64]. After their terminal differentiation, CD4+ T 
cells exert their function as either helper T cell subsets (Th1, Th2, and Th17) or 
Treg cells. This section describes the epigenetic regulation of naïve T (Tn) cells 
to a specific differentiation program upon activation. Genome wide analysis of 
H3K4me3 (permissive mark) and H3K27me3 (repressive mark) in Tn, Th1, Th2, 
Th17, and Treg cells demonstrated the enrichment of H3K4me3 in genes that encode 
signature transcription factors and cytokine production for the corresponding cell 
subsets, while these genes are enriched in the repressive mark H3K27me3 in the 
other subsets (Figure 3). For example, the permissive mark H3K4me3 is found in 
the Tbx21 (encoding Tbet) and Ifng loci in Th1 cells, in the Gata3 and Il4 loci in Th2 
cells, in the Rorc (encoding RORγt) and Il17 loci in Th17 cells, and Foxp3 in Treg 
cells. However, these same loci show the repressive mark H3K27me3 in the oppos-
ing cell subsets, for example, the Tbx21 locus in Th2. Most interesting, the master 
transcription factors for each T cell subset (Tbx21, Gata3, Rorc, and Foxp3) have a 
bivalent status (permissive H3K4me3 and repressive H3K27me3) in the opposing 
cell subsets (i.e., Tbx21 loci in Treg cells), thus suggesting functional plasticity 
among Th subsets and Treg cells [65] (Figure 3).
Suv39H1, which mediates the repressive H3K9me3 mark, is a key to keep Th1 
commitment since disruption of Suv39H1 results in an aberrant induction of IFNγ 
in Th2 cells after re-culture under Th1 polarizing conditions. However, the absence 
of Suv39H1 does not disturb Th2 cell differentiation [66]. The histone demethylase 
JMJD3 has a controversial role in CD4+ T-cell differentiation. One study showed 
that JMJD3 ablation promotes Th2 and Th17 differentiation, while decreases 
Th1 cells [67]. However, another study shows that JMJD3 induction is crucial to 
induce Th17 cells. The same study described that the epigenetic drug GSK-J4, a 
JMJD3 inhibitor, dramatically suppressed Th17 cell differentiation in vitro [68]. 
Nevertheless, our own studies reveled that GSK-J4 promotes Treg differentiation 
by DCs. Also, we showed that GSK-J4 treatment decreases the plasticity of Treg to 
become Th1 or Th17 cells in vivo [49]. This is in concordance with another report 
where the JMJD3 deficiency also restrains plasticity in the conversion of Th2, Th17, 
or Treg cells into Th1 cells [67].
The vast majority of Foxp3+ Treg cells are generated during thymic develop-
ment (tTreg). A small portion of Treg cells can also be converted from conventional 
CD4+ T cells in the periphery. They are called inducible Treg cells (iTreg). This 
population has specificity towards nonpathogenic foreign antigens, including 
commensal microbiota, food, and fetal antigens. All Treg cell types (tTreg and 
iTreg) rely on a proper Foxp3 expression for the acquisition of the immunosup-
pressive phenotype as well as for the maintenance of their phenotype and function, 
particularly under inflammatory conditions. Mutations within the Foxp3 gene 
or deletion of Foxp3 result in the development of autoimmunity [69]. H3 and H4 
acetylation as well as H3K4me2 and H3K4me3 are found at the Foxp3 promoter in 
Treg cells but not in other CD4+ conventional T cell phenotypes. On the contrary, 
H3K27me3 (repressive mark) is found in conventional CD4+ T cells, but not in Treg 
cells [70]. In Treg cells, the polycomb repressor complex is replaced by p300/CREB-
binding protein-associated factor (PCAF), a histone acetyltransferase recruited 
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via the zinc-finger transcription factor Krüppel-like factor 10 (KLF10) to the Foxp3 
promoter, a process that finally results in the opening of the Foxp3 promoter by 
permissive histone modifications [71]. In addition, our own results showed that 
treatment with Trichostatin A (TSA), a histone deacetylase inhibitor, increases Treg 
population as well as H3 acetylation [72]. The data indicate that modulating histone 
acetylation on Treg might also be a key to improve Treg function and stability.
Foxp3 gene has three conserved noncoding sequences (CNS) that are the primary 
targets of epigenetic regulation and are necessary to modulate its expression depend-
ing on the environmental cues that T cells receive. CNS1, which is a TGF-β-sensitive 
enhancer element and critical for the generation of Treg cells, does not contain any 
CpG motifs and thus is solely regulated via histone modifications [70, 73]. Indeed, 
H3/H4 acetylation and H3K4me2/3 are enriched in both tTreg and iTreg cells com-
pared to other conventional CD4+ T-cell phenotypes [70]. CNS2 is a Treg cell-specific 
demethylated region (TSDR). Demethylation of this CpG region, mediated by TET2, 
is mandatory for stable Foxp3 expression. Also, CNS2 contains H3K4 methylation 
as well as H3/H4 acetylation in Treg cells, suggesting that DNA demethylation and 
permissive histone modifications generate an open chromatin status at CNS2 that 
promotes stabilization of Foxp3 expression [70, 74]. Conversely, DNA methylation 
Figure 3. 
Epigenetic status of “Master” transcriptional factor gene in CD4+ T cells. DNA methylation and bivalent 
marks (H3K27me3 repressive and H3K4me3 permissive) present on the promoter of the “master” transcription 
factors for Th1 (T-bet), Th2 (GATA3), Th17 (Rorγt), and Treg (Foxp3) inhibit their expression on naïve CD4+ 
T cells (nT cells). Upon TCR stimulation and depending on the cytokines present in the milieu, nT cells will 
adopt one of those phenotypes. During differentiation of nT cells to Th1, Tbx21 gene promoter (encoding T-bet) 
is hypomethylated, and repressive marks such as H3K27me3 removed while gaining permissive marks such as 
H3K4me3, thus allowing Tbx21 expression (in green) while the rest of “master” transcription factors associated 
to other T subsets are repressed (in red) through the acquisition of bivalent or repressive marks. The same 
process has been described on the promoters for the master transcription factors critical in the differentiation of 
the Th2, Th17, and Treg subsets, in which Gata3, Rorc, and Foxp3 are expressed, respectively. The transcription 
factor expressed on each phenotype is written in green, whereas transcription factors that are not expressed on 
that particular phenotype are written in red. It should be noted that the acquisition of bivalent marks and the 
absence of DNA methylation in master transcription factors associated to opposite T subsets are linked to the 
plasticity described on CD4+ T cells.
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3.9  Epigenetics on the regulation of terminal differentiation and effector functions 
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of CNS2 can prevent Foxp3 expression in non-Treg cells [74]. Furthermore, Foxp3 
expression cannot be maintained when Treg cells are exposed to inflammatory 
cytokines such as IL-4 and IL-6 upon deletion of CNS2 [75]. CNS3 has been called 
“pioneer element,” since it plays a critical role for the initiation of Foxp3 expression 
in Treg cells, but is dispensable once Foxp3 is expressed. It is enriched in the permis-
sive H3K4me1/2 marks, modifications that are increased in the Foxp3-thymocyte 
subsets, suggesting that CNS3 facilitates the opening of the Foxp3 locus in Treg cell 
precursors [70].
Epigenetic modifications also play important roles in the regulation of CD8+ 
T-cell effector functions. For example, H3K27me3 modification at the Ifng locus in 
naive CD8+ T cells is removed upon activation and differentiation to effector cells, 
whereas the permissive histone modifications H3K9ac and H3K4me3 are deposited 
in this locus. The Ifng locus has reduced levels of total histone H3 in activated CD8+ 
T cells, suggesting that the depletion of nucleosomes from the locus allows the tran-
scriptional machinery to access the promoter [76]. The Gzmb locus, which encodes 
another CD8+ T-cell effector molecule, granzyme B, also shows similar epigenetic 
regulation during differentiation from naive to effector cells [77].
4.  Epigenetic regulation of autoimmune diseases and the prospect of 
epigenetic drug as therapeutic agents
Autoimmune diseases are a complex group of diseases in which each one present 
with a unique epidemiology, pathology, symptoms, and origin. There are intrinsic 
and extrinsic components that predispose to autoimmunity. The following section 
describes some important epigenetic changes in systemic lupus erythematosus 
(SLE), rheumatoid arthritis (RA), multiple sclerosis (MS), and inflammatory 
bowel diseases (IBD), and how epigenetic drugs can modulate these changes.
4.1 Systemic lupus erythematosus (SLE)
It is a chronic inflammatory disease with a significant long-term morbidity that 
affects principally women, with an estimated population frequency in the United 
States of about 150 for white women to about 400 for African-American women 
per 100,000. SLE is a systemic multiorgan autoimmune disease characterized by 
an autoantibody response to nuclear and/or cytoplasmic antigens. Autoreactive T 
and B cells lead to a gradual loss of self-tolerance leading over time to high levels of 
autoantibodies.
A global DNA hypomethylation occurs on several promoter regions in CD4+ 
T cells derived from SLE patients, including genes related to immune response 
such as Itgal, Cd40l, Cd70, Ifgnr2, Il-4, and Il-13. These hypomethylated regions 
are correlated with an upregulation in the expression of those genes causing cell 
hyperactivity and, consequently, perpetuation of inflammatory responses. DNA is 
hypomethylated on interferon genes in B cells, monocytes, and neutrophils, leading 
to the upregulation of these genes and a predisposition to produce an increased 
interferon response, a factor that plays a key role in SLE pathogenesis [78]. 
Consistently, DNA methyltransferase inhibitors, such as procainamide and hydrala-
zine, induce lupus-like disease in mice [79]. So far, the accumulative evidence show 
that changes on DNA methylation in immune cells are key during SLE development.
Modified histones, such as H3K4me3, H3K27me3, H4K8ac, H4K16ac, and 
H2BK12ac, are known to be relevant autoantigens in SLE. These autoantigens 
trigger NETosis, a phenomenon whereby neutrophils extrude their nuclear mate-
rial (Neutrophils Extracellular Traps) to kill pathogens [80]. However, very little 
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attention has been paid to histone modifications in SLE and in the induction or 
repression of gene expression. In SLE monocytes, H3K4me3 is enriched on type I 
interferon response genes, which is consistent with the type I interferon effect in 
lupus [81]. Nevertheless, the histone methyltransferase Ezh2 seems to be important 
in autoimmune responses of CD4+ T cells. Ezh2 is highly enriched on genes such 
as Il-4, Il-10, Il-13, Cd70, and Tnf [82]. Since Ezh2 mRNA levels are decreased in 
human lupus CD4+ T cells, this leads to an elevated expression of these genes [98]. 
Gene expression profile of CD4+ T cells generated from Ezh2-deficient mice shows 
a similar behavior to lupus CD4+ T cells [82]. These results suggest that Ezh2 and 
histone modifications have a relevant role in SLE.
4.2 Rheumatoid arthritis (RA)
RA is a disease characterized by the progressive destruction of joints by invasive 
synovial fibroblasts. RA synovial fibroblasts (RASFs) play a major role in this 
pathology. This disease is characterized by painful joint swelling, cartilage damage, 
bone erosion, severe joint deformation, disability, and premature mortality.
Global DNA hypomethylation is observed in RASF, T cells, B cells, and mono-
cytes. In RA, Cxcl12 gene is hypomethylated in RASF cells, which allows for 
overexpression of Cxcl12 and thus promoting infiltration of inflammatory cells 
in the synovium [83]. The promoter of the transcription factor Tbx5 is also DNA 
hypomethylated, and its overexpression induces pro-inflammatory cytokines 
production [84]. In monocytes, DNA methyltransferase expression is reduced lead-
ing to a reduction of DNA methylation in inflammatory response promoter genes. 
For example, hypomethylation in the Il6 promoter gene causes an overexpression 
of IL-6, furthering B cell response [85]. In CD4+ T cells, Cd40l promoter is DNA 
demethylated in female patients, leading to the overexpression of this gene and 
an increased immune response. On the other hand, Tregs responses fail to control 
the activity of T helper cells in RA. Foxp3 is the master transcription factor for the 
differentiation of Tregs, and DNA methylation controls its expression (see T cell 
section above). Methotrexate, a drug that inhibits S-adenosylmethionine (SAM) 
synthesis (the donor methyl group during methylation reaction), restores the sup-
pressive function of Tregs by demethylating the Foxp3 promoter [86].
Destruction of cartilage on RA synovial tissue is characterized by an imbal-
ance between HAT and HDAC activities (acetylation vs. deacetylation). For 
example, hyperacetylation on p16 and p21 gene promoters induce their expression 
with a subsequent decrease in TNFα synthesis leading to an improvement of RA 
symptoms in a murine RA model [87]. Many studies have described the beneficial 
effects of HDAC inhibitors in vitro and in an in vivo mouse model of arthritis. 
HDAC inhibitors such as Givinostat [NCT00570661] have already started to be 
used in clinical trials, revealing benefits in patients with systemic-onset juvenile 
idiopathic arthritis after 12 weeks of treatment. On the other hand, HDAC class 
III enzymes showed a contradictory function in RA. For example, the levels of the 
NAD-dependent protein deacetylase SIRT6 are increased in the joint tissues of 
collagen-induced arthritis (CIA) in mice, and further studies revealed that SIRT6 
overexpression attenuates the severity of arthritis by reducing both the inflam-
matory response and tissue destruction, whereas SIRT1 levels were increased 
and its overexpression contributed inflammatory cytokine production [88, 89]. 
Finally, Pan-inhibitors against the BET protein family (acetylation readers) have 
anti-inflammatory and anti-destructive properties in vitro [90] and in CIA mice 
[91, 92]. The effects of BET inhibitors in CIA are attributed to the suppression of 
Th17 cell differentiation and function, suggesting that BET inhibitors are potential 
targets for RA treatment [91].
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section above). Methotrexate, a drug that inhibits S-adenosylmethionine (SAM) 
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NAD-dependent protein deacetylase SIRT6 are increased in the joint tissues of 
collagen-induced arthritis (CIA) in mice, and further studies revealed that SIRT6 
overexpression attenuates the severity of arthritis by reducing both the inflam-
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[91, 92]. The effects of BET inhibitors in CIA are attributed to the suppression of 
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targets for RA treatment [91].
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4.3 Multiple sclerosis (MS)
MS is an autoimmune disease of the central nervous system (CNS) character-
ized by the abnormal entry of inflammatory cells into the CNS followed by chronic 
inflammation, myelin destruction, and axonal loss. MS affects more than 2 million 
people worldwide and has an incidence rate of approximately 5–6 per 100,000 
population per year in the United States and 83 per 100,000 in Europe. MS is caused 
by an autoimmune response against myelin proteins in neurons.
CD44 is an interesting protein in the MS pathophysiology because the signal-
ing induced by its activation modifies DNA methylation patterns in key immune 
response genes that have been associated to MS in T cells. CD44-ligand interaction 
leads to hypomethylation of the IFNγ and Il-17 genes and promotes differentiation 
towards Th1 and Th17 cells [93]. CD44 deficiency decreases Th1 and Th17 differen-
tiation and promotes Th2 differentiation via hypomethylation of the Il-4 promoter. 
This may explain why CD44-deficient mice are protected against experimental 
autoimmune encephalomyelitis (EAE) (a mouse model of MS) [94]. Similar effect 
has been showed in CD4+ T cells from MS patients, where Th17 differentiation 
and IL-17 expression are increased following DNA hypomethylation of Il-17α gene 
promoter [95]. On the other hand, the Foxp3 promoter is DNA hypermethylated 
in CD4+ T cells of relapsing-remitting MS patients leading to a reduction of the 
Treg population and their control of immune response [96]. Decitabine (5-aza-
2′-deoxicytidine), which is a DNMT inhibitor, induces Foxp3 expression in mice 
exposed to experimental autoimmune encephalomyelitis (EAE, a MS murine 
model) by demethylating CpG islands in the gene encoding Foxp3. As a result, this 
drug decreases spinal infiltration and ameliorates disease progression [97]. A cross-
talk has been described between DNA methylation and histone acetylation. For 
example, MeCP2, a reader of methylated DNA, suppresses the brain neurotrophic 
factor expression, which is necessary for myelin repair, whereas histone acetyltrans-
ferase expression and HDAC inhibitors reduce MeCP2 expression and thus favor 
remyelination [97].
The oligodendrocytes are a key to maintain the central nervous system by 
providing support and insulation to axons. Stem cell commitment to oligoden-
drocyte is modulated by histone acetylation levels since deacetylation promotes 
oligodendrocyte differentiation, while acetylation is associated with inhibition of 
differentiation. For example, HDAC1 and HDAC2 are needed for oligodendrocyte 
differentiation, while an increase in H3 acetylation is associated with high levels of 
oligodendrocyte-differentiation inhibitors such as TCF7 and SOX2 [98]. In PBMCs, 
high H3K9ac levels correlate with a decrease in the expression of SIRT1, a class III 
deacetylase (HDAC) during MS relapse when compared to stable MS patients and 
controls [99]. Therefore, SIRT1 expression has been proposed as an activity marker 
as well as therapeutic target in MS. Resveratrol, a SIRT1 activator, has shown 
promising results when tested in EAE mice, preventing neuronal loss during optic 
neuritis, providing neuroprotection, and a demonstrated secondary benefit in 
clinical dysfunction [100]. These results have also been shown using other SIRT1 
activators. However, these treatments did not prevent inflammatory cell infiltration 
in these tissues.
Histone acetylation also plays a direct role on immune response. For example, 
IL-17 expression is regulated by the T cell transcription factor TCF1 through 
the acetylation of histones. Hyperacetylation on IL-17 promoter was found in 
TCF1 knockout mice and correlated with more susceptibility to EAE induction 
[101]. Modification of histone acetylation has emerged as therapeutic treatment 
for MS. In this context, HDAC inhibitors have potential therapeutic value in MS 
because of their anti-inflammatory and neuroprotective effects both in vitro and 
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in vivo. For example, sodium phenylacetate (SPA) suppresses neurological dam-
age in mice pretreated with myelin basic protein (MBP)–primed T-cells [102]. 
Valproic acid reduces the duration and severity of EAE by regulating inflammation 
through a decrease of macrophage and lymphocyte infiltration into the spinal 
cord and of proinflammatory cytokines such as IFNγ, TNFα, and IL-17 [103]. 
Several a histone deacetylase inhibitors have been used in the EAE mouse model as 
potential drugs for human treatment. Trichostatin A (TSA) treatment after myelin 
oligodendrocyte glycoprotein (MOG) immunization reduces inflammation, cell 
infiltration, demyelination, and neuronal loss in the spinal cord and ameliorates 
the disability of EAE relapse [104]. Likewise, Largazole, another powerful class 
I histone deacetylase (HDAC) inhibitor, decreases IL-17 and IFNγ production, 
reduces CNS inflammatory infiltrates, and produces a clinical effect on the 
incidence, severity, and disability scores in MS murine model [105]. Vorinostat 
prevents human CD14 monocyte-derived dendritic cell differentiation and reduces 
Th1 and Th17-mediated inflammation and demyelination in the CNS of EAE mice 
[106]. Curcumin reduces cytokine synthesis such as IL-17, TGFβ, IL-6, and IL-21 
and transcription factors STAT3 and RORγt as well as reduces inflammatory cell 
infiltration into the spinal cord, thus leading to reduction in clinical severity in 
EAE mice and MBP-reactive lymphocyte proliferation in a dose-dependent man-
ner [107, 108]. Studies using inhibitors of histone demethylase in EAE model are 
less extended. However, GSK-J4, a JMJD3 inhibitor, improves EAE disease by the 
generation of tolerogenic DCs and enhancing Treg function leading to a decrease 
in CNS inflammatory infiltrates [49]. Histone modifying drugs are promising MS 
therapies based on their properties to modulate overactive immune system and 
neuroprotective pathways to prevent CNS damage.
4.4 Inflammatory bowel diseases (IBD)
IBD is the term used to describe disorders that involve chronic inflammation of 
the digestive tract. Crohn’s disease and ulcerative colitis are the main subtypes of 
IBD. Crohn’s disease represents a discontinuous, transmural inflammation that can 
occur anywhere in the gastrointestinal tract, whereas ulcerative colitis is a continu-
ous inflammation of the mucosal layer of the colon. In addition to the gastrointesti-
nal tract inflammation, so-called extraintestinal symptoms are common, affecting 
the joints, eyes, skin, and liver.
Active inflamed tissue from ulcerative colitis patients is characterized by 
global DNA hypomethylation compared to patients with inactive ulcerative 
colitis or to healthy individuals [109]. The higher turnover of colonic epithelial 
cells leads to an increase in DNA methylation in tumor-suppressor genes and a 
decrease on pro-tumorigenic elements which could lead to genome instability 
and cancer development [110]. A comparison between colonic mucosa from 
ulcerative colitis patients with dysplasia and/or carcinoma and quiescent mucosa 
from the same patients showed differential DNA methylation on several genes. 
For example, the gene encoding cell adhesion molecule E-cadherin (CDH1) is 
hypermethylated in dysplasia and/or carcinoma samples, a modification that 
leads to the downregulation of CDH1 expression [111]. In addition, the pro-
tein levels of DNA methyltransferases DNMT1 and DNMT3b are increased in 
inflamed mucosa from ulcerative colitis patients compared with noninflamed 
paired samples [112].
There are fewer studies regarding histone methylation and acetylation in 
IBD. Histone acetylations such as H4K8ac and H4K12ac were found in inflamed 
mucosa compared with non-inflamed mucosa from mice treated with sodium 
dextran sulfate (DSS) and 2,4-trinitrobenzene sulfonic acid (TNBS). Identical 
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4.3 Multiple sclerosis (MS)
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people worldwide and has an incidence rate of approximately 5–6 per 100,000 
population per year in the United States and 83 per 100,000 in Europe. MS is caused 
by an autoimmune response against myelin proteins in neurons.
CD44 is an interesting protein in the MS pathophysiology because the signal-
ing induced by its activation modifies DNA methylation patterns in key immune 
response genes that have been associated to MS in T cells. CD44-ligand interaction 
leads to hypomethylation of the IFNγ and Il-17 genes and promotes differentiation 
towards Th1 and Th17 cells [93]. CD44 deficiency decreases Th1 and Th17 differen-
tiation and promotes Th2 differentiation via hypomethylation of the Il-4 promoter. 
This may explain why CD44-deficient mice are protected against experimental 
autoimmune encephalomyelitis (EAE) (a mouse model of MS) [94]. Similar effect 
has been showed in CD4+ T cells from MS patients, where Th17 differentiation 
and IL-17 expression are increased following DNA hypomethylation of Il-17α gene 
promoter [95]. On the other hand, the Foxp3 promoter is DNA hypermethylated 
in CD4+ T cells of relapsing-remitting MS patients leading to a reduction of the 
Treg population and their control of immune response [96]. Decitabine (5-aza-
2′-deoxicytidine), which is a DNMT inhibitor, induces Foxp3 expression in mice 
exposed to experimental autoimmune encephalomyelitis (EAE, a MS murine 
model) by demethylating CpG islands in the gene encoding Foxp3. As a result, this 
drug decreases spinal infiltration and ameliorates disease progression [97]. A cross-
talk has been described between DNA methylation and histone acetylation. For 
example, MeCP2, a reader of methylated DNA, suppresses the brain neurotrophic 
factor expression, which is necessary for myelin repair, whereas histone acetyltrans-
ferase expression and HDAC inhibitors reduce MeCP2 expression and thus favor 
remyelination [97].
The oligodendrocytes are a key to maintain the central nervous system by 
providing support and insulation to axons. Stem cell commitment to oligoden-
drocyte is modulated by histone acetylation levels since deacetylation promotes 
oligodendrocyte differentiation, while acetylation is associated with inhibition of 
differentiation. For example, HDAC1 and HDAC2 are needed for oligodendrocyte 
differentiation, while an increase in H3 acetylation is associated with high levels of 
oligodendrocyte-differentiation inhibitors such as TCF7 and SOX2 [98]. In PBMCs, 
high H3K9ac levels correlate with a decrease in the expression of SIRT1, a class III 
deacetylase (HDAC) during MS relapse when compared to stable MS patients and 
controls [99]. Therefore, SIRT1 expression has been proposed as an activity marker 
as well as therapeutic target in MS. Resveratrol, a SIRT1 activator, has shown 
promising results when tested in EAE mice, preventing neuronal loss during optic 
neuritis, providing neuroprotection, and a demonstrated secondary benefit in 
clinical dysfunction [100]. These results have also been shown using other SIRT1 
activators. However, these treatments did not prevent inflammatory cell infiltration 
in these tissues.
Histone acetylation also plays a direct role on immune response. For example, 
IL-17 expression is regulated by the T cell transcription factor TCF1 through 
the acetylation of histones. Hyperacetylation on IL-17 promoter was found in 
TCF1 knockout mice and correlated with more susceptibility to EAE induction 
[101]. Modification of histone acetylation has emerged as therapeutic treatment 
for MS. In this context, HDAC inhibitors have potential therapeutic value in MS 
because of their anti-inflammatory and neuroprotective effects both in vitro and 
199
Exploring Epigenetic Drugs in the Regulation of Inflammatory Autoimmune Diseases
DOI: http://dx.doi.org/10.5772/intechopen.85168
in vivo. For example, sodium phenylacetate (SPA) suppresses neurological dam-
age in mice pretreated with myelin basic protein (MBP)–primed T-cells [102]. 
Valproic acid reduces the duration and severity of EAE by regulating inflammation 
through a decrease of macrophage and lymphocyte infiltration into the spinal 
cord and of proinflammatory cytokines such as IFNγ, TNFα, and IL-17 [103]. 
Several a histone deacetylase inhibitors have been used in the EAE mouse model as 
potential drugs for human treatment. Trichostatin A (TSA) treatment after myelin 
oligodendrocyte glycoprotein (MOG) immunization reduces inflammation, cell 
infiltration, demyelination, and neuronal loss in the spinal cord and ameliorates 
the disability of EAE relapse [104]. Likewise, Largazole, another powerful class 
I histone deacetylase (HDAC) inhibitor, decreases IL-17 and IFNγ production, 
reduces CNS inflammatory infiltrates, and produces a clinical effect on the 
incidence, severity, and disability scores in MS murine model [105]. Vorinostat 
prevents human CD14 monocyte-derived dendritic cell differentiation and reduces 
Th1 and Th17-mediated inflammation and demyelination in the CNS of EAE mice 
[106]. Curcumin reduces cytokine synthesis such as IL-17, TGFβ, IL-6, and IL-21 
and transcription factors STAT3 and RORγt as well as reduces inflammatory cell 
infiltration into the spinal cord, thus leading to reduction in clinical severity in 
EAE mice and MBP-reactive lymphocyte proliferation in a dose-dependent man-
ner [107, 108]. Studies using inhibitors of histone demethylase in EAE model are 
less extended. However, GSK-J4, a JMJD3 inhibitor, improves EAE disease by the 
generation of tolerogenic DCs and enhancing Treg function leading to a decrease 
in CNS inflammatory infiltrates [49]. Histone modifying drugs are promising MS 
therapies based on their properties to modulate overactive immune system and 
neuroprotective pathways to prevent CNS damage.
4.4 Inflammatory bowel diseases (IBD)
IBD is the term used to describe disorders that involve chronic inflammation of 
the digestive tract. Crohn’s disease and ulcerative colitis are the main subtypes of 
IBD. Crohn’s disease represents a discontinuous, transmural inflammation that can 
occur anywhere in the gastrointestinal tract, whereas ulcerative colitis is a continu-
ous inflammation of the mucosal layer of the colon. In addition to the gastrointesti-
nal tract inflammation, so-called extraintestinal symptoms are common, affecting 
the joints, eyes, skin, and liver.
Active inflamed tissue from ulcerative colitis patients is characterized by 
global DNA hypomethylation compared to patients with inactive ulcerative 
colitis or to healthy individuals [109]. The higher turnover of colonic epithelial 
cells leads to an increase in DNA methylation in tumor-suppressor genes and a 
decrease on pro-tumorigenic elements which could lead to genome instability 
and cancer development [110]. A comparison between colonic mucosa from 
ulcerative colitis patients with dysplasia and/or carcinoma and quiescent mucosa 
from the same patients showed differential DNA methylation on several genes. 
For example, the gene encoding cell adhesion molecule E-cadherin (CDH1) is 
hypermethylated in dysplasia and/or carcinoma samples, a modification that 
leads to the downregulation of CDH1 expression [111]. In addition, the pro-
tein levels of DNA methyltransferases DNMT1 and DNMT3b are increased in 
inflamed mucosa from ulcerative colitis patients compared with noninflamed 
paired samples [112].
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acetylation pattern is observed in biopsies from patients with Crohn’s disease 
[113]. The administration of HDAC inhibitors in DSS and TNBS-induced experi-
mental colitis reduces the expression of proinflammatory cytokines and, conse-
quently, disease severity [114]. Furthermore, HDAC9 inhibition prevents colitis in 
mice as a consequence of an increase in both, Treg frequency and its suppressive 
function [115]. An interesting perspective when talking about IBD is the effect of 
the gut microbiota. Bacterial metabolites, such as short-chain fatty acids (SCFAs), 
possess HDAC inhibitory activity [116]. Many bacteria from the Firmicutes and 
Bacteroides produce SCFAs, such as acetate, propionate, and butyrate, at high 
concentration, and IBD patients have reported to have a reduced number of 
those SCFA-producing bacteria [117]. In the same line, ulcerative colitis patients 
treated with microbiota therapy with Roseburia, a bacterium known to produce 
butyrate, an HDAC inhibitor, showed a positive effect in patient recovery by 
reducing inflammatory cytokines production [118]. The potential mechanism 
is through the generation of Tregs from naïve CD4+ T cells. Butyrate increases 
H3 acetylation on Foxp3 loci, the master transcription factor required for Treg 
cell differentiation [116]. In addition, butyrate might modulate the function of 
intestinal macrophages since macrophages treated with butyrate downregulated 
LPS induced IL-12 and IL-6 cytokine expressions [119]. Thus, the commensal 
microbiota may play a beneficial role in IBD treatment via epigenetic regulation 
of gene expression.
5. Conclusions
During the recent years, several studies have focused on a better understand-
ing of epigenetic processes as well as its connection with biological processes such 
as immune response and inflammation (Figure 4). Currently, many epigenetic 
studies are being carried out in cells of the immune system related to the inflam-
masome such as DCs, macrophages, and lymphocytes. Most of those studies 
are related to the epigenetic mechanisms associated to the development, dif-
ferentiation, and function of these cells, leading to a better knowledge about how 
epigenetics of the immune system relates to its function in pathogenesis. However, 
further studies on the epigenetics of immune cells and/or the associated biological 
processes are much needed as a means for improving our understanding of the role 
of epigenetics in inflammation.
The interactions between genetic and epigenetic factors significantly contribute 
to inflammation and autoimmune diseases. Epigenetic research has grown and is 
providing new insights into inflammatory autoimmune diseases, insight that will 
allow us to explain the etiology of these diseases. Furthermore, studies on epigen-
etic changes could lead us to understand disease progression and to identify future 
markers for therapy. Although further studies are needed to address the potential of 
epigenetic factors to act as biomarkers and drug targets, epigenetic enzymes are the 
current target of drug development and new therapeutic trials.
Epigenetic analyses, including DNA methylation and histone modifications, 
require a large number of cells making these studies difficult. Recent advances 
in technologies such as in single-cell analysis provide a new solution to this prob-
lem. Nevertheless, an important issue to be addressed is the limited information 
obtained so far for several cell subsets, specifically those with small representation 
within the immune system. As conclusion, although some important advances have 
been achieved in our understanding on the epigenetics of immune cells, inflam-
mation, and autoimmune diseases, new technologies are required to improve our 
knowledge on these processes.
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AID activation-induced cytidine deaminase
APC antigen-presenting cells
ATF activating transcription factor
BET bromodomain and extra-terminal motif proteins
Bcl6 B-cell lymphoma 6 protein
Blimp1 B lymphocyte-induced maturation protein-1
cDC conventional DCs
CDP common dendritic cell progenitors
CIA collagen-induced-arthritis
Figure 4. 
Epigenetics influences on the development of autoimmune diseases. Epigenetic changes on the promoter of several 
genes are triggered by yet unknown factors, inducing transcriptional activation or repression. These changes bring 
up alterations in development, differentiation, and effector function of immune cells. All these changes result 
in aberrant immune responses, including increased production of proinflammatory cells and cytokines or the 
reduction of anti-inflammatory cells and cytokines that lead to increased inflammation and autoimmune diseases.
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epigenetics of the immune system relates to its function in pathogenesis. However, 
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processes are much needed as a means for improving our understanding of the role 
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CNS conserved non-coding sequences
Cxcl12 C-X-C motif chemokine 12
C/EBP CCAAT enhancer-binding protein
DCs dendritic cells
DNTMs DNA methyltransferases
DSS dextran sulfate sodium
EAE experimental autoimmune encephalomyelitis
Ezh2 enhancer of zeste homolog 2
Foxp3 forkhead box P3
GATA3 GATA-binding protein 3
Gzmb granzyme B
H2BK12ac acetylation of lysine 12 on histone H2B
H3ac H3 acetylated
H3K4me3 trimethylation of lysine 4 on histone H3
H3K9ac acetylation of lysine 9 on histone H3
H3K9me3 trimethylation of lysine 9 on histone H3
H3K14ac acetylation of lysine 14 on histone H3
H3K27me3 trimethylation of lysine 27 on histone H3
H3K36me3 trimethylation of lysine 36 on histone H3
H4ac H4 acetylated
H4K8ac acetylation of lysine 18 on histone H4
H4K16ac acetylation of lysine 16 on histone H4
H4R3 arginine 3 of histone H4
HAT histone acetyltransferases
HDAC histone deacetylases
HSCs hematopoietic stem cells
IBD inflammatory bowel diseases
Ifgnr interferon receptor
IRF interferon regulatory factor
iTreg inducible Treg cells
JmjC Jumonji C
KAT lysine acetyltransferases
KDM histone lysine demethylase
KLF10 Krüppel-like factor 10
KMT lysine methyltransferases





Pax5 paired box gene 5
PC plasma cells
PCAF p300/CREB-binding protein-associated factor
pDC plasmacytoid DCs
PHD plant homeodomain
PRTM protein arginine methyltransferase
RA rheumatoid arthritis
RAG recombination-activating gene
RASFs RA synovial fibroblasts
RNAPII RNA polymerase II
Rorγt RAR-related orphan receptor gamma t
Runx1 runt-related transcription factor 1
Runx3 runt-related transcription factor 3
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Abstract
The chapter is devoted to the research of experimental complete mechanical spinal 
injury in adult rats and attempts at bioengineering restoration of the structure and 
function of the spinal cord using a protein-polysaccharide construct that includes 
bovine collagen, highly purified crab chitosan ascorbate, nanostructuring additives 
in the form of sodium chondroitin sulfate, sodium hyaluronate, heparin sulfate in the 
presence of complete nutrient medium DMEM, neural supplement N2, conditioned 
nutrient medium, obtained about brain cell mouse embryos and mouse embryonic 
stem cells, retinoic acid, and mouse neural progenitor cells derived from embryonic 
stem cells. After a complete intersection of the spinal cord at the level of the ninth tho-
racic vertebra, the authors directly implanted a collagen-chitosan construct into the 
gap between the ends of the spinal cord. Analysis of the recovery of motor and sen-
sory and vegetative functions of the spinal cord for 20 weeks after surgery using the 
cytological immune-fluorescent method showed a high viability of the transplanted 
neural cell precursors during the entire observation period and the early emergence 
of activity of mediators of nerve signal transmission in the implantation zone of the 
structure with accompaniment active dynamics of reducing neurodeficiency.
Keywords: collagen-chitosan scaffold, complete intersection of the spinal cord,  
mouse neuronal progenitor cells, adult rats, neurological deficiency, 
neurotransmitters, immunofluorescence analysis
1. Introduction
Solid biodegradable constructs as an implant in the spinal cord based on proteins 
and polysaccharides are able to create favorable conditions for the adaptation, 
proliferation, differentiation, and sprouting of the precursors of neural cells placed 
in the implant. At the same time, direct transplantation of the structure together 
with the precursors of neural cells substantially eliminates weight loss during cell 
transfer and the apoptosis reaction and increases the survival time of cells in new 
conditions, and the polysaccharide components of the matrix not only play the 
role of shielding the protein base from the immune system, and also provide a 
high function cell transfer system to the central and peripheral ends of the central 
nervous system. The problem of spinal injury remains acute without addressing 
the issues of effectively eliminating neuro-inflammation in the area of injury and 
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creating conditions for the formation of pathways and sprouting axons under the 
conditions of glial scar formation.
1.1 Embryonic stem cells in the correction of spinal cord injury
A significant improvement of the neurological deficit was achieved by Bottai 
et al. by intravenous administration of undifferentiated ESCs at a dose of 1 mil-
lion cells 2 hours after injury [1]. The protective role of multipotent cells was 
demonstrated during the development of an inflammatory reaction, accompanied 
by a decrease in the intensity of infiltration of the affected area with elements of 
microglia. The presence of hESCs in the spinal cord injury zone in adult rats or 
mini-pigs for 4.5 months induces the formation of embryoid bodies with expres-
sion of specific (hNUMA, HO14, hNSE, and hSYN) and nonspecific (DCX, MAP2, 
CHAT, GFAP, and ACP) antigens. Research results of Yang et al., in a rat spinal cord 
contusion injury model using green fluorescent protein-labeled pig embryonic stem 
cells (pES/GFP (+)), indicate a decrease in expression of green fluorescent protein 
within 3 months, and positively stained cells for neural are detected in the trans-
plant area of specific antigens: anti-NFL, anti-/MBP, anti-SYP, and anti-Tuj 1 [2]. 
The use of undifferentiated cells significantly reduces the efficiency of functional 
restoration of the hind limbs in rats, compared to the use of neural progenitors 
derived from ESCs. The value of indicators of the neurological status on the BBB 
scale was 15.20 ± 1.43 points on the 24th week of the posttransplant period.
1.2 Neural stem cells and their precursors
Under certain conditions, these cells are able to differentiate into neurons, 
astrocytes, and oligodendrocytes. Neuronal progenitors and precursors of oligo-
dendrocytes showed positive dynamics in reducing neuro-deficiency in spinal cord 
injury models. The use of two cell populations with neurogenic and gliogenic activ-
ity leads to the restoration of locomotor functions and stimulates angiogenesis, the 
growth of axons, and their re-myelination [3–11]. A monolayer of neural precur-
sors (NPs) from ESCs is obtained by a combination of diffusion of nutrients and 
growth factors; it includes extracellular matrices such as laminin, poly-d-lysine, and 
matrigel [12]. A three-dimensional matrix with the precursors of neuronal cells or 
oligodendrocytes creates the conditions for the formation of intercellular contacts, 
ensures survival, differentiation, and proliferation [13, 14]. Cultivation of neural 
precursors on a three-dimensional substrate forms oligodendrocyte precursors with 
the expression of Nestin and PAX6 [15, 16]. At the same time, NP cultivation condi-
tions and their micro-environment are of key importance [17].
1.3 Neurotrophic support in the area of spinal cord injury
Re-myelination of damaged axons and improvement of their conductivity are 
possible with transplantations of neural progenitors in the experiment [18, 19]. The 
effect of transplantation is enhanced by trophic support of neurons and immune 
modulation [20–23]. Transplantation of spinal cord precursors of neuronal cells to 
the zone of spinal cord injury is accompanied by activation of axon growth, their 
locomotion, and registration of G-CSF, BDNF, CNTF, FGF, EGF, and NT-3 growth 
factors in cells [24–27]. Consequently, neurotrophic support is a prerequisite for 
the regeneration of specialized nervous tissue when it is lost. The presence of 
neurospheres of exogenous growth factors such as EGF, bFGF, and CNTF in the 
environment creates conditions for the long-term cultivation of viable precursors of 
neurons, differentiation into mature neurons, and successful transfer to the area of 
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spinal injury [28]. Spinal cord regeneration with the help of neural cell progenitors 
indicates the important role of stem cells under conditions of intensive neuro-
trophic support by NGF, BDNF, CNTF, GDNF, and IGF-1 molecules [24, 29].
1.4  Use of degradable biopolymer substrates as implants in the damaged  
spinal cord
Modern technologies for obtaining biomaterials with unique consumer proper-
ties make them the most important link in the task of reconstruction of spinal cord 
injury. Neuroprotection from re-inflammatory response is possible, provided that 
the growth of neurites is artificially oriented with the inclusion of neurotrophic 
support in this system. Studies confirm that the creation of such conditions leads to 
the restoration of lost tissue, enhancement of axonal growth and active sprinting to 
the head and caudal segments of the damaged area, suppression of astrocytosis,  
and the appearance of inter-synaptic connections.
The strategy of reconstruction of the damaged spinal cord includes the use of 
prepared cell mass in solid or liquid, biodegradable, highly compatible 3D matrices 
with favorable conditions for its cultivation, proliferation, and differentiation. Such 
constructions allow direct transfer of cellular material to the area of spinal cord injury.
Matrigel, laminin, type-1-collagen, fibronectin, chitosan, glycosaminoglycans, 
poly-d-lysine, and fibrin are used in experimental practice. The final results of the 
studies do not allow asserting one of the mentioned polymers as the best sample, 
despite the use of combined materials with a neurotrophic microenvironment [30].
The differentiation of hESC in contact with neuronal progenitors occurred more 
actively when laminin was used [31]. In other conditions of cultivation of neuronal 
precursors, the efficiency of using Matrigel is confirmed [32, 33]. A number of 
authors obtained satisfactory results when using a combination of collagen IV, 
laminin, and poly-L-lysine [12, 16, 34]. Such nonstandardized approaches to the 
creation of culture conditions do not exclude the risk of immune reactions.
1.5 Materials based on chitosan to obtain neural substrates
Chitosan, a linear copolymer consisting of N-acetylglucosamine and 
N-glucosamine, when in contact with the wound surface biodegrades without 
causing toxic reactions from surrounding somatic cells and is capable of screening 
protein molecules from the immune system during biodegradation. The number 
of scientific publications on the use of chitosan polymers as the basis of the matrix 
for implantation in the spinal cord in trauma is immeasurably small compared 
to the use of other biopolymers in spinal injury models. The strategy for using 
chitosan polymers for spinal cord reconstruction is developed by Freier et al. [35] 
and Nomura et al. [36]. The advantages of liquid and solid substrates are known for 
cell mass transplantation and neurotrophic support in the spinal cord in trauma. 
However, sponge structures are capable of covering extensive defects in the damage 
zone. An important aspect of the technology is the formation of oriented micro-
channels in the matrix for the directed growth of axons and, thus, enhanced sprout-
ing of cells in the graft area and beyond. The polycationic properties of chitosan 
ensure constant contact of cells with a biopolymer, which enhances cell migration 
and axon regeneration [37] and lengthens and thickens neurites [35], and in low 
concentrations, the biopolymer is able to shield stem and progenitor cells [38].
In 2008, experimental transplantation of neural cell precursors as part of a 
chitosan microchannel biomaterial was performed first after complete transection of 
the spinal cord. The use of NSPS in the spinal cord of Sprague-Dawley rats as a base 
of a highly de-acetylated chitosan hydrochloride micro-channel substrate confirmed 
Translational Studies on Inflammation
214
creating conditions for the formation of pathways and sprouting axons under the 
conditions of glial scar formation.
1.1 Embryonic stem cells in the correction of spinal cord injury
A significant improvement of the neurological deficit was achieved by Bottai 
et al. by intravenous administration of undifferentiated ESCs at a dose of 1 mil-
lion cells 2 hours after injury [1]. The protective role of multipotent cells was 
demonstrated during the development of an inflammatory reaction, accompanied 
by a decrease in the intensity of infiltration of the affected area with elements of 
microglia. The presence of hESCs in the spinal cord injury zone in adult rats or 
mini-pigs for 4.5 months induces the formation of embryoid bodies with expres-
sion of specific (hNUMA, HO14, hNSE, and hSYN) and nonspecific (DCX, MAP2, 
CHAT, GFAP, and ACP) antigens. Research results of Yang et al., in a rat spinal cord 
contusion injury model using green fluorescent protein-labeled pig embryonic stem 
cells (pES/GFP (+)), indicate a decrease in expression of green fluorescent protein 
within 3 months, and positively stained cells for neural are detected in the trans-
plant area of specific antigens: anti-NFL, anti-/MBP, anti-SYP, and anti-Tuj 1 [2]. 
The use of undifferentiated cells significantly reduces the efficiency of functional 
restoration of the hind limbs in rats, compared to the use of neural progenitors 
derived from ESCs. The value of indicators of the neurological status on the BBB 
scale was 15.20 ± 1.43 points on the 24th week of the posttransplant period.
1.2 Neural stem cells and their precursors
Under certain conditions, these cells are able to differentiate into neurons, 
astrocytes, and oligodendrocytes. Neuronal progenitors and precursors of oligo-
dendrocytes showed positive dynamics in reducing neuro-deficiency in spinal cord 
injury models. The use of two cell populations with neurogenic and gliogenic activ-
ity leads to the restoration of locomotor functions and stimulates angiogenesis, the 
growth of axons, and their re-myelination [3–11]. A monolayer of neural precur-
sors (NPs) from ESCs is obtained by a combination of diffusion of nutrients and 
growth factors; it includes extracellular matrices such as laminin, poly-d-lysine, and 
matrigel [12]. A three-dimensional matrix with the precursors of neuronal cells or 
oligodendrocytes creates the conditions for the formation of intercellular contacts, 
ensures survival, differentiation, and proliferation [13, 14]. Cultivation of neural 
precursors on a three-dimensional substrate forms oligodendrocyte precursors with 
the expression of Nestin and PAX6 [15, 16]. At the same time, NP cultivation condi-
tions and their micro-environment are of key importance [17].
1.3 Neurotrophic support in the area of spinal cord injury
Re-myelination of damaged axons and improvement of their conductivity are 
possible with transplantations of neural progenitors in the experiment [18, 19]. The 
effect of transplantation is enhanced by trophic support of neurons and immune 
modulation [20–23]. Transplantation of spinal cord precursors of neuronal cells to 
the zone of spinal cord injury is accompanied by activation of axon growth, their 
locomotion, and registration of G-CSF, BDNF, CNTF, FGF, EGF, and NT-3 growth 
factors in cells [24–27]. Consequently, neurotrophic support is a prerequisite for 
the regeneration of specialized nervous tissue when it is lost. The presence of 
neurospheres of exogenous growth factors such as EGF, bFGF, and CNTF in the 
environment creates conditions for the long-term cultivation of viable precursors of 
neurons, differentiation into mature neurons, and successful transfer to the area of 
215
The Experimental Bioengineering of Complete Spinal Cord Injury in Adult Rats
DOI: http://dx.doi.org/10.5772/intechopen.85353
spinal injury [28]. Spinal cord regeneration with the help of neural cell progenitors 
indicates the important role of stem cells under conditions of intensive neuro-
trophic support by NGF, BDNF, CNTF, GDNF, and IGF-1 molecules [24, 29].
1.4  Use of degradable biopolymer substrates as implants in the damaged  
spinal cord
Modern technologies for obtaining biomaterials with unique consumer proper-
ties make them the most important link in the task of reconstruction of spinal cord 
injury. Neuroprotection from re-inflammatory response is possible, provided that 
the growth of neurites is artificially oriented with the inclusion of neurotrophic 
support in this system. Studies confirm that the creation of such conditions leads to 
the restoration of lost tissue, enhancement of axonal growth and active sprinting to 
the head and caudal segments of the damaged area, suppression of astrocytosis,  
and the appearance of inter-synaptic connections.
The strategy of reconstruction of the damaged spinal cord includes the use of 
prepared cell mass in solid or liquid, biodegradable, highly compatible 3D matrices 
with favorable conditions for its cultivation, proliferation, and differentiation. Such 
constructions allow direct transfer of cellular material to the area of spinal cord injury.
Matrigel, laminin, type-1-collagen, fibronectin, chitosan, glycosaminoglycans, 
poly-d-lysine, and fibrin are used in experimental practice. The final results of the 
studies do not allow asserting one of the mentioned polymers as the best sample, 
despite the use of combined materials with a neurotrophic microenvironment [30].
The differentiation of hESC in contact with neuronal progenitors occurred more 
actively when laminin was used [31]. In other conditions of cultivation of neuronal 
precursors, the efficiency of using Matrigel is confirmed [32, 33]. A number of 
authors obtained satisfactory results when using a combination of collagen IV, 
laminin, and poly-L-lysine [12, 16, 34]. Such nonstandardized approaches to the 
creation of culture conditions do not exclude the risk of immune reactions.
1.5 Materials based on chitosan to obtain neural substrates
Chitosan, a linear copolymer consisting of N-acetylglucosamine and 
N-glucosamine, when in contact with the wound surface biodegrades without 
causing toxic reactions from surrounding somatic cells and is capable of screening 
protein molecules from the immune system during biodegradation. The number 
of scientific publications on the use of chitosan polymers as the basis of the matrix 
for implantation in the spinal cord in trauma is immeasurably small compared 
to the use of other biopolymers in spinal injury models. The strategy for using 
chitosan polymers for spinal cord reconstruction is developed by Freier et al. [35] 
and Nomura et al. [36]. The advantages of liquid and solid substrates are known for 
cell mass transplantation and neurotrophic support in the spinal cord in trauma. 
However, sponge structures are capable of covering extensive defects in the damage 
zone. An important aspect of the technology is the formation of oriented micro-
channels in the matrix for the directed growth of axons and, thus, enhanced sprout-
ing of cells in the graft area and beyond. The polycationic properties of chitosan 
ensure constant contact of cells with a biopolymer, which enhances cell migration 
and axon regeneration [37] and lengthens and thickens neurites [35], and in low 
concentrations, the biopolymer is able to shield stem and progenitor cells [38].
In 2008, experimental transplantation of neural cell precursors as part of a 
chitosan microchannel biomaterial was performed first after complete transection of 
the spinal cord. The use of NSPS in the spinal cord of Sprague-Dawley rats as a base 
of a highly de-acetylated chitosan hydrochloride micro-channel substrate confirmed 
Translational Studies on Inflammation
216
that massive cellular transitional bridges containing a high number of differentiated 
cells are formed in the spinal cord within 100 days after the surgical intervention. 
Cell-free channel matrices also formed transition zones, but the thickness of the 
transitions was significantly less [39]. If precultured neural progenitor cells (NSPCs) 
are placed in the micro-channels of the chitosan substrate, in the damaged rat spinal 
cord, one can demonstrate very high cell survival for 5 weeks and their differentia-
tion not only into neurons but also astrocytes and oligodendrocytes [40]. High cell 
survival and differentiation of not only neurons but also glial cells in chitosan extra-
medullary channels and in the spinal cord after transplantation and active sprouting 
from the central to the caudal segment of the spinal cord with the formation of 
active transitional brain tissue are accompanied by significant restoration of the 
motor and sensory functions of the hind limbs [41]. The inflammatory process in the 
area of spinal cord injury stimulates the synthesis of type IV collagen in endothelial 
cells, fibroblasts, and Schwann cells, which leads to the formation of a massive glial 
scar. Productive inflammation in the connective tissue inhibits the growth of axons 
[42–44]. Exogenous suppression of the synthesis of collagen type IV prolongs axonal 
growth. The introduction of type I collagen into the system enhances the growth of 
axons and neural connections between the central and peripheral zone of injury [45, 46].  
It is convincingly shown that the presence of stem cells in the composition of the 
polymer chitosan in the area of spinal cord injury improves cell viability and stimu-
lates their differentiation and the expression of neurotrophic factors. As a result, 
functional neurodeficiency is reduced. Prolonged presence of chitosan in the brain 
tissue and its biodegradation do not stimulate the immune response [47, 48].
Preliminary studies have resulted in 4 variants of the neural matrix that can 
support long-term human ESC and animals (rats) in complete medium and 
translate them into a state of differentiation with reception on the 5th day of cells 
with neuronal markers exposed on its membrane (neuro-filament, MBP, and 
GFAP) [49]. The approaches proposed in this work to the reconstruction of the 
spinal cord in experimental complicated spinal injury (total mechanical spinal 
cord transection) are based on modern biodegradable polysaccharide matrices 
containing the necessary microenvironment, including the products of growth and 
differentiation of stem cells and neuronal cells and neuronal precursor cells for the 
reconstruction of spinal cord to restore its motor and sensory functions. Consumer 
properties of the proposed cellular matrix showed competitive advantages due to 
the lack of matrices satisfying the task. They are as follows: high biocompatibility, 
biodegradability, nontoxicity, the system of information transfer, the creation of a 
strict orientation of the tissues in tissue engineering implant thanks to a rigid linear 
structure of chitosan, the regulation of collagen synthesis, stimulation of breeding 
passaged cell precursor neuronal tissue, vascular endothelial cell proliferation, and 
tumor micro-vessel recovery of the intracellular substrate. Implantation of such a 
matrix can be done in an open manner of the operative spinal cord diastasis.
2. Materials and methods
2.1 Neuronal matrix getting
To create a neural matrix base poly-ion complex consisting of nano-micro-
structured ascorbate chitosan with a molecular weight of 695 kDa and a degree of 
deacetylation of 98%, when the content of 1 g dry chitosan 1.8 g of ascorbic acid, 
comprising anionic salt forms chondroitin acid (Sigma) (20 mg\d), hyaluronic acid 
(Sigma) (10 mg\d) and heparin (5 mg\d) (Russia), serum growth factors in cattle 
“adgelon” (110 mcg\d) were used.
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To obtain the basic collagen-chitosan complex, we used a triply purified chitosan 
obtained in Vostok-Bor-1, Dal’negorsk, Russia with a molecular weight of 695 kDa 
and a deacetylation degree above 95%, protonated with an ascorbic acid solution 
(dissolution of the polymer in ascorbic solution acid in a ratio of 1: 1.5). Introduction 
of a heparin solution, serum low-molecular growth factor “adgelon” (SLL “Endo-
Pharm-A,” Moscow region, Shchyolkovo, Russia), neural supplement N2 (Sigma), 
and retinoic acid (Sigma) stimulated embryonic stem cells (ESCs) in the chitosan 
gel to neuronal differentiation. A conditioned nutrient medium obtained after 
culturing embryonic neuronal cells of brain tissue of mice or conditioned nutrient 
medium obtained after culturing embryonic allogeneic stem cells of mice was added 
to the base poly-ionic complex (Krasnoyarsk Center for Reproductive Medicine, 
Russia). Embryonic stem cells (ESCs) were obtained from mouse blastocysts by 
eluting the uterus with DMEM medium of the anesthetized animal on the 4th–5th 
day after copulation. Getting the inner cell mass (ICM) and the further expansion 
of ESC colonies was performed according to the protocol [50, 51]. Overage human 
blastocysts were taken from patients undergoing IVF. Full consultation was done 
and informed consent was received before embryo processing. This research fol-
lowed the directives of the Russian Association of Human Reproduction. Embryos 
were obtained for research use only, without other restrictions and compensation.
Cultivation of cells was performed in DMEM supplemented with 10% 
fetal calf serum (FCS F0926, Sigma), 100 mg/ml kanamycin sulfate (Sigma), 
1 mM L-glutamine (G7513, Sigma) in bottles Corning, gelatin-coated (Sigma).
In the experiments to obtain the conditioned medium from neural stem embry-
onic mouse cells (cells from the brains of 17–20 day fetus outbred mice (Institute of 
biophyisic SD RAS, Russia) after the dispersion and processing of 0.5% collagenase 
solution (Sigma) for 30 minutes in medium DMEM (Sigma) at 37°C for increasing 
cell biomass used DMEM under light microscopy with 10% fetal calf serum (FCS), 
100 mg/ml canamycin sulfate, 1 mM L-glutamine, which is added 4 ng\ml basic 
fibroblast growth factor (bFGF, Sigma), 1 mM solution of essential amino acids 
(Sigma-Aldrich). The cell biomass was grown at 37°C in vials coated with 0.1% 
gelatin solution. The environment was collected daily. The condition of cells was 
estimated by light microscope. After subculturing with 0.5% collagenase solution, 
the matrix cells were cultured in medium supplemented with neuronal differentia-
tion agent—N2 component, according to the manufacturer’s instructions. The 
medium was collected, filtered through a 0.22 mcm cellulose acetate filter, and used 
hereinafter as a conditioned medium.
Next performed covalent compounds derived polysaccharide gel structure (The 
Developer is SBEU HPT Krasnoyarsk State Medical University, Russia) with bovine 
collagen gel (SLL Belkosin, Russia) in a ratio of 1: 3, a freeze-drying deep frozen sam-
ples to install FC500 (Germany). This mixture was poured on pallets of duralumin, a 
layer thickness of 2 mm, frozen at −20°C, and then freeze-dried at 10−5 Pa for 8 hours; 
the product is packaged and sterilized by the electron beam method (neuronal dry 
matrix courtesy SLL “Medical Company Collachit,” Krasnoyarsk Region, Russia).
The manipulation above yielded a neuronal matrix of the size 50 × 50 × 2 mm, 
suitable for not only the culture and in vitro differentiation of embryonic stem cells 
into neurons and oligodendrocyte progenitor of mice, but also for direct transplan-
tation into the spinal cord gap in experimental injury in adult rats.
When using a sponge matrix, they need to be previously soaked in sterile bicar-
bonate buffer (Sigma) to reduce their acid properties. After neutralization phase of 
collagen-chitosan substrate was washed three times with sterile phosphate-buffered 
Dulbecco’s modified eagle’s medium (Biolot), placed in a vial, and carefully layered 
on top of them the cell suspension in a medium with all the components, depending 
on the cell type.
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tation into the spinal cord gap in experimental injury in adult rats.
When using a sponge matrix, they need to be previously soaked in sterile bicar-
bonate buffer (Sigma) to reduce their acid properties. After neutralization phase of 
collagen-chitosan substrate was washed three times with sterile phosphate-buffered 
Dulbecco’s modified eagle’s medium (Biolot), placed in a vial, and carefully layered 
on top of them the cell suspension in a medium with all the components, depending 
on the cell type.
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The cultivation of pluripotent cell experiments on collagen-chitosan 
substrates initially used for biomass growth basal medium DMEM (Sigma) 
supplemented with 10% SR (serum substitute), 100 μg/ml kanamycin sulfate, 
1 mM L-glutamine, 4 ng/ml primary engine of growth fibroblast (bFGF), 1 mM 
solution of amino acids, and the inhibitor Rock 5 ng/ml kinase (Sigma). Capacity 
cell biomass was performed in flasks coated with 0.1% gelatin. The environment 
was changed daily. The colonial state was assessed visually using a microscope 
AxioVert-200. To assess the state of maintenance of pluripotency, limmune-
cytochemical analysis of the expression of markers—oct4, TRA-1-60, SSEA4, and 
cd30 (Sigma)—was performed.
To differentiate embryonic cells in the neuronal direction, they were seeded into 
vials in a medium with all additives except bFGF, with the addition of retinoic acid 
and N2 component.
Every three days, formaldehyde fixation was performed followed by immune-
cytochemistry of the cells with antibodies (Abcam, USA) against GFAP glial fibril-
lar acid protein, neuro-filament, and nestin. Detection of markers was carried out 
by the method according to the instructions of the antibody manufacturer. The cell 
nuclei were stained with DAPI (Sigma) (0.1 μg/ml) for 10 minutes. The Olympus 
BX-51 fluorescence microscope (Japan) and the software products “Applied Spectral 
Imaging” (USA) were used to obtain images and analysis. For the analysis of each 
marker, the experiment was repeated three times, increasing three vials, each of 
which was randomly assigned into 6 zones for carrying out immunocytochemistry. 
Microscopy was carried out for each zone in 30 fields of vision.
2.2 The experimental complete transection of the spinal cord in rats
The conditions of biological test systems in the CDI CI correspond to Guide for 
the Care and Use of Laboratory Animals, 8th edition, 2011, NRC, USA (Manual 
on the content and use of laboratory animals, 8th edition, 2011, national research 
Committee, USA). The content of animals in individually ventilated cells from 
polysulfone seal-safe, 461 × 274 × 228 mm (production TECHNIPLAST.P. A.)
The rooms contain biological test systems, controlled temperature (18–24°C), 
humidity (30–70%), illumination (12/12 hours), and the multiplicity of air (X11 
without recirculation). Control of climatic parameters is carried out in accordance 
with the SOP “control of climatic parameters in the premises of the vivarium.”
Distribution of feed and water is carried out at a fixed time; the change of litter 
is made once a week in accordance with the SOP “preparation of cells for biological 
test systems. Marking. Change of bedding, feed, water.”
Biological test systems receive food “ CHARA” for the maintenance of laboratory 
animals of the SPF-category, production of LLC “Assortment agro” and “VAKA,” 
and production of LLC “BIOSPHERE,” auto-clavable, with confirmation of the 
absence of microbial contamination. The feed is balanced in amino acid composi-
tion, minerals, and vitamins, made of high quality components. Laboratory tests 
for toxicity have been carried out. The food is not toxic, but a environmentally 
friendly product. Certificates of feed quality are present. Sterilization of feed is 
carried out in the steam sterilizer TOUCHCLAVE LAB K14 369 manufactured by 
LTE Scientific LTD, with confirmation of sterilization (multi-parameter chemical 
indicators of sterilization 3 M Comply Steri Gage manufactured by 3 M). After 
sterilization, the feed is stored in closed containers for no more than 7 days (SOP 
“operation of steam sterilizer with automatic control Touchclave-LAB model TC/
R300E/PL/PASS”).
For watering of biological test systems, we used water that had been trained 
in the reverse osmosis production unit JSC “Scientific-production company 
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Mediana-Filter,” confirming the absence of microbial contamination, and bottled in 
pro-anti-cianidinas bottle. Access to food and water is unrestricted throughout the 
study.
The cells consist of a mixture of litter “Golden cat,” produced by “the zone” “the 
Gold Ear,” Russia and “Lignosol,” produced by J. Rettenmaier and Sohne Gmbh, 
Germany, in the ratio of 1:4 subjected to autoclaving, control of microbiological 
purity in accordance with SOP “Operation of a steam sterilizer with automatic 
control Touchclave-LAB model TC/R300E/PL/PASS.”
Veterinary protocol was considered and approved at the meeting of the 
Commission on Bioethics, minutes of the meeting No 57 dated 01.10.2016.
The research methods used in the planned experiment, capable of causing pain 
and stress to animals, cannot be replaced by more humane ones. The possible negative 
effects on animals are minimized and the principles of their humane use are observed.
Premedication: 30 minutes prior to surgery—Sol. Tramadoli 2.5 mg/m; Sol. 
Atropini sulfatis 0.1%–0.1 ml/m; Sol. Dimedroli 0.1%–0.1 ml/m Anesthesia: anes-
thesia (diethyl ether). About 12 white female rats, Wistar line, weighing 250 g with 
Carl Zeiss optics, individually reproduced model of spinal cord injury at the IX-X 
thoracic vertebrae with a complete transverse intersection of the spinal cord after 
first performing a laminectomy.
2.3 Operation course
After preliminary treatment of the operating field with a 70% solution of ethyl 
alcohol under anesthesia, an incision was made along the midline of the animal’s 
back at a level of Th7 to L4 4–5 cm in length. Hemostasis was performed during the 
operation. After dissection of the skin, subcutaneous fat layer, the wound edges 
were mobilized and diluted with Edson’s retractors. The acristoid-trapezius and 
the broadest muscle were cut off from the places of their attachment to the spinous 
processes of Th9-L3. The muscles of the deep layer were separated from the spine 
and diluted with a microsurgical retractor, and the Th9-Th12 vertebrae were bared. 
The Th10 arch resection was performed, and the dura mater was dissected and 
diluted to the sides in the horizontal plane.
A complete transverse intersection of the spinal cord was performed using a 
microscalpel and micro-scissors and individual optics of Carl Zeiss. A neuronal 
cell matrix with a size of about 2 mm3 containing about 100 thousand precursors of 
neuronal cell implant was placed immediately in the formed neural tissue defect. 
The bony wound was closed as a film with polysaccharide hydrogel mass “bolchit” 
[52], which does not contain animal collagen. The wound was closed layer by layer 
using suture material Vicril 4–0 (muscle) and Polyester 3–0 (skin). The stitches 
were treated with an alcohol solution of iodine (Figures 1–6).
Figure 1. 
Quick access to back extensor and awned appendages of vertebras Th VIII-X.
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Figure 1. 
Quick access to back extensor and awned appendages of vertebras Th VIII-X.
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Figure 3. 
Resection of the ninth chest vertebra handle with removal of a firm brain cover, and spinal cord exposure.
Figure 4. 
Full spinal cord transection.
Figure 2. 
Skeletization of the ninth chest vertebra handle.
Figure 5. 
Cellular neuromatrix implantation of spinal cord diastases.
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2.3.1 The composition of transplantable matrices
On the basis of collagen-chitosan structures, two different implants were 
prepared containing the following components:
1. A lyophilic collagen-chitosan matrix obtained as described above, which does 
not contain cells, including in its composition the complete DMEM nutrient 
medium, conditioned medium from neuronal cells and neural supplement N2, 
and retinoic acid (6 rats of the control group);
2. A lyophilic collagen-chitosan matrix, obtained as indicated above in the 
control group, containing about 100,000 neuronal precursor cells obtained by 
culturing and differentiating mouse embryonic stem cells (ESCm) (6 rats in 
the test group).
Variants of porous matrix substrates were cut into 1 or 2 mm3 before embry-
onic stem cells were placed on them and, in sterile conditions, were unfolded 
in the wells of a 96-well plate without coating with 0.1% gelatin solution. The 
cells from the culture flasks were removed with a 0.5% collagenase solution, 
then washed three times with DMEM medium from the enzyme and transferred 
to wells with a cut matrix in the ESC medium. Cells were cultured for at least 
3 days prior to the appearance of neuronal markers under humid conditions at 
37°C and 6% CO2. The number of attached cells was evaluated by dispersing 5–6 
pieces of the matrix in the enzyme solution, followed by counting the cells in 
the Goryaev chamber. Each future neuron implant during cultivation contained 
about 100 thousand of neuronal precursor cells. Before the implantation in the 
spinal cord, the pieces with a micro pincer were carefully transferred to micro-
tubes with DMEM/F12 culture medium (Nutrient mixture F-12 HAM, Sigma) 
and transported to the operating room.
2.4 Postoperative care
Within 3–5 days after the operation, the animals received Sol as an analgesic; 
Tramadoli 2.5 mg 3 times daily IM. Sutures were removed after 10 days. During 
the first 24 hours, animals were admitted to the water. Feeding was performed 
48 hours after the operation solely with a mixture of “Polyproten-nephro” (SLL 
“Protenpharma,” Russia) for 1–4 weeks. The rats were kept in separate boxes with 
a double bottom. Drug support was provided with a broad-spectrum antibiotic, 
antispasmodics, and vessel-dilator drugs.
Figure 6. 
Restoration of vertebral channel integrity by means of a сhitosan film (it is pointed by an arrow).
Translational Studies on Inflammation
220
Figure 3. 
Resection of the ninth chest vertebra handle with removal of a firm brain cover, and spinal cord exposure.
Figure 4. 
Full spinal cord transection.
Figure 2. 
Skeletization of the ninth chest vertebra handle.
Figure 5. 
Cellular neuromatrix implantation of spinal cord diastases.
221
The Experimental Bioengineering of Complete Spinal Cord Injury in Adult Rats
DOI: http://dx.doi.org/10.5772/intechopen.85353
2.3.1 The composition of transplantable matrices
On the basis of collagen-chitosan structures, two different implants were 
prepared containing the following components:
1. A lyophilic collagen-chitosan matrix obtained as described above, which does 
not contain cells, including in its composition the complete DMEM nutrient 
medium, conditioned medium from neuronal cells and neural supplement N2, 
and retinoic acid (6 rats of the control group);
2. A lyophilic collagen-chitosan matrix, obtained as indicated above in the 
control group, containing about 100,000 neuronal precursor cells obtained by 
culturing and differentiating mouse embryonic stem cells (ESCm) (6 rats in 
the test group).
Variants of porous matrix substrates were cut into 1 or 2 mm3 before embry-
onic stem cells were placed on them and, in sterile conditions, were unfolded 
in the wells of a 96-well plate without coating with 0.1% gelatin solution. The 
cells from the culture flasks were removed with a 0.5% collagenase solution, 
then washed three times with DMEM medium from the enzyme and transferred 
to wells with a cut matrix in the ESC medium. Cells were cultured for at least 
3 days prior to the appearance of neuronal markers under humid conditions at 
37°C and 6% CO2. The number of attached cells was evaluated by dispersing 5–6 
pieces of the matrix in the enzyme solution, followed by counting the cells in 
the Goryaev chamber. Each future neuron implant during cultivation contained 
about 100 thousand of neuronal precursor cells. Before the implantation in the 
spinal cord, the pieces with a micro pincer were carefully transferred to micro-
tubes with DMEM/F12 culture medium (Nutrient mixture F-12 HAM, Sigma) 
and transported to the operating room.
2.4 Postoperative care
Within 3–5 days after the operation, the animals received Sol as an analgesic; 
Tramadoli 2.5 mg 3 times daily IM. Sutures were removed after 10 days. During 
the first 24 hours, animals were admitted to the water. Feeding was performed 
48 hours after the operation solely with a mixture of “Polyproten-nephro” (SLL 
“Protenpharma,” Russia) for 1–4 weeks. The rats were kept in separate boxes with 
a double bottom. Drug support was provided with a broad-spectrum antibiotic, 
antispasmodics, and vessel-dilator drugs.
Figure 6. 
Restoration of vertebral channel integrity by means of a сhitosan film (it is pointed by an arrow).
Translational Studies on Inflammation
222
2.5 Dynamic neurological control
To assess the neurological disturbances and recovery dynamics, a scale was 
used to assess the severity of the neurological deficit for complete transection (BBB 
scale) [53] within 20 weeks after implantation.
2.6  The immunofluorescence analysis of sections of the spinal cord after direct 
implantation of cellular neuronal matrices in the dislocation of a spinal 
trauma
Histological sections were subjected to immunofluorescence treatment for the 
search for transplanted cells expressing the green fluorescent protein GFP and the 
presence of neurotransmitters in the upper and lower areas of the spinal cord adja-
cent to the graft, as well as in the collagen chitosan transplant itself: acetylcholine, 
serotonin, and GABA (Abcam, USA). The Olympus BX-51 fluorescence microscope 
and the software products “Applied Spectral Imaging” (USA) were used to obtain 
images and analysis.
Spinal cord preparations obtained by careful and judicious selection of tissue 
from the spinal canal through the 20 weeks after surgery.
3. Results and discussion
Analysis of neurological deficits in rats after complete spinal cord transection 
indicates that transplantation of the cell-free collagen-chitosan matrix into spinal 
cord diastase at the level of thoracic vertebra IX leads to a marked reduction in 
the volume of violations by restoring the function of the pelvic organs in full, and 
provides 5–6 level recovery of motor and sensory functions of the spinal cord 
within 20 weeks of follow-up (Table 1). Implantation into the spinal cord diastasis 
collagen-chitosan substrate of about 100,000 mouse neuronal precursor cells leads 
to virtually eliminate neuronal lack, reaching over 20 weeks 19.5 replacement level 
(Table 1, Figure 7). The serial photo shows the animals in the control and experi-
ment at different times of the postoperative period with different levels of reduc-
tion of neurological deficit (Figures 8–14).
3.1  Immunofluorescent analysis of neurotransmitters in the spinal cord  
sections at its complete transection
Immunofluorescence neurotransmitter control of serial sections of the cerebral 
spinal cord rats 20 weeks after its full transection (the zone above the transplant 
area) shows that the interstitial tissue filled with nuclear cell mass actively express 
GABA, acetylcholine, and serotonin. The number of these cells is the uniformity of 
the distribution center to the area of the graft (Figure 15).
Serial immunofluorescence zone collagen-chitosan graft shows that 20 weeks 
after the operation area is filled with interstitial brain tissue with a large number 
of viable neuronal cells, maternal spinal cord actively expresses markers GABA, 
acetylcholine, and serotonin. Furthermore, zone graft contains many newly formed 
micro-capillaries containing the body of erythrocytes with auto-fluorescence effect. 
The number of nucleated cells in maternal spinal cord transplant decreases  
toward the tail region (Figure 16). In the rear area of the spinal cord (below the 
graft), the number of nucleated cells is substantially less than in the head area and 
in the control graft. However, viable cells express neurotransmitters GABA, acetyl-
choline, and serotonin (Figure 17).
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Figure 9. 
The fourth week after transplantation, level of reduction of neurological deficiency 1 (control).
Figure 7. 
The neurological analysis results of a full transection of a spinal cord. Red (left) and burgundy (right) color 
(experience) back extremities, blue (right) and navy blue (left) color (control) back extremities. Down – levels 
of reduction of neuronal deficiency, across – weeks of supervision.
Figure 8. 
The first week after transplantation, level of reduction of neurological deficiency 0 (control).
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Figure 10. 
The sixth week after transplantation, level of reduction of neurological deficiency 3.9 (control).
Figure 11. 
The eighth week after transplantation, level of reduction of neurological deficiency 4.9 (control).
Figure 12. 
The twentieth week after transplantation, level of reduction of neurological deficiency 5.1 (control).
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Figure 13. 
The eighteenth week after transplantation, level of reduction of neurological deficiency 19.5 (experience).
Figure 14. 
The eighteenth week after transplantation, level of reduction of neurological deficiency 19.5 (experience).
Figure 15. 
The immune fluorescent analysis of serial cut neurotransmitters (from top to down, control): head department 
of a spinal cord in 20 weeks after its full transection (above-transplant zone): GABA (а and b), acetylcholine 
(c–e), and serotonin (f–h).
227
The Experimental Bioengineering of Complete Spinal Cord Injury in Adult Rats
DOI: http://dx.doi.org/10.5772/intechopen.85353
Figure 16. 
The immune fluorescent analysis of serial cut neurotransmitters (from top to down, control): zones of a spinal 
cord transplant in 20 weeks after its full transection: GABA (a–g), acetylcholine (h–o), and serotonin (p–y).
Figure 17. 
The immune fluorescent analysis of serial cut neurotransmitters (from top to down, control): a tail zone of a 
spinal cord in 20 weeks after its full transection: GABA (a and b), acetylcholine (c–e), and serotonin (f–h).
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Figure 13. 
The eighteenth week after transplantation, level of reduction of neurological deficiency 19.5 (experience).
Figure 14. 
The eighteenth week after transplantation, level of reduction of neurological deficiency 19.5 (experience).
Figure 15. 
The immune fluorescent analysis of serial cut neurotransmitters (from top to down, control): head department 
of a spinal cord in 20 weeks after its full transection (above-transplant zone): GABA (а and b), acetylcholine 
(c–e), and serotonin (f–h).
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Figure 16. 
The immune fluorescent analysis of serial cut neurotransmitters (from top to down, control): zones of a spinal 
cord transplant in 20 weeks after its full transection: GABA (a–g), acetylcholine (h–o), and serotonin (p–y).
Figure 17. 
The immune fluorescent analysis of serial cut neurotransmitters (from top to down, control): a tail zone of a 
spinal cord in 20 weeks after its full transection: GABA (a and b), acetylcholine (c–e), and serotonin (f–h).
Translational Studies on Inflammation
228
Figure 18. 
The immune fluorescent analysis of serial cut neurotransmitters (from top to down, experience): head 
department of a spinal cord in 20 weeks after its full transection (above-transplant zone): GABA (a and b), 
acetylcholine (c–e), and serotonin (f–h).
Figure 19. 
The immune fluorescent analysis of serial cut neurotransmitters (from top to down, experience) zones collagen-
chitosan of a transplant of a spinal cord in 20 weeks after its full transection: GABA (a–i), acetylcholine (j–r), 
and serotonin (s-a4).
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Research prototypes spinal cord, containing besides the neuronal microenvi-
ronment of growth factors 100,000 neuronal progenitor cells of mice, showed 
that by the transplant register sprouting cells producing GFP, in the area of  the 
central end of the parent spinal cord. Broadcast nucleated cells are accompanied 
by the expression of neurotransmitter GABA, acetylcholine, and serotonin 
(Figure 18). A detailed analysis of the serial sections of the actual donor cells in 
the spinal cord indicates a rich content of viable neurons, producing GFP while 
expressing neurotransmitters. Transplanted cell mass in addition to the par-
ent who came to neuronal cell occupies the entire volume of collagen-chitosan 
scaffold (Figure 19). In the tail of the spinal cord of the experimental group, the 
number of registered nucleated cells with expression and without expression of 
neurotransmitters reduced. The study of serial sections below collagen-chitosan 
cell transplant (tail of the spinal cord) did not reveal the GFP-cell sprouting 
phenomenon (Figure 20).
4. Conclusion
Thus, the results obtained in the course of the studies suggest that the collagen-
chitosan matrix containing the neural progenitor cells is suitable for the repair of 
the damaged cells in the artificial three-dimensional environment. Transplantation 
of acellular collagen-chitosan substrate at full experimental spinal cord transection 
is accompanied by active sprouting maternal cell mass neuronal origin, actively 
expressing markers of neurotransmitters. This change is accompanied by a partial 
recovery of motor, sensory, and autonomic functions of the spinal cord, reaching 
the level of reduction, which is 5.6 point neuronal lack in BBB scale. Transplantation 
of collagen-chitosan matrix containing 100,000 progenitor neuronal cells fol-
lowed for 20 weeks of the maintenance of their viability, in addition to expressing 
neuronal marker mediators of transmission of nerve signals. Transplanted cell mass 
broadcast their axons in the maternal side of the central segment of spinal cord 
beyond the graft. The tail part of the spinal cord after its complete intersection 
demonstrates a reduced number of viable neurons. However, the transplantation of 
a matrix containing precursors of neurons, resulting in significant recovery of lost 
motor and sensory functions of the spinal cord, reaching the level of reduction neu-
ronal lack is equal to 19.5 on a BBB scale. Recent studies show that the inclusion of 
Figure 20. 
The immune fluorescent analysis of serial cut neurotransmitters (from top to down, experience): a tail zone of 
a spinal cord in 20 weeks after its full transection: GABA (a and b), acetylcholine (c–e), and serotonin (f–h).
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Figure 18. 
The immune fluorescent analysis of serial cut neurotransmitters (from top to down, experience): head 
department of a spinal cord in 20 weeks after its full transection (above-transplant zone): GABA (a and b), 
acetylcholine (c–e), and serotonin (f–h).
Figure 19. 
The immune fluorescent analysis of serial cut neurotransmitters (from top to down, experience) zones collagen-
chitosan of a transplant of a spinal cord in 20 weeks after its full transection: GABA (a–i), acetylcholine (j–r), 
and serotonin (s-a4).
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implantable structures and aminated polysaccharide polymer in a state of compac-
tion to nanoscale alert direct contact of immune cells with allogeneic or xenogeneic 
cells of nervous tissue that is included in the implant, which substantially reduces 
the immunological conflict in this area of privilege [54–56].
It is known that primary objectives of SCI therapy are processes of neuron 
re-myelination, reduction in apoptosis, damaged neuron and oligodendrocyte 
regeneration, neural cell sprouting, formation of new synaptic connections, reduc-
tion in astrogliosis intensity, neurotrophic support, reduction in leucocytes, and 
macrophage reactions. [57]. Combined therapy of SCI is dictated by complicated 
mechanisms of pathophysiological changes in critical and chronic periods after 
trauma [36, 58–61]. Based on the multifactorial mechanism of spinal trauma the 
main directions of the problem solution of spinal cord bioengineering after its 
damage are formed. The authors of the paper confirm that the cell therapy is an 
attractive therapeutic way of spinal cord function regeneration. The main idea 
formulates the necessary regeneration of deficiency in specialized cells, remaining 
after the injury, which leads to auto-allo-transplantation of exogenic neural stem 
cells (NSCs) and neural precursor cells (NPCs), and stimulation of endogenic 
potential of neural cells. Using optimal neurotrophic support for spinal cord cells 
such as exogenic injections including cocktails from conditioned environments 
and endogenic stimulation is an indispensable component of an integral strategy 
for repairing spinal cord injury. The use of cells as part of biodegrading and highly 
compatible 3D matrix, constituting carcass and benevolent conditions for cultiva-
tion, proliferation, and differentiation of cell material and the possibility of direct 
translation into problematic areas in spinal cord constitute an important part of 
the algorithm in the treatment of spinal cord injury. Biopolymer substrates should 
play the role of protection against permeabilization and progressing destruction of 
neural tissue, and also should regenerate barrier function of damaged membranes.
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